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Abstract 
 
Each year, 15 million infants are delivered preterm (< 37 weeks of gestation) and this accounts for 
10% of all births worldwide. Preterm births can be further classified by the gestational age at which 
the infant is delivered into early preterm (< 32 weeks of gestation) or late preterm (LPT; 32 – 36 
weeks). Greater than 75% of all preterm births occur LPT; however, the aetiology of LPT birth is 
currently unclear. Upper genital tract (UGT) infections are a major antecedent of preterm birth and 
the human Ureaplasma species are the bacteria most frequently isolated from the amniotic fluid or 
placentae of women who deliver preterm.  
 
Within this thesis, the prevalence and diversity of microorganisms within placentae (n = 535) of 
women (n = 477) who delivered LPT or at term (≥ 37 weeks of gestation) were investigated, and the 
incidence of chorioamnionitis was determined. Microorganisms were detected in 9.9% of LPT and 
14.1% of term chorioamnion tissues and of these, Ureaplasma spp. were the most prevalent clinical 
isolates (42/61; 68.8%). The presence of microorganisms was correlated with a history of 
chorioamnionitis in previous pregnancies (p = 0.025), and this may be a risk factor used by clinicians 
to identify women ‘at-risk’ of UGT infection in a current pregnancy. Significantly, the presence of 
Ureaplasma spp. within the chorioamnion (but not other microorganisms) was associated with 
histological chorioamnionitis (68.4% vs. 26.7%, p < 0.001). Despite the strong association between 
Ureaplasma spp. and histological chorioamnionitis, the detection of ureaplasmas within the 
chorioamnion was not always associated with histological chorioamnionitis and 14 (33.3%) 
placentae that were infected with Ureaplasma spp. demonstrated no evidence of histological 
chorioamnionitis. We identified no correlation between the number of ureaplasma CFU within the 
chorioamnion and the severity of disease, indicating that there may be other factors which influence 
the progression of disease.  
 
To better understand why only some women with ureaplasma chorioamnion infection developed 
histological chorioamnionitis, the ureaplasma clinical isolates (n = 42) that were isolated from 
chorioamnion tissues were characterised. A novel real-time polymerase chain reaction (PCR) and 
high resolution melt (HRM) assay was designed and optimised to serotype the U. parvum clinical 
isolates. While U. parvum was the most frequently isolated species (85.7%) and the U. parvum 
serovars 1, 3 and 6 were the most frequently isolated serovars (23.8%, 21.4% and 28.6%, 
respectively); there was no association with ureaplasma species or serovars and the development of 
adverse pregnancy or neonatal outcomes. The clinical ureaplasma isolates were also tested by 
western blot and PCR to investigate changes/alterations in a major surface-exposed lipoprotein, the 
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multiple banded antigen (MBA), which is a predicted virulence factor of Ureaplasma spp. UGT 
infection. Previously, MBA size variation has been identified within a pregnant sheep model of UGT 
infection and differences in the size of the MBA was associated with differences in the severity of 
histological chorioamnionitis, but as yet no studies have investigated ureaplasma MBA size variation 
in human pregnancies. Within our study, some clinical isolates demonstrated MBA protein bands 
that were the same size as Ureaplasma spp. American Type Culture Collection (ATCC) strains (i.e. no 
MBA variation was occurring), but in numerous clinical isolates, different sized MBA protein bands 
were observed. Clinical ureaplasma isolates that demonstrated MBA size variation were associated 
with a decreased incidence of histological chorioamnionitis (p = 0.023). By contrast, when 
ureaplasmas isolated from the chorioamnion demonstrated no MBA size variation then these 
placentae demonstrated severe histological chorioamnionitis. Furthermore, MBA size variation 
correlated with the concentration of specific cytokines within cord blood. When Ureaplasma spp. 
were detected within the chorioamnion, this was associated with significantly increased levels of 
cord blood granulocyte colony-stimulating factor (G-CSF) (489.35 ± 183.8 pg/mL, p = 0.04), when 
compared to uninfected placentae. Furthermore, when MBA size variation was also present, there 
were differences in the levels of cord blood cytokines. In placentae which were infected with 
ureaplasmas, but no MBA variation was detected, there were significantly higher levels of G-CSF and 
interleukin (IL)-8; while ureaplasma-infected placentae in which MBA size variation was detected 
had significantly lower levels of G-CSF and IL-8 (p = 0.008 and p = 0.04, respectively). These results 
are consistent with Ureaplasma spp. modulation of the host immune response.  
 
The specific host immune responses to U. parvum within an ex vivo placental tissue model of 
chorioamnion infection was further investigated. This pilot study utilised chorioamnion tissue from 
four human placentae that were processed within one hour of delivery. From each placenta, six 
sections of chorioamnion tissue were cut and suspended within Ussing chambers (n = 6 chambers 
per placentae). The chorioamnion tissue within each Ussing chamber acted as a barrier (both 
physical and immunological, mimicking its function in vivo) and each side of the membranes was 
separately perfused with sterile M199 media supplemented with urea and fetal calf serum. In each 
experiment, the maternal (chorion) side of the membranes was stimulated with live U. parvum 
serovar 6 clinical isolate (n = 2 chambers), UV-inactivated U. parvum serovar 6 clinical isolate (n = 2 
chambers) or vehicle control (n = 2 chambers) and perfusing media was collected from both the 
maternal and fetal compartments of the Ussing chambers over time. Exposure of the maternal side 
of the chorioamnion membrane to live U. parvum, but not UV-inactivated U. parvum resulted in 
elevated secretion of the anti-inflammatory cytokine IL-10 (20.4 ± 2.8 pg/mL, p = 0.046) within the 
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maternal perfusates at 20 and 30 hours post-infection. Exposure of the chorioamnion to live U. 
parvum also resulted in increased MMP-9 production, ureaplasma invasion of the chorioamnion 
tissue, degradation of the chorioamnion membrane and detachment of the chorioamnion 
membranes, and these changes are consistent with the initial stages of membrane rupture (pPROM). 
 
The data presented within this thesis has improved our understanding of Ureaplasma spp. infections 
of the placenta within human pregnancies. Here, we confirm that Ureaplasma spp. are an  
aetiological agent of adverse pregnancy outcomes and demonstrated, for the first time, that 
infection with Ureaplasma spp. alone within the chorioamnion was associated with histological 
chorioamnionitis. It was also identified that ureaplasma clinical isolates obtained from the 
chorioamnion of human pregnancies demonstrated differences in the size of their MBA protein and 
variation of the size of the surface-exposed MBA was associated with a decreased incidence of 
histological chorioamnionitis. Furthermore, we demonstrated that the presence of Ureaplasma spp. 
infection in human pregnancies was associated with host immune responses and elevated levels of 
cord blood G-CSF; however, when MBA protein variation was present, there was a significant 
reduction in of G-CSF and IL-8 within cord blood, despite high numbers of ureaplasmas being present 
within the chorioamnion. We also identified that ex vivo stimulation of chorioamnion tissues 
resulted in elevated levels of the immunosuppressive cytokine, IL-10. Taken together, these results 
identify the initial host immune responses to ureaplasma infections within the chorioamnion, and 
these first immune responses by the host may be integral for the establishment of chronic, 
asymptomatic UGT Ureaplasma spp. infections during pregnancy.  
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Chapter One:  
 
Introduction 
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1.1 Description of the scientific problem investigated 
 
One in ten infants (10% of all births) are delivered preterm (<37 weeks of gestation) each year. 
Despite significant research and targeted intervention strategies, rates of preterm birth (PTB) 
continue to rise in almost every country (March of Dimes 2012). The most significant increase in 
PTBs has occurred within the late preterm (LPT) period (32 – 36 weeks of gestation), and in the last 
decade the rates of LPT birth have increased by more than 40% and LPT infants now account for 80% 
of all preterm infants (Raju 2006; Goldenberg et al. 2008b). Infection of the upper genital tract (UGT) 
is one of the most common causes of preterm delivery, with 25 – 40% of all PTBs associated with 
intrauterine infection (DiGiulio et al. 2008; Goldenberg et al. 2008b; DiGiulio 2012). Whilst these 
estimated rates of PTB associated with infection appear to be high, these may actually be minimal 
estimates, as some microorganisms have fastidious nutritional requirements and are not always 
detected/cultured during routine microbiological processing.  
 
The human Ureaplasma species (Ureaplasma parvum and Ureaplasma urealyticum) are the 
microorganisms most frequently isolated from the amniotic fluid (AF) and placentae of women who 
deliver preterm and this finding is consistent in studies which utilise traditional culture-based 
methods and/or newer molecular based methods (DiGiulio et al. 2008; DiGiulio 2012). Unlike other 
intraamniotic pathogens, which often cause acute infections resulting in PTB and fetal deaths, 
infections with Ureaplasma spp. are frequently chronic and asymptomatic. Ureaplasmas have been 
isolated from amniotic fluid as early as 15 weeks of gestation (Cassell et al. 1983; Cassell et al. 
1993a; Gerber et al. 2003). Despite the absence of signs of infection, ureaplasma infections are 
frequently associated with adverse pregnancy and neonatal outcomes, including chorioamnionitis, 
funisitis, neonatal infections (including pneumonia, sepsis and meningitis) (Hillier et al. 1988; Cassell 
et al. 1993b; Goldenberg et al. 2002; Schelonka and Waites 2007; Waites et al. 2009; Kasper et al. 
2010). Remarkably, these fastidious microorganisms are able to survive (and thrive) within the 
amniotic cavity, even in the presence of maternal/fetal immune responses. Given this, it is likely that 
Ureaplasma spp. have developed specific mechanisms that facilitate access to the amniotic cavity 
and the ability to chronically colonise/infect the AF during pregnancy without eradication. The 
overall hypotheses of this PhD program of study are:  
(i) The Ureaplasma spp. infiltrate the placenta and chorioamnion during pregnancy; 
(ii) Ureaplasma spp. are an aetiological agent of late preterm births and may be associated 
with adverse pregnancy and neonatal outcomes.  
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(iii) The host immune system may not always recognise ureaplasmas, as these 
microorganisms possess the ability to vary the size of their surface-exposed lipoprotein, 
the multiple banded antigen (MBA).  
These hypotheses were examined in human pregnancies, and in a human chorioamnion tissue ex 
vivo model of ureaplasma infection. 
 
1.2 Specific aims of this study: 
 
(i) To determine the prevalence and diversity of microorganisms, particularly Ureaplasma 
spp. within the chorioamnion of late preterm placentae.  
(ii) To detect, identify and serotype the most prevalent Ureaplasma species and serovars 
using a novel real-time polymerase chain reaction (PCR) and high resolution melt (HRM) 
assay.  
(iii) To characterise the immunodominant surface lipoprotein of clinical ureaplasma isolates 
(the multiple banded antigen (MBA)) and to detect variations of this surface-exposed 
protein.  
(iv) To investigate the host-microbe interactions of Ureaplasma spp. using an ex vivo model 
and human chorioamnion tissue.  
By understanding these fundamental aspects of Ureaplasma spp. UGT infections, this project may 
lead to a better understanding of the role of host immune responses during Ureaplasma spp. 
infections, the identification of novel biomarkers which may predict or identify women at-risk of 
delivering preterm due to infections and may inform targeted therapeutic strategies. These are 
greatly needed in order to reduce the high rates of PTB and its associated neonatal morbidity and 
mortality.  
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2.1 Preterm birth: A global issue 
  
Preterm birth (PTB: delivery < 37 weeks of gestation; term = 40 weeks) remains the single greatest 
obstetric challenge in the Western world (March of Dimes 2012). In 2012, 15 million births (10% of 
all births worldwide) occurred preterm, and whilst intervention strategies have reduced the 
neonatal mortality associated with PTB, rates of PTB continue to increase in almost every country 
(Bick 2012; March of Dimes 2012). Unlike many other health issues, PTB is a truly global issue with 
low- (LI), middle- (MI) and high-income (HI) countries being affected. While rates of PTB range from 
5 – 18% in different countries (March of Dimes 2012), the highest reported rates of PTB are in India 
(MI), China (MI), the Democratic Republic of the Congo (LI) and the United States (HI) (March of 
Dimes 2012). In HI countries, there were 1.2 million (8%) PTBs in 2012 and more than 42% of these 
occurred within the United States alone (March of Dimes 2012). 
 
Within Australia, rates of PTB increased from 6.8% in 1991 to 7.7% in 2012 (Lancaster et al. 1994; 
Hilder et al. 2014). Similarly, within the United States, rates of PTB have increased from 10.9% in 
1991 to 11.7% in 2011 (Hamilton et al. 2012). These figures suggest that the current intervention 
strategies employed by clinicians are not effectively curbing the high rates of PTB, and due to the 
high number of surviving infants this places an increased burden on our healthcare system. Many 
countries are only now experiencing and reporting on the full extent and long-term outcomes of PTB 
survivors (March of Dimes 2012). Whilst the adverse effects of PTB are seen most frequently in 
infants born extremely preterm, there is increasing evidence that all preterm infants (regardless of 
their gestational age) are at increased risk of adverse sequelae (Figure 2.1).  
 
2.1.1 Consequences of prematurity: why term babies are worth the wait 
 
PTB remains one of the most significant threats to the health and wellbeing of infants, claiming the 
lives of more than 1 million children each year (Bick 2012; March of Dimes 2012). Forty percent of all 
newborn deaths (death within four weeks of delivery) are as a consequence of PTB, and PTB is also 
the second leading cause of death in children under the age of 5 (the leading cause of death is 
pneumonia) (March of Dimes 2012). Whilst mortality rates are inversely proportional to the age at 
which the child is delivered, there are also discrepancies in mortality rates between LI, MI and HI 
countries. A child delivered at 24 weeks of gestation has a 50% chance of survival in an HI country, 
whilst a child delivered at 34 weeks of age has only a 50% chance of survival in LI or MI countries 
(Figure 2.1) (March of Dimes 2012).  
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Those infants who survive their prematurity are often faced with a lifetime of disability or 
impairment, and this is predominantly as a consequence of immature organ systems. The most 
frequently encountered adverse outcome of preterm infants is lung injury, resulting from 
bronchopulmonary dysplasia (BPD; also known as chronic lung disease of prematurity) (Doyle et al. 
1999). Higher incidences of recurrent respiratory infections/illnesses (Greenough 2012) and 
childhood asthma (Hack et al. 2005) are also commonly associated with PTB. Other organ systems 
are also at risk and children born preterm may experience visual and hearing deficiencies and 
language or behavioural problems (Moster et al. 2008). PTB is also associated with more severe 
sequelae, such as neuromotor and coordination disorders (Gorga et al. 1988), autism spectrum 
disorders (Abel et al. 2013)  and cerebral palsy (Oskoui et al. 2013).  
 
The childhood and long-term health outcomes of premature children are also inversely proportional 
to their gestational age at birth. Preterm infants (< 32 weeks of gestation) have higher rates of 
severe conditions (e.g. cerebral palsy), whilst those delivered at later gestations have less severe 
conditions (such as increased risk of non-communicable diseases later in life; Figure 2.1). Despite the 
apparent decreased severity of outcomes in later gestations, infants born late preterm (LPT) account 
for more than 75% of all PTBs and are therefore likely to have the greatest long-term impact on our 
healthcare system (Wang et al. 2004; Raju 2006). A review article on the prevention of preterm birth 
stated that “the true costs of prematurity, especially on a long-term, global level, are poorly 
understood and likely to be grossly underestimated” (Simmons et al. 2010). This is particularly true 
for infants born LPT, as despite their large numbers this cohort has remained largely unstudied.  
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Figure 2.1. Overview of preterm birth and its associated outcomes. 
HI – high income, MI – middle income, LI – low income. Image adapted from (March of Dimes 2012)
MONTHS                     5        6               7                            8                       9                            
 First Trimester       Second Trimester                             Third Trimester 
PREGNANCY 
 
 
FETAL OUTCOMES 
PRETERM BIRTH 
Very preterm 
Birth 
291 - 316  
Extremely preterm 
birth  
≤ 28 weeks  
Term 
 
≥ 37 
Late preterm 
birth 
320 - 366  
34 weeks:  
50% chance of survival 
in LI/MI country 
24 weeks:  
50% chance of survival 
in HI country 
 
 
OUTCOMES FOR  
CHILDREN 
Children with moderate/severe long-term 
disability e.g. cerebral palsy, mental retardation 
Children with mild long-term 
disability e.g. learning 
difficulties, respiratory disorders 
Children with other short/long-
term outcomes e.g. respiratory 
illness, rehospitalisation, 
asthma, behavioural problems 
FETAL DEATHS 
2.6 million stillbirths annually 
 
1.1 million neonatal deaths annually  
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2.2 Late preterm birth: A seldom studied population at risk 
 
Worldwide (Australia and the United States included), the most significant increase in PTB has been 
for neonates delivered within the LPT period (320 – 366 weeks of gestation), increasing by more than 
40% between 1981 and 2005 (Loftin et al. 2010). LPT infants were traditionally referred to as “near 
term” as they were delivered just a few weeks early and were thought to be comparable to infants 
delivered at term (≥ 37 weeks). There is compelling evidence that LPT infants are physiologically and 
developmentally immature, and are at greater risk of severe outcomes (Table 2.1) than term-born 
infants. In the United States, the total cost of treating children born very preterm (at 25 weeks of 
gestation) was found to be $38.3 million dollars, while the cost of treating LPT infants was $39.3 
million dollars (Gilbert et al. 2003). Despite the high costs of treating very premature children, the 
cost of treating LPT infants is higher due to the greater numbers born in this period and the 
increased number of surviving children. In Australia, an alarming 79.9% of preterm infants are born 
in the LPT period and in the US this statistic is even higher at 84.5% (Hamilton et al. 2012; Li et al. 
2013). This represents a very large number of children who are at risk of chronic health problems.  
 
LPT infants are at increased risk of temperature instability (Wang et al. 2004; Laptook and Jackson 
2006), hypoglycaemia (Wang et al. 2004; Adamkin 2011), respiratory distress (Escobar et al. 2006a; 
Escobar et al. 2006b; Ramachandrappa and Jain 2009; Colin et al. 2010; Harijan and Boyle 2012), 
apnea (Raju 2006) and jaundice (Boyle and Boyle 2013) within the first month of life. Of those LPT 
infants delivered before 34 weeks of gestation, more than half will require admission to the neonatal 
intensive care unit (NICU) (Mally et al. 2010), highlighting the risk of being born “just a few weeks” 
preterm. The adverse outcomes for LPT infants include a higher rate of rehospitalisation, with these 
infants being readmitted twice as frequently as term-born infants (Escobar et al. 2006a; 
Ramachandrappa and Jain 2009; Harijan and Boyle 2012). A study by Wang and colleagues identified 
that the cost of caring for LPT infants during their initial admission at birth was three times higher 
than the cost for term infants (Wang et al. 2004). These infants are also at greater risk of ongoing 
morbidities including acute bronchitis, otitis media and pneumonia, which were associated with 2-
fold higher healthcare costs for the first three years of life, when compared to the costs of treating 
term-born infants (Berard et al. 2012). More recently, a study by Gunay et al. (2013) examined the 
blood pressure and renal function of LPT children (age range: 4 – 13 yrs; n = 65) and compared these 
to sex- and age-matched term-born children. While the renal function of LPT children was similar to 
that of the term-born cohort, the mean blood pressure levels were significantly different between 
the cohorts. Day time, night time and 24-hour readings for both systolic and diastolic blood pressure 
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levels were significantly higher in the LPT group, compared to the term-born group. This may lead to 
childhood hypertension and ongoing health issues later in life .  
 
2.3 Adverse outcomes associated with late preterm birth 
 
Most organ systems of preterm infants remain vulnerable, even at late gestational ages and this 
predisposes infants to a range of short- and long-term adverse outcomes (Table 2.1). The final six 
weeks of gestation are crucial for fetal brain development, making this organ particularly vulnerable 
to insult following LPT birth. The brain of a LPT infant weighs one third less and the cerebral volume 
is approximately half the volume of a term-born infants’ brain. LPT myelination and interneuronal 
connectivity remains incomplete, and any insult (including preterm birth) during this stage of 
development can lead to poor long-term outcomes for the neonate (Ramachandrappa and Jain 
2009). The brainstem, which controls the suck-swallow rhythm associated with feeding is also less 
mature and this may result in feeding difficulties and “failure of the offspring to thrive” (Darnall et al. 
2006; Mally et al. 2010). This exacerbates other sequelae of LPT infants, including dehydration, 
hypoglycaemia and jaundice (Boyle and Boyle 2013). Other studies have shown that preschool 
children who were born LPT (n = 44) performed poorly on ‘verbal inhibitory control’ and ‘short-term 
verbal memory tests’, compared to term-born infants of the same age (Brumbaugh et al. 2013) and 
these LPT infants had lower ‘general conceptual abilities’, lower ‘verbal and non-verbal scores’ and 
poorer ‘visual and dexterity outcomes and adaptability’, compared to term-born children (p < 0.01) 
(Baron et al. 2013). Up to one third of 7 year old children delivered LPT were reported by their 
teachers to have difficulties in basic motor skills (29%), speaking (21%), writing (32%) and 
mathematics (19%) (Huddy et al. 2001).  
 
LPT birth has also been associated with more severe neurological conditions such as cerebral palsy, 
and rates of cerebral palsy are up to three times higher for children delivered late preterm, 
compared to their term-born counterparts (Adams-Chapman 2006; Petrini et al. 2009; Mally et al. 
2010), particularly where intraamniotic infection and/or inflammation are also reported at birth 
(Goldenberg et al. 2008b). A study of 900 000 children, including almost 33 000 children born LPT 
reported higher incidences of cerebral palsy (relative risk: 2.7 - 14.1), mental retardation (relative 
risk: 1.6 – 2.1), behavioural and emotional disturbances (relative risk: 0.8 – 1.0) as well as other 
severe disabilities including blindness or decreased vision, hearing loss and epilepsy (relative risk: 1.5 
– 2.3) for children born LPT (Moster et al. 2008).  
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The fetal lung is also particularly vulnerable following LPT birth. A study by Colin and colleagues 
likened the function/development of the LPT lung as more similar to that of a very preterm infant 
than that of a term infant (Colin et al. 2010). LPT infants’ lungs are at the saccular stage of 
development, which is characterised by an increase in the number of bronchi, alveoli and at this 
time, surfactant is produced. Associated with these changes is the rapid increase in lung volume and 
lung development can be altered if infants are delivered LPT. Respiratory distress (RDS) may occur as 
a consequence of interrupted alveolar development and is associated with poor gas exchange due to 
lack of surfactant production. Infants born LPT are 8 times more likely to be diagnosed with RDS, and 
9 times more likely to require continuous positive airway pressure (CPAP) ventilation due to their 
immature lungs, compared to term-born infants (Wang et al. 2004) (Ramachandrappa and Jain 
2009).   
 
This is consistent with other studies which identified LPT infants as having significant respiratory 
morbidities as evidenced by high rates of assisted ventilation, the use of oxygen at 36 weeks 
(gestational age of the infant following LPT birth) (Escobar et al. 2006b) and with reduced respiratory 
compliance, when compared to matched term-born control infants (McEvoy et al. 2013). A follow-up 
study identified a significant link between late PTB and recurrent wheezing up to three years of age 
(Escobar et al. 2010). Another study of 7295 children monitored the outcomes of infants from birth 
to 18 months of age (age at enrolment: 34 - 36 weeks) and showed a significant correlation between 
birth in the LPT period and a diagnosis of asthma within the first 18 months of age (adjusted odds 
ratio: 1·68) (Goyal et al. 2011). These studies confirm the significant impact of late PTB and identify 
and that the burden associated with late PTB may be underestimated. Both the short- and long-term 
adverse outcomes for these infants born LPT place further strain on our healthcare system and 
further research is required to understand the pathogenesis of LPT birth and to identify risk factors 
and causes of LPT birth.   
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Table 2.1.  A comparison of neonatal and long-term outcomes for extremely preterm, very preterm, 
late preterm and term infants. Outcomes of children born late preterm are more closely related to 
those of children born very preterm, rather than those delivered at term. 
 
 
  
 Extremely 
Preterm 
Very Preterm Late Preterm Term n =  Reference 
Gestational age at 
birth (week
day
) 
≤ 276 280 - 316 320 - 366 ≥ 370 N/A (March of Dimes 
2012) 
Proportion of total 
birth 
0.4% 0.8% 6.5% 92.3% 301 810 (Li et al. 2011) 
Proportion of 
preterm birth 
5.2% 10.4% 84.4% N/A 301 810 (Li et al. 2011) 
Mortality rate  
(per 1000 live births) 
392.7 27.2 3.5 0.4 301 810 
 
(Li et al. 2011) 
 
INITIAL STAY AND REHOSPITALISATION  
Mean weight 
(grams) 
752.6 ± 350.3 1420.2 ± 454.2 2643.1 ± 580.3 3607.5 ± 478.4 1 390 742 (Raisanen et al. 2013) 
Initial length of stay 
(days) 
 
78.2 ± 0.70 35.92 ± 1.21 7.28 ± 0.29 2.0 ± 0.78 458 366 
 
(Gilbert et al. 2003) 
Rehospitalisation 28.75% 19.5% 13.74% 2.0% 263 883 
 
33 276 
(Underwood et al. 
2007) 
(Escobar et al. 2005) 
Average cost of 
rehospitalisation 
$ 15.12 million $ 16.66 million $ 64.9 million Insufficient data 263 883 (Underwood et al. 
2007) 
NEUROLOGICAL DISORDERS 
Cerebral palsy 
 
9.1% 6% 2.2% 0.1% 903 402 (Moster et al. 2008) 
Mental retardation 
 
4.4% 1.8% 1.7% 0.4% 903 402 
141 321 
(Moster et al. 2008) 
(Petrini et al. 2009) 
Autism spectrum 
disorder 
0.6% 0.4% 0.08% 0.05% 903 402 (Moster et al. 2008) 
Psychological and 
behavioural 
disorders 
2.5% 0.7% 0.6% 0.2% 903 402 (Moster et al. 2008) 
RESPIRATORY DISORDERS  
Respiratory distress 
 
74.3% 44.2% 28.9% 4.2% 458 366 
7 474 
(Gilbert et al. 2003) 
(Wang et al. 2004) 
Bronchopulmonary 
Dysplasia 
Up to 40% 
 
Up to 24.8% 
 
28.9% 
 
4.2% 4 185 (Gortner et al. 2011) 
OTHER  
Visual impairment, 
blindness, hearing 
loss and epilepsy 
10.6% 8.2% 6.6% 
 
1.7% 903 402 (Moster et al. 2008) 
TOTAL COST 
Average cost per 
gestational age 
group 
$ 38.3 million $ 35.95 million $ 39.26 million $ 69.95 million 458 366 
 
(Gilbert et al. 2003) 
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2.4 In utero infections: the (often) silent threat to a healthy pregnancy  
 
In utero infection during pregnancy is the most common (potentially) preventable antecedent of PTB 
(Goldenberg et al. 2000b; Goldenberg et al. 2008b). A seminal study conducted by Hillier and 
colleagues tested the placentae of women following delivery and identified that 61% of women (n = 
38) who delivered preterm had bacteria present within the chorioamnion (membranes which 
surround the fetus during pregnancy) and of these, 47% were infected/colonised with Ureaplasma 
spp. (Hillier et al. 1988). It has been consistently shown that the human Ureaplasma spp. are the 
microorganisms most frequently isolated from the amniotic fluid and placentae of women who 
deliver preterm (Gray et al. 1992; Cassell et al. 1993b; Knox et al. 1997; Goncalves et al. 2002; 
Gerber et al. 2003; Aaltonen et al. 2007; Hecht et al. 2008; Onderdonk et al. 2008; DiGiulio et al. 
2010; Kasper et al. 2010). DiGiulio compared the results from 37 studies that reported on the 
prevalence and diversity of bacteria within amniotic fluid (15 – 37 weeks) and found that this clinical 
fluid was most frequently infected with Ureaplasma spp. (24%), Fusobacterium spp. (20%) or 
Streptococcus spp. (16%), and less frequently with Mycoplasma spp. (4%), Bacteroides spp. (4%) and 
Gardnerella spp. (8%). It was also reported that Ureaplasma spp. was the most frequently isolated 
microorganism in cases of preterm premature rupture of membranes (pPROM); and the second 
most frequently isolated organism from women who delivered preterm without rupture of the 
membranes (DiGiulio 2012). Ureaplasma spp. infection has been identified in the amniotic sac as 
early as 15 weeks of gestation (Gerber et al. 2003) and whilst it has been reported that ureaplasmas 
can be isolated from discoloured amniotic fluid without any other clinical signs of infection (Cassell 
et al. 1983), they are most frequently isolated from women with clear amniotic fluid (as ureaplasmas 
are so small that they do not produce turbidity in liquids – including in vitro cultures in broth) and 
macroscopically normal placentae (though there may be histological evidence of 
inflammation/chorioamnionitis). This means that not only are ureaplasma infections of the amniotic 
cavity asymptomatic, but also that ureaplasma infection is not immediately suspected as a cause of 
preterm birth or adverse pregnancy outcomes.  
 
Furthermore, it has been identified that only 35% of preterm births are medically indicated; whilst 
the remaining 65% of preterm births occur as a result of spontaneous premature labour and pPROM 
(Goldenberg et al. 2008b), most frequently as a result of intrauterine infection (approximately 25 – 
40% of all preterm births are as a result of intrauterine infection) (Goldenberg et al. 2000b; 
Goldenberg et al. 2008b; DiGiulio 2012). Taken together, this indicates that intrauterine infection is 
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prevalent and often extremely difficult to identify/diagnose, as women appear to be apparently 
healthy until preterm labour ensues.  
 
Kenyon et al. published two of the largest randomised clinical trials investigating antibiotic 
treatment of women with pPROM (Kenyon et al. 2001a) and spontaneous preterm labour (Kenyon et 
al. 2001b) (both are classical symptoms of intrauterine infection). The ORACLE I trial studied the 
efficacy of erythromycin or amoxicillin and clavulanic acid (augmentin) treatment versus placebo 
controls in 4826 women with pPROM. The administration of antimicrobials was effective, reducing 
adverse neonatal outcomes (oxygen dependency and surfactant therapy of the neonate, cerebral 
abnormalities and positive blood cultures); however, the use of augmentin was associated with 
necrotising enterocolitis (NEC) in neonates (p = 0.0005). Therefore, augmentin was contraindicated 
for use in pPROM (Kenyon et al. 2001a). The ORACLE II clinical trial investigated the effectiveness of 
erythromycin or augmentin treatment in a cohort of 6295 women with spontaneous preterm labour. 
In contrast to the ORACLE I trial, the ORACLE II clinical trial showed no significant improvements for 
neonates outcomes (parameters mentioned above) in either of the erythromycin (useful in the 
treatment of ureaplasmas) or augmentin (not useful in the treatment of ureaplasmas) treatment 
groups, or in the placebo (no antimicrobial treatment) control group; however, there was a reduced 
incidence of maternal infection in those women who were administered antimicrobials. They 
therefore concluded that women in spontaneous preterm labour should not be routinely 
administered antimicrobials unless there was clinical evidence of infection (Kenyon et al. 2001b). 
However, the problem largely remains that identification of intrauterine infection is extremely 
difficult, due to the predominantly asymptomatic nature of the infection.  
 
A 7-year follow-up of the children born to mothers administered antimicrobials vs. placebo during 
the ORACLE II randomised clinical trial found there were no significant differences in the children’s 
rate of death, the medical conditions they developed, their behavioural patterns or the educational 
attainment levels of the children. However, children born to mothers who received erythromycin 
had greater functional impairment (mild, moderate or severe impairment of vision, speech, 
dexterity, emotion, cognition or pain) compared to those children born to mothers who did not 
receive erythromycin (658/1554, compared to 574/1498, odds ratio: 1·18). Even more significant 
was the risk of developing cerebral palsy (in both erythromycin/augmentin treatment groups); 
children born to women treated with either antimicrobial were more likely to develop cerebral palsy 
compared to children who did not receive antimicrobials (erythromycin: 53/1611 compared to 
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27/1562, odds ratio: 1·93; augmentin: 50/1587 compared to 30/1586, odds ratio: 1·69) (Kenyon et 
al. 2008).  
 
More recently, Acosta et al. (2014) identified that multiple-dose maternal intravenous azithromycin 
eradicated U. parvum with a 95% success rate in a non-human primate model. However, other 
studies investigating the effectiveness of erythromycin treatment during pregnancy have reported 
conflicting results. Dando et al. (2010) showed that maternal intramuscular administration of 
erythromycin failed to eradicate intrauterine ureaplasma infection in an ovine model. The failure of 
erythromycin treatment may be due to poor trans-placental transfer; as a previous study reported 
that the trans-placental transfer rate of erythromycin was as low as 3%, so these antimicrobials may 
not be reaching the placentae or amniotic fluid in therapeutic concentrations (Heikkinen et al. 2000). 
Dando et al. (2014) subsequently sequenced the domain V of the 23S rRNA gene of ureaplasmas 
isolates from their 2010 study and demonstrated significant genetic differences between 
ureaplasmas isolated from the chorioamnion and amniotic fluid of pregnant sheep. While 
ureaplasmas isolated from amniotic fluid showed 100% 23S rRNA sequence homology to the original 
strain injected, isolates from the chorioamnion demonstrated significant genetic variation (only 64 – 
82% sequence homology) when compared to the original strain injected. Furthermore, the 
ureaplasmas isolated from the chorioamnion of sheep demonstrated the presence of macrolide 
resistance genes and the presence of these genes (erm(B) and msr(D)) were associated with variable 
minimum inhibitory concentrations (MICs), regardless of whether the isolates were exposed to 
erythromycin in vivo. Therefore, these results suggest that the microbial niche (i.e. amniotic fluid or 
chorioamnion tissue) may act as a selective pressure that allows the growth of some ureaplasma 
variant strains in vivo. This may also explain why it is so difficult to treat intraamniotic Ureaplasma 
spp. infections.  
 
Other studies have also reported mutations within the 23S rRNA gene and erythromycin resistance 
patterns; however, macrolide resistance in these populations was low (Xiao et al. 2011a). A follow-
up study in sheep by Kemp et al. (2014) attempted to resolve intraamniotic ureaplasma infections 
with erythromycin treatment and combinations of single or repeat intraamniotic and maternal 
intramuscular injections but failed to eradicate ureaplasmas from the amniotic cavity of pregnant 
sheep. While erythromycin treatment reduced the number of viable ureaplasmas present, the 
authors demonstrated the presence of several erythromycin-resistant strains following in vivo 
treatment (Kemp et al. 2014). Redelinghuys et al. (2014) have also demonstrated increasing 
antimicrobial resistance in human clinical isolates. Self-collected vaginal swabs were obtained from 
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pregnant women (n = 96) attending an antenatal clinic in South Africa. Specimens were screened 
and 76% (73/96) contained Ureaplasma spp. and the majority of isolates were U. parvum. 
Antimicrobial susceptibility assays were performed and > 80% of isolates were resistant to 
erythromycin (a class A antimicrobial therapy suitable for treating pregnant women), and 
surprisingly 73% of ureaplasma isolates were also found to be resistant to tetracycline (a class D 
antimicrobial therapy – contraindicated during pregnancy). Other studies have also indicated that 
tetracycline resistance of Ureaplasma spp. is increasing (Xiao et al. 2011a). These studies highlight 
the failure of erythromycin to treat intraamniotic ureaplasma infections. These findings highlight the 
need for further studies to identify methods to detect asymptomatic UGT infections and adequate 
treatment strategies to eradicate these complex pathogens during pregnancy.  
 
In a review of drug therapies for the prevention of preterm birth, it was stated that “if the right 
antibiotics (with appropriate activity against a particular microorganism) were administered to 
women prior to 22 weeks of gestation (and before inflammation/damage in utero) then the 
incidence of preterm birth may be reduced by 40 – 60%” (Lamont and Jaggat 2007). However, the 
difficulty remains that: (i) intrauterine infections in early gestational periods are often polymicrobial 
and require more than one antibiotic to effectively treat the different microorganisms causing the 
infection (Kallapur et al. 2013); (ii) a large proportion of women have clinically silent intrauterine 
infections (Goldenberg et al. 2000b); and (iii) routine screening/testing of pregnant women for UGT 
infection is not part of current obstetric practice (Australian Government Department of Health and 
Ageing 2012). 
2.4.1 Routes of in utero infections 
 
The female upper genital tract (UGT) was traditionally considered to be a sterile site, as it was 
thought that infants developed within a sterile site and were first exposed to bacteria during birth 
(Tissier 1900; Wilson 2005). However, increasing evidence suggests that the UGT is not sterile and 
that there are specific mechanisms by which microorganisms gain access to the UGT. Goldenberg et 
al. (2000) proposed four major mechanisms: retrograde spread from the peritoneal cavity (via the 
Fallopian tubes), haematogenous dissemination via the placenta and maternal blood supply, 
accidental contamination at the time of invasive procedures such as amniocentesis or chorionic 
villus sampling, and ascending invasive infections from the LGT to the UGT (Fig. 2.2). Of these, the 
most widely accepted mechanism is that microorganisms originating from the LGT (e.g. Ureaplasma 
spp.) ascend through the cervix into the choriodecidual space and cross the chorioamnion 
membrane to reach the amniotic fluid and the fetus (Kim et al. 2009). A study by Hansen et al. 
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(2014) identified that despite the presence and intense antimicrobial activity of the cervical mucus 
plug (a gel-like structure which fills the cervix), Ureaplasma spp. were still isolated within the cervical 
mucus plug, indicating that its presence does not block the movement of Ureaplasma spp. to the 
UGT. A previous study identified that migration of radio-labelled particles from the vagina to the 
UGT can occur within 2 minutes (Zervomanolakis et al. 2007) and further studies conducted by 
Kundsin et al. (1984) demonstrated the recovery of Ureaplasma spp. increased as the duration of 
rupture of membranes increased, providing further evidence that bacteria can ascend from the LGT 
and are likely to be the primary source of UGT infections. Knox et al. (2003) also demonstrated that 
Ureaplasma spp. were adherent to human spermatozoa and were not always removed by assisted 
reproductive technology (ART) washing procedures (29/73, 39.7% remained ureaplasma-positive). 
By attaching to the surface of sperm, ureaplasmas may gain access to the UGT (Nunez-Calonge et al. 
1998; Knox et al. 2003) and it is possible that ureaplasmas and other microorganisms may 
asymptomatically colonise the endometrium at (or prior to) the time of conception.  
 
A recent study found that 10% of all endometrial samples contained Ureaplasma spp. (Cicinelli et al. 
2012). This is in accordance with previous studies that report the isolation of ureaplasmas (and other 
bacteria) from the endometrium of healthy, asymptomatic women (Idriss et al. 1978; Cassell et al. 
1993b). Pathogenic microorganisms have been identified within the endometrium of women 
without any evidence of pelvic infection and with negative cervical cultures (Lucisano et al. 1992), 
and there is a low correlation between microorganisms isolated from the cervix and those found 
within the endometrium, with 67% of endometrial specimens having distinct microbial populations, 
when compared to the corresponding cervical specimen (Cicinelli et al. 2012). It has been suggested 
previously that endometrial infection/colonisation may be present at the time of implantation, and 
that this may explain abnormal placentation (Jones et al. 1998), pre-eclampsia (Viniker 1999), 
adverse pregnancy outcomes (Gibbs et al. 1992) and spontaneous and recurrent abortions 
(Naessens et al. 1987). These studies provide significant evidence that not only is the UGT not sterile, 
but that it contains a unique population of microorganisms that may be suited to this anatomical 
niche. Further studies are required to determine the diversity of microorganisms present within the 
UGT and to follow the outcomes of women who fall pregnant whilst bacteria are present in the UGT, 
in order to determine the effects of these microorganisms during gestation.  
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Figure 2.2. Ascending invasive infections are predicted to be the most common route of in utero infection. 
Bacteria may ascend from the LGT; invade the chorioamnion (maternal/fetal) membranes, gaining access to 
the amniotic fluid and fetus during pregnancy. Image source: Goldenberg et al. (2000). 
 
2.4.2 Microbial mechanisms leading to preterm birth  
 
Infection-associated PTB is most commonly thought to occur from microbial invasion of the UGT, 
specifically the choriodecidual space (maternal/fetal interface). Activation of the host immune 
system at the time of invasion is recognised by pattern-recognition receptors (PRRs), such as the 
Toll-like receptors (TLRs). Activation of host TLRs result in the production of cytokines, such as 
interleukin (IL)-1β, IL-6, IL-8, IL-10 and tumour necrosis factor (TNF)-α. These cytokines and microbial 
toxins initiate prostaglandin synthesis, which in turn initiates contractions of the myometrial and 
cervical muscles, triggering uterine contractions and opening of the cervix in preparation for labour 
(Goldenberg et al. 2000b; Challis et al. 2009). Increased levels of cytokines at the site of microbial 
invasion/infection also result in the recruitment of neutrophils and the expression of matrix 
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metalloproteinases, which attack and weaken the chorioamnion membranes, ultimately leading to 
rupture of membranes (Goldenberg et al. 2000b). The combination of these events results in 
premature labour and preterm delivery of the baby, unless intervention strategies are quickly put in 
place. 
 
2.5 Ureaplasma species: Taxonomy and classification  
 
Ureaplasma species are among the smallest self-replicating microorganisms. These were first 
isolated from urethral exudates in males with primary and recurrent non-gonococcal urethritis 
(Shepard 1954). Due to their close resemblance to Mycoplasma spp. and small colony size (size 
range 5 – 20 µm, compared to 200 – 500 µm of Mycoplasma spp.) (Shepard 1954), they were 
referred to as the T (tiny) strain mycoplasmas. In 1974, Shepard distinguished the T-strain 
mycoplasmas from other Mycoplasma spp. by their unique ability to hydrolyse urea as their major 
(95%) energy source, and so he proposed that these organisms be reclassified into their own genus: 
Ureaplasma (Shepard 1974).  The urease enzyme of ureaplasmas breaks down urea (present within 
urine, the genital tracts of men and women and also within amniotic fluid) to produce ammonia, 
resulting in de novo ATP synthesis (Smith et al. 1993). Production of ammonia is also the 
distinguishing characteristic used for the identification of ureaplasmas in routine diagnostic in vitro 
broth culture (Shepard and Lunceford 1976), the growth of ureaplasmas is confirmed by an alkaline 
shift and pH indicator colour change.  
 
Ureaplasmas belong to the division Tenericutes, within its own class, the Mollicutes (Latin: mollis – 
soft; cutis – skin). The Mollicutes are unique in their cell structure, lacking a peptidoglycan cell wall 
and are surrounded only by a plasma membrane. Ureaplasma spp. are further classified in the order 
Mycoplasmatales and the family Mycoplasmataceae, along with the closely related Mycoplasma 
spp. (Figure 2.3) (Bergey et al. 1994; Krieg 2012). U. urealyticum was initially proposed as a single 
species infecting humans, containing eight antigenically distinct serovars; however, 14 serovars have 
now been identified based on the results of metabolic inhibition tests and epifluorescence assays 
(Robertson and Stemke 1982). These 14 serovars were divided into two distinct biovars, the “parvo” 
biovar (also known as biovar 1 or A; containing serovars 1, 3, 6 and 14) and the “T960T” biovar (also 
known as biovar 2 or B; containing serovars 2, 4, 5, 7 - 13) (Christiansen 1981). However, the 
accumulation of phenotypic and genotypic differences between these biovars, including differences 
in genome size, restriction fragment length polymorphisms (RFLPs), DNA-DNA hybridisation, 16S 
rRNA and 16S-23S rRNA intergenic region differences as well as manganese inhibition patterns and 
clustering of antigenic types prompted the revision of this taxonomy into two distinct species: U. 
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parvum (the “parvo” biovar) and U. urealyticum (the “T960T” biovar), which were formally proposed 
(Robertson et al. 2002). This revised taxonomy of two species and 14 serovars of Ureaplasma spp. 
was formally accepted, however, this taxonomy has not been widely adopted within the literature, 
and often the 14 serovars are still referred to as U. urealyticum. 
  
There are currently seven species of ureaplasmas: U. parvum, U. urealyticum, U. diversum, U. cati, U. 
gallorale, U. felinum and U. canigenitalium (Robertson et al. 2002). Of these, U. parvum and U. 
urealyticum (often referred to as “the ureaplasmas”) infect human hosts and are most closely 
related to the Mycoplasma pneumoniae taxonomic group. Ureaplasma spp. have unique genomes, 
with the highest A+T content of all bacteria (Glass et al. 2000). They have the second smallest 
genome of all free-living prokaryotes (the smallest being M. genitalium) with genomes ranging in 
size from 0.75 Mbp – 1.2 Mbp (Glass et al. 2000). These minimal genomes are thought to have 
evolved from closely related low G+C-content Gram positive bacteria by extensive degenerative 
evolution (Glass et al. 2000) and phylogenetic analysis identified Clostridium spp. (Clostridium 
innocuum and Clostridium ramosum) as the closest relatives of ureaplasmas and mycoplasmas 
(Woese et al. 1980). More recently, studies have revealed that ureaplasmas are also closely related 
to the Bacillus spp., Streptococcus spp. and Lactobacillus spp.; and of these the Lactobacillus spp. 
and Streptococcus spp. are the closest relatives of ureaplasmas, based on phosphoglycerate kinase 
sequencing (Wolf et al. 2004). It is also very interesting to note that several key genes found in all 
other bacteria are absent in Ureaplasma spp. The genes encoding the heat shock proteins GroEL and 
GroES that mediate protein folding are found in all sequenced microbial genomes, with the 
exception of Ureaplasma spp. (Glass et al. 2000). Perhaps the most interesting absence within the 
ureaplasma genome is the gene which encodes the cell division protein FtsZ (Glass et al. 2000). This 
protein forms the “Z-ring” that constricts between two dividing cells during replication and is 
thought to be essential in the binary fission of free-living bacteria. However, Ureaplasma spp., 
Chlamydiae and Aeropyrum pernix are the only bacteria that do not contain this protein. Given this, 
the genetic mechanisms by which ureaplasma cells divide currently remain unknown.  
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Figure 2.3. Phylogenetic relatedness of Ureaplasma spp., along with other Mollicutes 
including Mycoplasma spp., Acholeplasma spp., Anaeroplasma spp. and Spiroplasma spp. 
and Firmicutes including Escherichia coli. 16S rRNA direct solid-phase DNA sequencing was 
employed on well-characterised variable regions of the 16S rRNA gene. In this figure, U. 
urealyticum is representative of all 14 serovar belonging to U. parvum and U. urealyticum 
and is most closely related to Mycoplasma pneumoniae. Image from (Pettersson et al. 1994) 
  
2.6 Ureaplasma species: Association with disease 
 
 2.6.1 LGT colonisation 
 
  2.6.1.1 LGT colonisation of females  
 
Ureaplasma spp. are considered to be normal flora of the urogenital mucosal epithelia and are 
found in 40 – 80% of females of reproductive age (Cassell et al. 1993b). Ureaplasma spp. 
colonisation of the genital tract has been associated with a number of factors, including: age (most 
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frequently in 14 - 25 year age group and carriage declines with increasing age) (Tibaldi et al. 2009; 
Ruzman et al. 2013), ethnicity (particularly African American and Indigenous women) (McCormack et 
al. 1986; Knox et al. 1997; Tibaldi et al. 2009), level of education (Tibaldi et al. 2009), the number of 
recent sexual partners (McCormack et al. 1986; Knox et al. 1997; Nelson et al. 2007; Ruzman et al. 
2013), age at first sexual intercourse (≤ 16 yrs) (Knox et al. 1997; Ruzman et al. 2013) as well as the 
use of non-barrier contraceptives (Knox et al. 1997) and IUDs (Tibaldi et al. 2009). Due to their high 
prevalence, ureaplasmas are considered to be of low virulence in the female LGT and are often 
referred to as asymptomatic colonisers (Volgmann et al. 2005). Studies have demonstrated that 
there were no significant differences in the isolation rates of Ureaplasma spp. from endocervical, 
vaginal or urethral swabs collected from women of reproductive age with or without symptoms of 
infection (and irrespective of pregnancy status) (Casari et al. 2010; Hunjak et al. 2013). By contrast, 
others have reported ureaplasmas as a potential source of genital tract infection, including urinary 
tract infections, bacterial vaginosis and vaginitis (Tibaldi et al. 2009; Patel and Nyirjesy 2010).  
 
The presence of Ureaplasma spp. in the female LGT has also been proposed as a risk factor for 
adverse outcomes including chorioamnionitis, low Apgar scores at birth (infants are scored at 1 and 
5 minutes after birth with respect to appearance, pulse rate, reflexes, activity and respiratory effort), 
admission of the infant to the NICU and preterm birth (Abele-Horn et al. 2000; Kwak et al. 2014). 
However, the majority of studies in pregnant women have demonstrated that Ureaplasma spp. 
colonisation of the LGT is not significantly associated with adverse pregnancy outcomes (Donders et 
al. 2009; Lee et al. 2009). A recent study conducted by Anderson et al. (2013) studied a population of 
47 pregnant and 16 non-pregnant women and obtained vaginal swabs on four occasions during 
routine clinical visits at gestations of: < 14 wks, 14 – 28 wks, > 28 wks and 4 – 6 wks postpartum. 
Non-pregnant women were also screened at 12 week intervals. Ureaplasma spp. was prevalent in 
vaginal swabs from pregnant women (> 60% in all visits during pregnancy), particularly within the 
first and second trimesters. However, there were no significant associations between the gestational 
age at delivery (mean: 39 wks; range: 33 – 41 weeks), birth weight (mean: 3255 g; range: 2070 – 
4640 g) or any adverse maternal or neonatal outcomes of those women colonised with Ureaplasma 
spp. (Anderson et al. 2013). Conversely, Breugelmans et al. identified Ureaplasma spp. as a risk 
factor for preterm delivery and 52/97 (53.6%) of women who had positive cervical cultures for 
Ureaplasma spp. delivered preterm (p = 0.02). However, they failed to comment on the fact that 
ureaplasmas were also isolated from the LGT of 783/1981 (41.4%) women who delivered at term 
(Breugelmans et al. 2010). Overwhelmingly, these studies indicate that Ureaplasma spp. are part of 
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the normal vaginal microflora of both pregnant and non-pregnant women and are LGT colonisation 
with ureaplasmas is not a significant predictor of preterm delivery.   
2.6.1.2 LGT colonisation of males 
 
Ureaplasma spp. are also considered to be asymptomatic colonisers of the male urogenital tract and 
can be found in up to 50% of urethral specimens (Cassell et al. 1993b; Volgmann et al. 2005; 
Nakashima et al. 2014). Ureaplasma spp. in the male LGT are often associated with non-gonococcal 
urethritis (Yoshida et al. 2005; Shimada et al. 2014), epididymitis (Zeighami et al. 2009) and chronic 
prostatitis (Skerk et al. 2002), though their role in these disease states are often controversial. 
Ureaplasmas have also been isolated in seminal fluid from both fertile and infertile men and have 
been associated with male infertility and adverse fertility parameters. The prevalence of Ureaplasma 
spp. in the sperm of infertile men varies from 10 – 40% (Keck et al. 1998) and has been correlated 
with: alterations in sperm motility (both increases/decreases) (Nunez-Calonge et al. 1998; Knox et al. 
2003; Liu et al. 2014), changes in sperm pH (Wang et al. 2005), altered sperm membrane 
morphology (Nunez-Calonge et al. 1998), reduced sperm concentration and viscosity (Wang et al. 
2006), decreased or abolished acrosomal reaction (impairing sperm penetration ability and 
increasing apoptosis of sperm) (Kohn et al. 1998) and membrane lipid peroxidation and oxidative 
stress in sperm (Fraczek et al. 2007). A study conducted by Shi et al. (2007) demonstrated cross-
reactivity between antigens belonging to Ureaplasma spp. and human sperm membrane proteins 
(hSMP). They identified anti-ureaplasma antibodies in the semen of infertile men with ureaplasma 
infections and these antibodies also reacted with hSMP. Immunofluorescent analysis showed 
specific reactivity at the posterior sperm head, the area where sperm-egg binding occurs. The 
authors suggested that this may be a mechanism by which ureaplasma-related infertility blocks or 
inhibits sperm-egg binding. The authors then explored this further by pre-incubating murine 
spermatozoa with antibodies generated against Ureaplasma spp. prior to in vitro fertilisation with 
murine ova. No significant impairment of sperm motility was seen, however, there was significant 
inhibition of sperm-egg binding in the group pre-incubated with the cross-reactive Ureaplasma spp. 
antibodies. This inhibition of binding was abolished when the antibodies were diluted to a lower 
level. A similar result was seen when female mice were pre-immunised with these cross-reactive 
antibodies, with more than 75% of female mice becoming sterile (Shi et al. 2007). These results 
suggest that not only are spermatozoa affected by these cross-reactive antibodies, but that the 
presence of cross-reactive antibodies in female mice may also be a cause of infertility. Furthermore, 
the presence of Ureaplasma spp. has also been correlated with molecular changes to spermatozoa, 
including premature chromatic decondensation (which compromises DNA integrity), mitotic 
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alterations and chromatid breaks and gaps (Wang et al. 2010). DNA damage may affect the ability of 
sperm to fertilise oocytes and can have a damaging effect on embryogenesis. This may have severe 
implications for infertility, abortion and overall reproductive health and so further studies are 
required to elucidate the role of Ureaplasma spp. in sperm function, DNA damage and infertility. 
2.7 In utero ureaplasma infection is associated with adverse neonatal 
outcomes 
 
Ureaplasmas may be acquired by the fetus in utero or during delivery and this can result in severe 
adverse neonatal outcomes. A recent study by Hahn et al. (2014) determined the rate of vertical 
transmission of microorganisms during delivery. Of the 455 women tested, 64 (14.1%) were found to 
have sexually transmitted infections (STIs) cultured/detected from the LGT. For 17.2% of these 
women, microorganisms were transmitted vertically from the mother to the neonate. The human 
Ureaplasma spp. were found to be the most frequently identified microorganisms isolated from the 
LGT of mothers (n = 36; 50%) and also from the oral secretions of the neonate immediately following 
delivery (8/11%; 72.2%).  
 
During development in utero, the fetus swallows and inhales amniotic fluid as part of normal fetal 
development, preparing fetal organs for their ex utero roles (such as swallowing and breathing). If 
this amniotic fluid is infected, this allows microorganisms, including ureaplasmas, to directly access 
the fetal lung and gut. Ureaplasmas have been isolated from the fetal lung following delivery and are 
associated with respiratory disorders including pneumonia (Cassell et al. 1993b), RDS, (Castro-
Alcaraz et al. 2002; Kotecha et al. 2004; Cultrera et al. 2006) and bronchopulmonary dysplasia (BPD) 
(Benstein et al. 2003; Viscardi et al. 2006; Schelonka and Waites 2007; Sung 2010). Systemic 
infections were also observed in a sheep model study by Knox et al. (2010), in which Ureaplasma 
spp. injected intraamniotically were detected in numerous fetal body sites, including the GIT, liver, 
kidney, lung and cerebrospinal fluid post-delivery.  
 
RDS is an acute dysfunction of the lung, where there is insufficient surfactant (liquid that aids gas 
exchange) (Hallman et al. 1991), while BPD is a more severe respiratory disease in which alveolar 
development is arrested, resulting in fewer but larger alveoli (Jobe and Bancalari 2001). Both disease 
states are strongly associated with inflammation, resulting from in utero exposure to ureaplasmas 
(or other microorganisms) and chorioamnionitis or funisitis. The relationship between ureaplasmas 
and BPD was first proposed in 1988, with several studies identifying a causative agent of BPD in low 
birth weight infants as Ureaplasma spp.(Cassell et al. 1988; Sanchez and Regan 1988; Wang et al. 
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1988). Since these reports, there has been an increasing body of evidence for the involvement of 
Ureaplasma spp. in BPD.  
 
Studies utilising animal models of ureaplasma infection and the impact on fetal lung development 
have been used extensively. In non-human primate animal models, intraamniotic injection of 
Ureaplasma spp. resulted in fetal pneumonia, alveolar type II cell proliferation and lung injury (Novy 
et al. 2009). Pregnant baboons were exposed to Ureaplasma spp. in utero for 2 days and their 
fetuses subsequently demonstrated either (i) clearance of the infection and had normal lung 
function at birth; or (ii) were colonised persistently in the fetal lung with Ureaplasma spp. with 
inflammation and poor lung function was demonstrated at the time of delivery (Yoder et al. 2003). 
Similarly in a sheep model of intraamniotic Ureaplasma spp. infection, it has been shown that both 
acute and chronic durations of exposure to ureaplasmas have been associated with fetal lung 
inflammation and increased cytokine (IL-1β, IL-8 mRNA) expression, altered elastin and α-smooth 
muscle actin deposition, increased surfactant production and improved lung gas volumes at the time 
of birth (Collins et al. 2010).  
 
Prematurely born babies exposed to Ureaplasma spp. in utero also have demonstrated signs of lung 
fibrosis, elastic fibre accumulation and increased levels of TNF-α and transforming growth factor 
(TGF)-β within their lungs at the time of autopsy (Viscardi et al. 2002; Viscardi 2010). Once 
ureaplasmas have access to the fetal lung, they are able to disseminate to distant anatomical sites 
and have been isolated in 23% of umbilical cord blood cultures in preterm neonates (Goldenberg et 
al. 2008a). Ureaplasma spp. are also the most frequently isolated microorganism from the 
cerebrospinal fluid (CSF) of neonates and are a causative agent of sepsis (Waites et al. 1989; Cassell 
et al. 1993b), meningitis (Garland and Murton 1987; Stahelin-Massik et al. 1994; Biran et al. 2010), 
brain lesions (Olomu et al. 2009) and intraventricular haemorrhage (Viscardi et al. 2008). In severe 
cases of infection, ureaplasmas are also a cause of fetal and neonatal death. The Ureaplasma spp. 
are associated with severe, potentially life-threatening neonatal infections and warrant further 
investigation. By first understanding the pathogenesis of fetal infections, more effective treatments 
may be developed in order to avoid severe infection or potential long-term morbidity.   
 
Ureaplasmas are able to gain direct access to the fetal gut when the fetus swallows infected 
amniotic fluid. A recent study by Wolfs et al. (2013) utilised an ovine model of ureaplasma infection; 
ewes were intraamniotically injected with ureaplasmas and fetal gut was collected after surgical 
delivery of the fetus at 3, 7 or 14 days post-infection. Inflammatory responses were detected within 
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the neonatal gut of all animals exposed to ureaplasmas. Within 7 days of infection, there was 
significant damage to the villus epithelium, deterioration of the gut barrier and enterocyte 
proliferation, differentiation and maturation were significantly reduced. By 14 days of infection, 
severe villus atrophy was evident in animals exposed to ureaplasma infection. When animals 
infected with ureaplasmas were also given recombinant human IL-1 receptor agonist, these 
outcomes were largely prevented (Wolfs et al. 2013). These results are very important, and are the 
first to discuss the outcomes of the fetal gut following exposure to ureaplasmas. It is unknown what 
effect ureaplasmas may have on the human fetal gut, particularly as in utero infection with 
Ureaplasma spp. may be chronic (Cassell et al. 1993b) (much longer than the exposure times utilised 
in this study). Further studies focused on the fetal and infant gut would be of great interest to 
determine if exposure to ureaplasmas in utero adversely affects the fetus/infant.  
 
2.8 Long-term sequelae of in utero ureaplasma infections 
 
The developmental origin of health and disease (DOHaD) paradigm was initially proposed 25 years 
ago and evolved from epidemiological studies correlating rates of infant mortality and birth weight 
with certain types of diseases in these same infants later in life. Hales and Barker (1992) stated that 
“environmental factors during a phase of developmental plasticity (in utero development) interact 
with genotypic variation to change the capacity of the organism (fetus) to cope with its environment 
in later life”. He further illustrated the severe consequences of this paradigm by identifying 
significant associations between chronic diseases in adulthood (e.g. heart disease, metabolic 
syndrome) and deficiencies and/or insults to the fetus during in utero development (Hales and 
Barker 1992; Hales and Barker 2001; Benyshek and Watson 2006). Whilst some studies have 
identified links between some microorganisms and long-term sequelae (Ternhag et al. 2008; 
Puntener et al. 2012), currently no studies have reported the long-term outcomes of infants exposed 
in utero to ureaplasmas. This is due to a lack of follow-up studies beyond the neonatal period and 
the difficulties in identifying a causative agent and the associated sequelae, particularly when the 
origin may be multifactorial.  
 
Studies have identified that Ureaplasma spp. intrauterine inflammation was associated with 
elevated IL-6 and IL-8 levels, a potential risk factor for cerebral palsy (Yoon et al. 1997). Further 
studies (Berger et al. 2009) confirmed that the presence of Ureaplasma spp. in utero  was associated 
with adverse neuromotor outcomes for two year-old children, compared to children who were not 
exposed to ureaplasmas in utero. Normann et al. (2009) examined the murine fetal brain after in 
utero exposure to Ureaplasma spp. Pups exposed to ureaplasmas showed decreased neuron density 
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and impaired production/maturation of interneurons, which are key to healthy cognitive function. In 
utero exposure to ureaplasmas was also correlated with abnormal myelination. This is the first 
report of Ureaplasma spp. altering brain development in an animal model of infection. A 
combination of animal model experiments and studies of neonates will further elucidate the role of 
Ureaplasma spp. in adverse neurodevelopmental outcomes.  
 
Studies have also linked Ureaplasma spp. in the upper respiratory tract with respiratory symptoms 
over the first three years of life. Kundsin et al. (1996) recruited children (n = 88) between 2 months 
and 3 years of age who presented with respiratory symptoms. Throat swabs were collected for each 
patient and were screened for the presence of Ureaplasma spp. and Mycoplasma hominis. Overall, 
29/88 (33%) of children within the study were positive for the presence of Ureaplasma spp. and 
colonisation was highest within the 0-12 month (25%) group and the 1- 2 year (43%) group. 
Significantly, the presence of Ureaplasma spp. was associated with a much higher incidence of 
wheezing of the infants (mean: 14 days; p < 0.01), compared to those infants with respiratory 
symptoms who were not colonised with Ureaplasma spp. (3 days) and the control group (0 days).  
The authors also noted no significant differences between infants with respiratory symptoms who 
were born prematurely and those born at term, which suggests that colonisation of infants occurs 
independently of gestational age and is associated with adverse respiratory outcomes (Kundsin et al. 
1996). 
 
A larger study of almost 3000 infants and their mothers identified a higher risk of wheezing in infants 
less than 3 years of age and the presence of Ureaplasma spp. (odds ratio: 2.0). The authors 
suggested that colonisation with ureaplasmas, acquired at or before birth, may cause reactive 
airway disease. Furthermore, the authors also suggested that the acquisition of certain 
microorganisms, such as Ureaplasma spp. contributes to the establishment of infant microflora and 
the subsequent development of allergies and wheezing (Benn et al. 2002). While these studies show 
significant associations between Ureaplasma spp. and the wheezing respiratory phenotype, it is 
unclear if Ureaplasma spp. also contribute to other long-term adverse respiratory diseases, such as 
asthma.  
 
2.9 Ureaplasmas as a controversial pathogen 
  
Although Ureaplasma spp. have been isolated most frequently from women who deliver preterm, 
the role of ureaplasmas in adverse pregnancy outcomes is complicated as not all pregnant women 
who are infected/colonised with Ureaplasma spp. in the UGT deliver preterm or experience adverse 
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pregnancy outcomes. Gerber et al. (2003) tested amniotic fluid from 254 asymptomatic pregnant 
women at 15 – 17 weeks of gestation by PCR and detected Ureaplasma spp. in 29/254 (11.4%) of 
subjects. Significantly, 24% of women with intra-amniotic Ureaplasma spp. infection delivered 
preterm with or without signs of P-PROM, compared to 4.4% of women without Ureaplasma spp. 
infection (p < 0.0001). However, 76% of women identified as having Ureaplasma spp. in utero 
delivered at term with no apparent adverse outcomes. Women who were infected with ureaplasmas 
and delivered preterm also had a higher rate of preterm labour in previous pregnancies (consistent 
with the proposal that Ureaplasma spp. may be present as colonisers or as an asymptomatic 
infection in the endometrium prior to conception), this study failed to comment on the large 
proportion of women who did not experience any adverse outcomes and delivered at term (Gerber 
et al. 2003).  
 
To explain the discrepancies in these studies, researchers have suggested that there may be more 
“virulent” serovars of Ureaplasma spp.; however, there is little evidence that particular ureaplasma 
serovars are more virulent than others. Studies have reported that (i) U. urealyticum serovar 4 was 
associated with recurrent abortion (Quinn et al. 1983; Naessens et al. 1988) (ii) U. parvum serovars 3 
and 14 were significantly associated with the absence of Lactobacillus spp. and genital tract 
symptoms including vaginal/cervical discharge or pain during urination (De Francesco et al. 2009) (iii) 
U. parvum serovars 3 and 6 were most frequently isolated from women who delivered preterm in an 
Australian population (Knox and Timms 1998); and (iv) U. parvum serovar 6 was the most adherent 
serovar to the surface of spermatozoa, following standard ART washing procedures (Knox et al. 
2003). Zheng et al. (1992) tested ureaplasma isolates from the CSF of neonates and identified that U. 
parvum serovars 1, 3 & 6 and U. urealyticum serovar 8 & 10 were capable of causing systemic 
infections (Zheng et al. 1992). These results suggest that there is no single “virulent” Ureaplasma 
species or serovar, and that the serovars isolated in these studies may simply be the most prevalent 
microorganisms within the population studied.  
 
It has been suggested that instead of “virulent” serovars, there may be other 
virulence/pathogenicity mechanisms by which microorganisms can affect the host immune response 
and the outcomes of those infected with Ureaplasma spp.  
 
2.10 Ureaplasma virulence factors 
 
Whilst Ureaplasma spp. are normal regional flora of the human LGT and are considered to be of low 
virulence, the Ureaplasma spp. have been implicated in adverse pregnancy outcomes (as described 
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in section 2.6) and specific virulence factors which enable ureaplasmas to contribute to disease have 
been investigated. There are five proposed proteins that have been investigated as virulence factors 
of Ureaplasma spp.: the multiple banded antigen (MBA), urease, immunoglobulin (Ig) A protease, 
phospholipase A and phospholipase C proteins (Robertson et al. 1984; De Silva and Quinn 1986; 
Teng et al. 1994; DeSilva and Quinn 1999; Glass et al. 2000).  
 2.10.1 The MBA 
 
The MBA is the major antigen recognised by the host immune system in response to ureaplasma 
infections (Shimizu et al. 2008). This major antigen was first detected by Watson et al. (1990) by sera 
from patients who were infected with ureaplasmas. These patients’ sera recognised a predominant 
71 kDa ureaplasmal protein and subsequent monoclonal antibodies identified less intensely stained 
MBA bands of varying molecular weights, which formed a laddering (multiple banded) pattern 
(Watson et al. 1990).  
 
Zheng et al. (1995) cloned and sequenced the gene, which encodes the U. parvum serovar 3 MBA 
protein. This gene was found to contain a single large open reading frame of 1230 bp, encoding a 
409 amino acid protein. The N-terminal region of the protein consisted of a typical prokaryotic signal 
peptide and a membrane lipoprotein attachment site (transmembrane domain). Following the 
transmembrane domain, a C-terminal hydrophilic (surface-exposed) gene region was identified and 
was found to contain tandem repeating units, which were unique to each Ureaplasma spp. serovar 
(Zheng et al. 1995). Glass et al. (2000) demonstrated that the mba gene had no homology to any 
other known gene and was unique to Ureaplasma spp. (Glass et al. 2000). Shimizu et al. (2008) 
further confirmed that the MBA is a lipoprotein, due to its ability to be isolated in the detergent 
phase of Triton X-144 partitioning, and confirmed the antigenicity of the MBA, with this major 
antigen activating nuclear factor (NF)-kB and the production of TNF-α via TLRs 1, 2 and 6.    
 
The first studies to characterise variation in the size of the MBA protein/gene used polymerase chain 
reaction (PCR) to demonstrate that the differences in MBA size correlated with differences in the 
number of tandem repeating units (Zheng et al. 1994). Antigenic size variation has been reported in 
other Mycoplasma spp. and is predicted to modulate the interaction between bacteria and host cells 
(Citti et al. 2010). Knox et al. (2010) demonstrated ureaplasma MBA size variation following 69 days 
of (chronic) intraamniotic ureaplasma infections within an established ovine model. A non-clonal U. 
parvum serovar 6 clinical isolate (with a single MBA antigen) was injected into the amniotic fluid and 
after delivery the number of MBA size variants within the amniotic fluid was assessed. When the 
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amniotic fluid of these pregnant ewes contained less than 5 MBA size variants, severe histological 
chorioamnionitis was seen within chorioamnion tissues. However, when amniotic fluid was found to 
contain nine or more MBA size variants, there was little or no evidence of histological 
chorioamnionitis within the chorioamnion of the ureaplasma-infected ewes. Based on these 
findings, it was suggested that the size variation of the ureaplasma MBA may be a mechanism by 
which Ureaplasma spp. can evade host immune recognition, allowing chronic infections to develop.  
 
Robinson et al. (2013) further confirmed the ability of clinical ureaplasma isolates to vary in size. A 
non-clonal U. parvum serovar 3 clinical isolate was injected into the amniotic fluid of pregnant ewes 
(n = 32) and the fetuses were then delivered surgically after acute (3 or 7 days) or chronic (69 day) 
infections. Harvested amniotic fluid was tested for the presence of MBA size variants by PCR and 
western blot. Amniotic fluid infected with ureaplasmas for 3 or 7 days showed minimal evidence of 
MBA variation (when compared to the original strain injected), whilst amniotic fluid infected with 
ureaplasmas for 69 days showed significant MBA size variation (Robinson et al. 2013).  
 
Dando et al. (2012) utilised Ureaplasma spp. isolated from the amniotic fluid of sheep infected in 
previous experiments (originally published in Knox et al. 2010). Two ureaplasma cultures were 
cloned and filtered to obtain two populations each derived from a single colony-forming unit (CFU). 
These two inocula were then injected into the amniotic fluid of cohorts of pregnant ewes. Amniotic 
fluid specimens were collected every two weeks of gestation and antigenic size variation was 
observed throughout gestation. Significantly, this is the first study to identify MBA size variations 
over the course of gestation. It was determined that there was an inverse correlation between the 
number of Ureaplasma spp. CFU/mL within amniotic fluid and the numbers of MBA size variants; the 
greater the number of MBA size variants within amniotic fluid, the fewer the numbers of ureaplasma 
(CFU/mL) present within the amniotic fluid. This suggests that the variation of the MBA is an 
important mechanism to maintain diversity within their population in vivo (Dando et al. 2012). It is 
proposed that the production of MBA size variants in vivo results in an inability of the host to 
accurately respond to the many antigens (MBA variants) present, and this may facilitate 
establishment of chronic infections. The ability of ureaplasmas to vary their surface-exposed MBA is 
a major virulence factor and requires further studies to fully elucidate the role of MBA variation and 
the host immune responses but as yet MBA variation in ureaplasmas from human infection has not 
been studied.  
 
 30 
 
The ureaplasma MBA is also able to undergo phase variation, which involves the “switching on/off” 
of the MBA in vitro. This alternating expression of surface-exposed proteins is also proposed to be an 
important microbial strategy for host adaptation and evasion of the immune response, in order to 
maintain diversity and a propagating population (Monecke et al. 2003; Zimmerman et al. 2011; 
Dando et al. 2012). Phase variation has been demonstrated previously in other Mycoplasmatales 
(Citti et al. 2010), such as the variable surface antigen (vsa) of Mycoplasma pulmonis (Bhugra and 
Dybvig 1992; Bhugra et al. 1995) and the variable protein of Mycoplasma agalactiae (vpma) (Glew et 
al. 2000; Glew et al. 2002; Chopra-Dewasthaly et al. 2008). Monecke et al. (2003) and Dando et al. 
(2012) showed the MBA protein was able to be “switched off” by serially passaging ureaplasmas in 
broth containing polyclonal antibodies specific to ureaplasmas. The absence of the MBA was shown 
by western blot and variation in the length of the mba gene was demonstrated by PCR. “Switching 
off” of the MBA was shown to be reversible and this mechanism may be used by ureaplasmas to 
evade the host immune response in vivo.  
 
Zimmerman et al. (2009) further investigated phase variation of the MBA by analysing the MBA 
locus. They identified the UU376 gene, a Ureaplasma spp.-specific conserved hypothetical gene, 
encoding a ureaplasmal protein. Expression of the MBA and UU376 was assessed by serially 
passaging ureaplasmas in the presence of polyclonal antibodies generated against the MBA or 
UU376. The alternate expression of the MBA and UU376 was associated with a DNA inversion event 
between the non-repetitive region and an intergenic region between the MBA and a region 
downstream of UU376. It was proposed that these DNA inversion events serve as a mechanism by 
which Ureaplasma spp. express their MBA protein or “switch off” the expression of this protein 
(Zimmerman et al. 2009).  
 
These same researchers provided further evidence of DNA inversion events between the ureaplasma 
genes UU171, UU172 and UU144. Using polyclonal antibodies, they again used selective pressures to 
mediate alternate expression of these genes, and found that the open reading frames associated 
with these genes were not expressed alone, but were only expressed in conjunction with the N-
terminal sequence of UU172. Phase variation was previously suggested to occur as a result of 
slipped-strand mispairing (Rocha and Blanchard 2002); however, Zimmerman et al. provided 
evidence that phase variation occurred between two inverted repeat regions – one of which is 
located in the ORF of UU172 and another in the intergenic region between UU171 and UU172  
(Zimmerman et al. 2011). As yet the mechanisms by which these organisms alter their surface-
exposed proteins have not been characterised nor is it known if these events occur in vivo. Further 
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investigation is required to elucidate the mechanisms, which govern surface antigen variation and 
the effect this has on infections within the host.  
 
Recently, Paralanov et al. (2012) sequenced the genomes of 19 ureaplasma clinical isolates and 
compared these to American Type Culture Collection (ATCC) strains. The major finding of this study 
was that the mba gene is part of a large and complex superfamily, comprising more than 180 genes. 
This study confirmed that each serovar/isolate contained an mba gene that consisted of a conserved 
upstream portion, attached to downstream unique tandem repeating units. Significantly, this study 
also identified that the majority of ureaplasma ATCC strains and clinical isolates contained additional 
tandem repeating unit sequences that were not attached to the mba gene. These extra tandem 
repeating units were found in other locations within the genome and were surrounded by putative 
recombination sites, which suggest that these tandem repeating units may also be part of a phase-
variable system. Experimental evidence is required to substantiate these claims, in order to observe 
the attachment of these additional tandem repeating unit sequences to the upstream conserved 
portion of the mba gene. It would be of great interest to investigate the potential phase variation of 
these tandem repeating units, as some may be immunogenic and contribute to the differential 
pathogenicity of ureaplasma clinical isolates/strains (Paralanov et al. 2012). These mechanisms of 
MBA gene expression and antigenicity are crucial in our understanding of why only a small 
proportion of patients with Ureaplasma spp. develop clinical symptoms whilst others remain 
asymptomatic. This is particularly pertinent to our current understanding of chronic asymptomatic 
ureaplasma intrauterine infections. 
 
2.10.2 Urease 
 
The ability of Ureaplasma spp. to hydrolyse urea was first identified in 1966, and the production of 
adenosine triphosphate (ATP) via this mechanism appears to be unique within ureaplasmas (Purcell 
1966; Shepard 1966; Ford 1967; Shepard 1967). The urease enzyme of ureaplasmas is 30 – 180-fold 
more efficient than those reported for any other bacterial urease (Mobley et al. 1995) and the 
hydrolysis of urea creates an electrochemical gradient due to intracellular ammonia accumulation 
(with ureaplasmas having extremely high intracellular ammonia levels, measured at 21 times the 
extracellular concentration) (Smith et al. 1993). This gradient creates a chemiosmotic potential, by 
which Ureaplasma spp. are able to generate 95% of their ATP (Smith et al. 1993).  
 
Urease enzyme activity is another key virulence factor of ureolytic bacteria, as the production of 
ammonia has been shown to be lethal following intravenous injection of bacterial ureases in a 
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murine animal model (Takebe et al. 1984). Urinary tract ureaplasma infection was found to be 
associated with urinary stone formation, which was attenuated when urease inhibitors were added 
(Takebe et al. 1984). Whilst the urease enzyme complex of ureaplasmas comprises a major portion 
of the cytoplasm, due to its location, it is unlikely to be involved in immune stimulation or 
inflammatory responses. However, a recent publication within our group identified that chronic (69 
day) in utero infection with Ureaplasma spp. resulted in a significant increase in amniotic fluid and 
fetal lung pH in an ovine model of intra-amniotic ureaplasma infection. The increased pH was most 
likely due to the accumulation of ammonia within the amniotic fluid, which has a high concentration 
of urea and the urea concentration increases during gestation. This study also identified that the 
increased pH within the fetal lung was associated with lung damage, even in the absence of 
inflammatory responses (Robinson et al. 2013). Whilst this study provides the first evidence of 
increased pH in vivo due to ureaplasma infection, it remains unclear what the long-term effect of 
exposure to this alkaline environment may have on other fetal outcomes. 
 
There are seven genes, which encode the ureaplasma urease enzyme and they are clustered 
together in a similar conformation to other ureolytic bacteria, such as Proteus mirabilis and 
Escherichia coli. Urease (Ure) A, UreB and UreC encode the structural subunits of the urease enzyme, 
whilst UreE, UreF, UreG and the truncated UreD encode for urease accessory proteins, involved in 
the synthesis of the nickel metallo-centre. Despite the high urease enzyme efficiency, it is interesting 
to note that ureaplasmas encode a urease enzyme but they do not assimilate ammonia into 
glutamate or glutamine (Williams and Wernegreen 2010).  
 
2.10.3 IgA Protease 
 
Immunoglobulin A (IgA) protease activity has been reported as one of the major contributing factors 
to ureaplasma pathogenesis (Kilian et al. 1984). A primary defence of the human immune system is 
the secretion of IgA antibodies at the surface of the mucosa and the cleavage of IgA may enable 
ureaplasmas to invade the upper genital tract (particularly during pregnancy), causing adverse 
outcomes. IgA protease activity was first documented in ureaplasmas in 1984  (Robertson et al. 
1984) and was confirmed experimentally by Kilian and Freundt (1984) colleagues who showed the 
specific cleavage of IgA1, resulted in intact Fab and Fc fragments. All 14 serovars of Ureaplasma spp. 
have been shown experimentally to possess IgA1 protease activity (IgA1 present in serum and vaginal 
secretions); however, they do not possess any proteolytic activity against IgA2 (present in vaginal 
secretions but not in serum), IgM or IgG antibodies (Kilian et al. 1984). Studies conducted by 
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Spooner et al. (1992) identified that the IgA protease of ureaplasmas (a serine protease) cleaved 
human IgA specifically between proline and threonine residues within the hinge of the heavy chain.  
Despite experimental evidence of IgA protease activity, sequencing of the entire U. parvum serovar 3 
genome failed to identify the genes homologous to those in other urease producing bacteria that 
encode IgA proteases within ureaplasmas (Glass et al. 2000). Furthermore, genomes of the 14 ATCC 
strains along with Ureaplasma spp., along with 19 clinical isolates were compared and again there 
was no evidence of an IgA protease gene(s) within any of the isolates tested (Paralanov et al. 2012). 
Based on experimental evidence and the lack of computational gene evidence for an IgA protease, it 
has been suggested that the genes encoding this protease have evolved so significantly that it is no 
longer recognisable (when compared to orthologues in other prokaryotes) or that ureaplasmas 
possess a unique IgA protease with no sequence similarity to other bacteria. However, further 
evidence is required to confirm IgA protease activity and to identify the genes involved in its 
proteolytic activity, as this is likely to be a key virulence factor of Ureaplasma spp.  
 
2.10.4 Phospholipase A and C  
 
Phospholipases are a group of enzymes that hydrolyse phospholipids, producing fatty acids and 
other lipophilic substances (Istivan and Coloe 2006). Phospholipases have long been recognised as 
virulence factors in a range of microorganisms (Schmiel and Miller 1999), including Legionella 
pneumophila (Dowling et al. 1992), Listeria monocytogenes (Rouquette and Berche 1996), 
Staphylococcus aureus (Nygren et al. 1966) and Pseudomonas aeruginosa (Pollack 1984). The 
pathogenesis of phospholipases result from the production of membrane-destabilising compounds 
or the widespread degradation of the host cell membrane phospholipids (Istivan and Coloe 2006). 
There are four major types of phospholipases: A (divided into A1 and A2), B, C and D. Phospholipase 
A1 and A2 are responsible for the cleavage of sn-1 and sn-2 acyl chains of fatty acids, respectively. 
Cleavage of the sn-2 acyl chain releases arachidonic acid. Phospholipase C cleaves the 
phosphodiester bonds, resulting in the production of 1,2-diglyceride and phosphorylesters 
(Vasudevan 2011). Phospholipase activity has been identified in Ureaplasma spp. previously by De 
Silva and Quinn (1986). Endogenous phospholipase activity was demonstrated in vitro in ureaplasma 
serovars 3, 4 and 8, which were active over a wide pH range (5 – 9; the pH growth range of 
Ureaplasma spp.), and phospholipase activity of A1 and A2 differed from that documented in other 
bacteria. The unique activity of these ureaplasma phospholipases was significantly higher during the 
exponential growth phase compared to stationery phase growth, suggesting that these 
phospholipases are membrane-bound. The authors also demonstrated that U. urealyticum serovar 8 
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had a three-fold higher phospholipase A2 activity than serovars 3 and 4. Phospholipase A2 cleaves sn-
2 acyl chain, producing free arachidonic acid, an important intermediate in inflammation and the 
synthesis of prostaglandins. Prostaglandins play a key role in pregnancy, with prostaglandin levels 
naturally increasing at the onset of childbirth (Pawelec et al. 2013). Prostaglandins trigger uterine 
contractility and high levels of prostaglandins prior to the normal onset of labour may result in 
premature uterine contractions and preterm delivery of the fetus (Goldenberg et al. 2000b). Due to 
the large differences in phospholipase A2 activity in the different ureaplasma serovars tested, the 
authors suggested that these differences may account for virulence of particular serovars and the 
differences between the serovar may be of physiological importance due to their interactions with 
host tissues (De Silva and Quinn 1986). However, despite these previous findings, whole genome 
sequencing of Ureaplasma parvum serovar 3 showed no evidence of genes encoding the 
phospholipase A1, A2 or C enzymes (Glass et al. 2000). Further genome analysis of a range of 
Ureaplasma spp. ATCC serovars and clinical isolates again showed no significant evidence of 
phospholipase A1, A2 or C genes (Paralanov et al. 2012). The experiments of De Silva and Quinn 
were repeated in conjunction with a commercial kit to detect phospholipase C activity. However, no 
phospholipase activity at either the stationery or exponential phases of ureaplasma growth was 
detected and so it was suggested that ureaplasmas do not possess a phospholipase C enzyme. 
However, a gene containing significant similarities to phospholipase D enzyme was identified in all 
Ureaplasma spp. ATCC strains and in all clinical isolates tested (Paralanov et al. 2012). Further 
functional characterisation and determination of phospholipase D activity would be of great interest 
to further our understanding of this ureaplasma virulence mechanism.  
 
2.11 Host immune response to ureaplasma infections  
 
Immunologically, pregnancy is a unique period in which the maternal immune system undergoes 
significant changes. The presence of the fetus, an amalgam of two individuals, expresses MHC cell 
surface markers that would normally be recognised as 'foreign' by the host immune system 
(Abrahams 2008). Because of the capacity of the fetus to elicit such a strong immune response, it 
was historically thought that the interface between the mother and the fetus was immunologically 
inert, in order to prevent the eradication or rejection of the fetus; however, this hypothesis does not 
take into account in utero infections.  
 
Infection of the UGT during pregnancy are complex, as there is not simply a single host; but multiple 
hosts (both the mother and the fetus) that may respond to the invading pathogen. Numerous 
studies have shown that the fetal-maternal interface adopts a predominantly 'protective' TH2 
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immune phenotype and reduces any TH1 (proinflammatory) immune responses to protect the fetus 
and placenta. However, the host is still capable of recognising and responding to "infectious, non-
self" threats, such as bacterial infections (Koga and Mor 2010; Mor and Cardenas 2010; Mor et al. 
2011). Importantly, while the maternal immune responses to intraamniotic infection have been well 
characterised (such as E. coli lipopolysaccharide [LPS]), the human maternal immune responses to in 
utero Ureaplasma spp. infections are not well understood.  
 
2.11.1 Innate immune responses 
 
The innate immune system is the immunological “first line of defence” during pregnancy, providing 
an immediate response to invading pathogens. The innate immune system is unique during 
pregnancy and there are high numbers of circulating leukocytes (70% natural killer cells, 20 – 25% 
macrophages and 1.7% dendritic cells) within the uterus and placenta (Abrahams et al. 2005). Within 
serum, the complement system acts to identify pathogens and trigger proteolytic cascades, resulting 
in the production of proinflammatory mediators, opsonisation of the pathogen and targeted cell 
lysis. More recently, the complement pathway has been described as the functional “bridge” 
between the innate and adaptive immune systems, allowing an integrated host response to 
pathogenic organisms (Dunkelberger and Song 2010). 
 
Recently, Beeton et al. (2013) demonstrated the serovar-specific bactericidal activity of serum 
against ureaplasmas. U. parvum serovars 1, 3, 6 and 14 were incubated with human sera collected 
from normal healthy patients (n = 12) and from immunodeficient patients (n = 4) to determine the 
bactericidal activity against each particular serovar. Ureaplasma spp. killing was calculated as the 
fold decrease in ureaplasma colour changing units (CCU), when compared to the ureaplasma CCU 
incubated with heat-inactivated human serum from the same patient. Western blots using patient 
sera were carried out against all U. parvum serovars to determine specific immunoreactivity. The 
study identified that sera from healthy patients was frequently associated with bactericidal activity 
against U. parvum, when compared to the sera collected from immunodeficient patients (83% serum 
killing from healthy patients, compared to 25% serum killing from immunodeficient patients, 
respectively). Serovars 1, 6 and 14 activated classical complement pathways and an increased 
bactericidal activity was correlated with the presence of immunoreactive bands by western blot. 
Interestingly, U. parvum serovar 3 complement activation was harder to define, but was 
demonstrated to be completely C1q-dependent. Significantly, the serum-killing ability for all U. 
parvum serovars was abolished following removal of IgG1 from serum, showing that the bactericidal 
activity of serum is antibody-dependent. The results of this study suggest that surface-exposed 
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antigens may play a significant role in complement activation, and the immunodominant MBA 
antigen of Ureaplasma spp. (as described in section 2.10.1) would be an excellent target for further 
studies of complement activation and bactericidal activity against Ureaplasma spp.  
 
Antimicrobial peptides are also produced as natural antimicrobial agents and are present during 
gestation. Defensins, including α-defensins 1 – 3, 5; as well as β-defensins 1 – 3 have been identified 
at various sites of the UGT during pregnancy (including the decidua, amnion, chorion, trophoblast 
and syncytiotrophoblast). Other antimicrobial peptides such as secretory leukocyte protease 
inhibitors and elafin have also been identified within amniotic fluid and other tissues, suggesting the 
production of these natural antimicrobials within the uterus play an important role in prevention of 
intraamniotic infections during pregnancy (King et al. 2007). More recently, Xiao and colleagues 
further elucidated the role of antimicrobial peptide production in response to Ureaplasma spp. (Xiao 
et al. 2014). Monocytic (THP-1) cells co-cultured with U. parvum and U. urealyticum demonstrated 
significantly lower gene expression of α-defensins 1 and 6, β-defensin 1 and down-regulation of 
human cathelicidin genes, when compared to uninfected controls. The down-regulation of α-
defensins resulted in an inability of the host to inhibit different types of pathogens (bacteria, fungi 
and enveloped viruses), while down-regulation of β-defensins hindered the epithelial surfaces 
resistance to microbial colonisation. Furthermore, cathelicidns serve a critical role in mammalian 
innate immune defences against invasive bacterial infections. While the authors found no evidence 
of chromatin modification or DNA methylation alterations, they concluded that down-regulation of 
these antimicrobial peptides may be an important mechanism for Ureaplasma spp. to establish 
chronic infections and “avoid” this portion of the innate immune defences (Xiao et al. 2014). 
 
Another major facet of the innate immune system includes the TLRs, which are key mediators of 
inflammation during infection (Abrahams 2005; Mor and Cardenas 2010). TLRs recognise pathogen-
associated molecular patterns (PAMPS, expressed on the surface of microorganisms) and damage-
associated molecular patterns (endogenous nuclear/cytosolic molecules released during cell and 
tissue injury). There are ten known TLRs (TLR 1 – 10), all of which are expressed within the placenta, 
along with their various co-receptors and accessory proteins (Mitsunari et al. 2006).  
 
TLR expression changes over the course of pregnancy, both spatially and temporally, in order to 
protect the fetus. For example, TLRs 2 and 4 are expressed within the trophoblast and 
cytotrophoblast cells (the embryo), but not in syncytiotrophoblast cells (the outer epithelial cell 
layer). It is thought that this syncytiotrophoblast remains “TLR negative” as there is no immediate 
threat to the embryo unless a pathogen is able to breach this cell layer and reaches the TLR-
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expressing trophoblast and cytotrophoblast (Abrahams et al. 2004; Kumazaki et al. 2004). TLR 6 is 
expressed by trophoblast cells in the third trimester, but not during the first trimester of pregnancy 
(Koga and Mor 2010).  
 
Shimizu et al. (2008) first investigated the TLRs that interact/bind to Ureaplasma spp. by exposing 
murine macrophages to ureaplasmas in vitro. The ureaplasma surface-exposed MBA protein was 
specifically recognised by TLRs 1, 2 and 6, which activated NF-kB and signalled the production of 
cytokines TNF-α, IL-1β, IL-6 and IL-8. Triantafilou et al. (2013) further elucidated the role of TLR 
signalling in vitro. Human amniotic epithelial cells were exposed to Ureaplasma parvum serovars 3 
and 14. These amniotic epithelial cells expressed minimal levels of all TLRs tested (TLR 1 – 9) prior to 
ureaplasma stimulation, but upon exposure to ureaplasmas, expression of TLRs 2, 6 and 9 was 
significantly increased and this also corresponded to significant increases in TNF-α, IL-1β, IL-6 and IL-
8. Amniotic epithelial cells were further exposed to a recombinant Ureaplasma spp. MBA antigen 
and significant increases in TLRs 2 and 6 were measured. TLR 2/6 heterodimers recognise the 
diacylated MBA protein on the cell surface of Ureaplasma spp. The expression of TLRs 2, 6 and 9 was 
then silenced by RNA interference with the silencing of TLR 2 resulting in the most significant loss of 
cellular activation (as evidenced by significantly decreased IL-6 concentration). Silencing of TLRs 6 
and 9 also inhibited cellular activation, but to a much lesser extent (Triantafilou et al. 2013). 
 
Taken together, the findings of Shimizu et al. (2008) and Triantafilou et al. (2013) confirm that the 
ureaplasma MBA (the major antigen and pathogen-associated molecular pattern of Ureaplasma 
spp.) is recognised by TLR 2 and stimulates the production of TNF-α, IL-1β, IL-6 and IL-8. These 
cytokines have also been detected in human cells infected with Ureaplasma spp. (Triantafilou et al. 
2013) and also in animal cells infected with Ureaplasma spp. (Shimizu et al. 2008). Additional studies 
should investigate the efficacy of these immune modulators, in combination with others, as markers 
of ureaplasma infection. However, cytokines are not only elevated in response to infection, but have 
been shown to be elevated in other pregnancy sequelae. For example, increased IL-8 levels have 
been detected in the amniotic cavity of women with preeclampsia, in the absence of infection (Yada 
et al. 2010), suggesting that more reliable and consistent biomarkers should be investigated. 
Additionally, panels of biomarkers may prove a useful addition to current clinical practices, as the 
use of multiple markers of UGT infection may also improve the efficacy of successful detection and 
identification of sequelae.  
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More recently, Allam et al. (2014) also confirmed that expression of TLRs 1, 2, 6 and the accessory 
protein CD14 was significantly increased following intraamniotic U. parvum infection in BALB/c mice. 
Immunohistochemistry revealed intense co-localisation of TLR 2 and CD14 in syncytiotrophoblast 
cells, which lined the chorionic plate and also in neutrophils at the choriodecidual junction/chorionic 
plate. CD14 is an important accessory protein, which is known to be a signal enhancer of TLRs 
(including TLR 1, 2 and 6). Animals which displayed significant placental histopathology (funisitis and 
chorionic vasculitis) and fetal pathology (encephalitis, pneumonitis, myocarditis or hepatic necrosis) 
demonstrated the most intense co-localisation of TLR 2 and CD14, suggesting that these factors 
together may enhance the maternal inflammatory response to in utero ureaplasma infections and  
result in severe adverse outcomes for the pregnancy and for the fetus. This is significant, as over 
activation of the host immune system can lead to serious acute or chronic outcomes that have 
deleterious effects during pregnancy. Intraamniotic ureaplasma infection and inflammation has been 
linked to human fetal inflammatory response syndrome (Dammann et al. 2003) and other serious 
long-term neurological conditions, such as cerebral palsy (Berger et al. 2009). 
 
Interestingly, in response to human intraamniotic infection with Ureaplasma spp. it has been 
reported that the levels of cytokines may be highly elevated (Holst et al. 2005; Witt et al. 2005), 
moderately elevated (Menon et al. 2009) or there may be no correlation between infection and 
cytokine levels (Perni et al. 2004). This could be, in part, attributed to the number of CFU of 
ureaplasmas present in utero; however, while some studies have shown correlations between the 
numbers of ureaplasmas present and the levels of inflammatory cytokines within amniotic fluid 
(Kasper et al. 2010), this is not always consistent. In sheep model experiments, the severity of 
inflammation within the chorioamnion and fetal tissues was different in each animal; varying from 
no inflammation in ureaplasma-infected tissues, to moderate/severe inflammation or to resolution 
of infection and scarring. This is despite the fact that all animals received identical inocula of the 
same strain and dose of Ureaplasma spp. (Knox et al. 2010; Robinson et al. 2013). Furthermore, 
after identical U. parvum strains/doses were introduced into the urinary tract of rats and different 
severities of infection ensued; non- complicated and complicated UTIs and urinary stone formation 
(Reyes et al. 2009). These animal models confirm that the severity of inflammation was independent 
of the numbers of ureaplasmas present. Similarly, human studies have also shown discordant host 
cytokine responses, depending on maternal ethnicity. Different cytokine profiles were generated in 
vitro within chorioamnion tissues incubated with autologous amniotic fluid. Tissues and amniotic 
fluid were derived from Caucasian and African-American women and were stimulated with either U. 
parvum or U. urealyticum (Peltier et al. 2012). These differences in host cytokine responses may be 
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as a result of the host-microbe interactions within the animals and individuals tested, but they may 
also be due to the ability of ureaplasmas to vary their surface-exposed antigens, including the MBA 
in vivo.  
 
2.11.2 Adaptive immune responses 
 
Adaptive immune responses to Ureaplasma spp. have been confirmed in pregnant women by the 
detection of circulating anti-ureaplasma IgA, IgM and IgG (Quinn 1986; Liepmann et al. 1988; 
Dinsmoor et al. 1989; Cunningham et al. 1996). Furthermore, the placenta allows circulating immune 
cells and some antibodies (IgG) to be transferred to the fetus, creating a feto-maternal 
microchimerism (Tan et al. 2011). However, the fetus also responds to ureaplasma infections in 
utero. A study by Cunningham et al. (1996) identified that immunoreactivity to ureaplasmas alters 
throughout pregnancy. Pregnant women (n = 80) were recruited for this study and maternal sera 
was collected at ≤ 30 weeks of gestation and again at the time of delivery. Anti-ureaplasma IgG and 
IgA antibodies were detected by western blot. Of the women tested, 93% were found to have serum 
IgG, which reacted against Ureaplasma spp. For five of these women (8%), the number of 
immunoreactive bands increased between the initial screening and at birth. Four of the five women 
who had increases in the number of immunoreactive bands also showed corresponding increases in 
the number of IgA bands against Ureaplasma spp. The authors concluded that maternal antibody 
responses to ureaplasmas altered during pregnancy and this may be a hallmark of ureaplasma 
infections (Cunningham et al. 1996).  
 
Other studies have correlated infection, anti-ureaplasma antibodies and pregnancy losses (Quinn et 
al. 1983), preterm delivery (Horowitz et al. 1995), postpartum fever (Lee and Kenny 1987) and low 
birth weight neonates and fetal death (Horowitz et al. 1995). Quinn et al. (1983) demonstrated 
strong links between serum anti-ureaplasma maternal antibodies and severe adverse neonatal 
outcomes. Anti-ureaplasma antibodies were detected in sera from mothers who experienced 
stillbirths (77%), neonatal deaths (69%) or had neonates with respiratory sequelae (58%). By 
contrast, only 6.5% of sera obtained from healthy mothers with healthy neonates had these anti-
ureaplasma antibodies (De Silva and Quinn 1986).   
 
Despite these results, the relationship between anti-ureaplasma antibodies and Ureaplasma spp. 
infection are not always clear. Anti-ureaplasma antibodies have been detected in the sera of women 
whose LGT specimens tested ureaplasma-negative (Liepmann et al. 1988), in women who delivered 
at term with no apparent complications and in healthy neonates (who were delivered at term) 
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(Horowitz et al. 1995). These reports demonstrate the variability in not only the innate inflammatory 
responses generated in vivo during ureaplasma infections, but also in the adaptive immune 
responses to ureaplasmas.   
 
In a sheep model study by Dando et al. (2012), ureaplasmas were isolated from the chorioamnion of 
a sheep with no apparent inflammation and from the chorioamnion of a sheep with severe 
inflammation (published in Knox et al. 2010). These isolates were cloned and filtered to produce two 
clonal cultures (an ‘avirulent’ strain and a ‘virulent’ strain) and the strains were then inoculated into 
the amniotic fluid of two pregnant sheep cohorts. Amniotic fluid from each animal was tested by 
western blot and these demonstrated that there was no difference in the propensity for these 
isolates to vary their surface-exposed MBA (i.e. antigenic variation is not specific to virulent strains 
of Ureaplasma spp.) and there was no difference in the maternal anti-ureaplasmal IgG antibody 
production in either the ‘virulent’ or ‘avirulent’ cohorts. Maternal and cord blood collected from 
these animals were also tested by western blot using the MBA proteins of the corresponding 
inocula. Interestingly, the anti-ureaplasma IgG antibodies detected in maternal sera by western blot 
did not always correlate with those MBA size variants found within the amniotic fluid of the same 
ewe. This is a novel finding and may be attributed to antigenic variation of Ureaplasma spp. in vivo. 
This further suggests that when antigenic variation occurs in vivo, the host may not be able to 
effectively produce neutralising antibodies to eradicate the Ureaplasma spp. Additionally, variation 
of the surface-exposed MBA throughout pregnancy may be a mechanism, which facilitates chronic in 
utero infections. These observations are significant, if ureaplasmas can evade/avoid host immune 
eradication; the fetus is exposed to live Ureaplasma spp. for extended periods, which may 
predispose the infant to severe adverse outcomes.  
 
2.12 Models for the study of ureaplasma infections 
 
Animal models including rats, mice sheep and non-human primates have been used to the study 
intraamniotic infections and their sequelae. The challenge is to use a cost-effective animal model, 
which accurately reflects disease pathogenesis in humans so that the findings are translatable to 
human gestation/parturition. There will always be concerns when comparing one animal model to 
another and ultimately extrapolating these data to human gestations. Therefore, it has been 
suggested that there is no “single best animal model”.  
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2.12.1 Murine models 
 
Rats and mice are among the most common cost-effective animal models. Rats and mice are easy to 
house, they have short gestations of approximately 20 and 22 days, respectively. Mice are able to be 
modified genetically they have well-characterised immune systems, with a wide variety of 
commercially available antibodies, small interfering ribonucleic acids (siRNAs) and microarrays are 
available (Kemp et al. 2010). Whilst studies have shown that treatment of mice with E. coli LPS 
resulted in an increase of IL-1 in maternal sera and preterm delivery of pups (Fidel et al. 1994); these 
models are not directly translatable to human intraamniotic infections as the major underlying 
mechanisms of parturition are very different. In mice and rats, labour and delivery results from the 
withdrawal of progesterone and corresponding luteolysis, brought about by the production of 
prostaglandin F2α (Mitchell and Taggart 2009). In contrast, human labour and delivery result from 
increased production of prostaglandin E2 or antiprogestin, oxytocin and their corresponding 
receptors. Furthermore, the placental anatomy of both mice and rats is very different to that of 
humans, with mice/rats having hemotrichorial labyrinthine placentae, whilst humans have 
hemomonochordial villous discoid placentae (Mitchell and Taggart 2009). Further to this, the short 
gestational period of rats and mice, as well as the poorly developed organ systems of the fetus 
(particularly the lung) at the time of birth limit the usefulness of these models for studying chronic 
intrauterine infections and fetal outcomes. This is particularly crucial in the study of Ureaplasma spp. 
infections, as these infections are often chronic and fetal outcomes are of great importance. Whilst 
mice are not particularly useful for studying pregnancy outcomes, both rats and mice have been 
used to study Ureaplasma spp. infections, including urogenital tract infections (Reyes et al. 2009; 
Allam et al. 2011), lung infections (Viscardi et al. 2002) and brain inflammation (Normann et al. 
2009) as well as infertility (Wang et al. 2010).    
 
In contrast to other rodent and mouse models, the Egyptian spiny mouse (Acomys cahirinus) is a 
more suitable rodent model for studying chronic intrauterine infections and fetal outcomes 
following infection and preterm delivery. The spiny mouse is a relatively new animal model, but is 
proving to be a valuable model in the studies of fetal and placental growth. This is due to the 
relatively long gestation (38 – 40 days) and small litter size (1 – 5; usually 2 – 3 pups per pregnancy). 
Furthermore, the offspring are relatively active from the time of birth with well-developed organ 
systems; including the kidney, liver, brain and immune system and are highly comparable to that of 
the human infant at the time of birth (Dickinson et al. 2008). Spiny mice have been utilised as the 
animal model of choice in birth asphyxia treatment and fetal neurodevelopmental outcomes (Hutton 
et al. 2009; Fleiss et al. 2012), fetal hypoxia (Ireland et al. 2011), placental development (O'Connell 
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et al. 2011), as well as fetal responses to a range of hormones (O'Connell et al. 2011; Quinn et al. 
2013). 
 
 2.12.2 Ovine models 
 
Both acute and chronic durations of ureaplasma intraamniotic infection have been studied using the 
ovine model; as their gestational period is significantly longer than that of rats and mice (term in 
sheep = approximately 147 days). Preterm fetal sheep are also comparable in weight to human 
fetuses (Mitchell and Taggart 2009) and have well-developed organ systems, particularly the lung; 
and so this also provides the opportunity to study fetal outcomes following in utero infections.  
 
Our research group has extensively utilised  ovine models for both acute and chronic Ureaplasma 
spp. infections (Moss et al. 2005; Moss et al. 2008; Moss et al. 2009; Collins et al. 2010; Dando et al. 
2010; Knox et al. 2010; Polglase et al. 2010; Dando et al. 2012; Robinson et al. 2013; Dando et al. 
2014). These studies have provided significant evidence that in utero Ureaplasma spp. infections are 
associated with increased surfactant production and lung maturation (Moss et al. 2005; Moss et al. 
2008; Polglase et al. 2010), histological chorioamnionitis (Knox et al. 2010) and infection and 
resultant inflammation caused by ureaplasmas within the fetal lung (Knox et al. 2010; Dando et al. 
2012; Robinson et al. 2013), fetal gut (Wolfs et al. 2013) and fetal cerebrospinal fluid (Knox et al. 
2010). However, there are several disadvantages in the use of an ovine model of intrauterine 
infection. Ovine parturitions are dependent on progesterone withdrawal, which occurs due to fetal 
adrenocorticotropic hormones and cortisol production (Mitchell and Taggart 2009). The production 
of cortisol stimulates the maturation of fetal lungs, signalling fetal tissues to produce estrogen and 
initiates labour (Mitchell and Taggart 2009). Other disadvantages of this model are that intrauterine 
inflammation does not trigger the induction of labour, nor does the production of inflammatory 
cytokines in the amniotic fluid and fetal tissues trigger preterm delivery. However, an advantage of 
this model is that long-term, chronic intraamniotic infections can be studied since preterm delivery is 
independent of inflammation. Furthermore, the placental anatomy of sheep is very different to that 
of humans. Sheep have a highly layered epithelial-chordial cotyledonary placenta, very different to 
the hemomonochodial villous, discoid placentae of humans (Enders and Carter 2004). The layered 
nature of the ovine placenta means that maternal antibodies and importantly antibiotics cannot 
effectively traverse the placenta to reach the amniotic fluid. This means that results relating to the 
maternal and fetal immune responses to UGT ureaplasma infections are not directly translatable to 
UGT infections within humans.  
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 2.12.3 Non-human primate models 
 
Pregnancies in non-human primates are the most similar to human pregnancies. The gestational 
length in non-human primates (term = 160 days) is longer than in the sheep model (term = 145 days) 
and is more comparable to that of human pregnancies (term = 266 days). The placental anatomy is 
very similar, with both humans and non-human primates having hemomonochordial villous, discoid 
placentae. Another major advantage of using non-human primates is that their labour and delivery 
are not dependent on progesterone withdrawal (as discussed above), and so this makes the non-
human primate an ideal model for studying intrauterine infection and preterm birth as a 
consequence of intrauterine infection/inflammation.  
 
Novy et al. (2009) utilised the non-human primate model (Rhesus macaques) for the study of 
Ureaplasma spp. intrauterine infection. Rhesus monkeys were infected with U. parvum serovar 1 
clinical isolate (n = 5; originally isolated from the placenta of a women who had chorioamnionitis and 
delivered an infant with ureaplasma sepsis) or with sterile media (n = 3). Intraamniotic injection of 
107 CFU of U. parvum resulted in the rapid proliferation of Ureaplasma spp. (to 14.8 ± 6.6 x 105 
CFU/mL) within the first 24 hours. Dramatic increases in cytokine concentrations of TNF-α, IL-1β, IL-6 
and IL-8 were detected in amniotic fluid within the first 48 – 72 hours. There were also dramatic 
increases in IL-1 receptor agonist (RA) in U. parvum infected animals at 48 – 72 hours, which 
persisted until preterm delivery. Levels of prostaglandins and matrix metalloproteinases (MMPs) 
were both significantly increased (p < 0.05), with prostaglandin E2 (PGE2), prostaglandin F2α and 
MMP-9 remaining significantly increased until delivery (however prostaglandin levels varied 
between animals preceding delivery). Infection with U. parvum also resulted in early acute 
chorioamnionitis or in animals with longer infection-to-delivery times, subacute inflammatory 
responses in both fetal membranes and decidua were evident.  
 
Non-human primate fetuses exposed to intraamniotic U. parvum were also affected by infection, 
with 100% of fetal lungs and fetal membranes testing culture-positive for Ureaplasma spp.. 
Bronchoalveolar lavage fluid and tracheal aspirates were predominantly culture-positive for 
ureaplasmas and this correlated with acute histological changes in fetal lungs. In some cases, 
pneumonia was evident (characterised by alveolar neutrophils and macrophages accompanied by 
necrosis of the airways). Fetuses infected with Ureaplasma spp. for greater than ten days showed 
partial resolution of acute inflammation, however, proliferation of epithelial cells and increased 
collagen deposition gave the appearance of thickened alveolar walls (a key characteristic of BPD) 
(Jobe and Bancalari 2001). Furthermore, in some experiments the fetal blood and cerebrospinal fluid 
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were also positive for the presence of Ureaplasma spp. The Rhesus monkey model of intraamniotic 
ureaplasma infection produced similar outcomes to those seen in human pregnancies; the severity 
of inflammation was consistent with human chorioamnionitis and human fetal bronchopulmonary 
dysplasia in the lung. Therefore, this model may be best used in future investigations to model the 
efficacy of treatment of Ureaplasma spp. infections (Novy et al. 2009). Other studies have utilised 
baboons to study the respiratory outcomes after the fetus was exposed to intraamniotic Ureaplasma 
spp. infection. Fetal lungs demonstrated extensive fibrosis and significant proinflammatory cytokine 
responses (Viscardi et al. 2006). Taken together, these studies confirm that non-human primate 
models of intraamniotic ureaplasma infections produce pregnancy and neonatal complications that 
are similar to those reported in humans’ pregnancies. However, there are strict ethical 
considerations in the use of human primates, and it has become increasingly difficult to obtain 
ethical clearance for these studies. This animal model is also very expensive to maintain and so 
fewer animals are tested in each cohort, reducing the scientific power gained from these 
experiments. This means that this animal model is not used routinely for the study of Ureaplasma 
spp., infections and is not available within Australia.  
 
An alternative is research that utilises human-derived cells and tissues. The ultimate goal of most 
research is to accurately model and reflect the mechanisms and consequences of intraamniotic 
infection, which is not always possible within a single animal model. This can be simplified by the use 
of human cells and tissues.  
 
 2.12.4 Human cell lines 
 
Cell lines derived from humans are frequently used for in vitro studies of cell-microbe interactions. A 
number of female reproductive tract cell lines and tissues have been used (either alone or in co-
culture systems) to model both healthy/normal interactions as well as disease states. Hormonal 
regulation of apoptosis by estrogen and progesterone has been studied using Ishikawa endometrial 
adenocarcinoma cell lines (Song et al. 2002), whilst another endometrial adenocarcinoma cell line, 
Hec1B, has been utilised for the study of invasive Neisseria gonorrhoeae infections (Shaw and 
Falkow 1988). Human placental (trophoblast) carcinoma cells (BeWo and JEG-3) have been used to 
model Toxoplasma gondii (Castro et al. 2013), hepatitis B virus (HBV) (Bai et al. 2013) and human 
immunodeficiency virus (HIV) 1 (Phillips and Tan 1992; David et al. 1995) infections to better 
understand invasion by these pathogens during pregnancy. Ureaplasma spp. have also been studied 
using cell culture systems, to investigate ureaplasma attachment to human cervical adenocarcinoma 
(HeLa) cells (Smith et al. 1994; Monecke et al. 2003). Human-derived cell lines offer a uniform 
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cellular population that originates from a well-defined tissue type, however, as with any model there 
are some disadvantages associated with the use of cell lines. Most cell lines used in research have 
undergone significant mutations to become immortalised, which can alter their cell biology and 
cellular processes. This means that some of the responses seen in vitro may not truly reflect the 
cellular responses seen in vivo. To circumvent these problems, primary cells obtained from human 
tissues have also been studied. Padmini et al. (2011) isolated placental endothelial cells from women 
with or without preeclampsia and these were exposed to U. parvum ex vivo to further understand 
stress responses to microbial stimuli in ‘healthy’ and ‘non-healthy’ pregnant women. Primary 
placental endothelial cells from both cohorts responded similarly to stimulation with U. parvum: 
changes in cellular iron, magnesium and calcium content were demonstrated, as well as increased 
apoptotic changes of the cells. While the responses seen in primary cell culture more closely mimics 
the responses seen in vivo, these experiments tested only a single cell type, which also limited study 
of the cell-to-cell signalling to a single cell type. This is different to the diverse cellular populations 
present in vivo and so therefore the immune responses seen may still not truly reflect what occurs 
during pregnancy.  
 
Human primary tissues may also be used to study the interactions of bacteria and human tissues. 
Again, whilst there are strict ethical and clinical considerations, which regulate the use of human-
derived samples, from a practical viewpoint, fetal tissues (such as placentae and umbilical cord) are 
easily obtained following delivery as these tissues are normally discarded as medical waste and are 
not often utilised for any other purpose. Primary tissue explants of the chorioamnion (also 
commonly referred to as the fetal membranes) have been used as the membranes are the major 
physical and immunological barrier of the amniotic sac, protecting the fetus against infection and 
insults during gestation. The chorioamnion contains a variety of cell types and the tissue integrity 
and 3-dimesional structure of tissue explants can be maintained ex vivo and utilised to study the 
host tissue immune response after exposure to microorganisms.  
  
2.12.5 Ex vivo models 
 
Abrahams et al. (2013) exposed chorioamnion explants to heat-killed M. hominis ex vivo and 
demonstrated increased mRNA expression of TLR 4, TLR 6 and TLR 8 and similarly U. parvum 
increased the mRNA expression of TLR 8. However, chorioamnion explants exposed to U. 
urealyticum induced no significant changes in mRNA expression of any TLRs. Menon et al. (2009) 
measured the cytokine and prostaglandin responses after chorioamnion tissue was exposed to heat-
killed microorganisms; E. coli stimulated the production of TNF-α and PGE2, whilst exposure to U. 
 46 
 
parvum resulted in significantly elevated TNF-α and IL-10 concentrations. The greatest increases in 
IL-10 levels were detected after chorioamnion tissue was exposed to U. parvum; however, there 
were no detectable changes in prostaglandin levels when chorioamnion tissue was exposed to U. 
parvum. 
 
To further understand the complexities of intraamniotic infection, this group also examined cytokine 
responses in tissues collected from women of different ethnicities. Chorioamnion explants were 
collected from Caucasian and African-American women and then incubated with heat-killed 
pathogens in the presence or absence of autologous amniotic fluid. U. parvum, M. hominis and U. 
urealyticum stimulated TNF-α and IL-10 production by the explants. Interestingly, the addition of 
autologous amniotic fluid affected the immune responses of both ethnicities in a race- and 
pathogen-dependent manner. Chorioamnion from African-American women exposed to U. parvum 
elaborated significantly higher TNF-α levels, compared to levels produced by tissues from Caucasian 
women. By contrast, tissues from Caucasian women when exposed to U. parvum secreted higher IL-
10 levels (p = 0.031) than the levels detected in tissues of African-American women (p = 0.630). The 
authors concluded that the host response to infection of the chorioamnion is complex and cannot be 
generalised, as evidenced by the significantly different racial differences and altered responses to 
the individual pathogens (Peltier et al. 2012). 
 
Whilst the results of these studies are intriguing, there are some experimental parameters that 
should be discussed. The use of heat-killed microorganisms may affect the results, due to a number 
of factors. Killing of the organisms means that the pathogen is no longer able to replicate and cannot 
produce biofilms, which may be a key to the pathogen’s successful invasion and establishment of an 
infection during pregnancy. Furthermore, the action of heat-killing may result in cell lysis and 
destruction of their surface receptors, such as the MBA lipoprotein of Ureaplasma spp. The lack of 
cell surface receptors may significantly augment TLR activation and subsequent immune responses. 
Therefore, the results of these experiments should be interpreted with caution as they may not truly 
reflect the immune responses to live Ureaplasma spp. (or other microorganisms) infections. Other 
limitations of these explant-based studies result from a lack of tissue structure and difficulties in 
distinguishing the specific cellular responses of the amnion and the chorion cells which comprise the 
chorioamnion.  
 
It is known that there are differences in cellular immune response of the amnion and chorion, so to 
further understand these differences, Keelan et al. (2009) developed and validated an ex vivo 
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chorioamnion tissue model to investigate an NF-kB pharmacological inhibitor in response to E. coli 
LPS. This model utilised an Ussing chamber, traditionally used to study permeability and secretory 
functions of the gut mucosa (Heyman et al. 1988; Foitzik et al. 1997; Hotz et al. 1998). The model 
produced by Keelan et al. contained two distinct compartments, separated by a barrier, the 
chorioamnion tissue itself. Each compartment was separately perfused with cell culture media that 
bathed the amnion and the chorion tissue. The ‘maternal’ (chorion) compartment was exposed to 
LPS over a 20 hour period. Aliquots of perfusing media were collected at different time-points and 
these samples were subsequently tested for cytokines, chemokines and prostaglandin levels in each 
chamber over the course of each experiment. The ex vivo Ussing chamber system used was found to 
be an accurate and valid method for studying immune responses to LPS, which approximated the 
conditions seen during pregnancy. Exposure of the decidual (‘maternal’) portion of the membranes 
to LPS resulted in increased accumulation of proinflammatory cytokines and chemokines, followed 
by an inflammatory response within the amniotic (‘fetal’) portion of the membranes. Most notably, 
increases in the concentrations of proinflammatory cytokines/chemokines macrophage-derived 
chemokine (MDC), TNF-α and PGE2 were seen, along with increases in the anti-inflammatory 
cytokine transforming growth factor (TGF)-β  were increased in both the ‘maternal’ and ‘fetal’ 
compartments following LPS exposure. Co-treatment with the NF-kB inhibitor resulted in an inability 
of nuclear translocation of NF-kB p65 and a subsequent inhibition of cytokine and chemokine 
production within the ‘maternal’ compartment. Similarly, cytokine and chemokine production was 
reduced within the fetal compartment, but to a much lesser extent. Whilst these results were 
promising, there was also a significant increase in the rate of apoptosis within the chorion, which the 
authors highlighted as a major concern regarding its effect on the placenta, if the treatment were to 
be administered during pregnancy (Keelan et al. 2009). However, these studies highlight the 
usefulness of human tissues, and in some cases human primary cells to better understand the 
variability observed in humans with intraamniotic Ureaplasma spp. infections. This ex vivo model 
may be further utilised to advance our current understanding of human placental host-microbe 
interactions occurring during ureaplasma infections.  
 
2.13 Summary 
 
This literature review has highlighted the need for further research, in order to better characterise 
the role of Ureaplasma spp. UGT infections during gestation. The results chapters (Chapters 4, 5 and 
6), which follow this review of literature report the findings of studies which investigate: the 
prevalence of Ureaplasma spp. chorioamnion infection in human pregnancies and the effect on 
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maternal and fetal outcomes; ureaplasma MBA variation in clinical isolates obtained from human 
chorioamnion tissue and the cord blood immune responses; and the optimisation and use of an ex 
vivo chorioamnion tissue model to investigate the host immune responses at the maternal and fetal 
interface, in response to Ureaplasma spp. exposure. This PhD project will address major knowledge 
gaps that have been identified within the area of research concerning Ureaplasma spp. infections 
during pregnancy and is the first major study to focus on ureaplasma infections within the 
chorioamnion (rather than the amniotic fluid) to investigate the role of ureaplasma infections on the 
mother and fetus. Within this thesis, the host immune response to Ureaplasma spp. infections in 
human cord blood and also within an ex vivo chorioamnion model of infection will be investigated to 
further our knowledge and understanding of host immune responses to infections caused by 
ureaplasmas. 
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Chapter Three:   
 
Materials and Methods 
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3.1 Experimental Design 
 
This thesis presents the results of a large prospective microbiological study of placentae obtained 
from 477 women within the United States of America (USA); and a second, smaller pilot study which 
examined the ex vivo immune responses of placentae from four women in Brisbane, Australia. 
 
For the microbiological component of this research, organisms were identified within placental 
tissue by traditional culture and molecular microbiological techniques (results discussed in Chapter 
Four) and the most prevalent microorganisms, the Ureaplasma spp., were characterised (results 
discussed in Chapter Five). A single clinical Ureaplasma parvum isolate cultured from the placenta of 
a woman enrolled in the study was used as an infectious agonist to challenge the maternal surface 
of human chorioamnion tissue immune response ex vivo. This pilot study is the final aim of this PhD 
study (results discussed in Chapter Six). All methods and materials pertaining to each of these 
research chapters are presented in this chapter.  
 
3.2 Microbiology study population and specimen collection  
 
From July 2010 to July 2013, women giving birth at the Good Samaritan Hospital (Ohio; United States 
of America) were recruited and enrolled in this study. Women who smoked during pregnancy and 
those with intrauterine growth restriction were excluded from this study. This study was approved 
by the ethics committees of the Good Samaritan Hospital (Ohio; USA) and Cincinnati Children's 
Hospital Medical Centre (CCHMC; Ohio, USA) and was reviewed by the human research ethics 
committee (HREC) of Queensland University of Technology (QUT; 2009001885) and deemed exempt 
from the need for university HREC review. Written informed consent was obtained from all women 
enrolled in this study. Placentae were collected and de-identified, with the demographic and 
outcome data from each pregnancy entered into the research electronic capture (REDCaP) database.  
 
Upon delivery, placentae were placed into sterile containers and transported to a procedure room 
for sampling under strict aseptic conditions within 24 hours of delivery. The external placental 
surface was decontaminated using 70% alcohol and areas in which the amnion had detached from 
the placenta were avoided for sampling, to minimise contamination of the membranes by vaginal 
microflora. Using sterile surgical implements, an incision was made into the amnion (fetal) 
membrane, until the interface of the chorion and amnion membranes was reached and identified. 
The amnion membrane was then lifted and chorioamnion specimens were excised from the placenta 
and placed into sterile cryogenic vials and then snap frozen. The exposed membrane interface was 
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then swabbed and swabs were placed into BBL-port-a-cul media (for isolation of bacteria and yeast; 
Becton Dickenson and Company, Maryland, USA) and into universal viral transport media (for 
isolation of ureaplasmas/mycoplasmas; Becton Dickenson and Company). All samples were stored at 
-80 °C and shipped on dry ice to the Institute of Health and Biomedical Innovation (IHBI), 
Queensland University of Technology (QUT), Queensland, Australia. Shipments were sent on a 
regular basis with 30 – 40 patient samples sets per shipment.  
 
3.3 Primary isolation media for culture of microorganisms  
 
Columbia horse blood agar and chocolate agar pre-prepared plates were purchased from Thermo 
Fisher Scientific (Thebarton, Adelaide; South Australia). Schaedler anaerobe agar, MacConkey no. 1 
agar, deMan Rogosa Sharpe agar, Sabauraud’s dextrose agar and Brewer’s thioglycollate medium 
were purchased from Thermo Fisher as dehydrated powders, were prepared according to the 
manufacturer’s instructions then poured into sterile Petri dishes. Thioglycollate broth was aliquotted 
into McCartney bottles and then autoclaved at 121 °C for 15 minutes.  
 
10B broth and A8 agar was used for cultivation of Ureaplasma spp. and these were prepared 
according to previously published protocols (Shepard and Lunceford 1976). The basal medium of 
both the broth and agar were autoclaved at 121 °C for 15 minutes. Sterile medium supplements 
were then added after the medium had cooled to < 56 °C. The complete medium was then 
dispensed into sterile single-use culture tubes or Petri dishes (Techno Plas, St Marys; South 
Australia).  
 
3.4 Ureaplasma spp. strains 
 
U. parvum and U. urealyticum strains were purchased from the American Type Culture Collection 
(ATCC, Virginia, USA), except for U. urealyticum serovar 8, which is a reference/progenitor strain of 
the ATCC strains (kindly provided by H. Watson; University of Sydney, Australia). All strains were 
cultured in 10B broth (Shepard and Lunceford 1976) and stored at -80 °C. Ureaplasma spp. strains 
have been summarised in Table 3.1. 
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3.5 Bacterial strains 
 
Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes, Streptococcus 
pneumoniae, Streptococcus agalactiae, Listeria monocytogenes, Haemophilus influenzae, Klebsiella 
pneumoniae and Pseudomonas aeruginosa were obtained from the QUT culture collection (see 
Table 3.1). These microorganisms were inoculated onto Columbia horse blood agar (Thermo Fisher 
Scientific) overnight, then three to five well-isolated colonies were aseptically collected and used to 
inoculate heat-inactivated horse serum supplemented with 20 % v/v glycerol prior to storage. DNA 
was extracted from each of these microorganisms and these served as controls for 16S ribosomal (r) 
RNA and multiple banded antigen (mba) PCR assays.  
 
Table 3.1. Microorganisms utilised within the PhD program of study. 
Organism Source 
Ureaplasma parvum serovar 1 ATCC 27813 
Ureaplasma parvum serovar 3 ATCC 27815 
Ureaplasma parvum serovar 6 ATCC 27818 
Ureaplasma parvum serovar 14 ATCC 33697 
Ureaplasma urealyticum serovar 2 ATCC 27814 
Ureaplasma urealyticum serovar 4 ATCC 27816 
Ureaplasma urealyticum serovar 5 ATCC 27817 
Ureaplasma urealyticum serovar 7 ATCC 27819 
Ureaplasma urealyticum serovar 8 Reference strain 
Ureaplasma urealyticum serovar 9 ATCC 33175 
Ureaplasma urealyticum serovar 10 ATCC 33699 
Ureaplasma urealyticum serovar 11 ATCC 33695 
Ureaplasma urealyticum serovar 12 ATCC 33696 
Ureaplasma urealyticum serovar 13 ATCC 33698 
Staphylococcus aureus QUT culture collection 
Staphylococcus epidermidis QUT culture collection 
Streptococcus pyogenes QUT culture collection 
Streptococcus agalactiae QUT culture collection 
Streptococcus pneumoniae type II QUT culture collection 
Listeria monocytogenes QUT culture collection 
Haemophilus influenzae QUT culture collection 
Klebsiella pneumoniae QUT culture collection 
Pseudomonas aeruginosa QUT culture collection 
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3.6 Propagation and quantification of Ureaplasma spp.  
 
3.6.1 ATCC and Reference strain propagation 
 
Ureaplasma spp. stocks stored at -80 °C were thawed on ice prior to use. One volume of the 
ureaplasma ATCC/reference stock was added to 9 volumes of 10B broth and these were then 
incubated at 37 °C; under O2 until log-phase growth was achieved (indicated by the phenol red pH 
colour change). 
 
3.6.2 Quantification of Ureaplasma spp. 
 
To determine the number of Ureaplasma spp. colony forming units (CFU) within a given sample, 
serial dilutions (doubling or ten-fold) were carried out in 10B broth. A total of four dilutions for each 
sample were carried out and from each broth dilution, six 5 µL drops were then subcultured onto A8 
agar plates. A8 agar were then incubated at 37 °C, under 5% CO2 for a minimum of three days before 
examining microscopically using a stereomicroscope (Leica Microsystems; North Ryde, New South 
Wales). The number of ureaplasma colonies per drop of 10B broth were then counted, averaged and 
then calculations were performed to determine the total number of ureaplasma colony forming 
units (CFU) per swab or per gram of tissue.  
 
10B broth dilutions were also incubated at 37 °C, under O2 and checked daily for signs of log-phase 
ureaplasma growth.  
  
3.7 Culture of microorganisms from clinical samples 
 
All tissue and swab specimens were thawed on ice prior to culture.  
 
3.7.1 Ureaplasma swab culture protocol 
 
Swabs stored in universal viral transport media were inoculated into 10B broth and then serially 
diluted in four two-fold dilutions. The number of Ureaplasma spp. CFU was determined as detailed 
above (section 3.6.2). For specimens that were blood-stained, the inoculated broths were incubated 
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for 24 hours and subcultured daily for up to 5 days to ensure any ureaplasma growth was detected. 
Broths and plates were incubated at 37 °C, O2 for up to 14 days. 
 
3.7.2 Bacterial swab culture protocol 
 
Swabs stored in BBL port-a-cul media were inoculated into thioglycollate broth and onto a range of 
microbiological media, including: Horse blood agar, Chocolate Agar with Isovitalex, Schaedler 
anaerobe agar, Sabauraud’s Dextrose agar, deMan Rogosa Sharpe agar and MacConkey no. 1 agar, 
using a 16-streak technique. Media were incubated either aerobically, under 5% CO2 or anaerobically 
in jars (Oxoid anaerogen gas pack, 2.5L; Oxoid) as appropriate. Agar plates were checked daily for 
signs of growth for up to 5 days. Thioglycollate broths were checked daily for signs of growth for up 
to 14 days. Any positive thioglycollate broths (as evidenced by turbidity) were subcultured onto 
media (as above) for the identification of microorganisms growing within the broth.  
The number of bacterial CFU was measured semi-quantitatively after 24 hours by counting the 
number of colonies on the plate and multiplying by a factor of 102 (for a 10 µL inoculation loop) to 
give the number of CFU/mL of each organism present (see table 3.2; quantitative analysis was only 
possible for organisms that grew on primary isolation media after the direct subculture of the 
specimens and not for those isolates that were first enriched and then subcultured from 
thioglycollate broths). Each colony type was Gram-stained and a stock of the organism was stored at 
-80 °C for subsequent DNA extraction, 16S rRNA PCR and sequencing to identify the genus/species of 
each organism present.  
Table 3.2. Semi-quantitative method for determining the number of bacterial colony forming units 
(CFU/mL) from swabs and tissue specimens. 
Total amount of growth Number of colonies  Approximate CFU/mL 
0+ (primary inoculum only) 1 103 
1+ 1 – 10 104 
2+ 10 – 100 105 
3+ 100 – 1000  106 
4+ > 1000 > 106 
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3.7.3 Chorioamnion tissue culture protocol 
 
Tissue specimens were weighed and homogenised in sterile cryogenic vials containing 1 mL of sterile 
phosphate-buffered saline (PBS) and sterile glass beads using the Mini Beadbeater-16 cell disruptor 
(Daintree Scientific; Tasmania, Australia). Tissues were homogenised in one minute cycles for up to 
four minutes (average: three minutes) and placed on ice between each homogenisation step. This 
was performed to ensure that the samples did not overheat and affect the viability of any 
microorganisms present.   
Tissue homogenates were inoculated into 10B broth and doubling or ten-fold serial dilutions were 
carried out. The Ureaplasma spp. were quantified as previously described (see section 3.6.2). For 
specimens that were blood-stained, the inoculated 10B broths were incubated for 24 hours and then 
subcultured daily for up to 5 days to distinguish the ureaplasma growth.  
Tissue homogenates were also inoculated into thioglycollate broth and onto a range of bacterial 
media (as described above) and incubated either aerobically, under 5% C02 or anaerobically in jars. 
Agar plates were checked daily for up to 5 days and thioglycollate broths were checked daily for 
signs of growth for up to 14 days.   
Each morphologically distinct colony type isolated was Gram-stained and a stock of each 
microorganism was stored at -80 °C for subsequent DNA extraction, 16S rRNA PCR and sequencing 
to identify the genus/species of each clinical isolate. 
 
3.8 DNA extraction 
 
DNA was extracted from all specimens using the QIAamp mini DNA extraction kit (Qiagen) according 
to the manufacturer’s instructions. For DNA extractions a Proteinase K solution (100 µg/mL; Sigma-
Aldrich) was used instead of the Proteinase K provided with the DNA extraction kit. All DNA samples 
were eluted in sterile DNAse/RNAse-free dH20. Extracted DNA was stored at -20 °C until required.  
 
3.8.1 Ureaplasma spp. ATCC and clinical isolate cultures 
 
For the extraction of DNA from Ureaplasma spp., each Ureaplasma spp. ATCC and clinical isolate was 
culture in 10 mL of 10B broth until exponential growth was achieved. Broths were then centrifuged 
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at 5000 x g for 30 minutes at 4 °C. The supernatant was aspirated and DNA was extracted from the 
pellet using the manufacturer’s instructions for ‘tissues’.  
Prior to extraction, the specimen was incubated with a Proteinase K solution (100 µg/mL; Sigma 
Aldrich) at 56 °C for a minimum of 1 hour. DNA was then eluted in 400 µL of sterile DNAse/RNAse-
free dH20 (Gibco) in two elutions and then stored at -20 °C until testing.  
 
3.8.2 Clinical isolates and ATCC strains of other cultured microorganisms 
 
For the extraction of DNA from microorganisms cultured from tissue and swabs, three to five well-
isolated bacterial colonies (of the same colonial morphology) were aseptically transferred from the 
agar plate to a tube containing 500 µL of sterile PBS. The bacterial suspension was then centrifuged 
at 5000 x g for 5 minutes at room temperature. The supernatant was aseptically removed and the 
pellet retained for DNA extraction using the manufacturer's instructions for ‘tissues’.  
 
3.8.3 Placental tissue  
 
Tissue homogenates (approximately 500 µL) from each patient were incubated at 56 °C with tissue 
lysis buffer (provided with the commercial DNA extraction kit) and 100 µL of 100 µg/mL Proteinase K 
solution overnight, or until the tissue had completely degraded. DNA was extracted as per the 
manufacturer’s protocol for ‘tissues’.  
 
3.9 Conventional polymerase chain reaction (PCR) assays for the 
identification of microorganisms and Ureaplasma spp.  
 
All tissue homogenates and cultured microorganisms were tested by conventional PCR assays using 
the PTC-2000 Thermal Cycler (BioRad; Gladesville, New South Wales).  
 
3.9.1 16S rRNA polymerase chain reaction (PCR) assays  
 
PCR primers targeting a variable region of the 16S rRNA gene were designed by using the Primer3 
primer design program in conjunction with Geneious gene alignment software (Biomatters Ltd). Each 
16S rRNA PCR reaction, in a total volume of 20 µL, contained 4 µL of extracted DNA, 100 µM dNTPs 
(Roche), 1 X PCR buffer (Tris HCl, KCl, (NH4)2SO4, pH 8.7; Invitrogen), 2 mM MgCl2 (Invitrogen), 0.5 
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µM of both forward and reverse primers (Bact_RNA1F and Bact_RNA1R – see Table 3.3; Sigma-
Aldrich), 2.5 U Platinum taq polymerase (Invitrogen) and sterile DNAse/RNAse free dH20 (Gibco). PCR 
cycling consisted of initial denaturation at 95 °C for 5 minutes, followed by 30 cycles of 94 °C for 30 
seconds, primer annealing at 60 °C for 30 seconds and extension at 72 °C for 30 seconds.  
DNA extracted from pure cultures of Gram positive and Gram negative organisms served as the 
template for positive control PCR reactions (see Table 3.1). Negative controls included replicates of 
master mix only and water substituted for template in order to identify contamination. 
 
3.9.2 mba polymerase chain reaction (PCR) assays 
 
Ureaplasma spp., within tissue homogenates and cultured clinical isolates, were detected and 
speciated using a conventional PCR assay targeting the mba gene. Optimised PCR assays were 
carried out in a total volume of 20 µL and consisted of 4 µL of extracted DNA, 100 µM dNTP mix 
(Roche), 1 X PCR buffer (Invitrogen), 1.5 mM MgCl2 (Invitrogen), 0.5 µM of both forward and reverse 
primers (UMS-125 and UMA-226 – see Table 3.3; Sigma-Aldrich), 2.5 U of Platinum taq DNA 
polymerase (Invitrogen) and sterile DNAse/RNAse-free dH20 (Gibco). PCR cycling involved initial 
denaturation at 95 °C for 5 mins; followed by 35 cycles of denaturation at 95 °C for 30 seconds, 
primer annealing at 55 °C for 30 seconds and extension at 72 °C for 30 seconds.  
 
Positive PCR control reactions included DNA extracted from pure cultures of ATCC U. parvum and U. 
urealyticum serovars (See Table 3.1). U. parvum isolates produced a PCR product of ~404 bp, while 
U. urealyticum serovars produced a PCR product of ~448 bp. Negative controls included replicates of 
master mix only and reaction mixtures in which DNAse/RNAse-free dH20 was substituted for 
template.  
 
Table 3.3. PCR primers used for the 16S rRNA and mba conventional PCR assays 
1 Y – combination of C/T included into the primer sequence 
 
Primer Name Sequence1 Tm Source 
Bact_RNA1 F 5’ CYGGYAGYCCACGCCGYAAA 3’ 60 °C novel 
Bact_RNA1 R 5’ ACAYCYCACGACACGAGCYG 3’ 60 °C novel 
UMS-125 (F) GTATTTGCAATCTTTATATGTTTTCG 55 °C (Teng et al. 1994) 
UMA-226 (R) CAGCTGATGTAAGTGCAGCATTAAATTC 55 °C (Teng et al. 1994) 
 58 
 
3.10 Agarose gel electrophoresis 
 
PCR amplicons were separated using a 2% agarose and Tris Borate-EDTA (TBE) gel containing 
ethidium bromide (final concentration 1 µg/mL). Products were electrophoresed at 100 V for 60 
minutes and then visualised using the Grab-It Gel Dock (Ultraviolet Products, Ltd., Cambridge, United 
Kingdom).  
 
3.11 Purification of PCR products 
 
PCR products were purified using the PureLink PCR purification kit (Invitrogen) according to the 
manufacturer’s instructions, with a final elution in sterile DNAse/RNAse-free dH20 (Gibco). 
 
3.12 Sequencing of PCR amplicons 
 
Purified PCR amplicons were then labelled with the BigDye Terminator (BDT) v3.1 cycle sequencing 
kit (Thermo Fisher Scientific; Scoresby, VIC) and both forward and reverse direction sequencing 
reactions were carried out for each PCR amplicon. In order to incorporate the BDT dye within the 
PCR amplicon, a BDT-labelling PCR assay was performed in a 20 µL reaction volume, which contained 
10 µL of purified PCR amplicon, 1 X BDT sequencing buffer, 1 µL of BDT ready reaction mix, 0.3 µM of 
the forward or reverse primer (16S rRNA or mba PCR primers – see Table 3.3; Sigma-Aldrich) and 
DNAse/RNAse-free dH20 (Gibco). PCR cycling included initial denaturation at 96 °C for 1 minute; 
followed by 35 cycles of denaturation at 96 °C for 10 seconds, primer annealing at 50 °C for 5 
seconds and extension at 60 °C for 4 minutes. BDT-labelled amplicons were purified using EDTA (125 
mM, pH 8.0), sodium acetate (3 M) and 100% ethanol. BDT-labelled amplicons were centrifuged at 
5000 x g for 20 minutes and the supernatant removed. Amplicons were then washed with 80% 
ethanol, centrifuged, and the tubes dried at 50 °C for 1 hour. Products were then sequenced at the 
Molecular Genetics Research Facility, QUT using the Ion personal genome machine (PGM) molecular 
sequencer (Life Technologies). 
Once generated, the forward and reverse sequence data were imported, manipulated and analysed 
using the Geneious bioinformatics software (Biomatters Ltd.). Forward and reverse sequences were 
trimmed and the sequence identity of each PCR amplicon was obtained using the basic local 
alignment search tool (BLAST; National Centre for Biotechnology Information [NCBI]).  
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3.13 Western blotting of Ureaplasma spp. multiple banded antigen (MBA) 
proteins 
 
All ureaplasma clinical isolates and ATCC strains were cultured in 10 mL of 10B broth until the late 
log-phase and then centrifuged at 5000 x g for 20 minutes at 4 °C. The supernatant was discarded 
and the pellet was resuspended in 100 µL of sterile PBS. The protein concentration was determined 
using the NanoDrop 1000 spectrophotometer (Thermo Fisher Scientific) and proteins were stored at 
-20 °C prior to use.  
Protein from each clinical isolate (30 µg) was added to SDS-PAGE loading buffer (Tris HCl, pH 6.8, 
50% glycerol, 8% w/v SDS, bromophenol blue, 1 M dithiothreitol [DTT]) and incubated at 95 °C for 5 
minutes then electrophoresed in a 10% SDS-PAGE gel at 150 V for 1 hour. Proteins were then 
transferred from the SDS-PAGE gel to a nitrocellulose membrane (Pall Corporation; Cheltenham, 
Victoria) in transfer solution (10 mM 3-(cyclohexylamino)-1-propanesulfonic acid, 10% methanol, 
dH20) at 90 V for 1 hour. After protein transfer, the membrane was blocked to prevent non-specific 
binding using a skim milk solution (5% skim milk, 150 mM NaCl, 50 mM Tris) for 1 hour, prior to an 
overnight incubation with the primary antibody at 4 °C (serovar-specific anti-ureaplasma rabbit 
antisera kindly provided by Emeritus Dr Patricia Quinn (The Hospital for Sick Children, Toronto). The 
primary antibodies used were raised against whole ureaplasmas and we have shown previously that 
the protein band(s) demonstrated by western blot correspond directly to the amplicons generated 
by mba PCR assays (Knox et al. 2010). Concentrations for each primary and secondary antisera are 
summarised in Table 3.4. After incubation, the membranes were washed and incubated with a goat 
anti-rabbit IgG secondary antibody conjugated with horse radish peroxidase (Sigma Aldrich) for 1 
hour with gentle agitation. Membranes were again washed and the MBA protein visualised using 3’, 
3’-diaminobenzidine tetrahydrochloride (DAB) with cobalt chloride enhancer (Sigma Aldrich). Images 
were then captured (CanoScan 8600F). For each western blot, proteins obtained from ATCC and 
reference Ureaplasma spp. serovars served as positive controls. Sterile 10B medium was treated in 
the same manner as the ATCC ureaplasmas and clinical isolate cultures and this served as a negative 
control, to confirm the antibody did not react with components within the 10B medium.   
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Table 3.4. Primary and secondary antibody concentrations used for western blot analysis of the 
Ureaplasma spp. MBA protein 
Ureaplasma 
serovars 
Primary antibody 
concentration a 
Secondary antibody 
concentration b 
U. parvum    
1 1/100 1/1000 
3 1/10000 1/5000 
6 1/2500 1/5000 
14 1/20 1/1000 
U. urealyticum   
2 1/20 1/1000 
4 1/500 1/5000 
5 1/20 1/1000 
7 1/20 1/1000 
8 1/20 1/1000 
9 1/20 1/1000 
10 1/20 1/1000 
11 1/20 1/1000 
12 1/20 1/1000 
13 1/20 1/1000 
a Serovar-specific anti-ureaplasma rabbit antisera kindly provided by Emeritus Dr Patricia Quinn, The 
Hospital for Sick Children, Toronto 
b Goat anti-rabbit IgG conjugated to horse radish peroxidase was commercially sourced from Sigma-
Aldrich 
 
3.14 Polymerase chain reaction (PCR) targeting the downstream repetitive 
region of the mba 
 
The downstream repetitive region of U. parvum clinical isolates was targeted using previously 
published PCR assays (Knox et al. 2010; Robinson et al. 2013). These primers amplified U. parvum 
serovars 1 and 6; or serovars 3 and 14, by binding to regions surrounding the repetitive region of the 
mba gene and revealed mba size variants that resulted due to variation in the number of tandem 
repeating units.  
These PCR reactions were carried out in a 50 µL volume and consisted of: 8 µL DNA template, 100 
µM dNTPs (Roche Diagnostics), 1 x PCR buffer (Tris HCl, KCl, (NH4)2S04, pH 8.7 – Invitrogen), 1.5 mM 
MgCl2 (Invitrogen), 0.5 µM of forward (MPDF3; see Table 3.5) and reverse primers (3DR3 or 6DR4; 
Sigma-Aldrich – see Table 3.5), 2.5 U Platinum taq DNA polymerase (Invitrogen) and DNAse/RNAse-
free dH20 (Gibco). PCR cycling involved initial denaturation at 94 °C for 9 minutes; followed by 40 
cycles of denaturation at 94 °C for 45 seconds, primer annealing at 54 °C for 75 seconds, extension at 
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72 °C for 2 minutes; with a final extension step at 72 °C for 15 minutes. Positive PCR controls 
included DNA extracted from ATCC strain serovars (Serovars 1, 3, 6 and 14). Negative controls 
included master mix only with DNAse/RNAse-free dH20 substituted for template.  
PCR amplicons were analysed by agarose gel electrophoresis (section 3.10). The mba amplicon 
profiles of Ureaplasma spp. clinical isolates were then compared to the mba amplicons produced by 
ATCC strains. Ureaplasma spp. clinical isolates, which produced mba amplicons of the same size as 
ATCC strain controls were designated as having ‘no mba variation’; whilst clinical isolates which 
produced amplicons of a different size to that of ATCC strains were considered to be ‘mba variants’. 
In some cases multiple mba variants were amplified from the same clinical isolate. These isolates 
were further characterised as having a “single” or “multiple” unique mba size variants. These mba 
amplicon profiles were also correlated to the outcome of western blot analysis, to ensure that true 
MBA variation was occurring, at both the genetic and protein level.   
Table 3.5. PCR primers targeting the downstream repetitive region of the mba gene 
Primer Name Sequence Serovars amplified Tm Source 
MPDF3  5’ TAATCAAGACTTCAGGTTTG 3’  All U. parvum serovars 54 °C (Knox et al. 2010) 
3DR3 5’ TCGCTTTTTTCATTACGAGTC 3’ Serovars 3 and 14 54 °C (Knox et al. 2010) 
6DR4 5’ TAATGTAAATAAAGCACTTATTC 3’ Serovars 1 and 6 54 °C (Knox et al. 2010) 
 
3.15 Real-time polymerase chain reaction (PCR) for the speciation and 
serotyping of U. parvum clinical isolates 
 
3.15.1 PCR Primer Design 
 
Whole genome sequences for the 14 serovars belonging to U. parvum and U. urealyticum were 
downloaded from the GenBank sequence database (NCBI; http://www.ncbi.nlm.nih.gov/) and 
interrogated using the Geneious bioinformatics software (Biomatters Ltd). From each ureaplasma 
whole genome sequence, the mba gene and its surrounding intergenic (non-coding) regions were 
located. These sequences for the 14 ureaplasma serovars were then aligned and regions which 
contained high levels of homology (either within U. parvum, U. urealyticum or high homology to 
both Ureaplasma species) were identified. Single nucleotide polymorphisms (SNPs) that were unique 
to each individual ureaplasma serovar were also identified. 
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These regions were further scrutinised using the basic local alignment (BLAST) search tool (NCBI) to 
identify any homology with other bacterial species or with human chromosomal DNA. Primers were 
then designed to amplify regions (no greater than 400 base pairs); ) with specific homology to only 
U. parvum species, areas which also contained SNPs for each of the U. parvum serovars (1, 3, 6 and 
14).  
Multiple primer sets were designed, purchased from Sigma-Aldrich and tested for their efficacy in 
real-time PCR assays for their ability to amplify only U. parvum serovars. Primers were further tested 
for their ability to differentiate U. parvum serovars 1, 3, 6 and 14 by high resolution melt analysis.  
A number of PCR primer sets were designed to specifically amplify U. parvum serovars at different 
regions of the mba.   
Table 3.6. Novel PCR primers targeting areas of the multiple banded antigen (mba) gene, designed 
for use in real-time PCR and high resolution melt assays 
Name Primer Sequence Tm Source 
UpuF 5’ CTAATAATGTTATTGATAATGCAG 3’ 55 °C novel 
UpmbaR 5’ GTTTTCAATTTCGTAAACTGC 3’ 53 °C novel 
UpuF2 5’ TTATAATAAAAAATATCTAATAATG 3’ 50 °C novel 
UpmbaR2 5’ CCAGCTCCAACTAAGGTAAC 3’  58 °C novel 
UpuF3 5’ TTATATAATTAAAAGTGCAAGTGC 3’  55 °C novel 
UpmbaR3 5’ TTGTTCATTAGGTTTTGGTTCACGA 3’ 61 °C novel 
UpuF4 5’ GTGCTAAATAAAAAGTATTTGC 3’ 53 °C novel 
UpmbaR4 5’ CCTGAAGTCTTGATTAATCCAC 3’ 58 °C novel 
UpmbaR5 5’ GTTTCAAAGTTCACTTTTTCTG 3’ 55 °C novel 
Once primers were received, each PCR assay was optimised and validated in order to assess the 
ability of each PCR assay to selectively amplify U. parvum serovars 1, 3, 6 and 14.   
 
3.16 Design of U. parvum real-time polymerase chain reactions  
 
Conventional PCR assays were used to optimise PCR parameters for each primer set. Optimisation 
included identifying the ideal annealing temperature, annealing time, MgCl2 concentration and 
primer concentrations. Once optimised parameters were obtained for each primer set, the ability of 
primers to specifically amplify U. parvum serovars was assessed. Primers which selectively amplified 
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U. parvum serovars 1, 3, 6 and 14, but not U. urealyticum or any other bacterial strain tested were 
utilised for further analysis.  
 
3.17 Validation of U. parvum real-time PCR assays 
 
The optimised real-time PCR assays were further assessed for their ability to differentiate U. parvum 
serovars 1, 3, 6 and 14 by real-time PCR and high resolution melt (HRM) analysis.  
 
PCR assays were performed in a total volume of 20 µL and contained 5 µL of DNA (all samples were 
standardised to 5 µg), 100 µM dNTPs, 1 X PCR buffer, 1 X SYBR green dye, 2.5 U taq DNA polymerase 
and DNAse/RNAse-free dH20 (Gibco). Assays also included optimised concentrations of forward and 
reverse PCR primers and MgCl2. All real-time PCR assays were carried out in the Rotor-Gene 6000 
real-time PCR cycler (Qiagen). Cycling conditions included 95 °C for 3 minutes to activate Platinum 
taq DNA polymerase; followed by 40 cycles of 95 °C for 15 seconds, optimised annealing 
temperatures for between 20 - 30 seconds, and extension at 72 °C for 20 seconds. Rotor-Gene Q 
Series Software (Version 1.7, Build 87; Qiagen) was programmed to acquire fluorescent signals with 
each extension step of cycling.  
 
Real-time PCR cycling was followed by a standard melting program, which included continuous 
fluorescent monitoring between 65 °C - 85 °C, with temperature increasing at a rate of 1 °C/s. 
Standard melting profiles were assessed for the presence of a single fluorescent 'peak', which was 
consistent with the presence of only a single PCR amplicon. This was further assessed by 
electrophoresing real-time PCR products on agarose gels and imaging for the presence of a single 
PCR band/amplicon.  
 
Following standard melting, a high resolution melt (HRM) assay was performed. This included 
continuous fluorescent monitoring between 70 °C - 85 °C, with temperatures increasing at a rate of 
0.02 °C/s. Upon completion of all programs, data was viewed and manipulated using the Rotor-Gene 
Q Series Software.  
 
3.18 Differentiation of U. parvum serovars using high resolution melt (HRM) 
 
The Rotor-Gene Q series software enables HRM data to be viewed and manipulated as both 
normalised melting curves, or as difference plots. Normalised melting curves plot the negative 
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derivative of fluorescence over temperature and illustrate the amplicon melting temperatures and 
patterns (which may differ, depending on the presence of SNPs). Difference plots display a user-
defined high resolution melting curve as the 'baseline' (x-axis), by which all other melting curves are 
plotted against. To differentiate U. parvum serovars 1, 3, 6 and 14, a user-defined 'baseline' was 
selected and all remaining serovars were compared to the baseline. Melt curves were considered to 
be the 'same' as the user-defined control (serovar) if the highest fluorescent peak was within ± 5 
units (U). By contrast, melt curves were classified as 'different' from the user-defined control 
(serovar) if the highest fluorescent peak was greater than ± 5 U (Stephens 2008).  
 
PCR primers which produced U. parvum serovar amplicons, which were unable to be differentiated 
using the criteria above were excluded from further analysis. Combinations of individual PCR primers 
were also assessed for their ability to differentiate U. parvum serovars 1, 3, 6 and 14.  
 
3.19 Analysis of U. parvum clinical isolates by real-time PCR and HRM  
 
Clinical specimens from several sources were used to assess the efficacy of the designed U. parvum 
real-time PCR and HRM assay. These consisted of 31 U. parvum clinical isolates obtained from the 
chorioamnion of women who delivered LPT or at term (see Chapter Four). Other U. parvum clinical 
isolates were obtained from previous studies, in which endocervical swabs, sperm and washed 
sperm samples were cultured for the presence of Ureaplasma spp. U. parvum isolates (characterised 
previously in (Knox et al. 2003)  were cultured in 10B broth (as per section 3.6.1) and DNA extracted 
(as per section 3.8.1). The remaining clinical isolates used to assess the U. parvum real-time PCR and 
HRM assays were obtained from pure (uncultured) amniotic fluid specimens taken from sheep that 
were injected with U. parvum serovar 6. The presence and amount of U. parvum serovar 6 within 
the amniotic fluid has been previously published (Dando et al. 2012). From these amniotic fluid 
samples, 200 µL of uncultured sample was used for DNA extraction and subsequent PCR. 
DNA from these clinical isolates was standardised to 5 µg/µL and used in optimised real-time PCR 
and HRM assays.  
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Fig 3.1.  Diagram of the mba gene and its surroundings, including areas targeted for primer design. The mba gene consists of an upstream, highly conserved 
region (depicted in green) and a highly variable downstream region that is composed of tandem repeating units (depicted in blue). The mba locus also 
contains two inverted repeat regions, which are proposed sites of DNA inversion events. The upstream conserved regions of the mba gene, including some 
intergenic (non-coding; depicted in dark grey) areas were targeted for primer design. 
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3.20 U. parvum inoculum preparation for the ex vivo model 
 
The ureaplasma strain selected for use in these experiments was isolated from the chorioamnion of 
a woman who delivered late preterm (at 34 weeks of completed gestation; Term = 40 weeks). 
Histological examination of the placenta demonstrated severe chorioamnionitis (Maternal grade 2; 
fetal grade 2; plate positive; using Redline et al. (2003) criteria). This clinical isolate, No. 429 was 
characterised as U. parvum serovar 6 – the ureaplasma serovar most frequently isolated in placentae 
delivered late preterm in our study population (discussed in Chapter Five). 
The ureaplasma inoculum was prepared as previously described (Moss et al. 2008). Briefly, a low 
passage culture of clinical isolate 429 was thawed on ice, serially diluted in 10B broth and incubated 
until exponential growth was achieved. The ureaplasma cultures were then pooled and centrifuged 
at 14 000 x g for 1 hour at 4 °C (Beckman and Coulter, Gladesville NSW). The supernatant was then 
removed and the pellet was carefully resuspended in cold 10B broth (held on ice). The concentrated 
ureaplasmas were vortexed to create an homogenous suspension, before being aliquotted into 
sterile cryogenic vials (all held on ice) and stored immediately at -80 °C until required. One aliquot of 
concentrated ureaplasmas then was thawed and the number of ureaplasma CFU/mL within the 
prepared inoculum was determined as described above (section 3.6.2).  
Sterile 10B broth (1 L) was also centrifuged and concentrated and prepared as above and this 
preparation served as the vehicle control inoculum.  
Prior to use, the prepared ureaplasma and 10B broth inocula were thawed on ice. The ureaplasmas 
were diluted in sterile PBS to achieve an inoculum of 2 x 107 CFU. The prepared 10B broth control 
inoculum was similarly diluted in sterile PBS and both were retained on ice until use.  
 
3.21 UV-inactivation of U. parvum inoculum 
 
An aliquot of the ureaplasma inocula was also exposed to ultraviolet light (UV), in order to kill the 
ureaplasmas (preventing replication of the microorganism), but preserving the surface-exposed 
lipoproteins of the organism.  
The ureaplasma inoculum was aliquotted into 100 µL volumes in a 96-well plate. The plate was 
attached to a retort stand at a distance of 5 – 10 cms from the UV lamp within a class II biohazard 
cabinet. The inoculum was then exposed to constant ultraviolet light for 20 minutes. The loss of 
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viability was then confirmed by subculturing the inoculum into 10B broth. No ureaplasma growth 
was detected (data not shown).   
 
3.22 Optimisation of Ussing chamber model  
 
Prior to performing the ex vivo experiments using human chorioamnion tissues; we first optimised 
the experimental conditions and parameters. We confirmed that the ureaplasmas were able to 
survive and propagate within the cell culture media (M199) when supplemented with urea and 
serum. We also determined an optimal concentration of U. parvum (CFU) to elicit an immune 
response. Finally, the oxygen tension, that best replicated the in vivo placental microenvironment 
and allowed the growth of ureaplasmas, was also optimised.  
 
3.23 Optimisation of U. parvum growth in M199 cell culture media 
 
The growth of U. parvum serovar 6 clinical isolate 429 in M199 media, supplemented with animal 
serum and urea at concentrations reported for term human amniotic fluid, was assessed. This 
growth was compared to the growth of ureaplasmas in 10B broth, the ideal in vitro growth medium 
for these bacteria (Shepard and Lunceford 1976).  
 
3.24 Immune study population and specimen collection 
 
From June 2014 to September 2014, women giving birth at the Royal Brisbane and Women’s 
Hospital (RBWH - Herston; Queensland, Australia) were recruited for this study. Women who 
delivered via Cesarean section (with uncomplicated pregnancies) were enrolled in this study and 
informed written consent was obtained for the collection of placentae following delivery. The work 
was approved by the ethics committees of the RBWH and The University of Queensland (UQ) 
(HREC/12/QRBW/391) and was reviewed by the HREC of QUT and deemed exempt from the need 
for university HREC review. Following delivery, theatre staff placed the placenta into a sterile 
container, which was then transported to the University of Queensland Centre for Clinical Research 
(UQ-CCR; Herston, Queensland). All placentae were de-identified.  
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3.24.1 Placental dissection 
 
Within one hour of delivery, each placenta (Fig 3.2A) was dissected under aseptic conditions. The 
placenta was placed onto a sterile tray where the chorioamnion membranes were carefully cut from 
the edge of the placenta (Fig 3.2 B and C) using sterile scissors. Areas in which the amnion had 
detached from the chorion were excluded. Once the chorioamnion was detached from the placenta 
(Fig. 3.2 D), the membranes were placed into sterile PBS and washed to remove any adherent blood 
clots. The membranes were then spread over a sterile Petri dish and six circular sections of the 
membrane (measuring approx. 6.5 cm diameter) were cut using a sterile membrane cutter (Fig 3.2 
E). The sections were then placed into pre-warmed M199 media (Invitrogen) (Fig. 3.2 F). Remaining 
tissue was then cut to size (measuring approx. 1 x 3 cm2) and placed into a tissue cassette and placed 
in paraformaldehyde for histology and into sterile cryogenic vials and stored at -80 °C.  
 
3.24.2 Ussing chamber preparation  
 
The chorioamnion tissue sections were then sandwiched between two discs of sterile semi-rigid 
mesh and secured within an Ussing chamber (Fig 3.2 G - I). Using sterile syringes, the maternal and 
fetal compartments were slowly filled with pre-warmed M199 media (Invitrogen), supplemented 
with 10% heat-inactivated fetal bovine serum (Sigma-Aldrich) and 100 U/mL penicillin (CSL 
Biosciences; Parkville, Victoria). The maternal membrane perfused media was also supplemented 
with fluorescein isothiocyanate (FITC)-dextran (4000 kDa, final concentration: 10 µM; Sigma-Aldrich) 
to assess membrane integrity/permeability over time. Different M199 media types were used for 
each maternal and fetal compartment (M199 with phenol red for maternal compartments; M199 
without the addition of phenol red for fetal compartments) in order to immediately identify any 
leaks between the compartments within each Ussing chamber.  
 
The entry/exit ports of the Ussing chambers (Fig 3.3) were connected to maternal and fetal media 
reservoirs via sterile silicone tubing (BioRad; Gladesville, New South Wales). This allowed the media 
to exit the maternal or fetal compartment, into the respective media reservoir thereby creating a 
closed loop for each compartment (Fig 3.2). Each compartment of the Ussing chamber held 
approximately 4 mL of media, with the tubing holding approx. 6 mL. Tubing from each ‘maternal’ 
and ‘fetal’ compartment was then connected to a pump (EconoGradient Pump; BioRad) with a set 
flow-rate of 1.5 mL/min and chambers were maintained within an incubator (Memmert INCO Trigas 
incubator; Schwabach, Germany) at 37 °C, 5% CO2 and 8% O2 for 30 hours. The Ussing chambers 
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were allowed to equilibrate within the incubator for 30 minutes prior to the commencement of each 
experiment.  
 
Immediately following the equilibration period, the experiment was started (t = 0 hrs) and media 
was collected from each of the maternal and fetal reservoirs to act as a baseline for all further 
measurements. Immediately following this baseline reading, duplicate chambers were injected with 
each experimental condition (total of 6 Ussing chambers per placenta) and were exposed to:  (i) 2 x 
107 CFU of live U. parvum serovar 6 clinical isolate 429; (ii) 2 x 107 CFU of UV-inactivated U. parvum 
serovar 6 clinical isolate 429; or (iii) 10B media vehicle control.  
 
The maternal and fetal perfusates were sampled via a three-way stopcock (decontaminated at each 
sampling using 70% ethanol) at 2, 4, 8, 20 and 30 hours post-infection; transferred to sterile 
cryogenic vials and stored at – 80 °C for future analysis. 
 
At the completion of the 30 hour experiment, the remaining media was drained from each maternal 
and fetal chamber (and reservoir) and centrifuged at 5000 x g for 20 minutes. The resulting pellet 
was then resuspended in 100 µL of sterile PBS and used for Western blot in order to assess MBA 
variation occurring within the ureaplasma population present within the media.  
 
Chorioamnion tissue from each chamber was also dissected and placed into paraformaldehyde for 
histology and the remainder was placed into sterile cryogenic vials and stored at -80 °C.
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Figure 3.2. Photos illustrating placental tissue dissection (panels A – F) and Ussing chamber assembly (panels G-I) for ex vivo immune response experiments. 
A B C 
D E F 
G H I 
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Figure 3.3. Ussing chamber design used for ex vivo chorioamnion infection with Ureaplasma spp. Chorioamnion tissue represents a physical barrier 
between the two compartments and both compartments were separately perfused with sterile supplemented M199 media. The experimental 
treatments were then added to the maternal compartment of each Ussing chamber (n = 6)  
Peristaltic pump Peristaltic pump 
‘Maternal’ reservoir 
M199 + phenol red + 10% 
FBS + 100 U/mL penicillin 
- 10 mM FITC-Dx 
- Experimental 
treatment  
 
‘Maternal’ 
compartment 
(Approx. 4 mL) 
 
‘Fetal’ 
compartment 
(Approx. 4 mL) 
‘Fetal’ reservoir 
M199 (no phenol red) + 
10% FBS + 100 U/mL 
penicillin 
Human chorioamnion tissue 
‘Sandwiched' between semi-rigid mesh 
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3.25 Analysis of maternal and fetal perfusates 
 
3.25.1 FITC-dextran analysis 
 
Alterations in the integrity or permeability of the chorioamnion tissue were monitored using FITC-
dextran, which was added to the maternal compartment. A measure of the transfer from the 
maternal to fetal compartment was assessed using a fluorescent plate reader (SpectraMax Paradigm 
plate reader, Molecular Devices). 100 µL of each maternal and fetal perfusate was aliquotted into 
the well of a 96-well plates and the levels of FITC-dextran were measured at excitation/emission of 
495/520 nm. FITC-dextran levels in each perfusate were then represented as the percentage transfer 
between the maternal and fetal compartment over the course of each 30 hour time-point 
experiment.  
 
3.25.2 BioPlex Assays for the detection of cytokines in maternal and fetal 
perfusates  
 
Maternal and fetal perfusates from replicate Ussing chambers within each experiment (n = 4 
experiments) were pooled for each of the time points (0 hr, 8hr, 20 hr and 30 hr) and analysed in 
duplicate using the BioPlex Pro Human proinflammatory cytokine immunoassay for interleukin (IL)-2, 
IL4, IL-6, IL-8, IL-10, granulocyte macrophage colony-stimulating factor (GM-CSF), tumour necrosis 
factor (TNF)-α and interferon (IFN)-γ (BioRad; Gladesville, New South Wales), according to the 
manufacturer’s instructions. 
 
 3.25.3 MMP-9 activity and gelatin zymography 
 
Pooled maternal and fetal perfusates from each individual Ussing chamber were also used to 
determine the presence of matrix metalloproteinase (MMP)-9 within each Ussing chamber. 50 µL of 
pooled perfusate was mixed with protein loading dye and loaded into 10% gelatin zymography gels. 
Gels were electrophoresed at 120 V for 1 hour and gels were then incubated in 0.5% Triton X 
solution (renaturing buffer) for 1.5 hours. Gels were then gently washed with water before the 
addition of incubation buffer (50 mM Tris, 10 mM CaCl2, 50 mM NaCl) at 37 °C for 24 – 48 hours. 
After incubation, each gel was then stained with Coomassie blue for 1 hour and then destained with 
dH20 for at least 1 hour before gel images were captured (CanoScan 8600F). MMP activity was 
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represented by a clear band of 92 kDa, with a blue stained background (MMP-9 positive control 
kindly provided by Dr Eliza Whiteside). Controls included an additional gel loaded with samples and 
positive controls treated in the same manner, but with the addition of 10 mM EDTA to the 
incubation buffer. EDTA prevents MMP activity and these gels showed no significant MMP activity 
and the absence of a clear band of 92 kDa following staining.  
 
3.26 Analysis of chorioamnion tissues following ex vivo experiments  
 
Tissue sections stored in paraformaldehyde were processed and embedded in paraffin. Tissue blocks 
were then cut into 5 µm sections, placed onto glass slides, dewaxed and then subsequently stained 
with Haemotoxylin and Eosin (QIMR Berghoefer Medical Research Institute Histology Department). 
Stained sections were viewed using a light microscope (Olympus CX21) and a total of ten 
representative images captured for each chorioamnion tissue from each placental experiment.  
 
As no previous studies have attempted to grade chorioamnion tissues within an ex vivo model, 
grading criteria were specifically devised for this study (Table 3.7) and provided to two impartial 
scientists (blinded to outcome) for pathology grading. Multiple images of chorioamnion tissue from 
each of the three treatment groups from each placental experiment (n = 4) were randomised and 
provided to the scientists, along with the grading criteria. Each image was given a score (1 – 3) and 
the total mean value for each treatment group were then calculated.  
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Table 3.7. Pathology grading and tissue severity guidelines for ex vivo chorioamnion tissues. Tissues were graded (score: 1 - 3) according to key features of 
the chorioamnion. Grading was performed by two independent researchers 
SCORE Example Key features 
 
 
1 
 
 
- No significant pathology 
 
- Intact amnion epithelial layer and connective 
tissue 
- Intact chorion epithelial layer and connective 
tissue 
 
 
 
2 
 
 
- Mild/moderate 
 
- Partial separation between the amnion 
connective tissue and the chorion epithelial layer 
 
 
 
 
3 
 
  
- Severe 
 
- The amnion and chorion layers are detached 
 
- Amnion epithelial is thickened 
Amnion epithelium 
Chorion connective 
Chorion epithelium 
Amnion connective 
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Chapter Four: 
 
 
 
Chorioamnion infection and histological 
chorioamnionitis in late preterm and 
term placentae
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Introduction 
 
Preterm birth (PTB; delivery < 37 weeks) is a major obstetric challenge, accounting for 50% of 
neonatal mortality and up to 70% of the long-term neonatal and infant morbidity (March of Dimes 
2012). Approximately 10% of all births occur preterm and despite improved intervention strategies, 
alarmingly the rates of PTB continue to increase in almost every country (March of Dimes 2012). 
PTBs can be grouped according to the gestational age at the time of delivery: infants who are born 
prior to 28 weeks of pregnancy are considered to be extremely preterm; very preterm infants are 
delivered at less than 32 weeks of completed gestation; while late preterm (LPT) infants are 
delivered between 32 – 36 weeks of gestation (Bick 2012). LPT infants are particularly important, as 
these infants account for 79 - 84% of all PTBs and their incidence has increased by more than 40% in 
the last 25 years (Raju 2006; Goldenberg et al. 2008b; Hamilton et al. 2012; Li et al. 2013). 
Importantly, while it has been determined that these infants are at increased risk of adverse 
sequelae, such as cerebral palsy (Soleimani et al. 2014), learning and visual deficits (Morse et al. 
2009; Soleimani et al. 2014) and increased risk of chronic diseases in adulthood (Sullivan et al. 2012), 
the aetiology of LPT birth is currently unknown.  
 
Infection within the female upper genital tract (UGT) is the most frequent (and potentially 
preventable) cause of PTB (Hillier et al. 1988; Goldenberg et al. 2000b; DiGiulio et al. 2008; DiGiulio 
et al. 2010; DiGiulio 2012). Of those women who experience PTB, up to 40% of have evidence of 
intraamniotic infections (March of Dimes 2012). While there is currently overwhelming evidence 
implicating intraamniotic (UGT) infection with early PTBs (< 32 weeks) (DiGiulio 2012), there is 
significantly less information on the prevalence of infection in later gestations. Researchers have 
stated that “spontaneous births at less than 30 weeks, an association with infection is the rule... 
while late spontaneous preterm births do not usually occur in association with infection” 
(Goldenberg et al. 2002), however, there is little scientific evidence to confirm this and the lack of 
association between birth in the LPT period and intraamniotic infection has not been adequately 
explained. Given this, it is necessary to further investigate the prevalence of infection in later 
gestations (in particular, the LPT and term periods).  
 
Numerous microorganisms have been isolated from the UGT of women who deliver very preterm 
(Figure 4.1) and infections early in gestation are often polymicrobial, making it difficult to determine 
if there is an association between individual microorganisms and adverse outcomes (Hillier et al. 
1988; DiGiulio et al. 2008; Onderdonk et al. 2008; DiGiulio et al. 2010). However, of the 
microorganisms associated with UGT infections, the human Ureaplasma spp. are among those most 
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frequently isolated bacteria from the amniotic fluid (Figure 4.1A) and placentae (Figure 4.1B) of 
women who deliver at less than 32 weeks of gestation. 
 
 
 
Figure 4.1. Prevalence and diversity of microorganisms isolated from (A) amniotic fluid and (B) 
chorioamnion tissue of women experiencing preterm birth (< 32 weeks). Only studies which included 
the classification and total number of positive patient samples (by culture or PCR) have been 
included. Data compiled from (Hillier et al. 1988; Jalava et al. 1996; DiGiulio et al. 2008; Onderdonk 
et al. 2008; Han et al. 2009; DiGiulio et al. 2010; Namba et al. 2010; Marconi et al. 2011)  
 
The presence of infections within the UGT have been widely associated with adverse pregnancy 
outcomes, including spontaneous preterm premature rupture of membranes (pPROM) (Jacobsson et 
al. 2009; DiGiulio et al. 2010), PTB (Hillier et al. 1988; Gibbs et al. 1992; Goldenberg et al. 2002; 
Goncalves et al. 2002) and spontaneous abortion or miscarriage (Naessens et al. 1988). Additionally, 
these infections may also affect the neonate and have been associated with both short- and long-
term adverse outcomes, including respiratory distress syndrome (RDS) (Gomez et al. 1998; Kramer 
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2008) or bronchopulmonary dysplasia (BPD) (Viscardi and Hasday 2009; Sung et al. 2010; Viscardi 
2010), sepsis (Goncalves et al. 2002), meningitis (Garland and Murton 1987) and adverse CNS 
outcomes, such as intraventricular haemorrhage and cerebral palsy (Viscardi et al. 2008; Berger et 
al. 2009; Oskoui et al. 2013). While infection has been associated with adverse pregnancy outcomes, 
it is important to note that not all women with intraamniotic infections will deliver preterm. A study 
by Gerber et al. (2003) identified that the Ureaplasma spp. was present in 29/257 (11.4%) amniotic 
fluid specimens collected at 15 – 17 weeks of gestation. However, only 21% of these women 
developed pPROM and 24% experienced PTB, while >70% of women with diagnosed ureaplasma 
infections delivered at term with no apparent adverse outcomes. Others have reported similar 
findings with up to 20% of women in these studies identified as infected with Ureaplasma spp. 
within the UGT at the time of term delivery (Hillier et al. 1988; Gray et al. 1992). It is currently not 
clear why some women with intraamniotic infections deliver preterm, while others do not; however, 
a consistent finding within the literature is the association between UGT infection and an 
inflammatory response, such as histological chorioamnionitis (Czikk et al. 2011).  
 
Chorioamnionitis is defined as inflammation within the chorioamnion membranes (which surround 
the developing fetus during pregnancy) and is present in up to 70% of pregnancies affected by 
infection (Eschenbach 1993). Diagnosis of chorioamnionitis may be associated with the presence of 
clinical signs or symptoms including: maternal temperature or tachycardia, uterine tenderness and 
pPROM; however, most cases of chorioamnionitis are clinically silent (Czikk et al. 2011; Martinelli et 
al. 2012). In suspected cases of chorioamnionitis, diagnoses can be made by performing culture 
and/or PCR of amniotic fluid (collection of this specimen is an invasive procedure) to identify 
microorganisms (DiGiulio et al. 2010; Romero et al. 2014), or by retrospective histological analysis of 
placentae for inflammation and necrosis (Redline et al. 2003). The prevalence of histological 
chorioamnionitis is inversely correlated with gestational age, with 40 – 70% of placentae from early 
PTBs showing evidence of chorioamnionitis; but chorioamnionitis is detected in only 2 - 4% of term 
placentae (Czikk et al. 2011). However, a study by Gordon et al. (2011) demonstrated an interesting 
bimodal trend in the prevalence of histological chorioamnionitis (Figure 4.2). This study 
retrospectively analysed placentae from 952 pregnancies and demonstrated histological 
chorioamnionitis in 22.6% of all women, with an increased prevalence of chorioamnionitis at ≤ 29 
weeks of gestation (up to 17%), and also later in gestation (≥ 36 weeks, up to 30%; Figure 4.2). While 
histological chorioamnionitis has been correlated with intraamniotic infections, there is some debate 
as to the cause of the host immune response, especially if there are polymicrobial infections. While 
studies have demonstrated an association between Ureaplasma spp. and the development of 
 79 
 
chorioamnionitis (Hillier et al. 1988; Goldenberg et al. 2008a; Hecht et al. 2008; Kasper et al. 2010; 
Namba et al. 2010), further studies are required to determine if these microorganisms can cause 
chorioamnionitis independently of other microorganisms.  
 
 
Figure 4.2 Prevalence (% of total pregnancies, n = 952) of histological chorioamnionitis (HCA; grey 
shading) and fetal inflammatory response (FR; black shading) at which each infant/placenta is 
delivered. Image adapted from Gordon et al. (2011).  
 
For this current study, we hypothesised that Ureaplasma spp. and other microorganisms would be 
isolated from the chorioamnion of women who delivered LPT or at term, and that the presence of 
these microorganisms may be associated with adverse outcomes, such as histological 
chorioamnionitis. The aims of this study were to (i) identify the prevalence and diversity of 
microorganisms from LPT and term chorioamnion tissue; (ii) to identify if infection was associated 
with adverse pregnancy or neonatal outcomes; and (iii) to identify if particular microorganisms were 
more frequently associated with adverse outcomes.  
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Materials and methods 
All methods pertaining to this chapter are summarised in Chapter three. Briefly, placentae were 
collected and processed aseptically post-delivery and tissue specimens were snap frozen as per 
Chapter Three, Section 3.2. Placental samples were shipped to QUT on a regular basis for 
microbiological testing. This included culture (Chapter three, section 3.7) of placental swabs and 
chorioamnion tissues to identify any microorganisms present. DNA was extracted from 
chorioamnion tissues and cultured clinical isolates (Chapter Three, section 3.8) and these specimens 
were tested by 16S rRNA (Chapter three, section 3.9) to identify any microbial species present. 16S 
rRNA amplicons were then detected by agarose gel electrophoresis (Chapter three, section 3.10) and 
these amplicons were subsequently purified and then sequenced (Chapter three, section 3.11) to 
identify the genera of the organisms present.  
Statistical analysis 
Data within the chapter are presented as the mean value, plus the standard error of the mean 
(SEM).  
All data within this study were imported and manipulated within the statistical package for social 
sciences (SPSS) software program. Relationships between patient outcomes (maternal demographic 
data, maternal pregnancy outcomes or neonatal outcomes) were analysed against the variables of 
late preterm/term birth; the presence/absence of microorganisms (regardless of the type of 
organisms present); presence/absence of Ureaplasma spp. and the presence/absence of 
microorganisms other than ureaplasmas. Analyses within this chapter included both binary logistic 
regression analysis and analysis of variance (ANOVA) to determine statistical significance between 
cohorts and the types of tests used within this study are noted throughout the chapter.  
Statistical significance was accepted as p < 0.05.  
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Results 
Study population  
A total of 517 women were recruited during this study period. Of those, 477 women and their 535 
offspring were included in the final microbiological study and data for these women and their 
offspring are presented in this chapter.  
 
The majority of women in this study were Caucasian (66.4%) or African American (25.8%), with 26 
women of mixed ethnicity and 8 women of Asian descent (Table 4.1). Of the 535 infants included in 
the study, 421 were singleton births and 114 infants were multiple births (54 sets of twins and two 
sets of triplets). The rate of fetal malformations and other syndromes such as isoimmunisation in 
this study population was very low (13/535; 2.4%). Since the prevalence of these factors was very 
low, these were not considered to be factors which contributed to LPT birth and so these infants 
were included in our analyses.  
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Late preterm vs. term pregnancy characteristics 
Maternal demographic  
There were no significant differences in maternal age, gravida, marital status, ethnicity, level of 
medical insurance (Table 4.1) or mode of delivery between women who delivered LPT or at term 
(Table 4.2). Almost all women included in this study (both cohorts > 97%) attended at least one 
prenatal care visit during their current pregnancy. However, there was a significant difference in the 
mean level of parity of women who delivered at term. These women had a lower parity (mean: 1.7 ± 
0.1) than those women who delivered LPT (mean: 2.1 ± 0.6; Table 4.1).   
Table 4.1. Demographic data of mothers (n = 477) who delivered late preterm and at term  
 Late Preterm (n = 385) Term (n = 92) Significance 
Maternal age in years (mean, range) 27.4 ± 0.3 (15 – 43) 27.7 ± 0.5 (18 – 39) NS1 
Gravida2 2.5 ± 0.1 (1 – 11) 2.2 ± 0.5 (1 – 8) NS 
Parity3 2.1 ± 0.1 (1 – 10) 1.7 ± 0.1 (1 – 6) 0.015 
Marital Status     
- Single 190/385 (49.4%) 32/92 (34.8%) NS 
- Married 191/385 (49.6%) 60/92 (65.2%) NS 
- Unknown 4/385 (1.0%) 0/92 (0.00%) NS 
Ethnicity    
- Caucasian 247/385 (64.2%) 69/92 (75.0%) NS 
- African-American 111/385 (28.8%) 15/92 (16.3%) NS 
- Mixed 19/385 (4.9%) 7/92 (7.6%) NS 
- Asian 7/385 (1.8%) 1/92 (1.1%) NS 
- Undisclosed 1/385 (0.3%) 0/92 (0.0%) NS 
Medical Insurance    
- Private 204/385 (53.0%) 91/92 (66.3%) NS 
- Medicaid 162/385 (42.1%) 24/92 (26.1%) NS 
- Self pay/uninsured 16/385 (4.1%) 4/92 (4.3%) NS 
- Undisclosed 3/385 (0.8%) 3/92 (3.3%) NS 
Evidence of one prenatal care visit 379/385 (98.4%) 90/92 (97.8%) NS 
1NS - Not statistically significant 
2Gravida - number of clinical pregnancies 
3Parity - number of viable offspring resulting from all pregnancies 
Data was analysed by logistic regression analysis and compared the maternal demographic data of 
women whose pregnancies were delivered late preterm to those delivered at term.  
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Adverse pregnancy outcomes 
There were no significant differences in the prevalence of signs/symptoms of infection in women 
who delivered LPT or at term, nor was there any difference in the rate of prior chorioamnionitis 
within these two cohorts. Women who delivered LPT had a higher incidence of hypertension 
(29.6%), compared to those women who delivered at term (7.6%), however this difference was not 
statistically significant. Unsurprisingly, the presence of pregnancy-induced hypertension was 
significantly higher in women who delivered LPT (30.4%), compared to those women who delivered 
at term (4.3%; p = 0.007) (Table 4.2).  
There was also a higher prevalence of cervical incompetence (66.7%) and pPROM (45.4%) in women 
who delivered LPT than for women who delivered at term (0.0% and 0.0%, respectively). Due to the 
nature of logistic regression analysis, it was not possible to derive p-values for these outcomes, due 
to complete separation of data within the LPT and term cohorts. Women who delivered LPT were 
treated with antibiotics significantly more frequently during their labour (62.9%), compared to those 
women who delivered at term (22.8%; p = 0.049). Despite the high number of women who delivered 
LPT, there were no differences in the rate of vaginal or Cesarean section deliveries in these two 
cohorts (Table 4.2).  
Table 4.2. Maternal pregnancy outcomes for mothers who delivered late preterm and at term  
 Late preterm (n = 385) Term (n = 92) Significance 
At least one sign/symptom of infection1 27/385 (7.0%) 7/92 (7.6%) NS2 
Previous history of chorioamnionitis documented 17/385 (4.4%) 3/92 (3.3%) NS 
Hypertension 114/385 (29.6%) 7/92 (7.6%) NS 
Pregnancy induced hypertension 117/385 (30.4%) 4/92 (4.3%) 0.007 
Cervical incompetence 257/385 (66.7%) 0/92 (0.0%) # 
Antibiotics administered during labour3 242/385 (62.9%) 21/92 (22.8%) 0.049 
Preterm premature rupture of membranes (pPROM) 175/385 (45.4%) 0/92 (0.0%) # 
Mode of delivery    
- Vaginal 265/385 (68.8%) 69/92 (75.0%) NS 
- Cesarean 120/385 (31.2%) 23/92 (25.0%) NS 
1Signs and symptoms of infection included: maternal temperature > 38 °C, uterine or abdominal 
tenderness, foul-smelling vaginal discharge, maternal tachycardia (> 120 bpm) or fetal tachycardia (> 
160 bpm) 
2NS - Not statistically significant 
3 While the antibiotic dose and type were not recorded, antibiotics were administered to women 
more than 3 hours prior to delivery. 
# - Logistic regression analysis was unable to derive p-values for these outcomes/conditions due to 
complete separation of data within the two cohorts.  
Data was analysed by logistic regression analysis and compared maternal pregnancy outcomes of 
women who delivered late preterm or at term 
 84 
 
Fetal characteristics  
The mean gestational age of LPT infants was 34.9 ± 0.1 weeks, compared to 39.4 ± 0.1 for those 
infants delivered at term. There were no differences in the mean Apgar scores of LPT and term 
infants at either 1 or 5 minutes post-delivery.  
There were, however, some interesting differences between these two cohorts. LPT infants had a 
lower birth weight, compared to term-delivered neonates (2535.9 ± 52.4 grams vs. 3489.0 ± 44.3 
grams, respectively; p = 0.001), but there was no difference in the mean placental weight for LPT and 
term pregnancies (422.2 ± 6.3 vs. 469.0 ± 7.9 grams, respectively).  There were no differences in the 
incidence of histological chorioamnionitis in LPT and term cohorts, nor were there any differences in 
the mean maternal and fetal stages of inflammation (Table 4.3). Following delivery, LPT infants 
displayed more signs of respiratory distress during their first 24 hours of life (23.7%), they were 
administered oxygen for prolonged periods (> 6 hours; 12.4%), and were treated with continuous 
positive airway pressure (CPAP) respiratory support more often (13.5%) than those infants who were 
delivered at term (3.3%, 0.0% and 0.0%, respectively) (Table 4.3). LPT infants were also diagnosed 
with respiratory distress syndrome more frequently than those infants delivered at term (12.0% vs. 
0.0%, respectively) (see Table 4.3).  As a consequence of these adverse outcomes, the overall length 
of stay for LPT infants was significantly higher than those infants who were delivered at term (7.1 
days vs. 2.2 days, respectively; p < 0.001; Table 4.3). 
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Table 4.3. A comparison of outcomes for neonates (n = 535) delivered late preterm and at term 
 Late preterm (n = 443) Term (n = 92) Significance 
Gestational age at delivery (mean, range) 34.9 ± 0.1 (32 – 36) 39.4 ± 0.1 (37 – 41) NS1 
Apgar2 score – 1 minute (mean, range) 7.8 ± 0.1 (1 – 10) 8.1 ± 0.2 (2 – 9) NS 
Apgar2 score – 5 minutes (mean, range) 8.8 ± 0.03 (2 – 10) 8.9 ± 0.03 (8 – 10) NS 
Birth weight (mean, range) 2535.9 ± 52.4 (1060 - 4530) 3489.0 ± 44.3 (2680 - 4350) 0.001 
Placental weight (mean, range) 422.2 ± 6.3 469.0 ± 7.9 NS 
Chorioamnionitis in current pregnancy3 69/443 (21.7%) 25/92 (27.2%) NS 
- Maternal stage inflammation 1.4 ± 0.03 (1 – 3) 1.5 ± 0.1 (1 – 3) NS 
- Fetal stage inflammation  2.3 ± 0.04 (1 – 3) 2 ± 0.1 (1 – 3) NS 
Male : Female 225 : 2174 51 : 41 NS 
Continuous positive airway pressure (CPAP) 60/443 (13.5%) 0/92 (0.0%) # 
Features of RDS5 < 24 hours after birth  105/443 (23.7%) 3/92 (3.3%) 0.100 
Required oxygen support for > 6 hrs 55/443 (12.4%) 0/92 (0.0%) # 
Diagnosed RDS5 53/443 (12.0%) 0/92 (0.0%) # 
Length of Stay 7.1 ± 0.3 (1 - 43) 2.2 ± 0.1 (1 - 7) < 0.001 
1NS - Not statistically significant 
2 Apgar – a measure of neonatal health scored at 1 min and 5 minutes post-delivery; measures 
appearance, pulse, reflex, activity and respiration of the newborn. 
3 Chorioamnionitis was determined by US pathologists (blinded to outcome) and was graded for 
severity of inflammation according to (Redline et al. 2003) 
4 The sex of one infant was not disclosed  
5RDS - respiratory distress syndrome 
# Logistic regression analysis was unable to derive p-values for these outcomes/conditions due to 
complete separation of data within the two cohorts. 
Data analysed by logistic regression analysis and compared the outcomes of neonates delivered late 
preterm or at term. 
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Chorioamnion infection 
Chorioamnion infection, as detected by PCR and/or culture of microorganisms from clinical 
specimens, was identified in 10.6% (57/535) placentae (Table 4.4, Supplementary Table 8.1). In some 
placentae, polymicrobial chorioamnion infections were identified; multiple microbial species were 
isolated from 4/57 (7.0%) placentae (Supplementary Table 8.1).  
 
Of the bacteria detected within chorioamnion tissue, the most prevalent were Ureaplasma parvum 
(36/59; 59.0%), Ureaplasma urealyticum (6/61; 9.8%), Streptococcus agalactiae (Group B beta 
haemolytic Streptococcus (GBS); 6/61; 9.8%), Bacteroides fragilis (2/61; 3.3%), Bifidobacterium spp. 
(2/61; 3.3%), Gardnerella vaginalis (1/61; 1.6%), Propionibacterium spp. (1/61; 1.6%) and Escherichia 
coli (1/61; 1.6%) (Table 4.4 and Figure 4.3). No Lactobacillus spp. were identified by culture or PCR 
methods, nor were any fungi or yeasts detected within any chorioamnion tissues sampled. Non-
cultivable bacteria were detected by molecular methods in six (9.8%) placentae.  
 
When comparing the prevalence of infection, there were no significant differences in the presence 
of microorganisms within the chorioamnion of women who delivered LPT or at term (9.9% and 
14.1%, respectively). Since there was no difference in the prevalence of infection between these 
groups, we also compared the microbial load (number of CFU per swab or per gram of tissue) in 
placentae delivered LPT and at term. The microbial load was determined by counting the number of 
colonies isolated on primary isolation media (this was not able to be determined for those 
microorganisms which did not grow on primary isolation media, or those cultured only after 
enrichment within thioglycollate broths). There was no significant difference in the mean microbial 
load within LPT or term placentae (9.73 x 107 CFU vs. 5.85 x 107 CFU, respectively; p = 0.159), nor 
was there any difference in the prevalence of histological chorioamnionitis in LPT or term placentae 
(59.1% and 38.5%, respectively).  
 
Regardless of when placentae were delivered, U. parvum and U. urealyticum were isolated most 
frequently within placentae (71.2%; (Figure 4.3). Ureaplasmas were also detected in higher numbers 
(CFU) than any other microorganism within this study (Table 4.4). 
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Table 4.4. The diversity and prevalence of microorganisms isolated from placentae delivered late preterm (n = 46) and at term (n = 9)  
MICROORGANISMS DETECTED WITHIN PLACENTAE 
 Late preterm (32 – 36 weeks) Term (> 37 weeks) 
Microorganism Frequency1 (%) Bacterial load (mean)2 Frequency1 (%) Bacterial load (mean)2 
Ureaplasma parvum 27 (58.7%) 4.86 x 108 9 (60.0%) 1.16 x 108 
Ureaplasma urealyticum 6 (13.0%) 2.92 x 108 0 (0.0%) -  
Uncultured bacterium 3 (6.5%) - 3 (20.0%) - 
Streptococcus agalactiae (GBS) 3 (6.5%) 1 x 103 3 (20.0%) 1 x 106 
Bacteroides fragilis 2 (4.3%) 1 x 103 0 (0.0%) - 
Bifidobacterium spp. 2 (4.3%) 1 x 103 0 (0.0%) - 
Gardnerella vaginalis 1 (2.2%) 1 x 103 0 (0.0%) - 
Escherichia coli 1 (2.2%) 1 x 103 0 (0.0%) - 
Propionibacterium spp. 1 (2.2%) 1 x 103 0 (0.0%) - 
TOTAL NUMBER OF ORGANISMS ISOLATED 46  15  
FREQUENCY OF INFECTION3 44/443 (9.9%) - 13/92 (14.1%) - 
Infection and chorioamnionitis 26/44 (59.1%) - 5/13 (38.5%) - 
1 Frequency- the total number of microorganisms isolated by standard culture, growth in enrichment broth or by PCR. No other statistically significant 
differences were seen in the incidence of infection 
2 Quantitative analysis was not always possible, as some microorganisms were isolated in enrichment broth or by PCR only. Quantitative analyses shown 
where possible 
3 Some placentae (n = 4) contained polymicrobial infections. This number represents the total number of placentae which were found to have infection, 
regardless of the number of organisms isolated from each placentae  
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Figure 4.3. The diversity and prevalence of microorganisms detected in late preterm (A) and term (B) placentae 
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Association of chorioamnion infection with adverse pregnancy and neonatal 
outcomes  
To determine if there was an association between infection and adverse outcomes, pregnancies 
were grouped based on the presence or absence of chorioamnion infection and the pregnancy 
outcomes and fetal outcomes for these women were compared.  
Maternal demographic data 
There were no statistically significant differences in the maternal demographic data of women 
whose chorioamnion was infected with microorganisms, when compared to those women whose 
chorioamnion had no detectable microorganisms (by culture and/or PCR; Table 4.5).  
 
Table 4.5. Demographic data for women (n = 474) whose pregnancies were complicated by 
chorioamnion infection compared to those who had no chorioamnion infection  
 Chorioamnion infection 
(n = 471) 
No chorioamnion detected 
(n = 4271) 
Significance 
Maternal age (mean, range) 25.0 ± 0.7 (17 – 38) 27.8 ± 0.3 (15 – 43) NS2  
Gravida3 (mean, range) 2.2 ± 0.2 (1 – 5) 2.5 ± 0.1 (1 – 11) NS 
Parity4 (mean, range) 1.9 ± 0.1 (1 – 4) 2.1 ± 0.1 (1 – 10) NS 
Marital Status    
- Single 28/47 (59.6%) 232/427 (54.3%) NS 
- Married 19/47 (40.4%) 190/427 (44.5%) NS 
- Undisclosed 0/47 (0.0%) 5/427 (1.2%) NS 
Health insurance    
- Private 16/47 (34.0%) 247/427 (57.9%) NS 
- Medicaid 25/47 (53.2%) 160/427 (37.5%) NS 
- Self pay/uninsured 3/47 (6.4%) 16/427 (3.7%) NS 
- Undisclosed 3/47 (6.4%) 4/427 (0.9%) NS 
Ethnicity    
- Caucasian 26/47 (55.3%) 289/427 (67.8%) NS 
- African-American 20/47 (42.6%) 104/427 (24.3%) NS 
- Mixed 1/47 (2.1%) 25/427 (5.8%) NS 
- Asian 0/47 (0.0%) 8/427 (1.9%) NS 
- Undisclosed 0/47 (0.0%) 1/427 (0.2%) NS 
Evidence of one prenatal care visit 46/47 (97.9%) 419/427 (98.1%) NS 
1 Some women (n = 3) delivered multiple placentae and one placenta was found to be infected, while 
the other was shown to be uninfected by culture and 16S rRNA PCR. Data from these women with 
contrasting placental microbiology results were excluded from this analysis 
2 NS – Not statistically significant 
3 Gravida - the number of clinical pregnancies 
4 Parity - the total number of viable offspring resulting from all clinical pregnancies 
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Adverse pregnancy outcomes 
There were no differences in the prevalence of hypertension or pregnancy-induced hypertension in 
those women (18.9% vs. 17.0%) with or without (26.7% and 26.9%, respectively) chorioamnion 
infection.  
Interestingly, there was no significant difference in the clinical histories or signs/symptoms of 
infection in women with or without chorioamnion infection; however, women in both cohorts were 
treated with antibiotics at approximately the same rate (53.2% and 55.7%, respectively). 
Significantly, those women in whom chorioamnion infection was identified also had a much higher 
incidence of chorioamnionitis in previous pregnancies (10.6%), when compared to women in whom 
no infection was identified (3.5%; p = 0.025) (Table 4.6).  
Women with UGT infection were more likely to deliver vaginally than women in whom no infection 
was identified (89.4% vs. 67.6%; p = 0.012); however, there was no significant difference in the 
prevalence of pPROM or cervical incompetence in women with or without chorioamnion infection 
(Table 4.6).  
Table 4.6. Outcomes for women (n = 474) whose pregnancies were complicated by chorioamnion 
infection compared to outcomes for women who had no chorioamnion infection  
 Chorioamnion 
infection 
(n = 471) 
No chorioamnion 
infection detected 
(n = 4271) 
Significance 
At least one sign/symptom of infection 2 5/47 (10.6%) 29/427 (6.8%) NS3 
Previous history of chorioamnionitis documented 5/47 (10.6%) 15/427 (3.5%) 0.025 
Hypertension 7/47 (18.9%) 114/427 (26.7%) NS 
Pregnancy induced hypertension 8/47 (17.0%) 115/427 (26.9%) NS 
Cervical incompetence 26/47 (55.3%) 230/427 (53.9%) NS 
Antibiotics administered during labour 25/47 (53.2%) 238/427 (55.7%) NS 
Preterm premature rupture of membranes (pPROM) 17/47 (36.2%) 158/427 (37.0%) NS 
Mode of delivery    
- Vaginal 42/47 (89.4%) 290/427 (67.9%) 0.012 
- Cesarean 5/47 (10.6%) 135/427 (31.6%) NS 
- Undisclosed 0/47 (0.0%) 2/427 (0.5%) NS 
1 Some women (n = 3) delivered multiple placentae and one placenta was found to be infected, while 
the other was shown to be uninfected by culture and 16S rRNA PCR. Data from these women with 
contrasting placental microbiology results were excluded from this analysis 
2 Signs and symptoms of infection included: maternal temperature > 38 °C, uterine or abdominal 
tenderness, foul-smelling vaginal discharge, maternal tachycardia (> 120 bpm) or fetal tachycardia (> 
160 bpm)  
3 NS – Not statistically significant 
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Adverse neonatal outcomes 
Neonates were classified into two groups, those whose chorioamnion was found to be infected and 
neonates whose placentae were non-infected. 
 
While there were no differences in the mean maternal or fetal stages of inflammation between 
these cohorts, the presence of histological chorioamnionitis was associated with chorioamnion 
infection (p < 0.001). For these neonates, there were no differences in the gestational age at 
delivery, the Apgar scores at 1 or 5 minutes, the birth weights and the weight of placentae (Table 
4.7). Those infants who were exposed to chorioamnion infections required prolonged oxygen 
support (> 6 hours) more frequently (21.0%) than those infants who were not exposed to 
chorioamnion infection (9.0%; p = 0.009) (Table 4.7). The infants exposed to chorioamnion infection 
were also diagnosed with respiratory distress syndrome  more often (17.5%) than infants who were 
not exposed to chorioamnion infection (9.0%), albeit this was not statistically significant. Despite the 
association between chorioamnion infection and adverse neonatal sequelae, there was no 
significant difference in the mean length of stay post-delivery (Table 4.7). 
Table 4.7. Outcomes for neonates (n = 535 placentae) after pregnancies complicated by 
chorioamnion infection compared to pregnancies without evidence of chorioamnion infection  
 Chorioamnion infection   
(n = 57) 
No chorioamnion infection 
detected (n = 478) 
Significance 
Gestational age at delivery (mean, range) 35.7 ± 0.3 (32 – 41) 35.6 ± 0.1 (32 - 41) NS2 
Apgar score1 – 1 minute (mean, range) 7.6 ± 0.3 (1 – 9) 7.8 ± 0.1 ( 1 - 10) NS 
Apgar score1 – 5 minutes (mean, range) 8.7 ± 0.1 ( 5 – 9) 8.9 ± 0.03 (2 - 10) NS 
Birth weight (mean, range) 2642.4 ± 84.6  
(1380 – 3925) 
2658.0± 29.8  
(1060 - 4530) 
NS 
Placental weight (mean, range) 441.3 ± 16.2 (199 – 710.7) 428.7 ± 5.8  (132 - 1099) NS 
Chorioamnionitis3 in current pregnancy 31/57 (54.4%) 90/478 (18.8%) < 0.001 
- Maternal Stage 1.6 ± 0.1 (1 – 3) 1.2 ± 0.02 (1 – 3) NS 
- Fetal Stage 2.4 ± 0.1 (1 – 3) 2.2 ± 0.04 (1 – 3) NS 
Male : Female 24 : 33 252 : 2254 NS 
Continuous positive airway pressure (CPAP) 12/57 (21.0%) 48/478 (10.0%) NS 
Features of RDS5 < 24 hours after birth  15/57 (26.3%) 93/478 (19.5%) NS 
Required oxygen support for > 6 hrs 12/57 (21.0%) 43/478 (9.00%) 0.009 
Diagnosed RDS5 10/57 (17.5%) 43/478 (9.00%) NS 
Length of Stay 7.0 ± 1.1 (1 – 37) 6.1 ± 0.3 (1 - 43) NS 
1 Apgar - a measure of neonatal health upon delivery and measures of appearance, pulse, reflex, 
activity and respiration. 
2 NS – Not statistically significant 
3 Chorioamnionitis was determined by US pathologists according to (Redline et al. 2003) 
4 The sex of one infant was not disclosed 
5 RDS - respiratory distress syndrome  
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Ureaplasma spp. and other microorganisms and their association with adverse 
pregnancy and neonatal outcomes  
To compare the outcomes of women infected with specific microorganisms, pregnancies with 
chorioamnion infection were further divided into two groups: those in which the placentae were 
infected with Ureaplasma spp., the most prevalent microorganisms detected within the 
chorioamnion, and those with chorioamnion infection caused by other microorganisms. It was not 
possible to further divide those women with ‘other microorganisms’ into individual groups due to 
the small sample sizes of women affected by each individual microorganism isolated.  
 
Maternal demographic data 
Women with chorioamnion infection caused by Ureaplasma spp. had a lower maternal age (24.2 ± 
0.8 yrs) than women infected with other microorganisms (28.2 ± 1.4 yrs) and women who had no 
chorioamnion infection (27.8 ± 0.3 yrs; p = 0.002).  
 
There was no other significant differences in maternal demographic data for women in whom other 
microorganisms were identified, when compared to those women in whom no microorganisms were 
detected (Table 4.8).  
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Table 4.8. Demographic data for women (n = 470) with chorioamnion infection caused by Ureaplasma spp., or other microorganisms compared to 
pregnancies that were not affected by chorioamnion infection  
1 Some women delivered multiple infants/placentae in which one placenta was found to be infected, while the other was not (n = 3); or placentae were 
found to contain both ureaplasmas and other microorganisms (n = 4). As a consequence, data from n = 7 women were excluded from this analysis 
2 NS – Not statistically significant 
3 Gravida - total number of clinical pregnancies 
4 Parity - the total number of viable offspring resulting from all clinical pregnancies 
Data analysed by ANOVA tests to identify differences among each group/cohort above. 
 Ureaplasma spp. detected 
(n = 311) 
Significance Other microorganisms 
detected (n = 121) 
Significance No microorganisms 
detected 
(n = 4271) 
Maternal age (mean, range) 24.2 ± 0.8 (17 - 32) 0.002 28.2 ± 1.4 (21 – 38)  NS2 27.8 ± 0.3 (15 – 43) 
Gravida3 (mean, range) 2.12 ± 0.2 (1 - 5) NS 2.3 ± 0.3 (1 – 4) NS 2.5 ± 0.1 (1 – 11) 
Parity4 (mean, range) 1.7 ± 0.2 (1 - 4) NS 2.3 ± 0.3 (1 – 3) NS  2.1 ± 0.1 (1 – 10) 
Marital Status      
- Single 22/31 (70.9%) NS 9/12 (75.0%) NS 232/427 (54.3%) 
- Married 9/31 (29.0%) NS 3/12 (25.0%) NS 190/427 (44.5%) 
- Undisclosed 0/31 (0.0%) NS 0/12 (0.0%) NS 5/427 (1.2%) 
Health insurance      
- Private 10/31 (32.2%) NS  7/12 (58.3%) NS 247/427 (57.9%) 
- Medicaid 17/31 (54.8%) NS 4/12 (33.3%) NS 160/427 (37.5%) 
- Self pay/uninsured 2/31 (6.5%) NS 0/12 (0.0%) NS 16/427 (3.7%) 
- Undisclosed 2/31 (6.5%) NS 1/12 (8.3%) NS 4/427 (0.9%) 
Ethnicity      
- Caucasian 17/31 (54.8%) NS 8/12 (66.7%) NS 289/427 (67.8%) 
- African-American 13/31 (42.0%) NS 4/12 (33.3%) NS 104/427 (24.3%) 
- Mixed 1/31 (3.2%) NS 0/12 (0.0%) NS 25/427 (5.8%) 
- Asian 0/31 (0.0%) NS 0/12 (0.0%) NS 8/427 (1.9%) 
- Undisclosed 0/31 (0.0%) NS 0/12 (0.0%) NS 1/427 (0.2%) 
Evidence of one prenatal care visit 31/31 (100.0%) NS 12/12 (100.0%) NS 419/427 (98.1%) 
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Adverse pregnancy outcomes 
 
There were no differences in the incidence of adverse pregnancy outcomes between women 
infected with Ureaplasma spp. within the chorioamnion, those infected with other microorganisms 
within the chorioamnion and those women in whom no infection was identified (Table 4.9).  
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Table 4.9. Pregnancy outcomes for women (n = 470) with chorioamnion infection caused by Ureaplasma spp. or other microorganisms, compared to those 
histories of women who were not exposed to chorioamnion infection 
1 Some women delivered multiple infants/placentae in which one placenta was found to be infected, while the other was not (n = 3); or placentae were 
found to contain both ureaplasmas and other microorganisms (n = 4). As a consequence, data from n = 7 women were excluded from this analysis 
2 Signs and symptoms of infection included: maternal temperature > 38 °C, uterine or abdominal tenderness, foul-smelling vaginal discharge, maternal 
tachycardia (> 120 bpm) or fetal tachycardia (> 160 bpm) 
3 NS – not statistically significant 
4 While the antibiotic dose and type were not recorded, antibiotics were administered to women more than 3 hours prior to delivery. 
Data analysed by ANOVA tests to identify differences among each group/cohort above. 
 
 
 
 Ureaplasma spp. detected 
(n = 311) 
Significance Other microorganisms 
detected  
(n = 121) 
Significance No microorganisms detected  
(n = 4271) 
At least one sign/symptom of infection2 3/31 (9.7%) NS3 1/12 (8.3%) NS 29/427 (6.8%) 
Previous history of chorioamnionitis documented 3/31 (9.7%) NS 1/12 (8.3%) NS 15/427 (3.51%) 
Hypertension 2/31 (6.4%) NS 3/12 (25.0%) NS 114/427 (26.7%) 
Pregnancy induced hypertension 3/31 (9.7%) NS 3/12 (25.0%) NS 115/427 (26.7%) 
Cervical incompetence 21/31 (67.7%) NS 6/12 (50.0%) NS 230/427 (53.9%) 
Antibiotics administered during labour4 16/31 (51.6%) NS 8/12 (66.7%) NS 238/427 (55.7%) 
Preterm premature rupture of membranes (pPROM) 12/31 (38.7%) NS 5/12 (41.7%) NS 158/427 (37.0%) 
Mode of delivery      
- Vaginal 27/31 (87.1%) NS 11/12 (91.7%) NS 290/427 (67.9%) 
- Cesarean 4/31 (12.9%) NS 1/12 (8.3%) NS 135/427 (31.6%) 
- Undisclosed 0/31 (0.0%) NS 0/12 (0.0%) NS 2/427 (0.5%) 
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Adverse neonatal outcomes 
The outcomes of neonates born after pregnancies were affected by chorioamnionitis due to 
Ureaplasma spp. and other microorganisms were also compared to neonates delivered from 
pregnancies in which no chorioamnion infection was identified. 
 
The most significant finding of this current study was that chorioamnion infection with Ureaplasma 
spp., but not caused by other microorganisms, was associated with the development of histological 
chorioamnionitis (p < 0.001). While there was no difference in the maternal or fetal stages of 
inflammation between any of these cohorts, pregnancies exposed to Ureaplasma spp. had a higher 
incidence of chorioamnionitis (68.4%) overall. Interestingly, the presence of ureaplasmas within the 
chorioamnion was not always associated with inflammation and 33.3% of placentae demonstrated 
no histological chorioamnionitis. Of the Ureaplasma spp.-infected placentae, 34.2% showed 
evidence of mild chorioamnionitis (maternal grade 1) and 31.6% of placentae demonstrated severe 
histological chorioamnionitis (maternal grade 2 or 3) (Figure 4.4).  
 
Chorioamnion infection with microorganisms other than Ureaplasma spp. was associated with the 
development of RDS (p = 0.016). While there was a higher incidence of sequelae in neonates 
exposed to Ureaplasma spp. chorioamnion infection and also to other organisms, there was no 
difference in the mean length of stay in the neonatal ward for these babies, when compared to the 
stay for babies who were not exposed to chorioamnion infection.  
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Table 4.10. Adverse outcomes for neonates (n= 527) delivered after pregnancies affected by chorioamnionitis caused by Ureaplasma spp. and other 
microorganisms, compared to outcomes for neonates who were not exposed to infection during pregnancy 
 
1 Some placentae (n = 4) were found to have polymicrobial infections and therefore could not be grouped into a single cohort in the above table. These 
placentae were excluded from this analysis 
2 NS – not statistically significant 
3 Apgar - a measure of neonatal health upon delivery and measures of appearance, pulse, reflex, activity and respiration. 
4 Chorioamnionitis was determined by US pathologists according to (Redline et al. 2003) 
5 only one placenta in this group was graded, therefore there was no SEM or range 
6 The sex of one infant was not disclosed 
7 RDS – respiratory distress syndrome 
Data analysed by ANOVA tests to identify differences among each group/cohort above. 
 Ureaplasma spp. detected 
(n = 381) 
Significance Other microorganisms 
detected 
(n = 151) 
Significance No microorganisms detected 
(n = 4781) 
Gestational age at delivery (mean, range) 35.4 ± 0.3 (32 - 40) NS 2 35.9 ± 0.7 (33 - 41) NS 25.6 ± 0.1 (32 - 41) 
Apgar score 3– 1 minute (mean, range) 7.9 ± 0.3 (1 - 9) NS 7.2 ± 0.6 (1 - 9) NS 7.8 ± 0.1 (1 - 10) 
Apgar score 3 – 5 minutes (mean, range) 8.8 ± 0.1 (7 - 9) NS 8.5 ± 0.3 (5 - 9) NS 8.8 ± 0.1 (2 - 10) 
Birth weight (mean, range) 2489.6 ± 88.53 (1380 - 3873) NS 2901.3 ± 180.3 (1865 - 3925) NS 2700.6 ± 51.4 (1060 - 4530) 
Placental weight (mean, range) 445.2 ± 20.5 (260 - 711) NS 432.4 ± 30.2 (199 - 617) NS 428.6 ± 5.8 (132 - 1099) 
Chorioamnionitis 4 in current pregnancy 26/38 (68.4%) < 0.001 4/15 (26.7%) NS 90/478 (18.8%) 
- Maternal stage inflammation 1.6 ± 0.1 (1 - 3) NS 1.5 ± 0.1 (1 - 2) NS 1.2 ± 0.1 (1 - 3) 
- Fetal stage inflammation  2.4 ± 0.1 (1 - 3) NS 35 NS 2.2 ± 0.1 (1 - 3) 
Male : Female 15 : 23 NS 7 : 8 NS 252 : 2256  
Continuous positive airway pressure (CPAP) 8/38 (21.0%) NS 4/15 (26.7%) NS 56/478 (11.7%) 
Features of RDS7 < 24 hours after birth  9/38 (23.7%) NS 4/15 (26.7%) NS 93/478 (19.4%) 
Required oxygen support for > 6 hrs 7/38 (18.4%) NS 4/165 (26.7%) NS 43/478 (9.0%) 
Diagnosed RDS7 6/38 (15.8%) NS 3/15 (20.0%) 0.016 43/478 (9.0%) 
Length of Stay 6.5 ± 1.2 (1 - 37) NS 7.9 ± 2.2 (1 - 24) NS 6.1  0.3 (1 - 43) 
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Figure 4.4. Severity of histological chorioamnionitis in pregnancies affected by chorioamnion 
infection with Ureaplasma spp. (n = 38), other microorganisms (n = 15) and those pregnancies in 
which no chorioamnion infection was identified (n = 478). Some placentae (n = 4) were not included 
in this analysis, due to conflicting microbiology results. Chorioamnionitis was determined by US 
pathologists (blinded to outcome) and graded according to Redline’s criteria (2003) 
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Discussion 
 
UGT infections in pregnant women are a leading aetiology of PTB, with up to 40% of all PTBs 
associated with infection (DiGiulio 2012). While there is a strong body of evidence which identifies 
UGT infections in association with very early PTBs (< 32 weeks), currently no studies have reported 
the prevalence of UGT infection later in gestation, in pregnancies delivered LPT (32 – 36 weeks) and 
at term. In this study, for the first time, we have investigated the prevalence of chorioamnion 
infection in women who delivered LPT or at term and identified that chorioamnion infection was 
present in 10.6% of all pregnancies studied. This supports the proposal by Goldenberg et al. (2011) 
that 10 – 15% of deliveries >32 weeks are associated with infection.  This study confirmed that there 
were no major differences in the prevalence of adverse outcomes or signs/symptoms of infection in 
women with chorioamnionitis caused by Ureaplasma spp. or other microorganisms and women with 
no evidence of infection (Table 4.9). This highlights why it is so difficult to identify and treat women 
with asymptomatic chorioamnionitis during pregnancy.  
 
In this current study we have also identified that a history of chorioamnionitis in previous 
pregnancies (p = 0.025), correlated with histological chorioamnionitis in the current pregnancy (p < 
0.001; Table 4.6) and that neonates exposed to UGT infection during pregnancy required oxygen or 
positive pressure support more frequently after delivery (p = 0.009; Table 4.7). The results of this 
study are similar to the findings of other researchers who focused on very PTBs and demonstrated 
that UGT infection was associated with decreased maternal age (Hillier et al. 1988), the 
development of histological chorioamnionitis (Hillier et al. 1988; Aaltonen et al. 2007; Hecht et al. 
2008; Kasper et al. 2010) and adverse respiratory outcomes for neonates (Abele-Horn et al. 1997b; 
Cultrera et al. 2006; Gwee et al. 2013).  
 
Significantly, this current study demonstrated that chorioamnion infection was associated with a 
history of chorioamnionitis in prior pregnancies, but was not a cause of LPT birth. Previous studies 
have also demonstrated that the most significant indicator of adverse outcomes in a current 
pregnancy is a past history of adverse pregnancy outcomes (Goldenberg et al. 2008b). Similarly, the 
most important predictor of LGT Streptococcus agalactiae (Group B Streptococcus or GBS) carriage 
during pregnancy is a prior history of harbouring this microorganism in the LGT during prior 
pregnancies (Di Renzo et al. 2014) and the most important indicator of delivering preterm in a 
current pregnancy is a prior PTB (Bloom et al. 2001). To the best of our knowledge, this is the first 
study to demonstrate an association between chorioamnion infection in a current pregnancy and a 
past history of chorioamnionitis. Previous studies have identified microorganisms within the 
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endometrium of reproductive-age women (Cassell et al. 1993b) and based on these findings, we 
propose that the female UGT (of both pregnant and non-pregnant women) may be colonised with 
microorganisms for prolonged periods. This may also explain the significant finding we reported for 
the first time, that women experience recurrent infections and adverse pregnancy outcomes, 
including histological chorioamnionitis, over multiple pregnancies.  
 
Of the microorganisms isolated, the human Ureaplasma spp. were the most prevalent 
microorganisms identified within the chorioamnion, accounting for more than 70% of all clinical 
isolates within this study. The other microorganisms isolated within this study included S. agalactiae 
(GBS), Bacteroides spp., Bifidobacterium spp., G. vaginalis, E. coli, Propionibacterium spp. and 
uncultured bacteria. Previously, studies have reported the presence of contaminating 
microorganisms in studies of placentae after very early PTBs, either from environmental sources or 
as a consequence of vaginal delivery (Leitich et al. 2003) and so it is first necessary to determine if 
the microorganisms isolated within our study are consistent with infection/colonisation of the 
chorioamnion. For this study, we defined ‘infection’ as the invasion of microorganisms accompanied 
by a reaction of the host (e.g. inflammation) (Schultz et al. 2003; Edwards and Harding 2004) and 
while many of the microorganisms isolated within our study are often found as normal flora of the 
female LGT (e.g. Ureaplasma spp., S. agalactiae, Bacteroides spp., Bifidobacterium spp., G. vaginalis 
and Propionibacterium spp.) (Anderson et al. 2013), ascending invasive infections are the most 
accepted route of intraamniotic infections (Kim et al. 2009). Therefore, the presence of these 
microorganisms within the chorioamnion is not unexpected and we further demonstrated that the 
presence of these microorganisms was associated with chorioamnionitis, strongly suggesting that 
these microorganisms found within chorioamnion tissue are consistent with infection and not 
contamination. Additionally, many of the microorganisms identified within our study have been 
implicated as a cause of intraamniotic infection in previous studies of very PTBs and have also been 
associated with bacterial vaginosis and a two-fold increase in the likelihood of delivering preterm 
(Nejad and Shafaie 2008). While 70% of the women in this study delivered vaginally, we identified no 
Lactobacillus spp. within any chorioamnion tissue specimens. Lactobacillus spp. have been isolated 
in more than 90% of vaginal specimens and the presence of this microorganism within placental 
tissue is consistent with contamination and not infection. Taken together, these results suggest that 
the aseptic sampling techniques used within our study prevented the contamination of 
chorioamnion tissues and that the microorganisms detected within our study are aetiological agents 
of chorioamnion infection and inflammation.  
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Within this current study, we also sought to determine the microorganisms most commonly 
associated with adverse pregnancy and neonatal outcomes. Women infected with Ureaplasma spp. 
were significantly younger (24.1 ± 07 yrs) than those women infected with other microorganisms 
(26.3 ± 1.3 yrs) or who were uninfected (27.8 ± 0.3 yrs; p = 0.002).  
 
For neonates, the diagnosis of respiratory distress syndrome was correlated with chorioamnion 
infection caused by other microorganisms (p = 0.016) but not with Ureaplasma spp. RDS is an acute 
respiratory condition associated with poor neonatal lung compliance following birth and is 
commonly reported for neonates delivered in the LPT period (Ramachandrappa and Jain 2009). 
Studies have demonstrated poor respiratory outcomes for neonates exposed to infections at < 32 
weeks of gestation (Benstein et al. 2003; Viscardi et al. 2006; Payne et al. 2010; Collins et al. 2013; 
Eun et al. 2013) and it is interesting that in this current study there was no association between 
Ureaplasma spp., the most common isolate in our study, and RDS. However, this is not surprising as 
previous studies in an ovine model have demonstrated that chronic fetal exposure to Ureaplasma 
spp. in utero resulted in improved neonatal lung gas volumes and increased production of 
surfactant, indicating that lung maturation was occurring (Moss et al. 2005; Kramer et al. 2009; Knox 
et al. 2010; Robinson et al. 2013). There are currently no studies which demonstrate similar 
respiratory outcomes in human neonates, and so further studies which test nasopharyngeal 
aspirates to determine if ureaplasmas are present at this site may determine if Ureaplasma spp. 
affect the LPT neonatal lung.  
 
The most significant finding of this current study was that chorioamnion infection with Ureaplasma 
spp., but not other microorganisms, was associated with the development of histological 
chorioamnionitis (p < 0.001). While we saw no significant association between the incidence of 
histological chorioamnionitis and LPT birth or the presence of other microorganisms; we did see a 
significant association between the presence of Ureaplasma spp. within the chorioamnion and 
chorioamnionitis (67.5%; p < 0.001). Previous studies have reported an association between 
infection with ureaplasmas and the development of histological chorioamnionitis (Table 4.11). 
Originally, Shurin et al. (1975) demonstrated that vaginal colonisation with Ureaplasma spp. was 
significantly associated with the development of histological chorioamnionitis during pregnancy, and 
these researchers suggested that it may be possible for these microorganisms to access the UGT at 
the time of pregnancy. Kundsin et al. (1984) identified that 53% of chorioamnion specimens 
contained Ureaplasma spp., and of these, 60% had evidence of histological chorioamnionitis.  
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Table 4.11. Previous of studies which demonstrate an association between Ureaplasma spp. and histological chorioamnionitis. While the prevalence of 
Ureaplasma spp. varies within these studies, the development of histological chorioamnionitis was consistently between 40 – 100% of all pregnancies, 
regardless of the gestational age at delivery 
1 Information not available for all placentae within study. Available data has been shown from each study 
Author Gestational 
age 
Specimen Number  Ureaplasma spp. 
positive1 
Ureaplasma spp. with 
chorioamnionitis1 
Ureaplasma spp. without 
chorioamnionitis1 
Shurin et al. (1975) all births Vaginal cultures 244 54 (22.1%) 32 (59.2%) 22 (40.7%) 
Yoon et al. (2003) ≤ 35 weeks Amniotic fluid 257 23 (9.0%) 15/20 (75%) 5/20 (25%) 
Park et al. (2013) < 34 weeks Amniotic fluid 213 35 (16.4%) 7/16 (43.7%) - 
Berger et al. (2009) < 28 weeks Amniotic fluid or placental tissue 435 32 (7.3%) 11/25 (44.0%)  3/46 (6.5%)  
Goldenberg et al. (2008) 23 – 32 weeks Cord blood 351 43 (12.2%) 33 (76.9%) - 
Viscardi et al. (2008) < 33 weeks Cord blood  313 46 (14.7%) 30 (65.0%) - 
Kundsin et al. (1984) < 37 weeks Placental tissue 156 53 (34.0%) 32 (60.4%) 21 (39.6%) 
Hillier et al. (1988) < 37 weeks Placental tissue 94  32 (34.0%) 19/29 (65.5%) 10/65 (15.4%) 
Van Marter et al. (2002) < 36 weeks Placental tissue 206 58 (28.1%) 51 (87.9%) 7 (12.1%) 
Miralles et al. (2005) < 33 weeks Placental tissue 14 6 (42.8%) 6 (100%) - 
Egawa et al. (2007) < 32 weeks Placental tissue 83 4 (4.8%) 4 (100%) - 
Hecht et al. (2008) < 28 weeks Placental tissue 1292 - 7 (70%) 3 (30%) 
Olomu et al. (2009) < 28 weeks  Placental tissue 866 52 (6%) 33 (65%)                  - 
Namba et al. (2010) ≤ 32 weeks Placental tissue 151 63 (42%) 52 (83.0%) 11 (17.0%) 
Sweeney et al. (current study) > 32 weeks Chorioamnion tissue 535 42 (7.8%) 28/42 (66.6%) 14/42 (33.3%) 
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Since these first reports, other studies have consistently demonstrated that the presence of 
Ureaplasma spp. in amniotic fluid (Yoon et al. 2003a; Berger et al. 2009; Park et al. 2013) and 
chorioamnion tissues (Kundsin et al. 1984; Hillier et al. 1988; Miralles et al. 2005; Egawa et al. 2007; 
Hecht et al. 2008; Berger et al. 2009; Olomu et al. 2009; Namba et al. 2010) correlated with 
histological chorioamnionitis. The prevalence of histological chorioamnionitis within Ureaplasma 
spp. positive placentae varied from 43.7% to 100% (Table 4.11). Similarly, several studies have also 
found that Ureaplasma spp. isolated from cord blood was associated with histological 
chorioamnionitis (Goldenberg et al. 2008a; Viscardi et al. 2008) and the presence of Ureaplasma 
spp. within cord blood may indicate a systemic spread of these organisms into the umbilical cord 
blood supply (Table 4.11). The major limitation of these studies was that they focused on the very 
early PTBs (< 32 weeks), when the majority of infections are often polymicrobial (Hillier et al. 1988; 
Jalava et al. 1996; Hecht et al. 2008; Onderdonk et al. 2008; Marconi et al. 2011). As a result, 
researchers have not been able to confidently claim that these microorganisms are true aetiological 
agents of histological chorioamnionitis. However, in our large study of LPT and term placentae we 
have demonstrated for the first time that infection with Ureaplasma spp. is independently 
associated with the development of histological chorioamnionitis, regardless of gestational age (LPT 
or term).  
 
While the presence of Ureaplasma spp. in this study was associated with the development of 
histological chorioamnionitis, we also assessed if the numbers of ureaplasmas present had an effect 
on the development of histological chorioamnionitis. Interestingly, there was no significant 
difference in the mean CFU of ureaplasmas present within placentae for pregnancies with or without 
histological chorioamnionitis. Within this study, we were only able to sample small sections of the 
placenta (not the entire placenta itself), which may be why we do not see a clear relationship 
between the numbers of microorganisms present and the severity of inflammation, these findings 
may also suggest that there are other factors which influence the development of histological 
chorioamnionitis. These findings are again in contrast to other studies, which have demonstrated a 
correlation between the mean CFU of Ureaplasma spp. and the severity of histological 
chorioamnionitis (Jacobsson et al. 2009; Kasper et al. 2010; Kacerovsky et al. 2011). Further studies 
that investigate the presence and concentration of innate and adaptive immune factors are required 
to determine if there are other host and/or microbe factors which may influence the development 
of chorioamnionitis.  
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UGT infection was demonstrated in ~11% of pregnancies within our current study. However, the 
question remains as to the other likely causes or aetiologies of birth in the LPT period. Some known 
precursors and risk factors (aside from infection) include: spontaneous preterm labour or pPROM, 
cervical incompetence, preeclampsia/eclampsia, placenta previa/accrete, multiple gestation 
pregnancies, intrauterine growth restriction, prior Cesarean section delivery, chorioamnionitis, fetal 
distress and/or adverse maternal outcomes requiring medically indicated preterm deliveries 
(Goldenberg et al. 2008b; Holland et al. 2009). Within our study population, many of these factors 
(which may predispose to PTB) were present. Of the women in our study, only 3.4% had evidence of 
a prior preterm delivery, while 32.9% experienced pPROM and 26.7% underwent Cesarean section 
delivery. Only 2.0% of these Cesarean section deliveries were medically indicated; while for the 
remainder it was not always clear if these deliveries were elective or medically indicated. Cervical 
incompetence was prevalent within our study population and was present in 48.2% of women. 
Preeclampsia and haemolysis, elevated liver enzymes and low platelet count (HELLP) syndrome were 
also present in 16.1% and 1.1% of our study participants. Other important factors, such as fetal 
distress, intrauterine growth restriction, placental abruption and non-reassuring fetal signs were 
present in this study; however their incidence was quite low (3.2%, 4.1%, 2.2% and 1.1%, 
respectively). By contrast, 22.6% of women in our study had evidence of histological 
chorioamnionitis. Multiple gestation pregnancies were also quite common in this study, with 54 sets 
of twins and two sets of triplets all delivered in the LPT period. Given the presence of these factors, 
it is probable that a combination of these various precursors/risk-factors contribute to delivery in 
the LPT period, and as such, the aetiology of LPT birth is likely to be multifactorial. Similarly, Holland 
et al. (2009) investigated those LPT births which were deemed to be unavoidable and those which 
were elective and identified that >80% of all LPT births were unavoidable, due to outcomes similar to 
those mentioned above (preeclampsia, HELLP syndrome, placental abruption, intrauterine growth 
restriction etc.).  
 
To the best of our knowledge, this is the first study to report the prevalence of chorioamnion 
infection in the LPT period and ~11% of LPT and term pregnancies were affected by infection. 
Greater than 70% of all PTBs worldwide occur in the LPT period (Laws et al. 2010; March of Dimes 
2012); therefore, the number of infants potentially exposed to chorioamnion infection in this period 
is far greater (1.3 million per year) than the number of infants delivered at less than 32 weeks of 
gestation (702 000; See table 4.12). These findings highlight that irrespective of gestation, infection 
during pregnancy is an important finding. UGT infection at any stage of pregnancy can have severe 
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adverse outcomes for the mother and for the child and these findings should be a major 
consideration for obstetricians.  
 
Table 4.12. Estimated number of pregnancies affected by intraamniotic infection in both early and 
late preterm gestation 
 Early PTB (< 31 weeks) Late PTB (32 – 36 weeks) 
Prevalence in the preterm population1 15.6% 84.4% 
Total number of pregnancies2 2.3 million 12.7 million 
Rate of UGT infection3 Approx. 30% 10.4% 
Number of births potentially affected by infection4 702 000  1.3 million 
1 Statistics from Li et al 2011  
2 Number of births estimated by multiplying the total number infants delivered preterm (15 million 
annually (Bick 2012) by the total prevalence (percentage) of each population.  
3 Early PTB rate of intraamniotic infection as quoted in (March of Dimes 2012), while LPT birth rate 
has been identified within the present study.  
4 Calculated values based on proportion of intraamniotic infection within each populations. 
 
While this study has greatly extended our understanding of chorioamnion infection in the LPT and 
term period, there are some limitations within this study which must be addressed. More than 50% 
of women in this study were treated with intrapartum antibiotics and the dosage and identity of 
these antibiotics were not recorded within the database. However, we utilised both culture and 
molecular detection and identification techniques and we isolated both cultivable and non-cultivable 
bacteria. The use of antibiotics for prolonged period (> 3 hrs) during labour may have decreased the 
overall numbers of microorganisms isolated from these placentae and therefore the true rate of 
chorioamnion infection in the LPT period may in fact be higher than is reported within this study. 
While we were able to isolate/detect microorganisms, including uncultured bacterium, from these 
placentae, further investigation using more sensitive techniques, such as deep sequencing, may be 
useful in determining the true prevalence of infection in the LPT and term period, in order to fully 
characterise infection throughout gestation.  
 
The major strength of this study is that chorioamnion tissue was the specimen of choice. The use of 
this tissue, coupled with the proven aseptic collection techniques meant that we were able to isolate 
microorganisms from the chorioamnion and that the presence of these microorganisms was directly 
correlated with chorioamnionitis at the same anatomical site. Additionally, the low prevalence of 
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polymicrobial infections within this data set meant that we were able to clearly demonstrate 
differences in the sequelae incurred by women and infants infected with Ureaplasma spp. or other 
microorganisms, which has not always been possible in previous studies focused on PTBs, which 
occur at less than 32 weeks of gestation. Finally, histological chorioamnionitis was graded by United 
States pathologists based on Redline’s criteria (Redline et al. 2003), which is a well-accepted and 
highly published method for grading chorioamnionitis. The presence of chorioamnionitis was 
determined prior to any microbiological testing, thereby reducing any chance of influencing the data 
set. This study also confirmed that LPT infants experience more adverse sequelae than their term-
born counterparts, including respiratory distress syndrome, CPAP ventilation or respiratory support 
in the form of required oxygen support for > 6 hours in the first 24 hours of life.  These findings 
correlate with other studies that are now prevalent within the literature (Adams-Chapman 2006; 
Darnall et al. 2006; Engle and Kominiarek 2008; Colin et al. 2010; Hibbard et al. 2010; Berard et al. 
2012; Boyle and Boyle 2013). 
Conclusion 
 
The presence of chorioamnion infection in LPT and term placentae is an important finding and 
should be a major consideration for obstetricians. This current study demonstrated that 
chorioamnion infection directly correlates with inflammation of the chorioamnion (chorioamnionitis) 
and adverse pregnancy and neonatal outcomes, including neonatal respiratory sequelae. We also 
determined that the presence of current chorioamnion infection correlated with a history of 
chorioamnionitis in prior pregnancies, confirming that this is a risk factor and suggests that these 
organisms may colonise/infect the endometrium for chronic periods. 
 
This is also the first study to determine that Ureaplasma spp. were independently associated with 
the development of histological chorioamnionitis. Interestingly, while the prevalence of histological 
chorioamnionitis was higher in Ureaplasma spp.-affected pregnancies, there was no correlation 
between the number of ureaplasma CFU and the severity of inflammation, suggesting that other 
host and/or microbe interactions may influence the development of histological chorioamnionitis. 
Further studies which focus specifically on the host/microbe interactions and the development of 
histological chorioamnionitis are required to fully elucidate the pathogenesis of Ureaplasma spp. 
infections during pregnancy.  
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Chapter Five:   
 
 
Characterisation of Ureaplasma spp. 
from late preterm and term placentae   
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Introduction 
 
Ureaplasma spp. are prevalent colonisers of the lower genital tract (LGT) and are found in up to 80% 
of females and 50% of males (Cassell et al. 1993b; Volgmann et al. 2005). These organisms are 
considered to be of low virulence; however they are capable of causing serious infections. During 
pregnancy, Ureaplasma spp. can ascend and invade the upper genital tract (UGT) and are associated 
with spontaneous abortion and miscarriage (Robertson et al. 1986; Joste et al. 1994), preterm birth 
(PTB) (Hillier et al. 1988; Gerber et al. 2003; Goldenberg et al. 2008a) and preterm premature 
rupture of membranes (pPROM) (Kacerovsky et al. 2011). Previous studies have also identified 
Ureaplasma spp. as the most prevalent microorganisms isolated from placentae with histological 
chorioamnionitis (Hillier et al. 1988; Eschenbach 1993; Aaltonen et al. 2007; Berger et al. 2009; 
Kasper et al. 2010; Namba et al. 2010; Czikk et al. 2011); in Chapter Four we have demonstrated for 
the first time that Ureaplasma spp. are independently associated with histological chorioamnionitis, 
regardless of gestational age (late preterm or at term). These microorganisms are also capable of 
causing severe neonatal outcomes, including sepsis (Waites et al. 1993), meningitis (Gwee et al. 
2013), bronchopulmonary dysplasia (BPD) (Viscardi et al. 2002; Kasper et al. 2010; Sung et al. 2010) 
and an increased risk of developing of cerebral palsy (Berger et al. 2009).  
 
While up to 42% of women may have in utero infection with Ureaplasma spp. during pregnancy 
(Miralles et al. 2005), the presence of these microorganisms is not always associated with the 
development of histological chorioamnionitis or adverse pregnancy outcomes. In particular, a study 
by Gerber et al. (2003) identified that of the women with intraamniotic infections caused by 
Ureaplasma spp. (n = 29), only 21% developed pPROM, 24% experienced PTB and more than 70% 
went on to deliver at term with no apparent adverse pregnancy outcomes. It is currently unclear 
why only some women experience adverse pregnancy outcomes, but it has been suggested that 
virulent species or serovars of Ureaplasma spp. may be associated with adverse pregnancy 
outcomes. The human Ureaplasma spp. are categorised into two distinct species and 14 serovars: U. 
parvum is comprised of serovars 1, 3, 6 and 14; while U. urealyticum is comprised of serovars 2, 4, 5 
and 7 - 13 (Robertson et al. 2002) and studies have identified some ureaplasma serovars as being 
associated with adverse pregnancy or neonatal outcomes. U. urealyticum serovar 4 has been 
associated with recurrent miscarriages (Naessens et al. 1988), while U. urealyticum serovar 9 was 
found to be the most prevalent ureaplasma serovar isolated from tracheal and gastric aspirates of 
infants (Eun et al. 2013). By contrast, Sung et al. (2011) detected U. parvum serovars 3 and 6 as the 
most prevalent serovars in respiratory secretions of infants, and their presence was associated with 
the development of BPD. Furthermore, U. parvum serovars 3 and 6 have been identified as the most 
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common ureaplasma isolates from the LGT of asymptomatic women (Knox et al. 1997; Knox et al. 
2003); while U. parvum serovar 6 was found to be associated with adverse pregnancy outcomes 
(Knox et al. 1998). Interestingly, U. parvum serovars 3 and 6 were found to be the most prevalent 
ureaplasma serovars within semen samples from infertile men in an Australian population and U. 
parvum serovar 6 was found to be the most adherent to sperm and was not always removed by 
assisted reproductive technology washing procedures (Knox et al. 2003). In an ovine model of 
intraamniotic infection with U. parvum serovars 3 or 6, low passage clinical isolates obtained from 
these infertile men were intraamniotically injected into pregnant ewes and induced chorioamnionitis 
and colonised the fetal lung tissue (Moss et al. 2005; Moss et al. 2008; Collins et al. 2010; Knox et al. 
2010; Dando et al. 2012; Collins et al. 2013; Robinson et al. 2013). In these studies, the presence of 
Ureaplasma spp. was not always associated with histological chorioamnionitis and this is similar to 
what has been reported in human pregnancies affected by ureaplasmas. These results demonstrate 
that different ureaplasma serovars may be more prevalent in geographically distinct study 
populations. Different methods were also used to detect, speciate and serotype these clinical 
isolates. Because of the variability in results of these studies, the question remains as to whether 
virulence/pathogenicity is species- or serovar-specific; or if it is the lack of consistent 
speciating/serotyping methods that has resulted in the variation reported by these studies. By 
designing a simple and effective diagnostic assay, which effectively speciates and serotypes clinical 
isolates, it may be possible to determine if there are 'virulent' species or serovars of Ureaplasma 
spp., or it may be that there are other virulence determinants that play an important role in the 
development of adverse pregnancy and neonatal outcomes.  
 
Culture for Ureaplasma spp. remains the gold-standard method for detection of these 
microorganisms within clinical specimens (DiGiulio 2012). However, this is often time-consuming and 
difficult to perform in clinical and diagnostic laboratories, as these fastidious organisms do not grow 
on standard bacteriological media. Instead specialised transport and culture media is required and 
these are not often available commercially and therefore must be produced 'in house'. To improve 
the detection of Ureaplasma spp., conventional and real-time PCR assays have been developed 
(Knox and Timms 1998; Yi et al. 2005; Xiao et al. 2010); however, not all of these assays are designed 
for high-throughput laboratories, they require highly stringent parameters and they are  time-
consuming. The Ureaplasma spp. are not routinely screened for during pregnancy or in placentae 
after delivery, despite the strong association between Ureaplasma spp. and adverse pregnancy 
outcomes (Australian Government Department of Health and Ageing 2012). By designing and 
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optimising a detection tool which speciates and serotypes the human Ureaplasma spp., it may be 
possible to identify 'virulent' ureaplasma species and/or serovars. 
 
Others have suggested that ‘virulence’ may not be limited to particular Ureaplasma spp., but that 
the maternal immune responses may also be crucial to the development of adverse sequelae. Dando 
et al. (2012) demonstrated that chronic intraamniotic Ureaplasma spp. infections in an ovine model 
resulted in the production of anti-ureaplasma IgG antibodies within the maternal serum in some 
ewes, but not in others. The presence of serum IgG antibodies was correlated with an increased 
expression of interleukin (IL)-1β, IL-6 and IL-8, but decreased expression of TNF-α and IL-10 within 
chorioamnion tissue. Similarly, in humans it has been demonstrated that different immune 
responses were detected, depending on the ethnicity of women (Peltier et al. 2012). Chorioamnion 
tissue derived from Caucasian (n = 6) or African-American (n = 5) women were exposed to 
Ureaplasma spp. Exposure of chorioamnion tissue in vitro to U. parvum resulted in elevated levels of 
TNF-α in the Caucasian-derived tissues; while in African-American-derived tissues, U. parvum was 
associated with low levels of IL-10. Additionally, U. urealyticum infection induced elevated levels of 
IL-10 and IL-1β in Caucasian tissues, but induced no immune response in Africa-American 
chorioamnion tissue (Peltier et al. 2012). These findings suggest that differences in the maternal 
immune response may influence the development and severity of disease and warrant further 
investigation.  
 
It has also been proposed that women may experience different pregnancy outcomes, depending on 
antigenic variation of the pathogen. The multiple banded antigen (MBA) is the major antigen 
recognised by the host immune system in response to ureaplasma infection and is composed of two 
major domains: an upstream conserved region that is similar in all Ureaplasma spp. serovars, and a 
downstream region that is composed of tandem repeating units which contain both cross-reactive 
and serovar-specific epitopes (Zheng et al. 1995; Zheng et al. 1996). Importantly, it is this surface-
exposed region that has been shown to vary in size in vivo (Zheng et al. 1994), and numerous studies 
by our group have demonstrated mba/MBA size variation within a well-established ovine model of 
ureaplasma intraamniotic infection (Knox et al. 2010; Dando et al. 2012; Robinson et al. 2013). In 
particular, a study by Knox et al. (2010) reported variation in the severity of inflammation of sheep 
tissues, including the chorioamnion. After pregnant ewes were intraamniotically injected with the 
same dose of Ureaplasma spp., this study showed that after delivery some sheep had no evidence of 
histological chorioamnionitis, whilst others had moderate or severe inflammation. Interestingly, it 
was identified that the number of mba/MBA size variants expressed by these ureaplasmas was 
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inversely correlated with the severity of inflammation and histological chorioamnionitis. Based on 
these findings, it was hypothesised that MBA size variation may be a mechanism by which 
Ureaplasma spp. modulate the host immune response or evade host immune detection/eradication 
(Knox et al. 2010). Importantly, it is yet to be determined if ureaplasmas isolated from human 
pregnancies are able to vary their surface-exposed MBA and if this has any effect on pregnancy 
outcomes.  
 
For this current study, we hypothesised that the host may not always recognise Ureaplasma spp., 
due to variation of the surface-exposed MBA. We further hypothesised that MBA variation may be 
associated with differences in the host immune response. The aims of this study were to (i) develop 
and optimise a real-time PCR and high resolution melt (HRM) assay to speciate and serotype U. 
parvum clinical isolates and to identify any 'virulent' U. parvum serovars; (ii) to assess the presence 
of MBA/mba variation occurring in clinical isolates; and (iii) to characterise the cytokines, 
chemokines and growth factors within cord blood in response to chorioamnion infection with 
Ureaplasma spp. and other microorganisms. The presence of Ureaplasma species and serovars, the 
degree of MBA/mba variation and the levels of cytokines, chemokines and growth factors were 
correlated with the development of adverse pregnancy and neonatal outcomes. 
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Materials and Methods: 
All methods pertaining to this chapter are summarised in Chapter Three.  
 
Briefly, Ureaplasma spp. clinical isolates that were isolated from late preterm placentae (Chapter 
Four) were stored (see Chapter Three, section 3.4) for use in these experiments. American type 
culture collection (ATCC) strains of U. parvum, U. urealyticum and other microorganisms (detailed in 
Chapter Three, section 3.5) were also used in this chapter.  
 
For real-time PCR and HRM assays, Ureaplasma spp. clinical isolates, ATCC strain ureaplasmas and 
other bacterial isolates were cultured (Chapter Three, sections 3.5 and 3.6.1) and the DNA extracted 
(Chapter Three, section 3.8). DNA template from each clinical isolate, ATCC strain ureaplasmas and 
other microorganisms were tested using designed PCR primers (Chapter Three, sections 3.15 and 
3.16) targeting the mba gene and were validated for their specificity and serotyping abilities 
(Chapter Three, sections 3.17 and 3.18). Once the ability of the real-time PCR assays to speciate and 
serotype U. parvum serovars 1, 3, 6 and 14 was confirmed, ureaplasma clinical isolates were then 
serotyped using these designed assays (Chapter Three, section 3.19). Serotyping results were then 
compared to the results of mba gene sequencing (as per Chapter Three, sections 3.9.2, 3.10, 3.11 
and 3.12). 
 
The presence or absence of mba/MBA size variation of these Ureaplasma spp. clinical isolates was 
also assessed. The proteins of these clinical isolates were extracted (Chapter Three, section 3.6.1) 
and MBA protein size variation was assessed by western blot (Chapter Three, section 3.13). mba 
gene size variation was also assessed following DNA extraction (Chapter Three, section 3.8.1) and 
PCR assays which targeted the downstream repetitive region of the mba gene (Chapter Three, 
section 3.14). 
 
Statistical analysis 
Data are presented as the mean value, plus the standard error of the mean (SEM). Ureaplasma spp. 
spp. and serovars were correlated with pregnancy outcome data (maternal demographic data, 
maternal pregnancy outcomes and neonatal outcomes) to determine if some Ureaplasma spp. and 
serovars were more ‘virulent’ than others. Additionally, the presence/absence of mba/MBA size 
variation was correlated with pregnancy outcome data (as above) and the concentrations of cord 
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blood cytokines, chemokines and growth factors. Data was analysed using analysis of variance 
(ANOVA) tests. Statistical significance was accepted as p < 0.05.  
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Results 
PCR Primers 
Four PCR primer pairs (see Table 5.1) were designed to specifically amplify U. parvum at different 
regions of the mba gene (see Supplementary Figure 8.1). Each of the forward (F) primers was 
optimised with each reverse (R) primer, to produce a total of 16 PCR assays. Six of these primer pairs 
(see Table 5.2) amplified U. parvum serovars without cross-reactivity to the U. urealyticum serovars 
(2, 4, 5, 7 - 13), or to any other microorganisms tested. The primer pairs which demonstrated cross-
reactivity were excluded from further analysis and six successful primer pairs were further 
investigated by real-time PCR.  
Table 5.1. Novel PCR primers targeting areas of the multiple banded antigen (mba) gene, designed 
for use in real-time PCR and high resolution melt assays 
Primer name Primer Sequence Tm % AT content 
UpuF 5’ CTAATAATGTTATTGATAATGCAG 3’ 55 °C 75% 
UpmbaR 5’ GTTTTCAATTTCGTAAACTGC 3’ 55 °C 67% 
UpuF2 5’ TTATAATAAAAAATATCTAATAATG 3’ 56 °C 92% 
UpmbaR2 5’ CCAGCTCCAACTAAGGTAAC 3’  56 °C 50% 
UpuF3 5’ TTATATAATTAAAAGTGCAAGTGC 3’  57 °C 75% 
UpmbaR3 5’ TTGTTCATTAGGTTTTGGTTCACGA 3’ 57 °C 64% 
UpuF4 5’ GTGCTAAATAAAAAGTATTTGC 3’ 57 °C 73% 
UpmbaR4 5’ CCTGAAGTCTTGATTAATCCAC 3’ 57 °C 59% 
 
U. parvum real-time PCR assay optimisation  
Using real-time PCR, each of the six PCR assays (UpuF/UpmbaR, UpuF2/UpmbaR, UpuF2/UpmbaR4, 
UpuF3/UpmbaR4, UpuF4/UpmbaR and UpuF4/UpmbaR4) again demonstrated amplification of only 
U. parvum serovars 1, 3, 6 and 14 and these assays produced a single fluorescent ‘peak’, consistent 
with the production of a single PCR amplicon.  
 
The high resolution melt (HRM) curve data generated for each of the six primer pairs were 
scrutinised and only a single PCR primer pair was able to differentiate the ATCC U. parvum serovars 
1, 3, 6 and 14 according to the differentiation criteria defined in the methods chapter (see Chapter 
Three, Section 3.14). The PCR assay utilising UpuF2 and UpmbaR primers demonstrated specificity 
and no cross-reactivity to any other microorganisms tested (including U. urealyticum; Figure 5.1A). 
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This assay produced a single amplicon as evidenced by the standard melting graph (Figure 5.1B) and 
differentiated U. parvum serovars 1, 3, 6 and 14 by HRM (Figure 5.1C and 5.1D). This real-time PCR 
and HRM assay was selected for further analysis of U. parvum clinical isolates.  
 
Table 5.2.  Comparison of real-time PCR assays for the amplification and differentiation of U. parvum 
serovars. Of the 16 assays optimised, only six were able to successfully amplify U. parvum serovars 
and one assay was also able to differentiate U. parvum serovars 1, 3, 6 and 14 by high resolution 
melt. 
Primer Pairs Amplicon Size Specificity 1
 
Cross-reactivity 2
 
Serotyping ability 3
 
UpuF / UpmbaR 429 bp Yes No No 
UpuF / UpmbaR2 314 bp No Yes - Kp - 
UpuF / UpmbaR3 594 bp No Yes - Uu - 
UpuF / UpmbaR4 631 bp No Yes - Kp - 
UpuF2 / UpmbaR 445 bp Yes No Yes 
UpuF2 / UpmbaR2 330 bp No Yes - Uu - 
UpuF2 / UpmbaR3 610 bp No Yes - Uu - 
UpuF2 / UpmbaR4 647 bp Yes No No 
UpuF3 / UpmbaR 373 bp No Yes - Uu - 
UpuF3 / UpmbaR2 258 bp No Yes - Uu - 
UpuF3 / UpmbaR3 538 bp No Yes - Sa, Kp - 
UpuF3 / UpmbaR4 575 bp Yes No No 
UpuF4 / UpmbaR 353 bp Yes No No 
UpuF4 / UpmbaR2 238 bp No Yes - Uu - 
UpuF4 / UpmbaR3 518 bp No Yes - Uu - 
UpuF4 / UpmbaR4 555 bp Yes No No 
1 Specificity – amplifies U. parvum serovars only. 
2 Cross-reactivity – other species that were amplified when the PCR assay was not specific to U. 
parvum. Uu – U. urealyticum, Kp – Klebsiella pneumoniae, Sa – Streptococcus agalactiae. 
3 Serotyping ability – the ability of each primer pair to amplify only U. parvum serovars 1, 3 6 and 14; 
and to differentiate each of the four serovars by HRM analysis (see Chapter three, section 3.18 for 
serotyping guidelines).  
 
Efficacy of U. parvum real-time PCR and HRM assay for serotyping of clinical 
isolates 
 
Clinical isolates of U. parvum (n = 55) were tested using the real-time PCR and HRM assay (with 
primers UpuF2 and UpmbaR), and of these isolates, 31 (56.4%) were amplified using the optimised 
assay. Ureaplasmas that had been cultured in vitro were detected and serotyped using this assay; 
however, many of the clinical specimens, which were not cultured (original clinical specimen) 
contained low DNA concentrations and were not always detected or typed (HRM plots were 
affected) using this assay.  
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Each cultured clinical isolate produced a single fluorescent ‘peak’ by standard melt, consistent with 
the production of a single amplicon. These fluorescent ‘peaks’ often matched, or were very similar to 
U. parvum serovars 1, 3, 6 and 14 ATCC positive controls and the amplicons produced by these 
clinical isolates were of the correct size, when compared to positive control U. parvum serovars 
(ATCC serovars 1, 3, 6 and 14). 
 
The standard melt analysis and HRM profiles produced by each clinical isolate demonstrated 
similarities to the HRM profiles produced by ATCC U. parvum serovars 1, 3, 6 and 14 (Fig 5.2A). The 
clinical isolates were serotyped and assigned to a serovar based on the results of HRM (Figure 5.2B) 
and difference plots (Figure 5.2C) 
 
For example, clinical specimens 122 and 429 produced HRM profiles that corresponded to U. parvum 
serovar 6 and these clinical isolates were identified as U. parvum serovar 6. Similarly, clinical isolate 
498B produced a HRM profile that was highly similar to U. parvum serovar 1 (Figure 5.2C). The 
serovar identity of 498B was confirmed using the software to be U. parvum serovar 1. When U. 
parvum serovar 1 ATCC strain was designated as the baseline genotype, the HRM curve of clinical 
isolate 498B was plotted within 5 fluorescent units (the cut-off, indicated by the red dotted line) of 
serovar 1 baseline controls and this confirmed that this clinical isolate was U. parvum serovar 1.  
 
Of the 31 clinical isolates which were successfully amplified, 20/31 (64.5%) were serotyped 
successfully using the designed real-time PCR and HRM assay (Supplementary Table 8.2). 
Unfortunately, in some instances clinical isolate HRM curves did not correlate with any of the U. 
parvum positive controls or were outside of the ± 5 fluorescent unit cut-off for successful serotyping 
and so these clinical isolates were unable to be successfully serotyped. It was hypothesised that the 
erroneous results seen may be due to differences (additional SNPs) in the genetic sequences 
amplified and so we selected a small group of clinical isolates for sequencing to confirm this theory. 
However, PCR amplicons generated from the real-time PCR and HRM were not found to contain any 
SNPs within their sequenced amplicons (data not shown).  
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Figure 5.1. Real-time PCR and HRM assays performed on ATCC strains of U. parvum serovars 1, 3, 6 and 14. Real-time PCR amplification (panel A) produced 
strong amplification of U. parvum serovars only, while standard melt analysis (panel B) demonstrated a single fluorescent ‘peak’, consistent with 
amplification of the gene target. Normalised melt curves (panel C) demonstrated differences in the melt profiles of U. parvum serovars 1, 3, 6 and 14, which 
were further differentiated by difference plots (panel D) 
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Figure 5.2. Real-time PCR and HRM assay performed on U. parvum ATCC strains and clinical isolates. PCR amplification (panel A) demonstrated strong 
amplification of U. parvum clinical isolates. Normalised melt curves (panel B) demonstrated similarities to U. parvum clinical isolates which were able to 
successfully serotype 64.5% of clinical isolates tested when difference plots (panel C) were analysed. Representative data is shown 
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Ureaplasma species associated with adverse pregnancy and neonatal outcomes 
 
The pregnancy and neonatal outcomes for participants whose placentae were infected with U. 
parvum and U. urealyticum were compared to determine if the different ureaplasma species were 
associated with adverse outcomes.  
 
Women from whom U. urealyticum (n = 6) was isolated in the chorioamnion had a lower maternal 
age (22.8 ± 2.0 yrs) than those women in whom U. parvum (n = 36; 24.7 ± 0.8 yrs, p = 0.046; Table 
5.3) was identified. Almost all women (> 97%) with ureaplasma infection attended at least one 
prenatal care visit during their pregnancy (Table 5.3). 
 
Women who were infected with U. parvum or U. urealyticum within the chorioamnion had no 
differences in pregnancy outcomes (Table 5.4); however, women infected with U. urealyticum 
reported a higher prevalence of histological chorioamnionitis in previous pregnancies (33.3%), 
compared to women who were infected with U. parvum (5.6%, p = 0.031; Table 5.3). Those women 
who were infected with U. urealyticum also had a higher incidence of pPROM (66.7%), when 
compared to those infected with U. parvum during their current pregnancies (30.6%, p = 0.06; Table 
5.4). 
 
For those babies born to women infected with Ureaplasma spp. during pregnancy, there were no 
differences in the neonatal outcomes for infants infected with U. parvum, compared to those 
infected with U. urealyticum (Chapter Nine, Suppmentary Table 9.3). 
 
  
A B 
C 
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Table 5.3. Maternal demographic data for women whose chorioamnion was infected with U. parvum and U. urealyticum during pregnancy. 
 U. parvum (n = 36) U. urealyticum (n = 6) Significance 
Maternal Age 24.7 ± 0.8 (17 – 32) 22.8 ± 2.0 (19 – 32) 0.046 
Gravida1 1.9 ± 0.2 (1 – 5) 3.2 ± 0.3 (2 – 4) NS2  
Parity3 1.7 ± 0.2 (1 – 4) 2.3 ± 0.4 (1 – 4) NS 
Marital Status    
- Married 12/36 (33.3%) 1/6 (16.7%) NS 
- Single 24/36 (66.7%) 5/6 (83.3%) NS 
Medical Insurance    
- Private 14/36 (38.9%) 1/6 (16.7%) NS 
- Medicaid 16/36 (44.4%) 5/6 (83.3%) NS 
- Self pay/uninsured 4/36 (11.1%) 0/36 (0.0%) NS 
- Unknown 2/36 (5.6%) 0/36 (0.0%) NS 
Ethnicity    
- Caucasian 22/36 (61.1%) 1/6 (16.7%) NS 
- African-American 12/36 (33.3%) 5/6 (83.3%) NS 
- Asian 0/36 (0.0%) 0/6 (0.0%) NS 
- More than one race 2/36 (5.6%) 0/6 (0.0%) NS 
Evidence of prenatal care 35/36 (97.2%) 6/6 (100.0%) NS 
1 Gravida – total number of clinical pregnancies 
2 NS - Not statistically significant 
3 Parity – total number of viable offspring resulting from pregnancies 
Data was analysed by ANOVA 
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Table 5.4. Maternal pregnancy outcomes for women whose chorioamnion was infected with U. parvum and U. urealyticum during pregnancy 
 U. parvum (n = 36) U. urealyticum (n = 6) Significance 
Signs/symptoms of infection1 4/36 (11.1%) 1/6 (16.7%) NS2 
Chorioamnionitis documented previously 2/36 (5.6%) 2/6 (33.3%) 0.031 
Chorioamnionitis in current pregnancy3 22/36 (61.1%) 5/6 (83.3%) NS 
- Maternal Stage 1.5 ± 0.1 (1 – 3) 1.6 ± 0.2 (1 – 2) NS 
- Fetal Stage 2.0 ± 0.2 (1 – 3) 3.0 ± 0.04  NS 
Antibiotics administered < 3hrs prior to delivery 15/36 (41.7%) 4/6 (66.7%) NS 
PTL/cervical incompetence 16/36 (44.4%) 4/6 (66.7%) NS 
preterm premature rupture of membranes (pPROM) 11/36 (30.6%) 4/6 (66.7%) NS  
1 Signs or symptoms of infection included: maternal temperature > 38 °C, uterine or abdominal tenderness,  foul-smelling vaginal discharge, maternal 
tachycardia (> 120 bpm) or fetal tachycardia (> 160 bpm) 
2 NS - Not statistically significant 
3 Chorioamnionitis was determined by US pathologists and graded for the severity of inflammation according to (Redline et al. 2003) 
4 No range or standard error of the mean was available for this data point, only one infant had evidence of amnion involvement  
Data was analysed by ANOVA 
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U. parvum serovars associated with adverse pregnancy and neonatal outcomes 
 
We also compared the pregnancy and neonatal outcomes for women infected with the different U. 
parvum serovars (1, 3, 6; n = 31) (Table 5.5). 
 
Women who were infected within the chorioamnion with U. parvum serovar 3 were younger (21.4 ± 
0.9 yrs) than women in whom U. parvum serovars 1 and 6 were identified (26.4 ± 1.1 yrs and 26.0 ± 
1.2 yrs, respectively; p = 0.024. Table 5.5). Women who were infected with U. parvum serovar 1 
were more likely to be married (p = 0.006), while women infected with U. parvum serovars 3 and 6 
were more frequently unmarried (p = 0.008).There were no other differences in the demographic 
data between these three groups of women, nor were there any differences in the incidence of 
adverse pregnancy or neonatal outcomes (Chapter Nine, Supplementary Tables 8.4 and 8.5).   
A B 
C 
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Table 5.5. A comparison of the demographic data of women infected with U. parvum serovars 1, 3 and 6 (n = 311).  
 Serovar 1 
(n = 10) 
Serovar 3 
(n = 9) 
Serovar 6 
(n = 12) 
Significance 
Maternal Age 26.4 ± 1.1 (20 – 32) 21.4 ± 0.9 (17 – 26) 26.0 ± 1.4 (19 – 32) 0.024 
Gravida2 2.1 ± 0.2 (1 – 4) 1.7 ± 0.4 (1 – 4) 1.9 ± 0.4 (1 – 5) NS3 
Parity4 2 ± 0.2 (1 – 4) 1.4 ± 0.2 (1 – 2) 1.8 ± 0.3 (1 – 4) NS 
Marital Status     
- Married 8/10 (80.0%) 3/9 (33.3%) 1/12 (8.3%) 0.006 
- Single  2/10 (20.0%) 6/9 (66.7%) 11/12 (91.7%)  0.008 
Medical insurance     
- Private 7/10 (70.0%) 2/9 (22.2%) 5/12 (41.7%) NS 
- Medicaid 2/10 (10.0%) 2/9 (22.2%) 7/12 (58.3%) NS 
- Self pay/uninsured 1/10 (10.0%) 3/9 (33.3%) 0/12 (0.0%) NS 
- Unknown  0/10 (0.0%) 0/10 (0.0%) 0/12 (0.0%) NS 
Ethnicity     
- Caucasian 9/10 (90.0%) 7/9 (77.8%) 6/12 (50.0%) NS 
- African-American 1/10 (10.0%) 2/9 (22.2%) 5/12 (41.7%) NS 
- Asian 0/10 (0.0%) 0/9 (0.0%) 0/12 (0.0%) NS 
- More than one race 0/10 (0.0%) 0/9 (0.0%) 1/12 (8.3%) NS 
Evidence of prenatal care 10/10 (100.0%) 9/9 (100.0%) 11/12 (91.7%) NS 
1 Five of the U. parvum clinical isolates were not serotyped by the real-time PCR and HRM assay  
2 Gravida  - total number of clinical pregnancies 
3 NS – not statistically significant 
4 Parity – total number of viable offspring resulting from pregnancies. 
Data was analysed by ANOVA 
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Characterisation of the Ureaplasma spp. multiple banded antigen (mba/MBA) by 
PCR and western blot   
 
Western blot of the MBA 
 
Western blot analyses of the U. parvum serovars 1, 3 and 6 ATCC strains demonstrated MBA protein 
bands of approximately 80 kDa; 90 kDa and 70 kDa, respectively (Figure 5.3). U. urealyticum serovars 
2, 4, 5 7 – 13 produced MBA protein bands of 70 kDa; 80 kDa; 70 kDa; 80 kDa; 100 kDa; 90 kDa; 75 
kDa; 80 kDa; 75 kDa and 70 kDa, respectively (serovars 8 and 10 shown in Figure 5.3). 
  
The MBA proteins expressed by clinical isolates were compared to the ATCC strains and variation in 
the size of MBA proteins ranged from 55 kDa – 100 kDa. The MBA proteins expressed by some 
clinical isolates demonstrated no variation, i.e. these proteins were the same size as the antigens 
expressed by ATCC strain serovars (Serovar 1 isolates: 1A, 1B, 262T, 507; Serovar 3 isolates: 33A, 
33B, 322T, 325; and Serovar 6 isolates: 334A, 334B, 364A; Figure 5.3). For other clinical isolates, 
variation in the size of their MBA proteins was demonstrated. These clinical isolates demonstrated 
either a ‘single MBA variant’, which was considered to be an individual protein band that differed in 
size when compared to the corresponding ATCC strain controls (Serovar 1 isolates: 43, 301, 483T, 
498A, 498B; Serovar 3 isolates: 44A, 44B, 314T, 365, 435; Serovar 6 isolates: 27, 50, 55B, 122, 182, 
310T and 429; Serovar 8 isolate: 8; and Serovar 10 isolate 300); or in some cases, ‘multiple MBA 
variant’ bands were seen, where more than one MBA band was identified by western blot (Serovar 1 
isolates: 290T, 473T; Serovar 6 isolates: 182, 429; Figure 5.3).  
 
For some clinical ureaplasma isolates (258, 297, 351, 438, 480T and 510T), we were unable to 
demonstrate MBA protein expression with any of the 14 serovar-specific antisera tested, and 
therefore we were unable to determine if MBA size variation occurred.  
 
PCR of the mba  
To assess if MBA size variation (as demonstrated in western blots) was also occurring within the 
gene (mba) encoding the MBA protein, we performed PCR assays which amplified the downstream 
repetitive region of the mba for clinical isolates of serovar 1, serovar 3 and serovar 6. Whilst western 
blots were performed on serovar 8 and serovar 10 clinical isolates, it was not possible to amplify the 
downstream region of the mba gene in U. urealyticum isolates due to differences in the gene regions 
targeted by available PCR primers (Figure 5.3).  
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The ATCC strain U. parvum serovars 1, 3 and 6 produced PCR amplicons of approximately 900 bp, 
950 bp and 800 bp, respectively (Figure 5.3). Similar to the results seen in western blots, we 
identified variation in the size of amplicons produced by U. parvum clinical isolates, and these 
amplicons ranged in size from 350 bp to 1200 bp. The variation in size of the PCR amplicons 
produced by U. parvum ATCC strains and the clinical isolates directly correlated with the variation in 
size seen in MBA proteins in western blots. Clinical isolates which demonstrated ‘no mba variation’ 
had amplicons which were the same size as the ATCC strain controls. Furthermore, those clinical 
isolates which demonstrated a ‘single mba variant’ or ‘multiple mba variants’ produced mba 
amplicons, which directly correlated with the size and number of MBA proteins expressed by each 
clinical isolate (Figure 5.3).  
 
U. parvum serovar 6 clinical isolate 480T did not produce an mba amplicon when tested using 
primers that amplified either U. parvum serovars 1 and 6; or U. parvum serovars 3 and 14. Due to 
the absence of a downstream mba amplicon and the absence of an MBA protein by western blot, a 
PCR assay targeting the upstream region of the mba was performed. This assay confirmed the 
presence of the upstream conserved portion of the mba gene.  
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Figure 5.3. Variation of the mba gene and MBA protein was detected by conventional PCR and western blot. Variation was identified by running each 
protein and PCR amplicon sample with both an ATCC strain positive control and a molecular weight marker. Images were then cropped and displayed at 
their correct molecular weight and sorted according to their serovar groupings.  
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mba/MBA variation and its association with adverse pregnancy outcomes 
 
The pregnancy and neonatal outcomes of women from whom Ureaplasma spp. with no mba/MBA 
variation was isolated were compared to the outcomes for pregnancies in which a single mba/MBA 
size variant was isolated, or those in which multiple mba/MBA size variants were isolated.  
 
There were no differences in the maternal demographic data associated with women in which 
mba/MBA variation was identified, when compared to those women in whom no mba/MBA 
variation was identified (Chapter Nine, Supplementary Table 9.6) 
 
However, a major finding of this study was that mba/MBA variation as demonstrated by western 
blot and PCR was associated with the prevalence of histological chorioamnionitis. Placentae from 
which no mba/MBA variation was seen demonstrated a higher incidence of histological 
chorioamnionitis (81.8%), compared to placentae from which ureaplasmas that expressed only a 
single mba/MBA variant were isolated (43.7%, p = 0.023; Table 5.6).  
 
There were no differences in the pregnancy or neonatal characteristics that were associated with 
mba/MBA variation. 
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Table 5.6. Comparison of pregnancy outcomes in pregnancies with Ureaplasma spp. infection and 
mba/MBA variation  
 No mba/MBA 
variants1 
(n = 11) 
Single 
mba/MBA 
variant 
(n = 16) 
Multiple 
mba/MBA 
variants 
(n =4 ) 
Significance 
Signs/symptoms of infection2 2/11 (18.2%) 0/16 (0.0%) 1/4 (25.0%) NS3 
Chorioamnionitis documented previously 0/11 (0.0%) 1/16 (6.2%) 1/4 (25.0%) NS 
Chorioamnionitis in current pregnancy4  9/11 (81.8%) 7/16 (43.7%) 3/4 (75.0%) 0.023 
- Maternal Stage 1.5 ± 0.2 (1 - 3) 1.1 ± 0.1 (1 - 2) 2 ± 0.5 (1 - 3) NS 
- Fetal Stage 2.5 ± 0.3 (1- 3) 2 ± 0.3 (1- 3) 1.5 ± 0.3 (1 - 2) NS 
Antibiotics administered < 3 hours prior to delivery 5/11 (45.4%) 8/16 (50.0%) 1/4 (25.0%) NS 
Cervical incompetence 3/11 (27.3%) 8/16 (50.0%) 2/4 (50.0%) NS 
preterm premature rupture of membranes (pPROM) 3/11 (27.3%) 7/16 (43.7%) 0/4 (0.0%) NS 
1 mba/MBA size variation was determined by conventional PCR and western blot targeting the mba 
gene and its expressed protein (MBA). Data was analysed using ANOVA tests.  
2 Signs and symptoms of infection included: maternal temperature > 38 °C, uterine or abdominal 
tenderness, foul-smelling vaginal discharge, maternal tachycardia (> 120 bpm) or fetal tachycardia (> 
160 bpm) 
3 NS – Not statistically significant 
4 Chorioamnionitis was determined by US pathologists and the severity of inflammation was graded 
according to (Redline et al. 2003).  
 
 
Figure 5.4. There was a trend between the presence of Ureaplasma spp. MBA variation (both single 
and multiple MBA variants) and a reduction in inflammation within the fetal (amnion; shown in dark 
green) portion of the chorioamnion membranes. Data are presented as mean, plus or minus the 
standard error of the mean (SEM). 
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Cytokines, chemokines and growth factors 
 
The presence of cytokines, chemokines and growth factors within cord blood was also tested for any 
correlation with the development of adverse pregnancy and neonatal outcomes. BioPlex assays 
detecting IL-6, IL-8, monocyte chemoattractant protein (MCP)-1 and granulocyte colony-stimulating 
factor (G-CSF) were performed by our collaborators and provided for analysis within this project.  
 
Cord blood sampled from pregnancies with chorioamnion infection, regardless of the aetiology of  
the infection, demonstrated significantly higher concentrations of IL-8 (536.9 pg/mL) and G-CSF 
(403.0 pg/mL), compared to concentrations in pregnancies in which no chorioamnion infection was 
detected (56.6 pg/mL and 231.7 pg/mL, p = 0.03 and p= 0.04, respectively; Figure 5.5). 
 
Figure 5.5. A comparison of the concentrations of cytokines, chemokines and growth factors within 
cord blood obtained from women with and without chorioamnion infection. Data was analysed by 
ANOVA and are presented as the mean, plus or minus the standard error of the mean (SEM). 
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The detection of Ureaplasma spp. within the chorioamnion was associated with higher 
concentrations of G-CSF (p = 0.02) within cord blood, but not with the factors IL-6, IL-8 and MCP-1. 
By contrast, cord blood collected from pregnancies in which the chorioamnion was infected by 
microorganisms (other than Ureaplasma spp.) demonstrated higher levels of IL-8 (p = 0.01, Figure 
5.6).  
 
 
Figure 5.6. Comparison of the concentrations of cytokines, chemokines and growth factors within 
cord blood of pregnancies with chorioamnion infections caused by Ureaplasma spp. or other 
microorganisms; compared to pregnancies in which no infection was detected. Data was analysed by 
ANOVA and are presented as the mean, plus or minus the standard error of the mean (SEM) 
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We also assessed if cord blood cytokines, chemokines and growth factor concentrations correlated 
with the presence or absence of histological chorioamnionitis. In Chapter Four, we demonstrated 
that infection with Ureaplasma spp. (but not other microorganisms) was associated with the 
development of histological chorioamnionitis. Pregnancies which were affected by histological 
chorioamnionitis demonstrated elevated levels of MCP-1 (p = 0.05) and G-CSF (p = 0.008; Figure 5.7).  
 
 
Figure 5.7. Cytokines, chemokines and growth factor concentrations within cord blood from 
pregnancies exposed to histological chorioamnionitis and those which had no evidence of 
chorioamnionitis. Data was analysed by ANOVA and are presented as the mean, plus or minus the 
standard error of the mean (SEM) 
 
 
Due to similarities in cord blood G-CSF levels in Ureaplasma spp.-infected placentae (Figure 5.6) and 
placentae with histological chorioamnionitis (Figure 5.7), we also assessed if mba/MBA variation was 
associated with variation in cord blood cytokine concentrations.  
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Concentrations of IL-8 and G-CSF were elevated in placentae, which were infected with ureaplasmas 
that demonstrated no mba/MBA variation, compared to placentae which were ureaplasma-infected 
but demonstrated a single or multiple mba/MBA variants (p = 0.044, p = 0.008, respectively; Figure 
5.8). By contrast, levels of MCP-1 were elevated in placentae which were infected with Ureaplasma 
spp. which demonstrated mba/MBA variation, when compared to those pregnancies which were 
infected with ureaplasmas but demonstrated no mba/MBA variation.  
 
 
Figure 5.8. Correlations of cytokines, chemokines and growth factors present in cord blood from 
Ureaplasma spp.-infected pregnancies. Concentrations of immune factors differed in pregnancies 
which demonstrated no mba/MBA variation (n = 11) and those which expressed a single (n = 16) or 
multiple (n = 4) mba/MBA variants. Data was analysed by ANOVA and are presented as the mean, 
plus or minus the standard error of the mean (SEM)  
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Discussion 
 
The pathogenic role of Ureaplasma spp. as an aetiological agent of adverse pregnancy outcomes is 
controversial. These microorganisms have been isolated from the amniotic fluid and placentae of 
women experiencing PTB and the development of histological chorioamnionitis (Hillier et al. 1988; 
Aaltonen et al. 2007; Berger et al. 2009; Namba et al. 2010); however, Ureaplasma spp. have also 
been isolated from women who delivered at term with no apparent adverse outcomes (Gray et al. 
1992; Gerber et al. 2003). To investigate the pathogenesis of Ureaplasma spp. within human 
pregnancies, we conducted a prospective study to investigate the prevalence of Ureaplasma spp. 
and serovars in late preterm and term pregnancies and also to characterise the variation of the MBA 
surface-exposed protein. We correlated the presence of ureaplasmas with adverse pregnancy and 
neonatal outcomes, including the development of histological chorioamnionitis. Furthermore, the 
presence of cytokines, chemokines and growth factors within cord blood was also correlated with 
the presence of ureaplasmas.  
 
In this current program of research (Chapter Four), we demonstrated that Ureaplasma spp. were the 
most prevalent bacteria detected within the chorioamnion of women who delivered late preterm 
(LPT) or at term, and were identified in 42/535 (7.8%) of placentae. U. parvum was the most 
prevalent ureaplasma species present, accounting for 85.7% of all ureaplasma isolates. Furthermore, 
we have now identified in this current chapter that U. parvum serovars 1, 3 and 6 were the most 
prevalent ureaplasma serovars within placentae obtained from women who delivered LPT or at 
term. The women who were infected/colonised with U. urealyticum had a higher prevalence of prior 
chorioamnionitis (Table 5.4); but we have demonstrated that regardless of the Ureaplasma spp. or 
serovar isolated within chorioamnion tissue, the presence of ureaplasmas was associated with 
histological chorioamnionitis. Chorioamnionitis was documented in 61.1% of U. parvum-infected 
placentae and 83.3% of U. urealyticum-infected placentae. Similarly, we demonstrated no difference 
in the prevalence of chorioamnionitis in placentae infected with U. parvum serovars 1, 3 or 6 (70.0%, 
55.5% and 58.3%, respectively) and no major differences in adverse pregnancy or neonatal 
outcomes were seen for women infected with these different serovars. These findings are consistent 
with previous studies that have shown Ureaplasma spp. to be associated with chorioamnionitis 
(Hillier et al. 1988; Aaltonen et al. 2007; Egawa et al. 2007; Hecht et al. 2008), but these ureaplasmas 
may also be isolated from placentae with no evidence of chorioamnionitis and the pregnancy may 
continue until term delivery (Gray et al. 1992; Gerber et al. 2003; Perni et al. 2004).  
 
 134 
 
One of the most significant findings of this current study was that Ureaplasma spp. isolated from 
placentae of human pregnancies demonstrated differences in their MBA proteins. Of the isolates 
obtained from chorioamnion tissue, some expressed no MBA variants (and their proteins were the 
same size as ATCC strain serovars), while other clinical isolates expressed a single or multiple MBA 
size variants (as evidenced by single or multiple MBA bands which differed in size, when compared 
to ATCC strain serovar controls). This study also demonstrated that regardless of the Ureaplasma 
species or serovar that were present, the lack of mba/MBA variation was associated with a higher 
incidence of histological chorioamnionitis and a more severe inflammatory response within the fetal 
(amnion) membranes (grade 2.5; Table 5.6, Figure 5.4). By contrast, when mba/MBA variation 
occurred (either a single or multiple MBA variants), this was associated with a lower incidence of 
histological chorioamnionitis and a decreased inflammatory response within the fetal (amnion) 
membrane (grade 2.0 and 1.5, respectively; Table 5.6. Figure 5.4). Previous studies have 
demonstrated that the severity of histological chorioamnionitis varied depending on the numbers of 
Ureaplasma spp. present within the amniotic fluid or chorioamnion (Jacobsson et al. 2009; Kasper et 
al. 2010; Kacerovsky et al. 2011). However, in Chapter Four, we did not find an association between 
histological chorioamnionitis and the numbers of ureaplasmas present within the chorioamnion 
(Chapter Four, Table 4.4) but in this current study, we demonstrated that mba/MBA variation was 
associated with the severity of inflammation and histological chorioamnionitis, particularly within 
the fetal membranes.  
 
Antigenic variation is an important mechanism used by pathogenic microorganisms to mediate the 
interactions between bacteria and their environment. Variation of antigens/proteins are thought to 
be an essential strategy for successful invasion, infection and to assist the microorganisms to survive 
in the presence of a host immune response in vivo (Darmon and Leach 2014). Antigenic variation can 
occur either through size variation (as demonstrated in our current study) or by selective "switching 
on/off" of a particular protein (often referred to as phase variation). Antigen variation is not a 
unique trait of Ureaplasma spp. and many different microorganisms possess the ability to vary their 
surface-exposed antigens. It has been shown that other Mycoplasma spp. are able to vary the size of 
their surface-exposed proteins, such as the MgpB and MgpC adhesins of M. genitalium, the Vpma 
protein of M. agalactiae and the Vaa putative adhesin protein of M. hominis (Glew et al. 2000; Glew 
et al. 2002; Chopra-Dewasthaly et al. 2008; Citti et al. 2010). Antigen variation in Ureaplasma spp. 
and other Mycoplasma spp. are regulated by two major mechanisms. The first mechanism involves 
DNA slipped strand mispairing and/or nucleotide insertion/deletion in tandem repeating units (Citti 
et al. 2010). The second mechanism involves phase variation or the selective “switching on/off” and 
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this involves DNA rearrangements mediated by site-specific recombinases (Citti et al. 2010). 
Importantly, both size and phase variation of the Ureaplasma spp. MBA have been demonstrated 
previously (Zheng et al. 1992; Zheng et al. 1994; Zheng et al. 1995; Monecke et al. 2003; Zimmerman 
et al. 2009; Knox et al. 2010; Zimmerman et al. 2011; Dando et al. 2012; Robinson et al. 2013; 
Zimmerman et al. 2013).  
 
Ureaplasma mba/MBA variation has been reported in a sheep model of intraamniotic Ureaplasma 
spp. infection (Knox et al. 2010; Dando et al. 2012; Robinson et al. 2013). Knox et al. (2010) 
demonstrated the first evidence of MBA variation within an ovine sheep model. In this study, the 
same number of Ureaplasma spp. were injected into the amniotic fluid of pregnant ewes, but 
differences in the severity of histological chorioamnionitis was observed. While some ewes 
developed mild/moderate or severe histological chorioamnionitis, in other sheep there was no 
evidence of histological chorioamnionitis, despite the presence of high numbers of Ureaplasma spp. 
within the amniotic fluid. This study also identified an inverse correlation between the number of 
MBA size variants and the severity of histological chorioamnionitis: in sheep amniotic fluid which 
contained five or fewer MBA size variants, severe histological chorioamnionitis was seen in 
placentae; however, sheep amniotic fluid which contained nine or more MBA size variants had mild 
or no evidence of chorioamnionitis. It has also been demonstrated that the degree of MBA size 
variation was reliant on the duration of infection, with no variation seen after 3 days of infection, 
some variation seen after 7 days of infection (Robinson et al. 2013) and numerous size variations 
observed following chronic (69 day) infections of the amniotic fluid (Knox et al. 2010; Dando et al. 
2012; Robinson et al. 2013). Interestingly, Dando et al. (2012) demonstrated that MBA variation was 
not limited to ‘virulent’ or ‘avirulent’ strains of Ureaplasma spp. Strains that were associated with 
severe chorioamnionitis (a ‘virulent’ strain) or the absence of chorioamnionitis (an ‘avirulent’ strain) 
were injected into the amniotic cavity of pregnant ewes. Whilst the size of the MBA varied 
throughout gestation, even within the same animal, this study showed no difference in the 
propensity for the ‘virulent’ and ‘avirulent’ strains of Ureaplasma spp. to vary their surface-exposed 
MBA. In this current PhD study, we have demonstrated the presence of MBA size variants within the 
chorioamnion of women who delivered LPT or at term. This study is also the first to demonstrate 
that there is a relationship between the variation of the Ureaplasma spp. MBA and the severity of 
inflammation within the UGT in human pregnancies. Some ureaplasmas demonstrated multiple MBA 
size variants, which suggests in vivo colonisation/infection of the UGT for 'sufficient time' to 
generate these MBA size variants or the presence of a host selective pressure on the ureaplasmas 
present.  
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Phase variation of the Ureaplasma spp. MBA has also been demonstrated in several studies. 
"Switching on/off" of the MBA has been demonstrated following serial in vitro passaging of 
ureaplasmas with high concentrations of MBA-specific antibodies (Monecke et al. 2003; Dando et al. 
2012). This "switching off" of the MBA was shown to be reversible, as ureaplasmas were again able 
to express the MBA lipoprotein following the removal of these antibodies. Zimmerman et al. (2009) 
further investigated the role of MBA phase variation and identified that a DNA inversion event 
between the MBA and an intergenic region downstream of a hypothetical gene (UU376) may serve 
as the mechanism by which MBA expression could be "switched off". These researchers also 
identified another gene (UU172), which may also serve as an additional DNA inversion site for 
"switching on/off" of the MBA (Zimmerman et al. 2011). This same group also further elucidated a 
putative tyrosine recombinase (XerC), which they proposed as the mediator of "on/off switching" of 
the MBA (Zimmerman et al. 2013) and similar tyrosine recombinases have been shown to mediate 
phase variation in other Mycoplasma spp. (Chopra-Dewasthaly et al. 2008). In our current study, a 
number of clinical isolates did not produce an MBA band by western blot when tested with the 14 
different anti-U. parvum or U. urealyticum serovar-specific antisera. U. urealyticum clinical isolates 
258, 297, 351 and 438 (n = 4) did not demonstrate the presence of an MBA in individual western 
blots probed with each of the ten U. urealyticum antisera. Similarly, a single U. parvum clinical 
isolate 480T did not produce an MBA band by western blot in response the four different U. parvum 
antisera, nor was an mba amplicon produced by PCR assays targeting the downstream repetitive 
region of the mba gene. These results are consistent with phase variation and the "switching off" of 
the MBA antigen and the mba gene. In 4/5 (80.0%) of placentae from which these ureaplasmas were 
isolated, there was evidence of histological chorioamnionitis; however, the maternal grading of 
inflammation was mild (mean 1.2) and only one placentae demonstrated inflammation of the fetal 
(amnion) portion of the chorioamnion membrane. Another possible explanation is that these 
isolates may be significantly different to the known ATCC strains of Ureaplasma spp. and therefore 
cannot be detected by the methods used within this study. Recent molecular subtyping of 
Ureaplasma spp. clinical isolates has shown extensive horizontal gene transfer (Xiao et al. 2011b; 
Paralanov et al. 2012) and this may account for the inability to type these strains (and could be a 
contributing factor as to why we were unable to fully characterise these isolates). Non-typeable 
clinical isolates of Ureaplasma spp. have been reported previously (Knox et al. 1998; Echahidi et al. 
2002; Knox et al. 2003) and so it is not surprising that we were unable to fully characterise all of the 
clinical isolates within our study. Regardless, this is an interesting finding and is potentially the first 
report of phase variation and "switching off" of the MBA in vivo.  
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Significantly higher concentrations of IL-8 and G-CSF were detected within cord blood in association 
with chorioamnion infection, regardless of the aetiology (ureaplasmas or other microorganisms), 
when compared to pregnancies with no infection (Figure 5.5). The presence of other microorganisms 
(not including Ureaplasma spp.) was associated with a higher concentration of IL-8 within cord blood 
(1269.4 pg/mL vs. 60.6 pg/mL for those who were uninfected; p = 0.01; Figure 5.6); while the 
presence of Ureaplasma spp. was associated with a higher concentration of G-CSF (489.3 pg/mL vs. 
230.2 pg/mL than for uninfected placentae; p = 0.023; Figure 5.6). Higher concentrations of G-CSF 
were also present in cord blood when histological chorioamnionitis was present within placentae 
(Figure 5.7). G-CSF is a cytokine that affects the proliferation and differentiation of neutrophil 
progenitors and previous studies have identified elevated levels of G-CSF associated with histological 
chorioamnionitis (Boggess et al. 1997; Hoskins et al. 1997). In Chapter Four, we demonstrated that 
the presence of Ureaplasma spp. was associated with histological chorioamnionitis (p < 0.01). In this 
current chapter, we further demonstrated that the presence of Ureaplasma spp. or the presence of 
histological chorioamnionitis is significantly associated with elevated levels of the cytokine G-CSF. 
This strengthens the finding of an association between ureaplasmas and the development of 
histological chorioamnionitis in utero and indicates that this cytokine may be a biomarker of 
asymptomatic chorioamnionitis during pregnancy.  
 
The concentrations of cytokines, chemokines and growth factors in cord blood were also correlated 
with ureaplasma MBA variation detected within chorioamnion clinical isolates. When no ureaplasma 
mba/MBA variation was detected in clinical isolates (identified within chorioamnion tissue), higher 
concentrations of IL-8 were detected within the cord blood (137.7 pg/mL, p = 0.04), when compared 
to those placentae which were infected with ureaplasmas that demonstrated mba/MBA size 
variation. By contrast, clinical ureaplasma isolates that demonstrated a single or multiple MBA 
variants were associated with lower levels of IL-8 (73.7 pg/mL and 46.8 pg/mL, respectively; p = 
0.044) within cord bloods obtained from ureaplasma-infected placentae. Other studies have also 
shown elevated levels of IL-8 in amniotic fluid of women with chronic histological chorioamnionitis 
(Ogge et al. 2011), in the umbilical cord blood of pregnancies complicated by preterm premature 
rupture of membranes and histological chorioamnionitis (Andrys et al. 2010) and the increased 
transcription of IL-8 within placental tissues in association with prostaglandin synthesis and preterm 
labour (Phillips et al. 2014). IL-8 is an important cytokine involved in the migration of neutrophils and 
granulocytes towards the site of infection (Bickel 1993). Neutrophil infiltration of Ureaplasma spp.-
infected placentae has been demonstrated previously and is associated with the development of 
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inflammation and the development of histological chorioamnionitis in a sheep model of 
intraamniotic ureaplasma infection (Dando et al. 2012). Within cord blood, the reduction of this 
inflammatory mediator would result in a decreased likelihood of the host mounting an immune 
response against these intraamniotic pathogens. The novel finding that G-CSF is elevated in cord 
blood when the placentae are infected with ureaplasmas that do not demonstrate MBA variation 
may be a biomarker of more severe chorioamnionitis and certainly requires further investigation.  
 
An interesting trend in the levels of G-CSF in association with MBA size variation was also observed. 
Despite the low numbers in our study groups, we were able to identify that low levels of G-CSF were 
present in ureaplasma-infected placentae, which also demonstrated size variation of the MBA. These 
placentae demonstrated approximately 40% lower concentrations of G-CSF, when compared to 
placentae which were infected with ureaplasmas that did not demonstrate any MBA size variation. It 
is important to note that while this difference was not statistically significant, it may be due to the 
small cohort sizes available. Again, further studies are required to confirm these findings.  
 
Studies in a rodent model of Ureaplasma spp. urogenital infection have also shown an association 
between adverse sequelae and host immune responses. Reyes et al. (2009) infected Fisher F344 rats 
with U. parvum and sampled bladder tissues at two weeks post-infection. Two major sequelae were 
seen in Ureaplasma-infected rats: moderate sequelae in the form of urinary tract infection (UTI) and 
inflammation and the more severe sequelae of UTI with struvite crystals. The cytokine profiles within 
the bladder tissues obtained from these animals were significantly different. There was no 
significant differences in the microbial load (number of CFU) of Ureaplasma spp. in bladder tissues; 
however, levels of IL-18, MCP-1 and interferon (IFN)-γ were elevated in those animals with moderate 
sequelae (UTI and inflammation). By contrast, animals with severe sequelae (UTI and struvite 
crystals) demonstrated significant decreases in IL-18, MCP-1, IFN-γ, while IL-1α, IL-1β and growth 
related oncogene/keratinocyte chemoattractant (GRO/KC - the rat analogue of human IL-8) were 
significantly elevated. This is similar to the findings of our current study, which demonstrated high 
levels of IL-8 within cord blood when no MBA variation was present; but when these organisms 
varied their surface-exposed MBA, the levels of this cytokine were significantly reduced. The results 
of this study further confirm that the numbers of ureaplasmas within tissue are not a critical factor 
in the development of pathology, however, the host inflammatory response appears to be a key 
determinant of the severity of inflammatory response and the development of adverse sequelae 
(Reyes et al. 2009).  
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A real-time PCR and HRM assay to speciate and serotype U. parvum clinical isolates was also 
designed and optimised. This assay successfully speciated and serotyped 64.5% of U. parvum clinical 
isolates but a further 11 isolates could not be subtyped. A number of conventional and real-time PCR 
assays that detect and subtype U. parvum and U. urealyticum have been published, however, many 
of these assays are time-consuming and laborious (Cao et al. 2007a; Cao et al. 2007b) to perform, 
multiple reactions are required to type the 14 known serovars and these are not all based on the 
same gene. These assays are not easily transferred into clinical and diagnostic laboratories and many 
laboratories still diagnose human infections using culture and PCR designed to detect rather than 
serotype.  
 
Knox et al. (1998) designed conventional PCR assays that serotyped the U. parvum serovars based on 
polymorphisms within a fragment of the mba gene. Conventional PCR assays and sequencing of the 
mba in this study confirmed that the upstream conserved portion of the mba demonstrates serovar-
specific differences in each of the four ATCC U. parvum serovars, however, additional 
SNPs/polymorphisms were also found in some clinical isolates. Kong et al. (2000) designed 
conventional PCR assays that were able to differentiate groups of U. parvum and U. urealyticum 
serovars based on 16S rRNA gene, the 23S rRNA intergenic spacer region, urease gene subunits and 
the mba gene. These assays detected and identified three groups within the U. parvum species: 
serovar 1, serovars 3/14 and serovar 6. The 10 U. urealyticum serovars were also detected and 
differentiated into three groups: (i) serovars 2, 5, 8 and 9; (ii) serovars 4, 10, 12 and 13; and (iii) 
serovars 7 and 11. These reactions were also laborious to complete and required post-PCR analyses 
such as agarose gel electrophoresis, which increased the risk of post-PCR contamination. Real-time 
PCR assays that detect, speciate and subtype the ureaplasmas simultaneously would be the most 
advantageous for use within a clinical laboratory setting. 
 
The major advantage of real-time PCR compared to conventional PCR assays are accessibility, 
sensitivity and cost-effectiveness. The real-time and rapid nature of real-time PCR is also a major 
benefit in clinical and diagnostic laboratories, when time-to-diagnosis is of great importance. Real-
time PCR assays have been developed to speciate and/or serotype the human Ureaplasma spp. 
(Mallard et al. 2005; Yi et al. 2005; Cao et al. 2007a; Cao et al. 2007b). Xiao et al. (2010) created real-
time PCR assays to differentiate U. parvum and U. urealyticum serovars. An initial real-time PCR 
assay differentiated U. parvum and U. urealyticum species, followed by 14 monoplex real-time PCR 
assays that serotyped all 14 serovars belonging to Ureaplasma spp. Each assay was specifically 
optimised for MgCl2 concentration, primer concentration and annealing temperature. Some assays 
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also utilised touch-down protocols in order to gain specificity and used numerous gene targets, 
some of which are hypothetical or have unknown functions and are yet to be fully characterised 
(Glass et al. 2000; Xiao et al. 2010). While these assays were able to serotype numerous clinical 
isolates, the combination of specific assay cycling parameters, coupled with the additional 
'speciating' PCR, followed by the 14 monoplex serotyping real-time PCR assays means that these 
assays are not suited to a high-throughput clinical and diagnostic laboratory. This large number of 
real-time PCR reactions (most of which would be done in duplicate or triplicate) significantly increase 
the cost and time associated with testing and serotyping ureaplasma clinical isolates and is 
predominantly a research tool. 
 
Our research group previously developed a real-time PCR and high resolution melt (HRM) assay that 
was able to amplify and differentiate U. parvum and U. urealyticum species; and that was also able 
to serotype the four U. parvum serovars. HRM is a post-PCR analysis in which the temperature of 
each tube is increased in precise increments to 'melt' the amplicon. By amplifying the upstream 
conserved region of the mba gene, this assay speciated and serotyped 20/31 (64.5%) of clinical 
isolates; however, some clinical isolates had additional SNPs and these organisms were unable to be 
typed successfully (Sweeney et al. (2010) unpublished findings). More recently, Payne et al. (2014) 
designed a real-time PCR and HRM assay very similar to the unpublished work within our research 
group. The assay previously optimised in our group and by Payne et al. (2014) amplified the 
upstream conserved region of the mba gene. However, the major shortcomings of both of these 
assays is that amplification produced two distinct fluorescent 'peaks', consistent with the 
amplification of more than one amplicon. Therefore, these assays required further optimisation.  
 
The real-time PCR and HRM assay designed within the current study is superior to previous real-time 
PCR and HRM assays and this assay specifically amplifies and speciates the four U. parvum serovars 
(Serovar 1, 3, 6 and 14; Figure 5.1). Only a single specific amplicon is produced and we have 
demonstrated the utility of real-time PCR and HRM for the speciation and differentiation of 
ureaplasma clinical isolates. While some isolates were unable to be successfully typed, this is 
consistent with other studies and further supports the proposal that there may be additional 
ureaplasma serovars, or that horizontal gene transfers affects our ability to fully characterise 
Ureaplasma serovars.  
 
The major advantage of this assay is that it targets a ureaplasma-specific gene and polymorphisms 
within this gene are able to distinguish each of the U. parvum serovars, which account for > 90% of 
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all clinical isolates (Knox et al. 1997; Knox et al. 2003; Sung et al. 2010). By selecting a well-
characterised gene, we have been able to create an easy and rapid method for the speciation and 
serotyping of U. parvum clinical isolates. The use of the mba gene is also more likely to reflect the 
antigenic differences in clinical isolates, as it is based on the MBA protein, the antigen which 
represents the basis for the current serotyping scheme (Robertson et al. 2002). Whilst this assay has 
been found to be a fast and easy way to serotype U. parvum clinical isolates, there are some 
limitations of the assay. Firstly, clinical specimens may contain a mixture of serovars and these may 
not be distinguished by this assay and additional assays which target specific serovars (such as those 
developed by Knox et al. 1997) would be required to identify mixtures. Furthermore, it is important 
to have similar initial concentrations of DNA amplicons for the successful serotyping of U. parvum 
clinical isolates. A recent study by Ng et al. (2014) demonstrated that the melting temperatures and 
curves seen by HRM are dependent on DNA starting concentration and that variation in this starting 
concentration of DNA may result in the inability to serotype some isolates. In an attempt to increase 
the sensitivity of this assay, some researchers have added MgCl2 following PCR cycling and prior to 
HRM analysis; this has been shown to reduce the variability of fluorescence and increase the ability 
to successfully 'type' clinical isolates (Ng et al. 2014). Within our study, we standardised the amount 
of DNA template added to each real-time PCR and HRM assay and this is a major strength of our 
study. However, uncultured clinical isolates could not always be serotyped using this real-time PCR 
and HRM assay due to low concentrations of template within the specimen, which affected HRM 
curves. The addition of MgCl2 in different concentrations following PCR cycling did not improve the 
ability of the assay to serotype the clinical isolates. Additionally, an important consideration in the 
use of speciating and serotyping assays for Ureaplasma spp. is that as yet there appears to be no 
intrinsically ‘virulent’ or ‘avirulent’ Ureaplasma species or serovars and we demonstrated no major 
differences in adverse pregnancy or neonatal outcomes amongst the different species (U. parvum or 
U. urealyticum) and prevalent serovars (1, 3 and 6).  
 
Conclusions: 
 
This is the first prospective study to demonstrate MBA variants within the chorioamnion of women 
who delivered LPT or at term. Regardless of the Ureaplasma species or serovar present, when MBA 
variation occurred there was a decreased incidence of histological chorioamnionitis, particularly in 
the amnion (fetal) membranes. This is also the first study to demonstrate differences in cord blood 
cytokines, chemokines and growth factors in association with MBA variation of ureaplasmas. The 
cytokine IL-8 and growth factor G-CSF were significantly higher in Ureaplasma spp.-infected 
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placentae which demonstrated no MBA variation. By contrast, placentae which were infected with 
ureaplasmas which varied their surface-exposed MBA were associated with significantly lower levels 
of IL-8 and G-CSF in the corresponding cord blood. 
 
The ability of Ureaplasma spp. to vary their surface-exposed MBA is consistent with the evasion of 
host immune detection and eradication. Ureaplasma spp. have been isolated from within the 
amniotic sac as early as 15 weeks of gestation (Cassell et al. 1993b; Gerber et al. 2003) and animal 
models have confirmed that ureaplasmas may survive and replicate in the amniotic cavity, even in 
the presence of an immune response, establishing chronic infections in vivo. It is likely that 
prolonged intraamniotic infections with Ureaplasma spp. will result in adverse neonatal outcomes, 
due to the prolonged exposure of the fetus to ureaplasmas in utero. Infection with Ureaplasma spp. 
has been associated with bronchopulmonary dysplasia (BPD), sepsis, meningitis and pneumonia. In 
severe cases, ureaplasmas have also been associated with the development of adverse CNS 
outcomes and cerebral palsy at 1 year of age (Berger et al. 2009).  
 
The findings of this study further suggest that it is unlikely that there are 'virulent' Ureaplasma 
species or serovars; however, the host-microbe interactions (as evidenced by MBA size variation) 
and the host immune response (as evidenced by cord blood cytokines) may determine the severity 
of inflammation and pathology. 
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Chapter Six: 
 
Ex vivo model of U. parvum 
chorioamnion tissue infection 
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Introduction   
 
Preterm birth (PTB); delivery < 37 weeks of gestation, accounts for 10% of all births worldwide (Bick 
2012; March of Dimes 2012). Despite an increased awareness and strategies for managing women at 
risk of delivering preterm, the rates of PTB continue to increase in almost every country. With 70% 
of neonatal morbidity and up to 50% of neonatal and infant mortality associated with PTB, there is a 
need to understand how these births occur and, in the long-term, to prevent these births from 
occurring (Goldenberg et al. 2008b). Infection of the female upper genital tract (UGT) is a major 
finding in women, and 40% of women who deliver preterm have evidence of UGT infections 
(Goldenberg et al. 2002; DiGiulio 2012). Of the pathogens associated with PTB, the human 
Ureaplasma species (U. parvum and U. urealyticum) are the bacteria most frequently isolated from 
the UGT of women experiencing PTB, histological chorioamnionitis, funisitis and preterm premature 
rupture of membranes (pPROM) (Hillier et al. 1988; Cassell et al. 1993b; Knox et al. 1997; Novy et al. 
2009; DiGiulio 2012).  
 
It is commonly believed that microorganisms within the female lower genital tract (LGT) may ascend 
and cause UGT infections (Goldenberg et al. 2000b). These microorganisms, often normal flora of 
the LGT, ascend through the cervix to infect/colonise the choriodecidual space and the 
chorioamnion. Within the chorioamnion, microorganisms (including Ureaplasma spp.) are able to 
elicit strong immune responses, including increased expression or production of inflammatory 
mediators such as cytokines, chemokines, growth factors, matrix metalloproteinases and 
prostaglandins (Goldenberg et al. 2002; Goldenberg et al. 2005). The induction of pro-inflammatory 
mediators activate and recruit granulocytes, including neutrophils and monocytes and macrophages 
to the site of infection, amplifying the inflammatory response and it is this inflammation that has 
been attributed to adverse pregnancy outcomes, such as histological chorioamnionitis, funisitis and 
pPROM. The general pathways that may lead to PTB or adverse pregnancy outcomes have been 
described previously (Goldenberg et al. 2002; Behrman 2007; Challis et al. 2009); however, we do 
not yet fully understand the host immune responses that are specifically triggered during infection 
with Ureaplasma spp.  
 
Previous studies have demonstrated that the Ureaplasma spp. multiple banded antigen (MBA) is the 
major pathogen-associated molecular pattern (PAMP) of ureaplasmas and this surface-exposed 
lipoprotein binds/interacts with Toll-like receptors (TLRs) 1, 2 and 6, activating nuclear factor (NF)-kB 
and the production of the proinflammatory cytokines (Shimizu et al. 2008). Immune responses to 
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Ureaplasma spp. UGT infections have been investigated previously using animal models, including 
mice (von Chamier et al. 2012; Allam et al. 2014), sheep (Moss et al. 2005; Knox et al. 2010; Dando 
et al. 2012; Robinson et al. 2013) and non-human primates (Yoder et al. 2003; Viscardi et al. 2006; 
Novy et al. 2009); however, the results of these studies may not always align with human host 
immune responses, as the signalling pathways which lead to PTB in animals are often different to 
those in humans (Mitchell and Taggart 2009). This limits the usefulness of these animal models in 
investigating the role of the host immune response during Ureaplasma spp. infections.  
 
More recently, host immune responses to infection have been studied using human gestational 
tissues. The placenta is a critical research specimen that offers researchers a unique opportunity to 
study the immune responses produced by both the maternal and fetal tissues upon exposure to 
stimuli. Previous studies have utilised chorioamnion tissue explants to study the host immune 
responses to ureaplasma infections. Abrahams et al. (2013) exposed chorioamnion explants to heat-
killed U. parvum and U. urealyticum and demonstrated significant increases in mRNA expression of 
TLR 8 when stimulated with U. parvum but not with U. urealyticum. A study by Aaltonen et al. 
(2007), similarly stimulated human chorioamnion explants with heat-killed Ureaplasma spp. and 
demonstrated significant increases in the production of TNF-α, IL-10 and prostaglandin (PG)-E2. 
Similarly, Menon et al. (2009) measured the cytokine and prostaglandin responses after primary 
chorioamnion tissues were exposed to ureaplasmas inactivated by heat and demonstrated that 
stimulation with ureaplasmas resulted in significant increases in TNF-α and IL-10. Other studies have 
also shown key cytokines to be increased following stimulation with heat-inactivated Ureaplasma 
spp., with levels of IL-1β, TNF-α, IL-8, IL-10 and PGE2 being significantly increased upon exposure to 
these pathogenic microorganisms (Estrada-Gutierrez et al. 2010; Peltier et al. 2012). However, each 
of these studies utilised ureaplasmas that had been heat-killed; which destroyed their viability and 
surface-exposed lipoproteins of these microorganisms. These changes were likely to affect how 
these microorganisms interacted with chorioamnion tissue cells and may also have affected TLR 
signalling; therefore, the immune responses seen within these studies may not truly reflect what 
occurs in vivo. In addition, each of these studies utilised primary chorioamnion explants incubated in 
well-plates, and so the origin of these immune responses could not be determined (i.e. they were 
unable to determine if these cytokines were produced by the maternal or fetal interfaces) and so 
further studies are required to fully elucidate human host immune responses to Ureaplasma spp.  
 
Infection of the chorioamnion may be modelled more accurately using an ex vivo Ussing chamber 
system. Keelan et al. (2009) adapted this Ussing chamber model, which had traditionally been used 
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to study the permeability and secretory functions of the gut epithelia (Heyman et al. 1988; Foitzik et 
al. 1997; Hotz et al. 1998), to study host immune responses with chorioamnion tissues. Intact 
chorioamnion tissue was suspended within an Ussing chamber, creating a barrier and the maternal 
(chorion) and fetal (amnion) surfaces of this tissue were separately perfused with cell culture media, 
to model the in vivo physical and immunological barrier properties of this tissue. The ‘maternal’ 
membrane was exposed to stimuli (Escherichia coli lipopolysaccharide [LPS]) over a 20 hour period 
and aliquots of the perfused cell culture media were collected over time from both compartments. 
Perfused media were subsequently tested for the presence of immune modulators by enzyme-linked 
immunosorbent assays (ELISA). Despite only the maternal membranes being exposed to LPS, 
increased concentrations of macrophage-derived chemokine (MDC), transforming growth factor 
(TGF)-β, TNF-α and PGE2 were detected in both the ‘maternal’ and ‘fetal’ perfusates, which confirms 
that immune responses were elicited separately in both the chorion and amnion cells. This model 
was validated as an accurate model with which to study host immune responses to infections 
(Keelan et al. 2009); however, as yet no studies have utilised live microorganisms using this model.   
 
Using this ex vivo model of chorioamnion infection, we sought to investigate the host-microbe 
interactions upon exposure to a U. parvum serovar 6 clinical isolate. We hypothesised that the 
ureaplasmas would infiltrate the chorioamnion and activate specific immune responses within the 
maternal and fetal membranes. By investigating the immune responses to Ureaplasma spp., this 
study may elucidate how ureaplasmas activate the host immune system and may identify key 
immune modulators that are present during ureaplasmas infections. Furthermore, the results of this 
work may provide additional evidence of biomarkers that could be used in future to identify or 
predict UGT infections with ureaplasmas.  
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Materials and Methods 
 
All methods pertaining to this chapter are documented in Chapter Three. Briefly, four placentae 
were obtained from women delivering at term and who had no complications. The placentae were 
processed within one hour of delivery (Chapter Three, section 3.22). In each of the four experiments, 
chorioamnion tissue was excised from the placenta and washed with sterile phosphate buffered 
saline (PBS). Six membrane discs were cut, and these were each sandwiched between semi-rigid 
mesh and suspended within six Ussing chambers. The 'maternal' and 'fetal' compartments of each 
Ussing chamber were separately perfused with phenol red-containing ('maternal' compartment) or 
phenol red-free ('fetal' compartment) M199 media. Media within the maternal compartment was 
also supplemented with FITC-dextran, as an indicator of membrane permeability or integrity 
throughout each Ussing chamber experiment. After the Ussing chambers had equilibrated, the 
maternal membrane was stimulated with (a) 2 x 107 CFU live U. parvum serovar 6 clinical isolate 429 
inocula (Chapter Three, section 3.20; n = 2 chambers), (b) 2 x 107 CFU UV-inactivated (non-
replicative, but with all surface-antigens intact) U. parvum serovar 6 clinical isolate 429 (n = 2 
chambers); or (c) vehicle control (n = 2 chambers). At 0, 2, 4, 8, 20 and 30 hours, perfused media was 
sampled from each maternal and fetal compartment and snap frozen. At the conclusion of each 
placenta experiment, the remaining media was drained and snap frozen and chorioamnion tissue 
was divided and fixed for histology or snap frozen. A small amount of chorioamnion tissue was also 
homogenised and cultured within 10B broth, in order to detect and characterise live ureaplasmas. 
 
Stored maternal and fetal perfusates were analysed at the conclusion of all experiments for: (i) the 
presence and number of viable ureaplasmas within the maternal and fetal compartments over time; 
(ii) FITC-dextran fluorescent intensity within both maternal and fetal perfusates, as a measure of 
membrane integrity or permeability; (iii) the cytokine, chemokine and growth factor responses 
within maternal and fetal compartments over time; (iv) chorioamnion tissue pathology at the 
conclusion of each 30 hour experiment; and (v) the production of matrix metalloproteinases (MMPs) 
at the conclusion of each tissue experiment.  
 
Statistical analyses 
 
Data are presented as the mean value, plus the standard error of the mean (SEM). Cytokine 
responses in maternal and fetal perfusates and post-infection pathology scores were analysed using 
analysis of variance (ANOVA) and data analysed/plotted using GraphPad Prism.   
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Results 
 
Optimisation of U. parvum growth in M199 cell culture media 
 
The growth of U. parvum serovar 6 clinical isolate 429 in M199 media, supplemented with animal 
serum and urea at concentrations reported for term human amniotic fluid, was assessed. This 
growth was compared to the growth of ureaplasmas in 10B broth, the ideal in vitro growth medium 
for these bacteria (Shepard and Lunceford 1976).  
 
No ureaplasma growth was detected by culture in serum deficient M199 media; however, there 
were differences in the ureaplasma growth rate and the concentration of ureaplasmas after the 
ureaplasmas were incubated in 10B broth and in M199 media supplemented with either fetal calf 
serum or horse serum. Higher concentrations of ureaplasmas were achieved in M199 media 
containing fetal calf serum, when compared to the growth in M199 media supplemented with horse 
serum (Figure 6.1). The highest concentration of ureaplasmas was achieved after growth in 10B 
broth at 20 hours. However, as expected, the concentration of ureaplasmas cultured in 10B broth 
decreased between 20 and 30 hours due to the accumulation of a metabolic by-product (ammonia) 
produced by ureaplasmas, resulting in an alkaline pH shift and the death of the ureaplasmas.  
 
Based on these results, we determined that M199 media supplemented with 10% fetal calf serum 
was the optimal growth media for use in ex vivo experiments, as this tissue culture medium would 
support the growth of ureaplasmas and would also maintain the viability of chorioamnion tissue 
during these experiments. 
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Figure 6.1 U. parvum growth in M199 cell culture media supplemented with fetal calf serum or horse 
serum. Optimal growth of ureaplasmas was achieved in M199 media supplemented with 10% fetal 
calf serum. Experiments were performed in duplicate and are plotted and analysed as the mean ± 
standard error of the mean (SEM). Replicate data from each experiment were remarkably similar 
and error bars were too small to be plotted on log-scale graphs (Raw data shown in Chapter Nine, 
page 224) 
 
Optimisation of HEC-1A cytokine production after exposure to U. parvum  
 
The HEC-1A endometrial cell line was maintained in media supplemented with 10% fetal calf serum 
at 20% O2 and 5% CO2 and exposed to 2 x 10
4 CFU or 2 x 107 CFU of U. parvum serovar 6 clinical 
isolate 429. The cell culture supernatant was sampled at 0, 8, 20 and 30 hours post-infection to 
assess cytokine production in response to these two different infectious doses of U. parvum.  
 
The pooled supernatants from duplicate experiments were tested by BioPlex assays for IL-2, IL-4, IL-
6, IL-8, IL-10, GM-CSF, IFN-γ and TNF-α. The HEC-1A cells exposed to high (2 x 107 CFU) and low (2 x 
104 CFU) doses of U. parvum serovar 6 clinical isolate 429 demonstrated differences in the 
production of the cytokines IL-8, GM-CSF and IL-10 (Figure 6.2) over time. The highest levels of these 
cytokines were elaborated by HEC-1A cells exposed to high dose U. parvum serovar 6 at 20 and 30 
hours post-infection. Concentrations of IL-8, IL-10 and GM-CSF were significantly upregulated in 
HEC-1A cells exposed to high dose U. parvum (p = 0.01, p = 0.006 and p = 0.025, respectively); while 
elevated levels of IL-8 were also seen in HEC-1A cells exposed to low dose U. parvum clinical isolates 
(p = 0.02; Figure 6.2). Based on these preliminary findings, a high dose inoculum (2 x 107 CFU) of our 
U. parvum clinical isolate was used subsequently for the placental ex vivo experiments.   
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Figure 6.2 High dose (2 x 107 CFU) of U. parvum serovar 6 clinical isolate elicited a strong immune 
response in the HEC-1A endometrial cell line, with elevated levels of IL-8, IL-10 and GM-CSF. Pooled 
culture supernatants from duplicate experiments were analysed by BioPlex assays for cytokines IL-2, 
IL-4, IL-6, IL-8, IL-10, GM-CSF, IFN-γ and TNF-α. Data are presented as the mean value of replicate (n 
= 2) samples that were pooled (to n = 1) for analysis. 
 
p = 0.025 
p = 0.02 
p = 0.01 
p = 0.006 
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Optimisation of U. parvum growth under different oxygen tensions 
 
Experiments to determine the optimal oxygen tension to best replicate the in vivo environment 
within the placenta and also to support the growth of U. parvum serovar 6 were then performed.  
No U. parvum growth was detected when incubated under 3% oxygen. However, similar growth 
patterns were observed when ureaplasmas were grown under 5% and 20% oxygen. The highest 
concentrations of ureaplasmas were achieved when ureaplasmas were grown under 8% oxygen 
(Figure 6.3).  
Based on these findings, it was determined that 8% oxygen would be the ideal oxygen tension for 
the growth of ureaplasmas in the ex vivo Ussing chamber model and this oxygen tension was also 
similar to the oxygen tensions (range = 5 - 8%) achieved within placentae in vivo (Kay 2011). 
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Figure 6.3. Growth of U. parvum under different oxygen tensions. The highest concentration of 
growth was achieved when ureaplasmas were cultured in supplemented M199 media under 8% 
oxygen. Experiments were performed in duplicate and data are presented as the mean, plus or 
minus the standard error of the mean. Replicate data from each experiment was remarkably similar, 
and therefore error bars were too small to be plotted graphs (Raw data shown in Chapter Nine, page 
243). 
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Ex vivo Ussing chamber experimental model results 
 
 Culture of U. parvum from chorioamnion tissues and perfusates 
 
Chorioamnion 
 
When setting up the Ussing chamber experiments, a portion of chorioamnion tissue from each of 
the four placentae were snap frozen for subsequent culture and 16S rRNA PCR. No Ureaplasma spp. 
or other microorganisms were detected within these chorioamnion tissues prior to commencing 
Ussing chamber experiments.  
 
Maternal and fetal perfusates 
 
After the completion of each placental experiment, the perfusates were also tested by culture. No 
viable ureaplasmas were detected within any of the maternal or fetal perfusates from Ussing 
chambers in which chorioamnion membranes were exposed to vehicle controls or to the UV-
inactivated U. parvum. 
 
At the completion of each experiment (t = 30 hours), U. parvum was cultured from each of the 
maternal perfusates (n = 2 for each of the 4 placentae tested) that were initially inoculated with live 
high-dose U. parvum. The numbers of U. parvum (CFU/mL) increased exponentially between 0 – 4 
hours; but the concentration of ureaplasmas did not differ significantly for the remainder of each 30 
hour experiment (Figure 6.4). In these same Ussing chambers, no ureaplasma growth was detected 
in the fetal perfused media that was collected at 0, 2, 4, 8 and 20 hours post-inoculation; however, 
at the final 30 hour time point ureaplasmas were detected within each of the fetal perfusates (n = 2 
for each of the 4 placentae tested (average: 2.53 x 104 CFU). 
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Figure 6.4. The number of U. parvum CFU did not differ significantly between replicate chambers or 
in each of the 4 placental experiments. Live ureaplasmas were subsequently cultured from each of 
the maternal perfusates (collected at 2, 4, 8, 20 and 30 hours). U. parvum was only cultured from the 
fetal perfusates that were collected at 30 hours post-infection (ureaplasmas were inoculated into 
the maternal compartment). Data are presented as the mean, plus or minus the standard error of 
the mean (SEM) 
 
Western blot of U. parvum MBA protein at 30 hours post-infection  
Uncultured perfusates collected from both the maternal and fetal compartments were centrifuged 
and tested by western blot. The initial inoculum (U. parvum serovar 6 isolate 429) was also tested by 
western blot and demonstrated two distinct MBA protein bands. Western blot analysis of uncultured 
maternal and fetal perfusates demonstrated the same MBA protein bands as the initial inoculum, 
with two clear MBA bands present in each compartment (Figure 6.5).  
 
 
              
 
Figure 6.5. Western blot demonstrating the MBA proteins detected in the maternal and fetal (M – 
maternal, F – fetal) compartments at 30 hours post-infection. No MBA antigen variation was 
demonstrated, when compared to the initial inoculum of U. parvum serovar 6 clinical isolate 429. 
Each perfusate was tested (n = 2 for each of the 4 placentae). Representative results are shown for 
each compartment of one Ussing chamber per experiment. 
Compartment        M        F       M        F       M         F        M       F                     429 
Experiment                    1                   2                  3                   4  
100 kDa 
75 kDa 
50 kDa 
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Response of chorioamnion tissue upon stimulation with U. parvum  
 Integrity of chorioamnion tissue within the Ussing chambers  
 
The integrity of chorioamnion tissue within each of the six Ussing chambers was evaluated for the 
duration of each 30 hour placental experiment (n = 4). FITC-dextran was added to each maternal 
compartment at the commencement of the experiments and the accumulation of FITC-dextran 
within the fetal perfusates was assayed as an indicator of membrane integrity (accumulation of FITC-
dextran within the fetal compartment is an indicator of membrane permeability or leakage).  
 
The fetal perfusates collected from Ussing chambers in which the maternal membrane was exposed 
to UV-inactivated U. parvum or vehicle control demonstrated no significant chorioamnion leakage or 
rupture over the course of the 30 hour ex vivo experiments, averaging approximately 1 – 1.5% per 
hour (Figure 6.6). By contrast, the concentration (% of total transfer) of FITC-dextran within fetal 
perfusates increased significantly at 30 hours after the maternal membrane was exposed to live 
ureaplasmas (p = 0.006; Figure 6.6). 
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Figure 6.6. Chorioamnion membrane permeability as measured using FITC-labelled dextran. Transfer 
of FITC-dextran from the maternal compartment to the fetal compartment (presented as percentage 
transfer) during placental experiments (duplicate chambers for n = 4 experiments). Significant 
increases in FITC-dextran transfer were demonstrated at 30 hours post-infection in the Ussing 
chambers in which the maternal side of chorioamnion membranes were exposed to live U. parvum. 
Data are presented as the mean, plus or minus the standard error of the mean (SEM) 
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Histological analysis of chorioamnion tissues 
 
Chorioamnion tissue from each placentae (n = 4) was fixed prior to the start of each placental 
experiment and these tissues were embedded, sectioned and stained with haematoxylin and eosin. 
These chorioamnion tissues demonstrated no significant pathology prior to the commencement of 
each Ussing chamber ex vivo experiment. 
 
Upon the completion of ex vivo experiments, chorioamnion tissues were again fixed, embedded and 
sectioned before staining with haematoxylin and eosin. Chorioamnion membranes that were 
exposed to live U. parvum demonstrated major differences in the overall tissue structure, when 
compared to tissues that were exposed to UV-inactivated U. parvum or vehicle controls. Very few 
studies histologically grade/score chorioamnion tissues for evidence of membrane rupture and so a 
pathology scoring system was developed for this study. Researchers blinded to outcome were given 
randomised images of chorioamnion tissue and the images were scored according to criteria 
described in Chapter Three, section 3.20.  
 
Chorioamnion tissues exposed to vehicle controls or to UV-inactivated U. parvum demonstrated no 
significant differences in the grading of the tissue pathology after each experiment (mean score 1.5 
and 1.75, respectively; Figure 6.7A and C). However, the chorioamnion tissues exposed to live U. 
parvum (duplicate tissues for n = 4 experiments) showed significant detachment/separation of the 
chorion and amnion membranes (mean score: 3; Figure 6.7B) and this was consistent with 
deterioration of the chorioamnion membranes as measured by the transfer of FITC-dextran at 30 
hours post-infection (detailed above).  
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Figure 6.7. Haematoxylin and eosin stained tissue sections exposed to (A) vehicle control, (B) 
live U. parvum and (C) UV-inactivated U. parvum. Following exposure to live ureaplasma (30 
hours), chorioamnion tissues demonstrated detachment/separation of the chorion and 
amnion (black arrow). All images shown at x 100 total magnification 
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Cytokine responses of human chorioamnion tissue exposed to live and UV-
inactivated ureaplasmas 
 
Duplicate perfusates collected from maternal and fetal compartments of Ussing chamber 
experiments stimulated with live or UV-inactivated U. parvum and vehicle controls were tested for 
the presence of IL-2, IL-4, IL-6, IL-8, IL-10, GM-CSF IFN-γ and TNF-α using BioPlex assays. This assay 
was chosen based on results of previous human in vitro and in vivo studies and included cytokines, 
chemokines and growth factors which have been reported to be upregulated in response to 
Ureaplasma spp. infections (Aaltonen et al. 2007; Jacobsson et al. 2009; Kacerovsky et al. 2011; 
Kacerovsky et al. 2013). 
 
No significant differences were demonstrated in the concentrations of IL-2, IL-4, IL-6, IL-8, GM-CSF, 
IFN-γ and TNF-α in either the maternal or fetal perfusates that were exposed to live U. parvum, UV-
inactivated U. parvum or vehicle control in supplemented M199 media. However, the 
concentrations of IL-10 were significantly higher within the maternal perfusates after exposure to 
live U. parvum for 20 and 30 hours (20.4 ± 2.8 pg/mL, p = 0.046; Figure 6.8) than the levels achieved 
when membranes were exposed to the vehicle control (7.2 ± 0.2 pg/mL) or UV-inactivated U. 
parvum (4.94 ± 0.9 pg/mL). No significant differences in the concentrations of IL-10 were seen in 
fetal perfusates.  
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Figure 6.8. Cytokine responses of duplicate maternal and fetal perfusates from n = 4 placental 
experiments. Concentrations of IL-10 were significantly increased at 20 and 30 hours post-infection 
within the maternal compartment of Ussing chambers when the maternal side of chorioamnion 
membranes were stimulated with live U. parvum. Data are presented as the mean, plus or minus the 
standard error of the mean (SEM) 
 
Gelatin zymography for matrix metalloproteinase (MMP)-9 activity 
 
For each placental experiment, maternal and fetal perfusates (x 2) from each Ussing chamber were 
pooled per condition (vehicle control, live U. parvum or UV-inactivated U. parvum). One sample in 
total per Ussing chamber was assessed by gelatin zymography for MMP-9 activity.  
 
p = 0.046 
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No MMP-9 activity was detected in pooled maternal and fetal perfusates at 0 hours, regardless of 
treatment (Figure 6.9); however, at 30 hours post-infection Ussing chamber perfusates 
demonstrated differences in MMP-9 activity. MMP-9 activity was detected in the perfusates of only 
one Ussing chamber stimulated with vehicle controls at 30 hours post-infection. Ussing chambers 
exposed to live or UV-inactivated U. parvum demonstrated upregulation of MMP-9 activity (Table 
6.1). MMP-9 activity in pooled perfusates from n = 4 placental experiments showed prominent 
gelatinase activity, the presence of clear bands and MMP-9 activity was detected in 6/8 (75.0%) 
perfusates. Perfusates from UV-inactivated U. parvum Ussing chambers showed lesser gelatinase 
activity, less prominent bands and 4/8 (50.0%) zymographs (Figure 6.9).  
 
Table 6.1. MMP-9 activity at 30 hours post-exposure in each Ussing chamber condition for n = 4 
placental experiments. No MMP-9 activity was detected in pooled maternal and fetal perfusates at 0 
hours. MMP-9 activity in pooled maternal and fetal perfusates at 30 hours is expressed as the total 
number of chambers positive for MMP-9 per placental experiment (n = 4).  
Placental experiment Vehicle control Live Ureaplasma spp. UV-inactivated Ureaplasma 
spp. 
1 0/2 1/2 1/2 
2 0/2 1/2 2/2 
3 1/2 2/2 0/2 
4 0/2 2/2 1/2 
 
   
 
 
 
 
 
 
 
                              
 
 
Figure 6.9. Gelatinase activity of matrix metalloproteinase (MMP)-9. While variable responses in 
MMP-9 activity was seen, overall there was a trend to upregulation of MMP-9 activity in perfusates 
exposed to live U. parvum, those exposed to UV-inactivated U. parvum infected chambers at the end 
of each 30 hour experiment. Representative results are shown from n = 4 experiments, alongside a 
92 kDa MMP-9 positive control (kindly provided by Dr Eliza Whiteside).  
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Discussion  
 
The human host immune response is integral for the success of pregnancy and is involved in all 
aspects of gestation, from preparation of the endometrium for implantation to immunotolerance of 
the fetus and initiation of normal term labour (Racicot et al. 2014). Any disruptions to these tightly 
regulated processes may contribute to adverse pregnancy outcomes, such as PTB and pPROM 
(Challis et al. 2009). Currently, the immune mechanisms which lead to PTB and adverse pregnancy 
outcomes are not well understood and this is particularly true for infection with Ureaplasma spp. To 
better understand the immune responses within host tissues during ureaplasma infections, we 
conducted a pilot study using an ex vivo Ussing chamber model to investigate the specific immune 
responses of the chorioamnion membranes (the chorion and the amnion) following stimulation with 
live or UV-inactivated (non-replicative) U. parvum.   
 
The most significant finding of this current study was that concentrations of IL-10 were only elevated 
at 20 and 30 hours post-infection within the maternal compartment after the maternal interface of 
the chorioamnion was stimulated with live U. parvum (Figure 6.8). While we also saw an increase in 
the production of IL-10 within the fetal compartment at 30 hours post-infection, this was not 
significant; suggesting that the responses seen are specific to the tissues that were initially exposed 
to the pathogen. While the production of IL-10 has been identified previously; within fibroblasts, 
resident macrophages and amnion epithelial cells of human chorioamnion tissues (Huleihel et al. 
2003), within cell culture supernatants collected from chorioamnion tissue explants stimulated with 
ureaplasmas (Aaltonen et al. 2007; Menon et al. 2009; Peltier et al. 2012) and also within amniotic 
fluid of women experiencing UGT ureaplasma infections (Kacerovsky et al. 2013); these increases 
were often accompanied by simultaneous increases in pro-inflammatory cytokines, including IL-1β, 
IL-8 and TNF-α. In this pilot study, we tested for the presence of both IL-8 and TNF-α but there were 
no significant increases in the production of these key pro-inflammatory cytokines. Despite this, our 
preliminary data suggests that IL-10 may be an important determinant of the host immune response 
to U. parvum infection and is the first cytokine produced by the chorioamnion. IL-10 is an anti-
inflammatory cytokine that plays a crucial role in the regulation of inflammatory pathologies and 
other research has also demonstrated a role for IL-10 in immunomodulation and 
immunosuppression of inflammatory responses (Moore et al. 2001; Saraiva and O'Garra 2010).  
 
In Figure 6.10, the major potential pathways that may be activated by Ureaplasma spp. infections of 
the UGT are summarised. Within the placenta and chorioamnion, pattern recognition receptors 
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(PRRs) are present on a range of cell types, including the chorioamnion and on the surface of 
macrophages (Hofbauer cells) (Abrahams 2008). These PRRs are able to actively sense and respond 
to pathogens by recognising their pathogen-associated molecular pattern (PAMP), such as the MBA 
lipoprotein of Ureaplasma spp. (Shimizu et al. 2008; Triantafilou et al. 2013), and recognition of the 
MBA by PRRs (e.g. TLRs) (Abrahams 2008) may stimulate different immune responses. Macrophages 
within the chorioamnion are capable of polarisation into M1 or M2 phenotypes, which respond to 
the presence of microorganisms in different ways (Mantovani et al. 2005).  Macrophage polarisation 
to an M1 phenotype results in the production of a TH1 immune response, generation of cytokines 
(e.g. IL-1β, TNF-α and interferon-γ), reactive oxygen species and the capacity to present antigens to 
antigen presenting cells (APCs); while M2 macrophage polarisation results in a TH2 immune 
response, the production of (predominantly immunosuppressive) cytokines (e.g. IL-4 and IL-10), 
generation of nitric oxide, increases in cell apoptosis and antibody-mediated host responses (Brown 
et al. 2014) and both M1 and M2 macrophage phenotypes within the placenta during pregnancy are 
shown to be associated with adverse pregnancy outcomes. For example, some strains of Toxoplasma 
gondii can actively induce M2 macrophage polarisation and minimal inflammatory responses within 
murine placentae, despite high numbers of parasites colonising the placenta. By contrast, other T. 
gondii strains injected into mice at the same dose induced M1 macrophage polarisation and high 
levels of inflammation within the placenta, which led to high intrauterine growth retardation (Liu et 
al. 2013; Kong et al. 2015). While pregnancy is a predominantly TH2 condition, which can further be 
regulated by fluctuation in estrogen levels (Behrman 2007); within our pilot study, we reported 
higher concentrations of IL-10 in chorioamnion tissues exposed to live U. parvum and this was 
consistent with a potential TH2 immune response.  
 
IL-10 has been shown to interact with NF-kB at the transcriptional level, inhibiting the activation of 
NF-kB and subsequently halting the production of pro-inflammatory cytokines by macrophages 
(Janeway 2005). In addition, during each of our four ex vivo chorioamnion experiments, we showed 
no significant increases in the production of the pro-inflammatory cytokines IL-2, IL-4, IL-6, IL-8, IFN-
γ or TNF-α in response to stimulation of primary chorioamnion tissues with live U. parvum. While 
within our experiments, we were unable to determine if M2 macrophage polarisation was occurring 
and if this was the factor which led to high levels of IL-10 within ex vivo chorioamnion tissue; this 
would be the next logical step in extending this work and would provide further novel information in 
the role of the host immune response to Ureaplasma spp.  
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By contrast, some studies have demonstrated that ureaplasma infections may signal the production 
of pro-inflammatory immune responses. Studies which utilise heat-killed Ureaplasma spp. have 
demonstrated the production of pro-inflammatory cytokines IL-1B, IL-8 and TNF-a within a range of 
placental cell types (Aaltonen et al. 2007; Menon et al. 2009; Peltier et al. 2012). Similarly, in vitro 
studies utilising human-derived monocytes obtained from cord blood demonstrated that a 
secondary infectious challenge with Ureaplasma spp. enhanced pro-inflammatory immune 
responses by blocking the expression of the immunosuppressive cytokine, IL-10 (Manimtim et al. 
2001). In Chapter Five, we did demonstrated the infiltration of neutrophils (chorioamnionitis) and 
the production of pro-inflammatory cytokines (IL-8 and G-CSF) within cord blood of placentae 
infected with Ureaplasma spp.; however, the levels of these pro-inflammatory cytokines were 
correlated with MBA size variation. In vivo, when MBA variation occurred, there was a significant 
reduction in pro-inflammatory cytokines within cord blood; despite the presence of large numbers 
of ureaplasmas infecting the chorioamnion. Similarly, C57BL/6 mice infected intraamniotically with 
U. parvum demonstrated lower levels of pro-inflammatory cytokines IL-1α, IL-1β, IL-6 and TNF-α, 
when compared to BALB/c mice infected with the same strain and dose of U. parvum (von Chamier 
et al. 2012). Our findings, along with studies by others suggest that there may be other factors (such 
as genetic background and antigen variation) which may influence the development of disease.  
 
It may be that induction of pro-inflammatory responses are dependent on the numbers of 
Ureaplasma spp. present within the chorioamnion, and/or the duration of infection. The presence of 
estrogen may also influence the immune response, and lower levels of estrogen are present earlier 
in gestation which may account, in part, for why Ureaplasma spp. infections in pregnancies which 
end < 32 weeks have reported predominantly pro-inflammatory immune responses (Li et al. 2000; 
Collins et al. 2010; Kasper et al. 2010; Kacerovsky et al. 2013). Future studies in this area will be 
important to investigate both pro- and anti-inflammatory immune responses, the presence and 
expression of PRRs (including TLRs) and additional immune factors, such as apoptosis and 
macrophage polarisation, which may play a key role in the regulation of host immune responses to 
UGT Ureaplasma spp. infections.  
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Within this pilot study, we also demonstrated that infection with live U. parvum, but not UV-
inactivated U. parvum resulted in chorioamnion tissue damage, including the loss of structure and 
integrity after only 30 hours of exposure. Histological analysis of chorioamnion tissues infected with 
live ureaplasmas demonstrated major structural differences, with the amnion being partially 
detached and a high tissue pathology score (mean: 3). This damage was independently scored by 2 
researchers using criteria developed specifically for these experiments. This same tissue pathology 
was not seen in chorioamnion tissues exposed to UV-inactivated U. parvum or those exposed to the 
vehicle control and this was reflected in lower pathology scores (mean: 1.75 and 1.5, respectively). 
Previous studies have identified significant pathological changes in UGT and fetal tissues infected 
with U. parvum. Intraamniotic infection with ureaplasmas resulted in increases in macrophages and 
neutrophils within chorioamnion tissues and structural changes to the neonatal lung within a 
pregnant sheep model (Moss et al. 2008; Collins et al. 2010; Knox et al. 2010; Dando et al. 2012; 
Robinson et al. 2013). Interestingly, within this sheep model, the severity of chorioamnionitis varied 
between animals, even when the animals received the same ureaplasma inoculum. In this current 
experiment, after just 30 hours of exposure to ureaplasmas, uniform changes and degradation of the 
chorioamnion were observed. Within non-human primates, infection with Ureaplasma spp. resulted 
in histological chorioamnionitis, funisitis and altered fetal lung structure (Yoder et al. 2003; Viscardi 
et al. 2006; Novy et al. 2009). Human pregnancies affected by Ureaplasma spp. have also shown 
changes in pathology, with inflammatory responses within the chorioamnion, cord and altered fetal 
lung function (Hillier et al. 1988; Gerber et al. 2003; Pandey et al. 2007; Schelonka and Waites 2007; 
Hecht et al. 2008; Viscardi 2010; DiGiulio 2012). Taken together, these studies confirm that 
Ureaplasma spp. are a cause of structural and inflammatory changes within maternal and fetal 
tissues of the host. In this pilot study, we identified notable pathology and detachment of the 
amnion membranes, which has not been previously identified within any animal model studies of 
UGT ureaplasma infections in pregnancy. This finding may be consistent with the initial stages of 
chorioamnion membrane rupture, often referred to as pPROM when it occurs in vivo during 
gestation. pPROM is a common cause of PTB, affecting up to 30% of all pregnancies which end 
prematurely (Goldenberg et al. 2008b). Studies have also demonstrated a significant correlation 
between women experiencing pPROM and the presence of UGT infections within these pregnancies 
(Goldenberg et al. 2008b; Kacerovsky et al. 2009; Kacerovsky et al. 2011); however, no studies have 
reported on the histological changes to the chorioamnion membranes involved in pPROM. The novel 
findings generated using this Ussing chamber model suggest that this may be an ideal model with 
which to further investigate not only the development of pPROM in response to ureaplasmas, but 
also investigate chorioamnion exposure to other bacteria commonly associated with adverse 
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pregnancy outcomes. In these current experiments, only the maternal membrane surface was 
challenged with ureaplasmas and additional experiments in which the fetal membrane surface is 
exposed to bacteria would further our understanding of these pathological changes during 
ureaplasma infections.  
 
In this pilot study we assessed the integrity of chorioamnion tissue over time using fluorescently 
(FITC)-labelled dextran and measuring the transfer from the maternal compartment to the fetal 
compartment over time. While all Ussing chambers demonstrated similar FITC-dextran transfer at 0, 
2, 4, 8 and 20 hours, averaging 1 - 1.5%, there was a significant difference in FITC-dextran transfer at 
30 hours but only in the Ussing chambers in which the maternal membranes were stimulated with 
live U. parvum (Figure 6.6). The sharp increase in FITC-dextran transfer seen in these Ussing 
chambers is consistent with live ureaplasmas negatively affecting the integrity of chorioamnion 
tissue and this may precede and be associated with membrane rupture (pPROM). This finding that 
live ureaplasmas can affect the structure and integrity of chorioamnion tissue is novel and also 
requires further investigation. Other studies have investigated membrane integrity in response to 
different stimuli but identified no significant alterations in chorioamnion tissue. Assays utilising 
chorioamnion tissues suspended within a Transwell system demonstrated no alterations in human 
chorioamnion tissue integrity when stimulated with γ-irradiated E. coli over 20 hours; with 99% of 
fluorescently-labelled beads added to the maternal compartment remaining on this side of the 
chorioamnion membranes (Stinson et al. 2014). The size of these spherobeads is not stated within 
this study, and so it is unclear if this result is comparable to the results of FITC-dextran within our 
current study. Keelan et al. (2009) stimulated human chorioamnion tissues with E. coli LPS when the 
tissues were suspended within an Ussing chamber system. In this study, FITC-dextran was added to 
the maternal chamber and transfer of FITC-dextran from the maternal compartment to the fetal 
compartment occurred at a rate of approximately 1% per hour over the course of each 20 hour 
experiment. Within our current study, we reported similar FITC-dextran transfer rates for vehicle 
control and UV-inactivated U. parvum Ussing chambers, when compared to the findings of Keelan et 
al. (2009). This further confirms the validity of the results reported within our study. However, the 
experiments in this current study were conducted for an additional 10 hours. At 30 hours post-
infection, just as was observed by Keelan for LPS, there was minimal transfer of FITC-dextran in UV-
inactivated U. parvum and vehicle control Ussing chambers and no major histological changes were 
observed within the membrane. This further confirms our finding that only live ureaplasmas 
negatively affected the structure and integrity of the chorioamnion tissue. 
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Other studies have identified that infection or exposure to Ureaplasma spp. in utero can affect the 
structure and development of the neonatal lung and gut. Ureaplasma spp. infections are 
demonstrated to cause structural changes in fetal lung, including altered lung structure, premature 
lung maturation, increased neonatal lung pressure-volume curves and fibrosis in fetal sheep or non-
human primates (Yoder et al. 2003; Viscardi et al. 2006; Moss et al. 2008; Robinson et al. 2013). 
Using a pregnant ovine model of intraamniotic Ureaplasma spp. infection, tissues harvested from 
ewes intraamniotically injected with ureaplasmas had significant inflammatory responses within the 
neonatal gut, alterations in the development and structure of the neonatal gut, cellular damage to 
the villus epithelium and perturbations in the formation of cellular tight junctions within the 
neonatal gut (Wolfs et al. 2013). These findings confirm that Ureaplasma spp. can alter the structure 
and integrity of host tissues. The findings reported within this study that infection with live 
Ureaplasma spp. result in altered chorioamnion membrane structure and integrity may be 
consistent with the early stages of bacterial invasion of the UGT.  
 
Perhaps the most interesting finding of this study was that Ureaplasma spp. can penetrate the 
chorioamnion membrane, travelling from the maternal compartment to the fetal compartment by 
the 30 hour time point. While Ureaplasma spp. have been isolated from within the amniotic fluid 
and placentae of women experiencing PTB and pPROM previously (Gerber et al. 2003; Jacobsson et 
al. 2009; Kacerovsky et al. 2009; DiGiulio et al. 2010; DiGiulio 2012), it has not been proven if these 
microorganisms can traverse the chorioamnion membrane. It has been suggested that these 
microorganisms may asymptomatically colonise the female UGT prior to pregnancy (Cassell et al. 
1993b; Cicinelli et al. 2012), or that these microorganisms may be present at the time of conception 
as these microorganisms may adhere to the surface of human sperm and can gain access to the 
female UGT (Knox et al. 2003). However, this current study is the first to demonstrate that ex vivo 
chorioamnion tissue can be penetrated by ureaplasmas and that these microorganisms can pass into 
the fetal compartment. Winram et al. (1998) demonstrated that Streptococcus agalactiae (Group B 
Streptococcus) was able to traverse the chorioamnion membrane in a transwell system; however, in 
that study the integrity of the membranes were not assessed. The finding that microorganisms may 
traverse/invade the chorioamnion membrane may have severe implications for the health and 
wellbeing of the pregnancy and for the neonate. If Ureaplasma spp. are able to pass through the 
chorioamnion membrane and access the UGT during pregnancy, these microorganisms may infect 
the UGT for chronic periods and currently it is not known what effect chronic in utero ureaplasma 
infections may have on the neonate. Previous evidence suggests that in utero infections caused by 
ureaplasmas are associated with respiratory sequelae and an increased incidence of adverse 
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neuromotor outcomes and cerebral palsy (Lyon 2000; Kotecha et al. 2004; Pandey et al. 2007; 
Berger et al. 2009). Combined, these results highlight the need to understand Ureaplasma spp. 
pathogenesis and the effect on pregnancy and fetal outcomes.  
 
The expression of MMP-9 was also upregulated in Ussing chambers in which the maternal side of the 
membranes were exposed to live U. parvum, and in some cases, those exposed to UV-inactivated U. 
parvum. MMP-9 is one of several matrix metalloproteinases whose activation results in the 
degradation of collagen fibres within tissues, such as the chorioamnion (Strauss 2013). Throughout 
pregnancy, MMPs are tightly regulated and there is a fine equilibrium of collagen degradation and 
synthesis to maintain the chorioamnion membrane throughout pregnancy (until labour is triggered) 
(Goldman et al. 2003; Yonemoto et al. 2006). However, during UGT infections, the degradative 
effects of MMPs are increased within the chorioamnion membrane, particularly for MMP-2 and 9 
(Strauss 2013). Within this small pilot study, we identified that MMP-9 activity was significantly 
increased in pooled maternal and fetal perfusates from Ussing chambers stimulated with live U. 
parvum, and some moderate MMP-9 activity was seen in Ussing chambers stimulated with UV-
inactivated Ureaplasma spp. With only one control chamber displaying evidence of moderate MMP-
9 activity after 30 hours, these findings suggest that that ureaplasmas can elicit a response which 
upregulates the production of degradative MMP-9. Previous studies have provided evidence that 
MMPs are upregulated during Ureaplasma spp. infections. In experimental ureaplasma UGT 
infections in Sprague Dawley rats, upregulation of MMP-9 was demonstrated (Peltier et al. 2007). 
Human pregnancies complicated by Ureaplasma spp. have also shown upregulation of MMP-9 
within their amniotic fluid (Kacerovsky et al. 2013); however, there are no previous studies that have 
tested ureaplasma infected and non-infected chorioamnion for the presence and production of 
MMP-9. Taken together, these preliminary results suggest that MMP-9 was upregulated in 
chorioamnion tissue exposed to U. parvum and this may further facilitate the degradation of the 
tissues as evidenced by alterations in FITC-dextran membrane integrity assays.  
 
Within this small pilot study, we did not observe any variation in the expression of the U. parvum 
serovar 6 MBA protein over the 30 hour period of each placental experiment. No MBA size variants, 
in addition to those present within the initial inoculum were observed for the ureaplasmas 
harvested at the end of each experiment. MBA variation has been reported previously in vivo within 
a pregnant ovine model. MBA size variation was seen after 7 days of infection, but not after 3 days 
of intraamniotic infection within pregnant sheep (Robinson et al. 2013). Within our study, we were 
only able to expose Ureaplasma spp. to chorioamnion tissue for 30 hours and so it was unlikely that 
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MBA variation would be produced within this short time period. Other experiments have attempted 
to induce MBA size variation in vitro through the use of anti-MBA antibodies. However, in these 
studies only MBA phase variation (the switching on/off of the MBA lipoprotein) was observed and 
this required high concentrations of anti-ureaplasma antibodies (Monecke et al. 2003; Dando et al. 
2012). Future experiments which utilise monocytes and macrophages (i.e. those that are activated 
by exposure to Ureaplasma spp.) may be used in an attempt to stimulate/produce MBA size 
variation to occur.  
 
As with many studies, there are limitations which should also be addressed. Only four placentae 
were tested in this pilot study, which limits the statistical power of this work. However, in this pilot 
study we have confirmed the utility of the Ussing chamber for use in ex vivo infection studies using 
live microorganisms. This model allows an additional level of complexity which mimics the role of 
the chorioamnion in vivo. Furthermore, for the first time this Ussing chamber model has been 
optimised to achieve physiological oxygen tensions and this is a major strength of this study. 
Previous studies investigating the immune responses to chorioamnion tissue explants have utilised 
standard cell culture incubators and the oxygen tension in this equipment is unlike the 
microenvironment within the placenta. It is not clear what effect these differing oxygen tensions 
have on the immune responses reported within these studies. The novel findings of this pilot study 
warrant further investigation and also raise further questions. The reason for amnion detachment 
following stimulation with live Ureaplasma spp. is currently unknown and it is not clear if apoptosis 
may also play a key role in amnion detachment or altered membrane integrity. Additionally, we 
identified elevated concentrations of MMP-9 and IL-10 in chorioamnion tissues stimulated with live 
ureaplasmas. By identifying specific mediators worthy of further investigation, it may be possible to 
identify the signalling pathways which lead to immune responses and pPROM during Ureaplasma 
spp. infections.  
 
Conclusions: 
 
This is the first study to utilise an Ussing chamber model to investigate the host immune responses 
to live bacteria (U. parvum) and we demonstrated that the presence of ureaplasmas was associated 
with tissue pathology, altered membrane integrity and increases in MMP-9 activity. The preliminary 
data within this study also demonstrated that the anti-inflammatory cytokine IL-10 was elevated 
within the maternal compartment in response to live ureaplasma infection, and this TH2-type 
response may be key to the long-term survival of these pathogens in the female UGT during 
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pregnancy and the establishment of chronic in utero infections. We also demonstrated, for the first 
time, that live ureaplasmas invade and cross the chorioamnion membrane and although this may be 
due to the degradative action of these microorganisms on the chorioamnion membrane, this 
provides a route for exposure of the fetus.   
 
 By further investigating the innate immune response of the chorioamnion (including responses after 
fetal membrane exposure to live ureaplasmas), the expression of TLR receptors, cytokines, 
chemokines, growth factors and other signalling pathways it may be possible to better understand 
the host immune response to ureaplasma infections of the female UGT and how this can be 
controlled for a future better outcome for the fetus.  
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General Discussion
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Discussion 
 
The human Ureaplasma spp. are the bacteria most frequently isolated from the female lower genital 
tract (LGT; 40 - 80%), male LGT (up to 50%) and the female upper genital tract (UGT) (Volgmann et 
al. 2005). These microorganisms are also among the most prevalent organisms isolated from the 
amniotic fluid (Cassell et al. 1983; Gray et al. 1992; Jalava et al. 1996; Knox et al. 1997; Yoon et al. 
2000; Gerber et al. 2003; Yoon et al. 2003b; Perni et al. 2004; Aaltonen et al. 2007; Berger et al. 
2009; Jacobsson et al. 2009; Kasper et al. 2010) and placentae (Kundsin et al. 1984; Hillier et al. 
1988; Miralles et al. 2005; Egawa et al. 2007; Hecht et al. 2008; Olomu et al. 2009; Namba et al. 
2010) of women who deliver preterm. However, the pathogenic role of Ureaplasma spp. is not 
always clear as these microorganisms may also be isolated from the amniotic cavity of women who 
deliver at term with no evidence of adverse pregnancy outcomes (Gray et al. 1992; Gerber et al. 
2003; Perni et al. 2004). Because there are different clinical presentations and pregnancy outcomes 
associated with female genital tract infection with ureaplasmas, it has been proposed that some 
Ureaplasma spp. or serovars may be more ‘virulent’ than others (Naessens et al. 1988; Sung et al. 
2010; Eun et al. 2013) or that some of these microorganisms may possess virulence factors, such as 
the ability to vary their surface-exposed protein, the multiple banded antigen (MBA), which may 
modulate host-microbe interactions (Monecke et al. 2003; Zimmerman et al. 2009; Knox et al. 2010; 
Zimmerman et al. 2011; Dando et al. 2012; Robinson et al. 2013; Zimmerman et al. 2013). The host 
immune response to ureaplasmas during infection may also influence the development of sequelae, 
such as histological chorioamnionitis or pPROM (Kim et al. 2003; Aaltonen et al. 2007; Goldenberg et 
al. 2008a; Kasper et al. 2010; Oh et al. 2010). Given this, research into the pathogenesis of 
ureaplasma infections and the host-microbe interactions that take place during infection may lead to 
the identification of biomarkers and ultimately therapeutic strategies aimed at reducing the high 
rates of preterm birth (PTB) and sequelae in neonates.  
 
Therefore, the overall hypotheses of this PhD program of research were that: (i) Ureaplasma spp. 
can infiltrate the placenta and chorioamnion during pregnancy; and (ii) Ureaplasma spp. are an 
aetiological agent during gestation and may be associated with adverse pregnancy and neonatal 
outcomes. We further hypothesised that (iii) the host immune system may not always recognise 
ureaplasmas, as these microorganisms possess the ability to vary the size of their surface-exposed 
lipoprotein, the MBA. These hypotheses were investigated in human pregnancies and also within an 
ex vivo chorioamnion tissue model of Ureaplasma spp. infection. The results of this research project 
have confirmed that Ureaplasma spp. are a major aetiological agent of infection in late preterm 
(LPT) and term pregnancies; and that the presence of ureaplasmas within the chorioamnion was 
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independently associated with histological chorioamnionitis. It was also identified that ureaplasma 
clinical isolates obtained from the chorioamnion of human pregnancies demonstrated differences in 
the size of their MBA protein and variation of the size of the surface-exposed MBA was associated 
with a decreased incidence of histological chorioamnionitis. Furthermore, we demonstrated that the 
presence of Ureaplasma spp. infection in human pregnancies was associated with host immune 
responses and elevated levels of the cord blood cytokine granulocyte colony-stimulating factor (G-
CSF); however, when MBA protein variation was present, there was a significant reduction in the 
levels of G-CSF and interleukin (IL)-8 within cord blood, despite high numbers of ureaplasmas being 
present within the chorioamnion. Finally, we utilised an ex vivo Ussing chamber system to model 
host immune responses to Ureaplasma spp. infection of the chorioamnion and demonstrated tissue 
pathology within 30 hours of exposure to ureaplasmas, including altered membrane integrity, 
ureaplasma infiltration within the chorioamnion tissue and the presence of ureaplasmas within the 
fetal membrane reservoir, confirming that ureaplasmas exposed to the maternal membrane surface 
had invaded through the chorioamnion membrane. We also identified increased activity of matrix 
metalloproteinase (MMP)-9 and elevated levels of the anti-inflammatory cytokine IL-10 within 
perfusates that were exposed to live U. parvum infection, consistent with the early stages of 
chorioamnion membrane rupture. Taken together, the data presented in this thesis provide novel 
insight into the complex host-microbe interactions which take place during Ureaplasma spp. 
infections and suggest that immune responses of the host may be a key determinant in the 
development of adverse pregnancy outcomes.  
 
The pathogenic role of Ureaplasma spp. has been strongly debated within the literature and 
ureaplasmas have been traditionally considered to be colonisers of the female lower genital tract 
(LGT) and were of low virulence (Volgmann et al. 2005). Additionally, only some studies identified 
causal links between Ureaplasma spp. infections and the development of adverse pregnancy 
outcomes (Cassell et al. 1983; Hillier et al. 1988; Cultrera et al. 2006; Egawa et al. 2007; DiGiulio 
2012), while other studies identified no significant association between the presence of ureaplasmas 
and adverse sequelae (Gray et al. 1992; Gerber et al. 2003; Perni et al. 2004). However, the data 
presented within this thesis clearly demonstrates that Ureaplasma spp. are an aetiological agent of 
chorioamnion infection in LPT and term pregnancies and the presence of these microorganisms is 
associated with the development of adverse pregnancy outcomes. Within our large study of 535 
placentae, we identified that chorioamnion infection was present in 10.6% of all LPT and term 
pregnancies and that the human Ureaplasma spp. and in particular U. parvum were the most 
prevalent microorganisms identified within this study, accounting for almost 70% of isolates. 
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Significantly, the presence of Ureaplasma spp. within the chorioamnion of LPT and term placentae 
was associated with the development of histological chorioamnionitis, and 68.4% of all placentae 
infected with ureaplasmas demonstrated evidence of chorioamnionitis. While previous studies have 
identified that the human Ureaplasma spp. were the most prevalent microorganisms isolated from 
the UGT of women who deliver prior to 32 weeks of gestation (Hillier et al. 1988; DiGiulio et al. 2008; 
Hecht et al. 2008; DiGiulio et al. 2010; Namba et al. 2010; Marconi et al. 2011), these infections were 
often polymicrobial and so a causal association with adverse pregnancy outcomes could not be 
attributed to a single bacterium. However, the findings of this current study demonstrate for the 
first time, that UGT chorioamnion infections at >32 weeks of gestation are most frequently caused 
by Ureaplasma spp. alone and that the presence of these microorganisms was independently 
associated with histological chorioamnionitis, regardless of gestation. The findings of this study also 
correlate with previous animal model studies, which identify Ureaplasma spp. as a sole pathogen of 
adverse pregnancy outcomes. Mouse model studies have demonstrated that a single intraamniotic 
injection of Ureaplasma spp. into the amniotic sac resulted in placental inflammation and fetal 
inflammatory response syndrome within 72 hours of infection (von Chamier et al. 2012; Allam et al. 
2014). Sheep intraamniotically injected with U. parvum clinical isolates demonstrated histological 
chorioamnionitis and fetal lung pathology following acute (7 day) or chronic (69 day) infections 
(Moss et al. 2005; Knox et al. 2010; Dando et al. 2012; Robinson et al. 2013). Novy et al. (2009) 
utilised a Rhesus macaque model of intraamniotic Ureaplasma spp. infection and demonstrated that 
Ureaplasma spp., as a sole pathogen, caused chorioamnionitis and fetal lung injury. Taken together, 
the data presented within this thesis and the findings of others confirm a strong clinical link between 
chorioamnion infection with Ureaplasma spp. and the development of histological chorioamnionitis.  
 
However, within this current study, not all women with ureaplasma chorioamnion infection 
developed histological chorioamnionitis and not all women with histological chorioamnionitis 
delivered preterm, which suggests that there may be other factors which are involved in the 
development and progression of disease. Therefore, we serotyped ureaplasma clinical isolates to 
determine if there was a ‘virulent’ spp. or serovar of ureaplasmas that was associated more 
frequently with adverse pregnancy outcomes. While we determined that U. parvum was the species 
isolated most frequently (accounting for 85.7% of all ureaplasma isolates within our study) and that 
U. parvum serovars 1, 3 and 6 were the ureaplasma serovars isolated most frequently (accounting 
for 23.8%, 21.4% and 28.6% of all ureaplasma clinical isolates, respectively), we were unable to 
demonstrate any association between particular ureaplasma species or serovars and the 
development of adverse pregnancy or neonatal outcomes. This finding is consistent with previous 
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reports. Zheng et al. (1992) serotyped ureaplasma clinical isolates obtained from neonatal 
cerebrospinal fluid or blood and demonstrated that there were no particular ‘virulent’ Ureaplasma 
serovars that were associated with invasive disease. Similarly, other studies have demonstrated that 
some Ureaplasma spp. and serovars are more prevalent in some patient populations. For example, 
U. parvum serovars 3 and 6 were most frequently isolated from the UGT of women who delivered 
preterm in an American population (Naessens et al. 1988). U. parvum serovars 3 and 6 were among 
the most frequently isolated ureaplasmas from the UGT of women who delivered preterm in 
Australia (Knox et al. 1997) and U. parvum serovar 6 was shown to be the most adherent 
ureaplasma serovar identified within washed semen samples (Knox et al. 2003) within an Australian 
population. Sung et al. (2010) identified that U. parvum serovars 3 and 6 and U. urealyticum serovar 
11 were the most prevalent ureaplasma isolates obtained from nasopharyngeal and endotracheal 
aspirates of American neonates, while Eun et al. (2013) identified that U. urealyticum serovar 9 was 
the most common ureaplasma isolate identified within tracheal and gastric aspirates of Korean 
neonates. Similar to our current study, these researchers reported prevalent Ureaplasma spp. and 
serovars; however, these studies were unable to provide convincing data to support the idea of 
‘virulent’ Ureaplasma spp. or serovars. The difference in prevalent species or serovars reported 
within these studies may simply be due to differences in the serovars endemic within these 
geographical locations. Taken together, the results of this study and others demonstrate that it is 
unlikely that ‘virulent’ ureaplasma species or serovars exist and so there may be other factors that 
are critical in the development of adverse pregnancy outcomes.  
 
Also within this PhD program of study, we investigated the role of antigenic variation in Ureaplasma 
spp. Antigenic variation is hypothesised to enable pathogens to avoid recognition by the host 
immune response and is a common trait among the Mycoplasmataceae family, including 
Mycoplasma hominis, Mycoplasma pulmonis, Mycoplasma agalactiae, Mycoplasma genitalium, 
Mycoplasma penetrans and the human Ureaplasma spp. A seminal study published by Watson et al. 
(1993) investigated the major differences between M. pulmonis isolates obtained from animals with 
severe sequelae (‘virulent’ isolates) and those isolated from animals with little evidence of disease 
(‘avirulent’ isolates) and identified that the only discernible differences in these isolates was the 
variation of their variable antigen (V)-1 surface-exposed lipoprotein. Similarly, the variable protein of 
M. agalactiae (Vpma) antigen has been shown to vary in size in vivo. While researchers determined 
that size variation of the Vpma was not involved in the establishment of infection, it was suggested 
that variation of the Vpma may critically influence the survival of these microorganisms in vivo and 
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may be responsible for invasive/systemic infections of M. agalactiae in ovine mastitis (Chopra-
Dewasthaly et al. 2012).  
 
Antigenic variation has been described previously within the human Ureaplasma spp. In a sheep 
model of infection, different MBA size variants were generated in vivo within amniotic fluid and the 
chorioamnion tissue of pregnant ewes (Knox et al. 2010; Dando et al. 2012; Robinson et al. 2013). 
Additionally, ureaplasma clinical isolates with different MBA size variants have also been isolated 
from humans (Watson et al. 1990; Zheng et al. 1994; Zheng et al. 1995). It has also been shown that 
ureaplasmas can undergo phase variation (on/off “switching”) and this has been demonstrated in 
vitro (Monecke et al. 2003; Zimmerman et al. 2009; Zimmerman et al. 2011; Dando et al. 2012). 
However, there are currently no studies which have investigated ureaplasma MBA size variation in 
clinical isolates from the UGT during human pregnancies. Importantly, the effect of MBA size 
variation on the outcomes of pregnancies is currently unknown.  
 
In this PhD project, using western blot and polymerase chain reaction (PCR) analysis we identified 
that in vivo size variation in both the mba gene and its expressed protein (MBA) was associated with 
a lower incidence of histological chorioamnionitis, despite the presence of high numbers of 
Ureaplasma spp. infecting/colonising chorioamnion tissue. These findings are consistent with 
previous studies which demonstrated that MBA size variants were associated with only mild 
histological chorioamnionitis or the absence of inflammation within the chorioamnion or other fetal 
tissues (Knox et al. 2010; Robinson et al. 2013). The results of these studies suggest that MBA size 
variation plays an integral role in host-microbe interactions. We further investigated the role of MBA 
variation on the host innate immune responses and identified a novel association between the 
presence of MBA variation and concentrations of key cord blood cytokines. When Ureaplasma spp. 
demonstrated either a single or multiple MBA size variant(s), significantly lower concentrations of 
the cytokines G-CSF and IL-8 were present in cord blood. By contrast, placentae infected with 
ureaplasmas that did not alter the size of their MBA (i.e. the size of their MBA was the same as ATCC 
strain serovars) had significantly higher concentrations of both G-CSF and IL-8 detected within cord 
blood. These results strongly support the finding that MBA size variation plays an integral role in 
host-microbe interactions (Shimizu et al. 2008; Triantafilou et al. 2013); further studies into the 
pathogenesis of these microorganisms is warranted. 
 
IL-8 and G-CSF are both inflammatory markers that are often produced by the host during infections. 
The production of these key cytokines triggers the recruitment of neutrophils towards the site of 
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infection. Our finding that both IL-8 and G-CSF concentrations are significantly lower within cord 
blood in association with ureaplasma infections which display MBA size variants is of great 
importance as this may be a mechanism by which ureaplasmas avoid eradication by the host 
immune system. Shimizu et al. (2008) demonstrated that the Ureaplasma spp. MBA is the 
immunodominant antigen recognised by the host and is capable of activating nuclear factor (NF)-kB 
via Toll-like receptors (TLRs) 1, 2 and 6. Alterations of the MBA protein may in turn affect TLR 
binding, activation and subsequent signalling of inflammatory pathways and this may result in 
reduction in the levels of G-CSF and IL-8, despite the presence of ureaplasmas within the 
chorioamnion. 
 
This may also mean that there is a reduced likelihood of ureaplasma infections being eradicated by 
the host and chronic infections may develop. MBA size variation is also predicted to affect the 
adaptive immune response, as each MBA size variant is consistent with a single B-cell epitope. The 
ability of these microorganisms may also be associated with the concept of 'original antigenic sin'. 
Antigenic sin refers to the ability of the host to preferentially utilise immunological memory based 
on a previous infection with the same microorganism (Stromberg and Carlson 2013). When a 
secondary infection occurs, there may be slightly different antigens encountered by the host (e.g. 
Ureaplasma spp. MBA size or phase variation); however, the host preferentially utilises 
immunological memory to produce high-affinity memory B-cells in order to produce antibodies 
against the original antigens encountered during the original infection. The production of large 
numbers of memory B-cells also inhibits the activation of naïve B-cells, which would be able to 
mount an effective immune response against the current infection which displays slightly different 
surface antigens. This preference then leaves the host 'trapped' and often unable to respond to the 
different surface antigens produced by Ureaplasma spp., thereby enabling prolonged infections to 
ensue. This is supported by the findings of Dando et al. (2012) who demonstrated that maternal 
serum of sheep exposed to intraamniotic U. parvum for 69 days demonstrated serum reactivity to 
MBA proteins, which were different in size to the MBA antigens expressed by ureaplasmas within 
amniotic fluid of the same ewe and this supports the idea that infections with ureaplasmas are often 
chronic.  
 
During these chronic infections, the fetus is also exposed to Ureaplasma spp. in utero and the 
inability of the host immune response to neutralise these infections may lead to serious infant 
morbidity, including bronchopulmonary dysplasia, sepsis, meningitis, and in severe cases, cerebral 
palsy (Cassell et al. 1993b; Abele-Horn et al. 1997a; Katz et al. 2005; Berger et al. 2009). Given this, 
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the identification of UGT ureaplasma infections during pregnancy is of great importance; however, 
these microorganisms are currently not screened for during pregnancy and there is no available 
assay that can easily detect, speciate or serotype ureaplasmas.  
 
During this PhD, a real-time PCR and HRM assay for the simultaneous identification, speciation and 
serotyping of U. parvum clinical isolates was developed and validated. Given that U. parvum are the 
most prevalent Ureaplasma spp. (accounting for up to ~95% of all clinical isolates (Knox et al. 1997; 
Knox et al. 2003; De Francesco et al. 2009; Sung et al. 2010)), we sought to develop an improved 
assay to detect and characterise these microorganisms. The current "gold-standard" method for the 
detection of Ureaplasma spp. in clinical specimens is culture, which is often time-consuming, 
laborious and ureaplasma broth culture media is not available commercially, so media must be made 
"in house", all of which greatly increases the cost and time taken to diagnose these infections. The 
assay developed for this research project targets the multiple banded antigen gene (mba), which 
encodes the major surface-exposed, immunodominant antigen of Ureaplasma spp. This gene is 
present in all 14 ureaplasma serovars and the upstream portion of this gene has a relatively high A+T 
content and is conserved (Glass et al. 2000), making it an ideal candidate for the identification and 
serotyping of U. parvum. The presence of numerous single nucleotide polymorphisms (SNPs) within 
the upstream region of this gene in all U. parvum serovars allowed us to utilise fragments of the mba 
gene for the simultaneous identification, speciation and serotyping of the four U. parvum serovars in 
a single closed-tube assay. This novel assay successfully speciated and serotyped 64.5% of all clinical 
isolates tested; however, a further 11 isolates were unable to be typed using this assay. Those 
isolates which were successfully typed using this assay demonstrated high resolution melt curves 
that were very similar to those of the American Type Culture Collection (ATCC) strain serovars, so 
with additional improvements, this assay has the potential to be incorporated into routine clinical 
and diagnostic laboratory testing for Ureaplasma spp. and this is a major contribution to this field of 
research. However, the problem largely remains that Ureaplasma spp. infections are predominantly 
clinically asymptomatic (Gerber et al. 2003; Zdrodowska-Stefanow et al. 2006) and in our study, we 
identified no clinical signs or symptoms that were associated with UGT infections. Additionally, LGT 
colonisation with ureaplasmas is not predictive of UGT infections with Ureaplasma spp. or the 
development of adverse pregnancy outcomes (Cassell et al. 1993b; Eschenbach 1993; Knox et al. 
1997) and identifying women with UGT ureaplamsa infections during pregnancy is extremely 
difficult.  
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Because of these difficulties in identifying women with UGT infection, many studies have sought to 
identify biomarkers for the prediction of UGT infections, PTB and other adverse pregnancy 
outcomes. Biomarkers are a valuable clinical tool for the identification of women at-risk of PTB who 
are clinically asymptomatic. Early detection of risk factors or signs and symptoms of infection may 
potentially inform treatment options and lead to a reduction in the high rates of PTB. Indicators of 
PTB (biomarkers) may include maternal pregnancy history and demographic characteristics, patient 
presentation during routine examination or the measurement of substances within bodily fluids. The 
preterm prediction studies are a series of publications, which attempt to identify a range of 
biomarkers to assist in the identification of women at-risk of delivering preterm. These studies 
identified a wide range of maternal risk factors, behavioural characteristics and bodily fluid markers 
which were predictive of PTB and other adverse pregnancy outcomes. These included maternal 
stress, cervical length, bacterial vaginosis or genital infection with C. trachomatis at < 24 weeks of 
gestation as well as other biomarkers such as elevated levels of cervical IL-6 or fetal ferritin and 
vaginal fetal fibronectin. These factors were all correlated with spontaneous PTB and pPROM 
(Andrews et al. 2000; Goepfert et al. 2000; Meis et al. 2000; Mercer et al. 2000; Goepfert et al. 2001; 
Newman et al. 2001; Moawad et al. 2002; Ramsey et al. 2002; Goldenberg et al. 2005; Hendler et al. 
2005; Newman et al. 2008).  
 
The data presented within this thesis has further identified a history risk factor and two potential 
biomarkers that were associated with UGT infection during pregnancy. In this large study, we 
identified for the first time women with UGT infections within the current pregnancy (reported in 
Chapter 4) had a history of chorioamnionitis in a prior pregnancy. This further suggests that the 
microorganisms causing infection in this current pregnancy may be the cause of chorioamnionitis 
within a prior pregnancy. While previous studies have identified that the best indicator of PTB within 
a current pregnancy is a history of prior PTBs in other gestations (Mercer et al. 1999); to the best of 
our knowledge, this is the first study to identify that a prior history of chorioamnionitis may be used 
as a marker to predict the likelihood of UGT infections within a current pregnancy. This finding 
appears to be regardless of gestational age, as women within our study with chorioamnionitis 
delivered LPT or at term (> 36 weeks of gestation). These findings are a major contribution to this 
field of research and should be of great importance to clinicians and aid in the identification of 'at-
risk' women during pregnancy. 
 
In addition, we identified two cord blood cytokines that were elevated in pregnancy in association 
with UGT infection and histological chorioamnionitis. Concentrations of both IL-8 and G-CSF were 
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shown to be increased in pregnancies complicated by infection; while levels of G-CSF were elevated 
within the cord blood of pregnancies affected by histological chorioamnionitis. Our findings are in 
agreement with previous studies which have shown that concentrations of IL-8 were significantly 
increased in pregnancies complicated by UGT infection (including infection with Ureaplasma spp.) 
(Marconi et al. 2011). Amniotic fluid G-CSF was found to be elevated within the amniotic fluid of 
pregnancies complicated by intraamniotic infection (Calhoun et al. 2001) or histological 
chorioamnionitis (Raynor et al. 1995; Hoskins et al. 1997). More recently, Payne et al. (2014)  sought 
to identify amniotic fluid biomarkers specific for Ureaplasma spp. infections. Amniotic fluid samples 
obtained at the time of amniocentesis (15 – 20 weeks of gestation) were collected from 480 Chinese 
and 492 Australian women and analysed for the presence of inflammatory markers (IL-1β, IL-6, IL-10, 
TNF-α and MCP-1). Ureaplasma spp. were identified in only two (0.2%) women within this study and 
there were no significant correlations between the infection with ureaplasmas and elevated levels of 
amniotic fluid cytokines. While this study did not test for the presence of IL-8 and G-CSF (markers 
which we have identified as elevated during UGT infections), the presence of Ureaplasma spp. 
within this study was also extremely low, suggesting that the PCR assays used for identification of 
these microorganisms did not identify low-level ureaplasma infection. These findings also suggest 
that amniotic fluid is not the most appropriate specimen for identifying biomarkers of UGT infection.  
 
Amniotic fluid is collected by an invasive procedure (amniocentesis) that is most frequently during 
pregnancies when there is an increased risk of neonatal genetic abnormalities. Amniocentesis can 
only be performed by clinicians and this procedure is associated with an increased risk of 
miscarriage, with approximately 1/200 women experiencing miscarriages after undergoing this 
procedure (Tabor and Alfirevic 2010). Given the increased risks and specialised training required, it is 
unlikely that pregnant women would routinely undergo amniocentesis to obtain amniotic fluid for 
biomarker analysis. Therefore, it is likely that non-invasive methods of screening would be more 
acceptable to pregnant women and so specimens such as serum or vaginal fluids are likely to be a 
superior specimen of choice. Additionally, women routinely undergo blood tests and most women 
will often undergo vaginal screening (specifically for S. agalactiae or GBS) throughout pregnancy and 
so testing for additional factors during these tests would likely be deemed acceptable by most 
pregnant women (Goldenberg et al. 2005). Currently, we are still yet to identify the most 
appropriate biomarker(s) for identification of UGT infections within these specimens. 
 
Previous studies  reported that maternal serum levels of IL-8 were elevated in women experiencing 
PTB with UGT infections (Bogavac and Brkic 2009). Additionally, maternal serum levels of G-CSF were 
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shown to be significantly increased in pregnancies complicated by histological chorioamnionitis 
(Boggess et al. 1997), pPROM (Murtha et al. 2007) and spontaneous PTB (< 28 weeks of gestation) 
(Goldenberg et al. 2000a). In our current study, we identified elevated levels of IL-8 and G-CSF within 
cord blood but unfortunately we were unable to test maternal serum for this marker. Cord blood is a 
derivative of maternal blood (maternal blood is passed through and filtered by the placenta) (Meyer 
et al. 1978) and it would be worthwhile to test for these key cytokines as they may also be increased 
within the maternal circulation.  
 
G-CSF is often found in extremely low levels in maternal circulation, unless infection or inflammation 
is present; making this a particularly attractive candidate for a pregnancy biomarker. Goldenberg et 
al. (2000) previously investigated the utility of G-CSF as a serum biomarker and identified that it was 
very useful in the prediction of PTB at < 32 weeks of gestation. However, our study has provided 
novel evidence that G-CSF may also be a useful biomarker at > 32 weeks of gestation for the 
prediction of Ureaplasma spp. infection and histological chorioamnionitis. Gravett et al. (2007) also 
investigated proteomic markers of UGT infection with Ureaplasma spp. in a non-human primate 
model and identified 205 unique proteins produced in amniotic fluid and cervicovaginal fluid of 
Rhesus monkeys following intraamniotic infection with Ureaplasma spp. Additionally, 27 other 
proteins were found to be differentially expressed (up- or down-regulated) within these fluids 
following infection with ureaplasmas and so with further investigation; it may be possible to identify 
a panel of biomarkers which can be used for the prediction or identification of women with UGT 
infections and/or histological chorioamnionitis. 
 
Within this PhD program of study, we also provided preliminary evidence which suggests that 
Ureaplasma spp. can infiltrate the placenta and chorioamnion. Using an ex vivo chorioamnion tissue 
model, we exposed the maternal surface of the membranes to live U. parvum (replicating) or UV-
inactivated (non-replicative, but still with their major surface-exposed antigens intact) U. parvum in 
order to study the host immune responses to these microorganisms. The numbers of U. parvum CFU 
within the Ussing chambers did not differ significantly over time; however, we did see differences in 
the immune responses to these pathogens. In this pilot study, we identified that concentrations of 
IL-10 were significantly increased in Ussing chambers in which the maternal membrane was 
stimulated with live U. parvum. It was interesting that we identified increased concentrations of IL-
10, and anti-inflammatory cytokine, within maternal perfusates but not in fetal perfusates in 
response to live U. parvum. Increased production of IL-10 can result in an immunosuppressive 
response on the chorioamnion tissues, ‘dampening’ or reducing the effects of any pro-inflammatory 
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immune responses. This finding is supported by the findings of Chapters Four and Five within this 
thesis; which showed that not all women whose chorioamnion was infected with Ureaplasma spp. 
demonstrate an inflammatory immune response (and some women with high numbers of 
ureaplasmas within their chorioamnion had little or no evidence of chorioamnionitis) and also that 
variation of the Ureaplasma spp. MBA may be associated with modulation of the host immune 
response. Significantly lower levels of cord blood pro-inflammatory cytokines IL-8 and G-CSF were 
detected in cord blood when placentae were infected with ureaplasmas that displayed variation of 
their surface-exposed MBA. The signalling of an immunosuppressive immune response in response 
to ureaplasma infections is interesting, and supports the hypothesis that these organisms may cause 
chronic, asymptomatic in utero infections for prolonged periods and the increase in 
immunosuppressive cytokines (IL-10) and the reduction of immunostimulatory cytokines (IL-8 and G-
CSF) may allow for the establishment of chronic UGT infections with ureaplasmas.  
 
Within this pilot study, we were also able to demonstrate that stimulation of the chorioamnion 
membranes with live U. parvum resulted in the significant loss of chorioamnion tissue integrity and 
the invasion of U. parvum through the chorioamnion membranes to the fetal compartment by 30 
hours of infection. This finding is novel, as no previous studies have investigated whether 
Ureaplasma spp. are able to cross the chorioamnion membrane; despite ascending invasive 
infections being the most commonly accepted origin/route of UGT infection. At the conclusion of 
these experiments, approximately 2 x 104 CFU of Ureaplamsa spp. was detected within the fetal 
compartment of all Ussing chambers that were stimulated with live ureaplasmas; and while it is 
currently not clear if these microorganisms were present simply due to membrane degradation, this 
is still a unique finding that warrants further investigation. A previous study has identified that S. 
agalactiae (Group B Streptococcus or GBS) was able to penetrate the chorioamnion membrane 
within a similar ex vivo model (using Trans-well assay plates) (Winram et al. 1998) and this supports 
the hypothesis that ureaplasmas and other microorganisms can infiltrate the placenta and 
chorioamnion during pregnancy. These findings have serious implications for the health and 
wellbeing of mothers and neonates. If Ureaplasma spp. are able to degrade the chorioamnion 
membrane in vivo, this may allow ureaplasmas and other microorganisms to cross the chorioamnion 
and infect the fetus and amniotic cavity. Previous studies of very early PTBs have shown that 
Ureaplasma spp. are commonly isolated in the presence of other microorganisms, including 
Fusobacterium spp., Streptococcus spp., Mycoplasma spp. and Bacteroides spp. (DiGiulio et al. 2010). 
The ability of these microorganisms to pass into the amniotic cavity at the time of pregnancy are 
associated with adverse pregnancy outcomes.  
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Furthermore, prolonged exposure to Ureaplasma spp. in utero has been associated with altered lung 
structure and altered gut structure in sheep (Collins et al. 2010; Robinson et al. 2013; Wolfs et al. 
2013); while in humans, exposure to ureaplasmas has been correlated with adverse neurological 
disorders, cerebral palsy and adverse respiratory outcomes (Viscardi et al. 2002; Berger et al. 2009; 
Payne et al. 2010).  
  
Additionally, our study identified significant increases in the presence and activity of MMP-9 
following exposure to U. parvum. This is perhaps not surprising, as MMP-9 has been shown 
previously to play a key role in maintenance in chorioamnion tissue. MMPs regulate the degradation 
and renewal of extracellular matrix proteins within the chorioamnion and any disturbance to this 
balance may result in chorioamnion degradation and membrane rupture. MMP-9 has been shown to 
be elevated in pregnancies that end prematurely (Tency et al. 2012) and combined, these findings 
further demonstrate that ureaplasmas have a negative effect on chorioamnion tissues in an ex vivo 
model.  
 
Numerous studies have identified associations between UGT infection with Ureaplasma spp. and the 
development of pPROM. A review by DiGiulio et al. (2012) identified that the human Ureaplasma 
spp. are the bacteria isolated most frequently from the amniotic fluid of women experiencing 
pPROM; however, many of the studies reported in this review article identified multiple 
microorganisms within the amniotic fluid. The presence of multiple microorganisms often makes it 
more difficult to identify the true causative agent of pPROM; but in this pilot study, we have 
demonstrated for the first time that infection of the chorioamnion with Ureaplasma spp. causes 
alterations that are consistent with the early stages of pPROM.  
 
Conclusions 
 
The data presented within this thesis has provided novel information on the role of Ureaplasma spp. 
infections within human pregnancies. Our findings have shown that the host immune responses 
during Ureaplasma spp. infections are complex, with both immunostimulatory and 
immunosuppressive pathways activated following infection with Ureaplasma spp. This is further 
complicated by the fact that these microorganisms can vary their surface-exposed lipoprotein, the 
MBA; and in this thesis we provided the first evidence that Ureaplasma spp. clinical isolates obtained 
from the chorioamnion of human pregnancies demonstrate differences in the size of their MBA.  
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We also identified that variation of the ureaplasma MBA was associated with a lower incidence of 
histological chorioamnionitis and lower levels of cord blood cytokines IL-8 and G-CSF; suggesting that 
this protein may be involved in host-microbe interactions and modulation of the host immune 
response. While we were unable to show that MBA variation prevented the recognition of these 
pathogens in utero, the constant varying of this major immunodominant antigen may aid in 
preventing the eradication of Ureaplasma spp. and assist in the establishment of chronic in utero 
infections.  
 
Also of importance, we have demonstrated that live Ureaplasma spp. infections can negatively affect 
chorioamnion tissue and are able to infiltrate and cross the chorioamnion membrane in an ex vivo 
Ussing chamber model of ureaplasma infection. Within this small pilot study, we provided the first 
evidence that live ureaplasmas can alter the integrity and structure of the chorioamnion membrane, 
and also elicit immune responses in the form of increased MMP-9 and IL-10 production.  
 
Given the new and novel information presented within this thesis, a potential model of UGT 
infection with Ureaplasma spp. based on these new findings has been proposed (Figure 7.1). 
Ureaplasmas may ascend from the LGT, through the cervix and reach the choriodecidual space, 
where they may then infiltrate the placenta and cross the chorioamnion membranes. Once inside 
the amniotic cavity, the host can recognise and mount an immune response to eradicate the 
ureaplasmas. However, ureaplasmas can vary the size of their immunodominant antigen, the MBA, 
and the Ureaplasma spp. are not eradicated. MBA size variation leads to a reduced inflammatory 
response within the placenta and amniotic cavity, resulting in mild or no histological 
chorioamnionitis and subclinical (asymptomatic), chronic ureaplasma infections may be established. 
Due to the reduced inflammatory responses, PTB is not triggered and chronic infections continue; 
until normal term delivery. Prolonged exposure to Ureaplasma spp. in utero may result in an 
increased risk of neonatal and childhood diseases, due to the constant exposure of the fetus to these 
microorganisms even in the absence of histological chorioamnionitis. In cases where Ureaplasma 
spp. do not vary their surface-exposed MBA, strong pro-inflammatory responses may be seen and 
these microorganisms may be eradicated, thus ‘healing’ the UGT infection and leaving evidence of 
prior infection in the form of histological chorioamnionitis. However, in most cases, ureaplasmas 
may not be eradicated and these strong pro-inflammatory responses (such as increased IL-8 and G-
CSF) result in recruitment of inflammatory cells, production of MMPs and other immune factors 
which weaken the chorioamnion membrane. This membrane weakening may result in pPROM and 
subsequent PTB. Those infants who are exposed to these severe pro-inflammatory responses are at 
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greater risk of developing severe sequelae, such as respiratory distress syndrome (RDS) or 
neurological sequelae, such as cerebral palsy.  
 186 
 
  Ureaplasma spp. 
colonisation of female LGT 
Ureaplasma spp. infiltrates 
the chorioamnion and 
placenta 
MBA variation occurs No MBA variation 
occurs 
Host immune response to 
Ureaplasma spp.  
Strong immune response  
↑ IL-8          ↑ G-CSF 
Minimal immune response  
↓ IL-8          ↓ G-CSF 
Mild or no histological 
chorioamnionitis 
'Healed' histological 
chorioamnionitis 
Moderate to severe 
histological 
chorioamnionitis 
Ureaplasma spp. 
infections continue 
Ureaplasma spp. 
eradicated 
Ureaplasma spp. not 
eradicated 
Increased risk of 
preterm delivery 
Pregnancy may 
continue until normal 
term delivery 
Risk of preterm or term 
delivery 
Risk of adverse neonatal 
outcomes 
Severe risk of adverse 
neonatal outcomes e.g. 
respiratory sequelae and 
cerebral palsy 
Risk of adverse neonatal 
outcomes due to 
prolonged exposure to 
microbes in utero 
Figure 7.1. Proposed model of UGT infections with Ureaplasma spp. 
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The Ureaplasma spp. are important pathogens of the female UGT during pregnancy and are 
associated with severe adverse pregnancy outcomes. While the results generated from this PhD 
project suggest that there are no ‘virulent’ Ureaplasma spp. or serovars, they do strongly suggest 
that host-microbe interactions play a crucial role in the development of pregnancy sequelae. The 
ability of ureaplasmas to vary their surface-exposed MBA also appears to contribute to the ability of 
these microorganisms to avoid eradication by the host immune system, facilitating chronic 
infections. As the host immune response alone is often unable to eliminate these pathogens, more 
effective treatment options or therapeutic strategies are required in order to eradicate these 
pathogens from the UGT, or to prevent in utero infections from occurring.  
 
Future Directions 
 
Based on the findings of this PhD project, we propose that Ureaplasma spp. are an underestimated 
pathogen during pregnancy and their role in adverse outcomes requires further investigation. The 
initiation of screening and identification of women at-risk of developing UGT infections with 
ureaplasmas is of great clinical importance. Additional studies which focus on the identification of 
clinical risk factors and other maternal serum biomarkers or improved  detection techniques (such as 
the real-time PCR and HRM assay developed within this PhD project) appear to be the most 
appropriate strategies for identifying these microorganisms during gestation. Collaborative studies, 
undertaken by researchers and clinicians are required to trial antimicrobial treatments or 
therapeutic strategies in order to improve pregnancy outcomes for women infected with 
Ureaplasma spp. in utero.  
 
Furthermore, the role of the MBA should be further investigated in order to determine the 
mechanisms by which variation of the surface-exposed lipoprotein modulates chronic UGT infections 
and the host immune system. Because mba/MBA variation has been shown to be associated with a 
reduction of inflammation, studies which investigate the outcomes of infants exposed to these 
organisms in utero are warranted to determine if the presence of these microorganisms in the 
absence of inflammation are associated with any immediate adverse neonatal outcomes and also 
with long-term outcomes of infants exposed to ureaplasmas. Additionally, further studies which 
investigate other host immune factors, such as TLR activation and signalling may improve our 
knowledge and understanding of host immune responses to these pathogens during such an 
immunologically unique period, where the host immune response is predominantly TH2-mediated. 
Further studies should include the investigation of macrophage polarisation (M1/M2 phenotypes) on 
the host immune response to Ureaplasma spp. infections in order to determine if a TH2-mediated 
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response to ureaplasmas may in fact prolong infection, due to the initiation of an immediate TH2 
response which may not eradicate the pathogen. Additionally, it would also be of great interest to 
determine if ureaplasmas are able to stimulate the polarisation of macrophages by exposing 
unpolarised macrophages to ureaplasmas and determining the responses generated, to better 
understand if macrophages play an important role in the host immune responses during pregnancy.    
 
As the ureaplasma MBA is known to be the major immunodominant antigen recognised by the host 
immune system, an MBA vaccine may be developed. However, problems such as the size and phase 
variation of this protein inherently diminish the efficacy of this approach. Furthermore, it has been 
shown that the presence of Ureaplasma spp. antibodies present within maternal serum may also be 
associated with adverse pregnancy outcomes, such as spontaneous abortions (Naessens et al. 1988) 
and so therefore an ureaplasma vaccine should be carefully considered. While there are currently no 
ureaplasma-specific vaccines which have been trialled, issues in the feasibility of these lie in the fact 
that these microorganisms are also commensals of the female LGT, and the eradication of these 
organisms at this site may result in significant alterations of female vaginal microflora, which could 
have serious consequences. 
Because there is such an interesting association between the presence of circulating maternal 
ureaplasma-specific antibodies and an association with adverse pregnancy outcomes; the concept of 
immune ‘tolerance’ should be investigated. Exposure to Ureaplasma spp. at a young age (e.g. infants 
exposed to Ureaplasma spp. at the time of birth) may develop an immune ‘tolerance’ to these 
microorganisms and this may potentially reduce their host immune response to ureaplasma 
infections later in life. Long-term animal studies which investigate immune tolerance to 
ureaplasmas, the presence of maternal ureaplasma antibodies and the outcome of pregnancies of 
these same subjects may further elucidate the role of the host immune response to ureaplasmas.  
Overall, it is likely that the best way forward in the identification, treatment and eradication of 
ureaplasmas involve the immediate improvement of the detection of these organisms or of 
biomarkers of infection during gestation and improvement in the management and treatment of 
these women. By further investigating the host immune response to ureaplasmas, it may also be 
possible to identify targeted therapies for the eradication of these Ureaplasma spp. from the UGT 
during pregnancy.   
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Supplementary Table 9.1. Comparison of culture- and PCR-positive placental specimens. Culture 
data was obtained from cultivation of organisms from swabs and chorioamnion tissue. PCR data was 
obtained from DNA extracted from chorioamnion tissues.  
Patient 
Number 
Ureaplasma spp.  Other microorganisms 
 Culture PCR Identity Culture PCR Identity 
1A Positive Positive U. parvum Negative Negative - 
1B Positive Positive U. parvum Negative Negative - 
8 Positive Positive U. urealyticum Negative Negative - 
13A Negative Negative - Positive Positive  Bifidobacterium spp. 
13B Negative Negative - Positive Positive Bifidobacterium spp. 
27 Positive Positive U. parvum Negative Negative - 
33A Positive Positive U. parvum Negative Negative - 
33B Positive Positive U. parvum  Negative Negative - 
43 Positive Positive U. parvum Negative Positive Uncultured bacterium 
44A Positive Positive U. parvum Negative Negative - 
44B Positive Positive U. parvum Negative Negative - 
46 Negative Negative  Positive Positive Gardnerella vaginalis 
50 Positive Positive U. parvum Negative Negative - 
55B Positive Positive U. parvum Negative Negative - 
79 Negative Negative - Positive Positive Propionibacterium spp. 
122 Positive Positive U. parvum Negative Negative - 
175 Negative Positive U. parvum Negative Negative - 
176 Negative Positive U. parvum Negative Negative - 
182 Positive Positive U. parvum Negative Negative - 
205T Negative Negative - Positive Positive Streptococcus agalactiae  
206T Negative Negative - Positive Positive Streptococcus agalactiae  
242A Negative Negative - Positive Positive Bacteroides fragilis 
242B Negative Negative - Positive Positive Bacteroides fragilis 
251 Negative Positive U. parvum Negative Negative - 
258 Positive Positive U. urealyticum Negative Negative - 
262T Positive Positive U. parvum Negative Negative - 
290T Positive Positive U. parvum Negative Negative - 
297 Positive Positive U. urealyticum Negative Negative - 
300 Positive Positive U. urealyticum Negative Negative - 
301 Positive Positive U. parvum Negative Negative - 
310 Positive Positive U. parvum Negative Negative - 
314T Positive Positive U. parvum Positive Positive Uncultured bacterium 
317 Negative Negative - Positive Positive Streptococcus agalactiae  
320T Negative Negative - Positive Positive Uncultured bacterium 
322T Positive Positive U. parvum Negative Negative - 
325 Positive Positive U. parvum Negative Negative - 
334A Positive Positive U. parvum Negative Negative - 
334B Positive Positive U. parvum Negative Negative - 
337 Negative Negative - Positive Positive E. coli 
340T Negative Negative - Negative Positive Uncultured bacterium 
351 Positive Positive U. urealyticum Negative Negative - 
364A Positive Positive U. parvum Negative Negative - 
365 Positive Positive U. parvum Negative Negative - 
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368T Positive Positive U. parvum Negative Positive Uncultured bacterium 
374B Negative Negative - Negative Positive Uncultured bacterium 
375 Negative Negative - Negative Positive Uncultured bacterium 
429 Positive Positive U. parvum Negative Negative - 
435 Positive Positive U. parvum Negative Negative - 
437 Negative Negative - Positive Positive Streptococcus agalactiae 
438 Positive Positive U. urealyticum Negative Negative - 
473T Positive Positive U. parvum Positive Positive Streptococcus agalactiae  
480T Positive Positive U. parvum Negative Negative - 
483T Positive Positive U. parvum Negative Negative - 
498A Positive Positive U. parvum Negative Negative - 
498B Positive Positive U. parvum Negative Negative - 
507 Positive Positive U. parvum Negative Negative - 
510T Positive Positive U. parvum Negative Negative - 
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U._parvum_Serovar_6_ATCC_27818            AATAATAAAACTTATTAAAAATAATAT---------AGATATATAATTA---AATTTTTA 
U._parvum_Serovar_1_ATCC_27813            --------------TTAAAAATAATAT---------AGATATATAATTA---AATTTTTA 
U._parvum_Serovar_14_ATCC_33697           --------------------ATAATAT---------AGATATATAATTA---AATTTTTA 
U._parvum_Serovar_3_ATCC_27815_           --------------------ATAATAT---------AGATATATAATTA---AATTTTTA 
U._parvum_Serovar_3_ATCC_700970_          AATAATAAAACTTATTAAAAATAATAT---------AGATATATAATTA---AATTTTTA 
U._urealyticum_Serovar_4_ATCC_27816       ------------TAGTGTAAAAATAGGAACAAAAAAAATTATAAAATTAAAAACTTTTGA 
U._urealyticum_Serovar_10_ATCC_33699      ----------CTTAGTGTAAAAATAGGAACAAAAAAAATTATAAAATTAAAAACTTTTGA 
U._urealyticum_Serovar_5_ATCC_27817       ------------------------------------------------------------ 
U._urealyticum_Serovar_11_ATCC_33695      --------AACTTAGTGTAAAAATAGGAACAAAA-AAATTATAAAATTAAAAACTTTTGA 
U._urealyticum_Serovar_9_ATCC_33175       AATAATAAAACTTAGTGTAAAAATAGGAACAAAA--AATTATAAAATTAAAAATTTTTGA 
U._urealyticum_Serovar_12_ATCC_33696      ------------------AAAAATAGGAACAAAAAAAATTATAAAATTAAAAACTTTTGA 
U._urealyticum_Serovar_13_ATCC_33698      ------------------------------------------------------------ 
U._urealyticum_Serovar_2_ATCC_27814       ----ATAAAACTTAGTGTAAAAATAGGAACAAA-AA-ATTATAAAATTAAAAATTTTTGA 
U._urealyticum_Serovar_7_ATCC_27819       ------AAAACTTAGTGTAAAAATAGGAACAAA-AAAATTATAAAATTAAAAACTTTTGA 
U._urealyticum_Serovar_8_ATCC_27618       ------------------------------------------------------------ 
 
         UpuF2         UpuF 
U._parvum_Serovar_6_ATCC_27818            ATCATAATTT--------------ATAATAAAAAATATCTAATAATGTTATTGA----TA 
U._parvum_Serovar_1_ATCC_27813            ATCATAATTT--------------ATAATAAAAAATATCTAATAATGTTATTGA----TA 
U._parvum_Serovar_14_ATCC_33697           ATCATAATTT--------------ATAATAAAAAATATCTAATAATGTTATTGA----TA 
U._parvum_Serovar_3_ATCC_27815_           ATCATAATTT--------------ATAATAAAAAATATCTAATAATGTTATCGA----TA 
U._parvum_Serovar_3_ATCC_700970_          ATCATAATTT--------------ATAATAAAAAATATCTAATAATGTTATCGA----TA 
U._urealyticum_Serovar_4_ATCC_27816       ATTATAAATTCAAAATAAACATTAATTTTTATTAACAACTTTATTTTTAATTAAAAATTT 
U._urealyticum_Serovar_10_ATCC_33699      ATTATAAATTCAAAATAAACATTAATTTTTATTAACAACTTTATTTTTAATTAAAAATTT 
U._urealyticum_Serovar_5_ATCC_27817       -------------------------------TTAACAACTTTATTTTTAATTAAAAATTT 
U._urealyticum_Serovar_11_ATCC_33695      ATTATAAATTCAAAATAAACATTAATTTTTATTAACAACTTTATTTTTAATTAAAAATTT 
U._urealyticum_Serovar_9_ATCC_33175       ATTATAAATTCAAAATAAACATTAATTTTTATTAACAACTTTATTTTTAATTAAAAATTT 
U._urealyticum_Serovar_12_ATCC_33696      ATTATAAATTCAAAATAAACATTAATTTTTATTAACAACTTTATTTTTAATTAAAAATTT 
U._urealyticum_Serovar_13_ATCC_33698      ------------------------------------------------------------ 
U._urealyticum_Serovar_2_ATCC_27814       ATTGTAAATTCAAAATAAACATTAATTTTTATTAACAACTTTATTTTTAATTAAAAATTT 
U._urealyticum_Serovar_7_ATCC_27819       ATTATAAATTCAAAATAAACATTAATTTTTATTAACAACTTTATTTTTAATTAAAAATTT 
U._urealyticum_Serovar_8_ATCC_27618       ---------------------------TTTATTAACAACTTTATTTTTAATTAAAAATTT 
                                                                                                    
             UpuF3 
U._parvum_Serovar_6_ATCC_27818            ATGCAGAAAAAT-------AAAAAAAATAAAAAAAATAGCAAAAATTATATAATTAAAAG 
U._parvum_Serovar_1_ATCC_27813            ATGCAGAAAAAT-------AAAAAA-A-TAAAAAAACAGCAAAAATTATATAATTAAAAG 
U._parvum_Serovar_14_ATCC_33697           ATACAGAAAAAT-------AAAAAA-ATAAAAAAAATAGCAAAAATTATATAATTAAAAG 
U._parvum_Serovar_3_ATCC_27815_           ATGCAGAAAAAT-------AAAAAA-ATAAAAAAAATAGTAAAAATTATATAATTAAAAG 
U._parvum_Serovar_3_ATCC_700970_          ATGCAGAAAAAT-------AAAAAA-ATAAAAAAAATAGTAAAAATTATATAATTAAAAG 
U._urealyticum_Serovar_4_ATCC_27816       CTTCAAAAAAACACATAAAAAA---AAAAAAAAAACTAATAAAAATTATAAA-ATTAAAT 
U._urealyticum_Serovar_10_ATCC_33699      CTTCAAAAAAACACATAAA---AAAAAAAAAAAAACTAATAAAAATTATAAA-ATTAAAT 
U._urealyticum_Serovar_5_ATCC_27817       CTTCAAAAA-ACACATTAAAAAAAAAAAAAAAAAACTAATAAAAATTATAAA-ATTAAAT 
U._urealyticum_Serovar_11_ATCC_33695      CTTCAAAAA-ACACATAAAAAAAAAAAAAAAAAAACTAATAAAAATTATAAA-ATTAAAT 
U._urealyticum_Serovar_9_ATCC_33175       CTTCAAAAA-ACACATTAAAAAA-AAAAAAAAAAACTAATAAAAATTATAAA-ATTAAAT 
U._urealyticum_Serovar_12_ATCC_33696      CTTCAAAAAAACACATA----AAAAAAAAAAAAAACTAATAAAAATTATAAA-ATTAAAT 
U._urealyticum_Serovar_13_ATCC_33698      ------------------------------------------------------------ 
U._urealyticum_Serovar_2_ATCC_27814       CTTCAAAA--ACACATTAAAAAAAAAAAAAAAAAACTAATAAAAATTATAAA-ATTAAAT 
U._urealyticum_Serovar_7_ATCC_27819       CTTCAAAAA-ACACATA--AAAAAAA-AAAAAAAACTAATAAAAATTATAAA-ATTAAAT 
U._urealyticum_Serovar_8_ATCC_27618       CTTCAAAAA-ACACATT--AAAAAAAAAAAAAAAACTAATAAAAATTATAAA-ATTAAAT 
                                                                                                       
        UpuF4         
U._parvum_Serovar_6_ATCC_27818            TGCAAGTGCTAAATAAAAAGTATTTGCAATCTTTATATGTTTTCGTTAAAATTAAAAATT 
U._parvum_Serovar_1_ATCC_27813            TGCAAGTGCTAAATAAAAAGTATTTGCAATCTTTATATGTTTTCGTTAAAATTAAAAATT 
U._parvum_Serovar_14_ATCC_33697           TGCAAGTGCTAAATAAAAAGTATTTGCAATCTTTATATGTTTTCGTTAAAATTAAAAATT 
U._parvum_Serovar_3_ATCC_27815_           TGCAAGTGCTAAATAAAAAGTATTTGCAATCTTTATATGTTTTCGTTAAAATTAAAAATT 
U._parvum_Serovar_3_ATCC_700970_          TGCAAGTGCTAAATAAAAAGTATTTGCAATCTTTATATGTTTTCGTTAAAATTAAAAATT 
U._urealyticum_Serovar_4_ATCC_27816       TGCAAGTGTTAAGCGAAAGACATTTGCAATCTTCATATGTTTTCGTTAAAATTAAAA--- 
U._urealyticum_Serovar_10_ATCC_33699      TGCAAGTGTTAAGCGAAAGACATTTGCAATCTTCATATGTTTTCGTTAAAATTAAAA--- 
U._urealyticum_Serovar_5_ATCC_27817       TGCAAGTGTTAAGCGAAAGACATTTGCAATCTTCATATGTTTTCGTTAAAATTAAAA--- 
U._urealyticum_Serovar_11_ATCC_33695      TGCAAGTGTTAAGCGAAAGACATTTGCAATCTTCATATGTTTTCGTTAAAATTAAAA--- 
U._urealyticum_Serovar_9_ATCC_33175       TGCAAGTGTTAAGCGAAAGACATTTGCAATCTTCATATGTTTTCGTTAAAATTAAAA--- 
U._urealyticum_Serovar_12_ATCC_33696      TGCAAGTGTTAAGCGAAAGACATTTGCAATCTTCATATGTTTTCGTTAAAATTAAAA--- 
U._urealyticum_Serovar_13_ATCC_33698      -------------------GTATTTGCAATCTTTATATGTTTTCGTTAAAATTAAAA--- 
U._urealyticum_Serovar_2_ATCC_27814       TGCAAGTGTTAAGCGAAAGACATTTGCAATCTTCATATGTTTTCGTTAAAATTAAAA--- 
U._urealyticum_Serovar_7_ATCC_27819       TGCAAGTGTTAAGCGAAAGACATTTGCAATCTTCATATGTTTTCGTTAAAATTAAAA--- 
U._urealyticum_Serovar_8_ATCC_27618       TGCAAGTGTTAAGCGAAAGACATTTGCAATCTTCATATGTTTTCGTTAAAATTAAAA--- 
                                                             . ************ ***********************    
 
U._parvum_Serovar_6_ATCC_27818            AATTACTATA-AAAATTATGTAAGAT--TAATAAATCTTAGTGTTCATATTTTTTACTAG 
U._parvum_Serovar_1_ATCC_27813            AATTACTGTA-GAAATTATGTAAGAT--TGCTAAATCTTAGTGTTCATATTTTTTACACA 
U._parvum_Serovar_14_ATCC_33697           AATTACTGTA-GAAATTATGTAAGAT--TAATAAATCTTAGTGTTCATATTTTTTACATA 
U._parvum_Serovar_3_ATCC_27815_           AATTACTGTA-GAAATTATGTAAGAT--TACCAAATCTTAGTGTTCATATTTTTTACATA 
U._parvum_Serovar_3_ATCC_700970_          AATTACTGTA-GAAATTATGTAAGAT--TACCAAATCTTAGTGTTCATATTTTTTACATA 
U._urealyticum_Serovar_4_ATCC_27816       --TTCCTATA-AAAACAACATGAGATTAAACAAAATCTTAATGTTGTTGTTATCTATACA 
U._urealyticum_Serovar_10_ATCC_33699      --TTCCTATA-AAAACAACATGAGATTAAACAAAATCTTAATGTTGTTGTTATCTATACA 
U._urealyticum_Serovar_5_ATCC_27817       --TTCCTATTAAAAACAACATGAGATTAAACAAAATCTTAATGTTGTTATTATCTATACA 
U._urealyticum_Serovar_11_ATCC_33695      --TTCCTATA-AAAACAACATGAGATTAAACAAAATCTTAATGTTGTTATTATCTATACA 
U._urealyticum_Serovar_9_ATCC_33175       --TTCCTATTAAAAACAACATGAGATTAAACAAAATCTTAATGTTGTTATTATCTATACA 
U._urealyticum_Serovar_12_ATCC_33696      --TTCCTATA-AAAACAACATGAGATTAAACAAAATCTTAATGTTGTTGTTATCTATACA 
U._urealyticum_Serovar_13_ATCC_33698      --TTCCTATA-AAAACAACATGAGATTAAACAAAATCTTAATGTTGTTGTTATCTATACA 
U._urealyticum_Serovar_2_ATCC_27814       --TTCCTATTAAAAACAACATGAGATTAAACAAAATCTTAATGTTGTTATTATCTATACA 
U._urealyticum_Serovar_7_ATCC_27819       --TTCCTATA-AAAACAACATGAGATTAAACAAAATCTTAATGTTGTTATTATCTATACA 
U._urealyticum_Serovar_8_ATCC_27618       --TTCCTATTAAAAACAACATGAGATTAAACAAAATCTTAATGTTGTTATTATCTATACA 
                                            **.**.*: .*** :* .*.****  :.. ********.**** :*.**:* ** : . 
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U._parvum_Serovar_6_ATCC_27818            TATTAAATTAAA--------------------------------AACA------------ 
U._parvum_Serovar_1_ATCC_27813            TATT-AAATAAA--------------------------------GACA------------ 
U._parvum_Serovar_14_ATCC_33697           TATT-AAATAAA--------------------------------AACA------------ 
U._parvum_Serovar_3_ATCC_27815_           TATT-AAATAAA--------------------------------AACA------------ 
U._parvum_Serovar_3_ATCC_700970_          TATT-AAATAAA--------------------------------AACA------------ 
U._urealyticum_Serovar_4_ATCC_27816       TTCTAAAGAAAAATATATTTGCAAAACTATAAATAGACACAAAAAACAATAGAATAATAA 
U._urealyticum_Serovar_10_ATCC_33699      TTCTAAAGAAAAATATATTTGCAAAACTATAAATAGACACAAAAAACAATAGAATAATAA 
U._urealyticum_Serovar_5_ATCC_27817       TTCTAAAGAAAAATATATTTGCAAAACTATAAATAGACACAAAAAACAATAGAATAATAA 
U._urealyticum_Serovar_11_ATCC_33695      TTCTAAAGAAAAATATATTTGCAAAACTATAAATAGACACAAAAAACAATAGAATAATAA 
U._urealyticum_Serovar_9_ATCC_33175       TTCTAAAGAAAAATATATTTGCAAAACTATAAATAGACACAAAAAACAATAGAATAATAA 
U._urealyticum_Serovar_12_ATCC_33696      TTCTAAAGAAAAATATATTTGCAAAACTATAAATAGACACAAAAAACAATAGAATAATAA 
U._urealyticum_Serovar_13_ATCC_33698      TTCTAAAGAAAAATATATTTGCAAAACTATAAATAGACACAAAAAACAATAGAATAATAA 
U._urealyticum_Serovar_2_ATCC_27814       TTCTAAAGAAAAATATATTTGCAAAACTATAAATAGACACAAAAAACAATAGAATAATAA 
U._urealyticum_Serovar_7_ATCC_27819       TTCTAAAGAAAAATATATTTGCAAAACTATAAATAGACACAAAAAACAATAGAATAATAA 
U._urealyticum_Serovar_8_ATCC_27618       TTCTAAAGAAAAATATATTTGCAAAACTATAAATAGACACAAAAAACAATAGAATAATAA 
                                          *: * ** :***                                .***             
 
          Start mba 
U._parvum_Serovar_6_ATCC_27818            -ATAAAATGACATATTTTTTATATTAGGAGAAC--CATAAATGAAATTATTAAAAAATAA 
U._parvum_Serovar_1_ATCC_27813            -ATAAAATGACATATTTTTTATATTAGGAGAAT--CATAAATGAAATTATTAAAAAATAA 
U._parvum_Serovar_14_ATCC_33697           -ATAAAATGACATATTTTTTATATTAGGAGAAT--CATAAATGAAATTATTAAAAAATAA 
U._parvum_Serovar_3_ATCC_27815_           -ATAAAATGACATATTTTTTATATTAGGAGAAT--CATAAATGAAATTATTAAAAAATAA 
U._parvum_Serovar_3_ATCC_700970_          -ATAAAATGACATATTTTTTATATTAGGAGAAT--CATAAATGAAATTATTAAAAAATAA 
U._urealyticum_Serovar_4_ATCC_27816       AACTAAATTTCGTATTTAGTTTATTAGGAGATCGTTATAAATGAAATTATTAAAAAATAA 
U._urealyticum_Serovar_10_ATCC_33699      AACTAAATTTCGTATTTAGTTTATTAGGAGATCGTTATAAATGAAATTATTAAAAAATAA 
U._urealyticum_Serovar_5_ATCC_27817       AACTAAATTTCATATTTAGTTTATTAGGAGATCGTTATAAATGAAATTATTAAAAAATAA 
U._urealyticum_Serovar_11_ATCC_33695      AACTAAATTTCGTATTTAGTTTATTAGGAGATCGTTATAAATGAAATTATTAAAAAATAA 
U._urealyticum_Serovar_9_ATCC_33175       AACTAAATTTCATATTTAGTTTATTAGGAGATCGTTATAAATGAAATTATTAAAAAATAA 
U._urealyticum_Serovar_12_ATCC_33696      AACTAAATTTCGTATTTAGTTTATTAGGAGATCGTTATAAATGAAATTATTAAAAAATAA 
U._urealyticum_Serovar_13_ATCC_33698      AACTAAATTTCGTATTTAGTTTATTAGGAGATCGTTATAAATGAAATTATTAAAAAATAA 
U._urealyticum_Serovar_2_ATCC_27814       AACTAAATTTCATATTTAGTTTATTAGGAGATCGTTATAAATGAAATTATTAAAAAATAA 
U._urealyticum_Serovar_7_ATCC_27819       AACTAAATTTCGTATTTAGTTTATTAGGAGATCGTTATAAATGAAATTATTAAAAAATAA 
U._urealyticum_Serovar_8_ATCC_27618       AACTAAATTTCATATTTAGTTTATTAGGAGATCGTTATAAATGAAATTATTAAAAAATAA 
                                           * :**** :*.*****: *:**********:    ************************ 
 
               UpmbaR2            
U._parvum_Serovar_6_ATCC_27818            AAAATTCTGAGCTATGACATTAGGAGTTACCTTAGTTGGAGCTGGAATAGTTGCTATAGC 
U._parvum_Serovar_1_ATCC_27813            AAAATTCTGAGCTATGACATTAGGAGTTACCTTAGTTGGAGCTGGAATAGTTGCTATAGC 
U._parvum_Serovar_14_ATCC_33697           AAAATTCTTAGCTATGACATTAGGTGTTACCTTAGTTGGAGCTGGAATAGTTGCTATAGC 
U._parvum_Serovar_3_ATCC_27815_           AAAATTCTGAGCTATGACATTAGGTGTTACCTTAGTTGGAGCTGGAATAGTTGCTATAGC 
U._parvum_Serovar_3_ATCC_700970_          AAAATTCTGAGCTATGACATTAGGTGTTACCTTAGTTGGAGCTGGAATAGTTGCTATAGC 
U._urealyticum_Serovar_4_ATCC_27816       GAAATTTTGAGCAATTACACTAGGGGTAACTTTAGTGGGAGCAGGGGTAGTTGCTGTGGC 
U._urealyticum_Serovar_10_ATCC_33699      GAAATTTTGAGCAATTACACTAGGGGTAACTTTAGTGGGAGCAGGGGTAGTTGCTGTGGC 
U._urealyticum_Serovar_5_ATCC_27817       GAAATTTTGAGCAATTACACTAGGGGTAACTTTAGTGGGAGCAGGGGTAGTTGCTGTGGC 
U._urealyticum_Serovar_11_ATCC_33695      GAAATTTTGAGCAATTACACTAGGGGTAACTTTAGTGGGAGCAGGGGTAGTTGCTGTGGC 
U._urealyticum_Serovar_9_ATCC_33175       GAAATTTTGAGCAATTACACTAGGGGTAACTTTAGTGGGAGCAGGGGTAGTTGCTGTGGC 
U._urealyticum_Serovar_12_ATCC_33696      GAAATTTTGAGCAATTACACTAGGGGTAACTTTAGTGGGAGCAGGGGTAGTTGCTGTGGC 
U._urealyticum_Serovar_13_ATCC_33698      GAAATTTTGAGCAATTACACTAGGGGTAACTTTAGTGGGAGCAGGGGTAGTTGCTGTGGC 
U._urealyticum_Serovar_2_ATCC_27814       GAAATTTTGAGCAATTACACTAGGGGTAACTTTAGTGGGAGCAGGGGTAGTTGCTGTGGC 
U._urealyticum_Serovar_7_ATCC_27819       GAAATTTTGAGCAATTACACTAGGGGTAACTTTAGTGGGAGCAGGGGTAGTTGCTGTGGC 
                                          .***** * ***:** *** **** **:** ***** *****:**..********.*.** 
 
U._parvum_Serovar_6_ATCC_27818            GGCTTCATGTTCTAATTCAACTGTTAAATCTAAGTTAAGTAGCCAATTTGTTAAATCAAC 
U._parvum_Serovar_1_ATCC_27813            AGCTTCATGTTCTAATTCAACCGTTAAATCTAAATTAAGTAACCAATTTGCTAAATCAAC 
U._parvum_Serovar_14_ATCC_33697           AGCTTCATGTTCTAATTCAACTGTTAAATCTAAGTTAAGTAACCAATTTGCTAAATCAAC 
U._parvum_Serovar_3_ATCC_27815_           AGCTTCATGTTCTAATTCAACTGTTAAATCTAAGTTAAGTAACCAATTTGCTAAATCAAC 
U._parvum_Serovar_3_ATCC_700970_          AGCTTCATGTTCTAATTCAACTGTTAAATCTAAGTTAAGTAACCAATTTGCTAAATCAAC 
U._urealyticum_Serovar_4_ATCC_27816       AGCTTCATGTTCTAGCTCAAATGTTAAATCTAAATTAAGTAGTCAACTTGTTAAATCAAA 
U._urealyticum_Serovar_10_ATCC_33699      AGCTTCATGTTCTAGCTCAAATGTTAAATCTAAATTAAGTAGTCAACTTGTTAAATCAAA 
U._urealyticum_Serovar_5_ATCC_27817       AGCTTCATGTTCTAGCTCAAATGTTAAATCTAAATTAAGTAGTCAACTTGTTAAATCAAA 
U._urealyticum_Serovar_11_ATCC_33695      AGCTTCATGTTCTAGCTCAAATGTTAAATCTAAATTAAGTAGTCAACTTGTTAAATCAAA 
U._urealyticum_Serovar_9_ATCC_33175       AGCTTCATGTTCTAGCTCAAATGTTAAATCTAAATTAAGTAGTCAACTTGTTAAATCAAA 
U._urealyticum_Serovar_12_ATCC_33696      AGCTTCATGTTCTAGCTCAAATGTTAAATCTAAATTAAGTAGTCAACTTGTTAAATCAAA 
U._urealyticum_Serovar_13_ATCC_33698      AGCTTCATGTTCTAGCTCAAATGTTAAATCTAAATTAAGTAGTCAACTTGTTAAATCAAA 
U._urealyticum_Serovar_2_ATCC_27814       AGCTTCATGTTCTAGCTCAAATGTTAAATCTAAATTAAGTAGTCAACTTGTTAAATCAAA 
U._urealyticum_Serovar_7_ATCC_27819       AGCTTCATGTTCTAGCTCAAATGTTAAATCTAAATTAAGTAGTCAACTTGTTAAATCAAA 
U._urealyticum_Serovar_8_ATCC_27618       AGCTTCATGTTCTAGCTCAAATGTTAAATCTAAATTAAGTAGTCAACTTGTTAAATCAAA 
                                          .*************. ****. ***********.*******. *** *** ********.    
 
           UpmbaR 
U._parvum_Serovar_6_ATCC_27818            AGATGATAAAAGTTTTTATGCAGTTTACGAAATTGAAAACTTTAAAGATCTAAGTGATAA 
U._parvum_Serovar_1_ATCC_27813            AGACGATAAAAGTTTTTATGCGGTTTACGAAATTGAAAACTTTAAAGATCTAAGTGATAA 
U._parvum_Serovar_14_ATCC_33697           AGACGGTAAAAGTTTTTATGCGGTTTACGAAATTGAAAACTTTAAAGATCTAAGTAATGA 
U._parvum_Serovar_3_ATCC_27815_           AGACGGTAAAAGTTTTTATGCGGTTTACGAAATTGAAAACTTTAAAGATCTAAGTAATGA 
U._parvum_Serovar_3_ATCC_700970_          AGACGGTAAAAGTTTTTATGCGGTTTACGAAATTGAAAACTTTAAAGATCTAAGTAATGA 
U._urealyticum_Serovar_4_ATCC_27816       AGACGAAAAGAGCTTTTACGCTGTTTACGACATTGAAAATTTCGATGATTTAAATGAAAA 
U._urealyticum_Serovar_10_ATCC_33699      AGACGAAAAGAGCTTTTACGCTGTTTACGACATTGAAAATTTCGATGATTTAAATGAAAA 
U._urealyticum_Serovar_5_ATCC_27817       AGACGAAAAGAGCTTTTACGCTGTTTACGACATTGAAAATTTCGATGATTTAACTGAAAA 
U._urealyticum_Serovar_11_ATCC_33695      AGACGAAAAGAGCTTTTACGCTGTTTACGACATTGAAAATTTCGATGATTTAACTGAAAA 
U._urealyticum_Serovar_9_ATCC_33175       AGACGAAAAGAGCTTTTACGCTGTTTACGACATTGAAAATTTCGATGATTTAACTGAAAA 
U._urealyticum_Serovar_12_ATCC_33696      AGACGAAAAGAGCTTTTACGCTGTTTACGACATTGAAAATTTCGATGATTTAAATGAAAA 
U._urealyticum_Serovar_13_ATCC_33698      AGACGAAAAGAGCTTTTACGCTGTTTACGACATTGAAAATTTCGATGATTTAAATGAAAA 
U._urealyticum_Serovar_2_ATCC_27814       AGACGAAAAGAGCTTTTACGCTGTTTACGACATTGAAAATTTCGATGATTTAACTGAAAA 
U._urealyticum_Serovar_7_ATCC_27819       AGACGAAAAGAGCTTTTACGCTGTTTACGACATTGAAAATTTCGATGATTTAACTGAAAA 
U._urealyticum_Serovar_8_ATCC_27618       AGACGAAAAGAGCTTTTACGCTGTTTACGACATTGAAAATTTCGATGATTTAACTGAAAA 
                                          *** *.:**.** ***** ** ********.******** ** .*:*** *** *.*:.* 
        
 217 
 
U._parvum_Serovar_6_ATCC_27818            TGATAAAAAATCATTAAATGACATTGAATTTAATGCTGCACTTACATCAGTTGAAAACAA 
U._parvum_Serovar_1_ATCC_27813            TGATAAAAAATCATTAAATGACATTGAATTTAATGCTGCACTTACATCAGTTGAAAACAA 
U._parvum_Serovar_14_ATCC_33697           TGATAAAAAATCATTAAGTAACATTGAATTTAATGCTGCACTTACATCAGCTGAAAACAA 
U._parvum_Serovar_3_ATCC_27815_           TGATAAAAAATCATTAAGTAACATTGAATTTAATGCTGCACTTACATCAGCTGAAAACAA 
U._parvum_Serovar_3_ATCC_700970_          TGATAAAAAATCATTAAGTAACATTGAATTTAATGCTGCACTTACATCAGCTGAAAACAA 
U._urealyticum_Serovar_4_ATCC_27816       TGATAAAAAAGCATTAAACGAAGCTGAATTCAATGTTGCAATTACATCAGCTGAAAATAA 
U._urealyticum_Serovar_10_ATCC_33699      TGATAAAAAAGCATTAAACGAAGCTGAATTCAATGTTGCAATTACATCAGCTGAAAATAA 
U._urealyticum_Serovar_5_ATCC_27817       TGATAAAAAAGCATTAAACGAAGCTGAATTCAATGTTGCAATTACATCAGCTGAAAATAA 
U._urealyticum_Serovar_11_ATCC_33695      TGATAAAAAAGCATTAAATGAAACTGAATTCAATGTTGCAATTACATCAGTTGAAAATAA 
U._urealyticum_Serovar_9_ATCC_33175       TGATAAAAAAGCATTAAACGAAGCTGAATTCAATGTTGCAATTACATCAGCTGAAAATAA 
U._urealyticum_Serovar_12_ATCC_33696      TGATAAAAAAGCATTAAACGAAGCTGAATTCAATGTTGCAATTACATCAGCTGAAAATAA 
U._urealyticum_Serovar_13_ATCC_33698      TGATAAAAAAGCATTAAACGAAGCTGAATTCAATGTTGCAATTACATCAGCTGAAAATAA 
U._urealyticum_Serovar_2_ATCC_27814       TGATAAAAAAGCATTAAACGAAGCTGAATTCAATGTTGCAATTACATCAGCTGAAAATAA 
U._urealyticum_Serovar_7_ATCC_27819       TGATAAAAAAGCATTAAATGAAACTGAATTCAATGTTGCAATTACATCAGTTGAAAATAA 
U._urealyticum_Serovar_8_ATCC_27618       TGATAAAAAAGCATTAAACGAAGCTGAATTCAATGTTGCAATTACATCAGCTGAAAATAA 
                                          ********** ******. .*.. ****** **** ****.********* ****** ** 
 
 
U._parvum_Serovar_6_ATCC_27818            AACAGAAAATCTAGTTACAAAAGGTCATTTGGTTGGTGAAAAAATTTACGTTAAATTACC 
U._parvum_Serovar_1_ATCC_27813            AACAGAAAATCTAGTTACAAAAGGTCATTTGGTTGGTGAAAAAATTTACGTTAAATTACC 
U._parvum_Serovar_14_ATCC_33697           AACAGAAAGTACACTTGAAAAAGGTCATTTAGTTGGTGAAAAAATTTACGTTAAATTACC 
U._parvum_Serovar_3_ATCC_27815_           AACAGAAAGTACACTTGAAAAAGGTCATTTAGTTGGTGAAAAAATTTACGTTAAATTACC 
U._parvum_Serovar_3_ATCC_700970_          AACAGAAAGTACACTTGAAAAAGGTCATTTAGTTGGTGAAAAAATTTACGTTAAATTACC 
U._urealyticum_Serovar_4_ATCC_27816       AACAGAAAACGCAACAACAAAAGGTCACTTACTTAACAAAAAAATCTATGTTAAATTACC 
U._urealyticum_Serovar_10_ATCC_33699      AACAGAAAACGCAACAACAAAAGGTCACTTACTTAACAAAAAAATCTATGTTAAATTACC 
U._urealyticum_Serovar_5_ATCC_27817       AACAGAAAACGCAACAACAAAAGGTCACTTACTTAACAAAAAAATCTATGTTAAATTACC 
U._urealyticum_Serovar_11_ATCC_33695      AACAGAAAACGCAACTATAAAAGGTCACTTACTTAACAAGAAAATCTACGTTAAATTACC 
U._urealyticum_Serovar_9_ATCC_33175       AACAGAAAACGCAACAACAAAAGGTCACTTACTTAACAAAAAAATCTATGTTAAATTACC 
U._urealyticum_Serovar_12_ATCC_33696      AACAGAAAACGCAACAACAAAAGGTCACTTACTTAACAAAAAAATCTATGTTAAATTACC 
U._urealyticum_Serovar_13_ATCC_33698      AACAGAAAACGCAACAACAAAAGGTCACTTACTTAACAAAAAAATCTATGTTAAATTACC 
U._urealyticum_Serovar_2_ATCC_27814       AACAGAAAACGCAACAACAAAAGGTCACTTACTTAACAAAAAAATCTATGTTAAATTACC 
U._urealyticum_Serovar_7_ATCC_27819       AACAGAAAACGCAACTATAAAAGGTCACTTACTTAACAAGAAAATCTACGTTAAATTACC 
U._urealyticum_Serovar_8_ATCC_27618       AACAGAAAACGCAACAACAAAAGGTCACTTACTTAACAAAAAAATCTATGTTAAATTACC 
                                          ********.   *  :. ********* **. **.. .*.***** ** *********** 
 
              UpmbaR3         UpmbaR4 
U._parvum_Serovar_6_ATCC_27818            TCGTGAACCAAAACCTAATGAACAATTAACTATTATTAATAAAAGTGGATTAATCAAGAC 
U._parvum_Serovar_1_ATCC_27813            TCGTGAACCAAAACCTAATGAACAATTAACTATTATTAATAAAAGTGGATTAATCAAGAC 
U._parvum_Serovar_14_ATCC_33697           TCGTGAACCAAAACCTAATGAACAATTAACTATTATTAGTAAAAGTGGATTAATCAAGAC 
U._parvum_Serovar_3_ATCC_27815_           TCGTGAACCAAAACCTAATGAACAATTAACTATTATTAGTAAAAGTGGATTAATCAAGAC 
U._parvum_Serovar_3_ATCC_700970_          TCGTGAACCAAAACCTAATGAACAATTAACTATTATTAGTAAAAGTGGATTAATCAAGAC 
U._urealyticum_Serovar_4_ATCC_27816       ACGTGAACCAAAAGCTAAAGAACAATTAACTATTATTAATAAAGGTGGCTTACTAAAAAC 
U._urealyticum_Serovar_10_ATCC_33699      ACGTGAACCAAAAGCTAAAGAACAATTAACTATTATTAATAAAGGTGGCTTACTAAAAAC 
U._urealyticum_Serovar_5_ATCC_27817       ACGTGAACCAAAAGCTAAAGAACAATTAACTATTATTAATAAAGGTGGCTTACTAAAAAC 
U._urealyticum_Serovar_11_ATCC_33695      ACGTGAACCAAAAGCTAAAGAGCAATTAACTATTATTAATAAAGGTGGATTACTAAAAAC 
U._urealyticum_Serovar_9_ATCC_33175       ACGTGAACCAAAAGCTAAAGAACAATTAACTATTATTAATAAAGGTGGCTTACTAAAAAC 
U._urealyticum_Serovar_12_ATCC_33696      ACGTGAACCAAAAGCTAAAGAACAATTAACTATTATTAATAAAGGTGGCTTACTAAAAAC 
U._urealyticum_Serovar_13_ATCC_33698      ACGTGAACCAAAAGCTAAAGAACAATTAACTATTATTAATAAAGGTGGCTTACTAAAAAC 
U._urealyticum_Serovar_2_ATCC_27814       ACGTGAACCAAAAGCTAAAGAACAATTAACTATTATTAATAAAGGTGGCTTACTAAAAAC 
U._urealyticum_Serovar_7_ATCC_27819       ACGTGAACCAAAAGCTAAAGAGCAATTAACTATTATTAATAAAGGTGGATTACTAAAAAC 
U._urealyticum_Serovar_8_ATCC_27618       ACGTGAACCAAAAGCTAAAGAACAATTAACTATTATTAATAAAGGTGGCTTACTAAAAAC 
                                          :************ ****:**.****************.****.****.***.*.**.** 
 
           Inverted Repeat 
U._parvum_Serovar_6_ATCC_27818            TTCAGGTTTGTTAATACCTAATAATTTGAATTATCAAACAGAAAAAGTGAACTTTGAAAC 
U._parvum_Serovar_1_ATCC_27813            TTCAGGTTTGTTAATACCTGATAATTTGAATTATCAAACAGAAAAAGTGAACTTTGAAAC 
U._parvum_Serovar_14_ATCC_33697           TTCAGGTTTGTTAATATCTGATAATTTGAATTATCAAACAGAAAAAGTGAACTTTGAAAC 
U._parvum_Serovar_3_ATCC_27815_           TTCAGGTTTGTTAATATCTGATAATTTGAATTATCAAACAGAAAAAGTGAACTTTGAAAC 
U._parvum_Serovar_3_ATCC_700970_          TTCAGGTTTGTTAATATCTGATAATTTGAATTATCAAACAGAAAAAGTGAACTTTGAAAC 
U._urealyticum_Serovar_4_ATCC_27816       TGCATCTTTAGTATTACCTGATAATTTGAATTATCAAACAGAAAAAGTGGAGTTCGA-AA 
U._urealyticum_Serovar_10_ATCC_33699      TGCATCTTTAGTATTACCTGATAATTTGAATTATCAAACAGAAAATATAGGTTTTGA-AA 
U._urealyticum_Serovar_5_ATCC_27817       TGCATCTTTAGTATTACCTGATAATTTTAATTATCAAACAGAAAATATAGGTTTTGA-AA 
U._urealyticum_Serovar_11_ATCC_33695      TGCATCTCTAGCATTACCTGATAATTTGAATTATCAAACAGAAAAAGTAGACTTTAAAAG 
U._urealyticum_Serovar_9_ATCC_33175       TGCATCTTTAGTATTACCTGATAATTTTAATTATCAAACAGAAAAAGTAGACTTTGAAAA 
U._urealyticum_Serovar_12_ATCC_33696      TGCATCTTTAGTATTACCTGATAATTTGAATTATCAAACAGAAAAAGTGGACTTTGAAAA 
U._urealyticum_Serovar_13_ATCC_33698      TGCATCTTTAGTATTACCTGATAATTTGAATTATCAAACAGAAAAAGTGGAGTTCGA-AA 
U._urealyticum_Serovar_2_ATCC_27814       TGCATCTTTAGTATTACCTGATAATTTTAATTATCAAACAGAAAAAGTGGACTTTGGAAA 
U._urealyticum_Serovar_7_ATCC_27819       TGCATCTCTAGCATTACCTGATAATTTGAATTATCAAACAGAAAAAGTGGACTTTGGAAA 
U._urealyticum_Serovar_8_ATCC_27618       TGCATCTTTAGTATTACCTGATAATTTTAATTATCAAACAGAAAAAGTGGAGTTTGAAAA 
                                          * **  * *.  *:** **.******* *****************:.*... ** .. *  
 
Figure 9.1. U. parvum serovars 1, 3, 6 and 14 gene alignment of intergenic upstream region of the 
mba and the upstream conserved portion of the mba. Gene alignments were performed using 
Geneious software and Clustal Omega. Designed primers are shown in shaded boxes and individual 
single nucleotide polymorphisms (SNPs) are highlighted in each of the U. parvum serovars. 
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Supplementary Table 9.2. Summary of serotyping based on the designed real-time PCR and HRM 
assay. Real-time PCR serotyping was confirmed by comparing U. parvum clinical isolates to ATCC 
strain serovars of U. parvum. Specimens had also been previously serotyped using sequencing 
and/or western blot using serovar-specific antisera. A total of 64.5% of clinical isolates were able to 
be successfully typed using the current real-time PCR and HRM assay.  
Patient 
Sample 
Number 
Previous 
serovar 
identified 
DNA successfully 
amplified? 
Serovar identified by 
novel real-time PCR 
and HRM assay 
Correct identity 
confirmed by real-time 
PCR and HRM assay? 
1A 1 Yes 1 Yes 
1B 1 Yes 1 Yes 
27 6 Yes 6 Yes 
33A 3 Yes 3 Yes 
33B 3 Yes 3 Yes 
43 1 Yes 6 No 
44A 3 Yes 3 Yes 
44B 3 Yes 3 Yes 
50 6 Yes   
55B 6 Yes 6 Yes 
182 6 Yes 6 Yes 
262T 1 Yes 6 No 
290T 1 Yes 1 Yes 
301 1 Yes 6 No 
310 6 Yes 1 No 
314T 3 Yes 14 No 
322T 3 Yes 3 Yes 
325 3 Yes 3 Yes 
334A 6 Yes 6 Yes 
334B 6 Yes 1 No 
364A 6 Yes 1 No 
365 3 Yes 1 No 
429 6 Yes 6 Yes 
435 3 Yes 3 Yes 
473T 1 Yes 1 Yes 
480T 6 Yes Did not serotype No 
483T 1 Yes 1 Yes 
498A 1 Yes 1 Yes 
498B 1 Yes 1 Yes 
507 1 No - - 
510 6 No 3 No 
912p 3 Late amplification - - 
46e 6 No - - 
402s 6 Late amplification - - 
231e 3 Late amplification - - 
291s 6 Late amplification - - 
84e 6 No - - 
33e 1 &3 Yes 6 No 
1040e2 1 Late amplification - - 
163w 6 No - - 
924e 1 Late amplification - - 
1043 6 No - - 
928e2 3 Late amplification - - 
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1020e2 1 Late amplification - - 
405e 1 No - - 
196e1 3 Late amplification - - 
268so 6 No - - 
405eo 1 Late amplification - - 
226so 3 Late amplification - - 
1630eo 3 Yes 3 Yes 
7.004 85 d 6 Late amplification - - 
7.005 99d 6 Late amplification - - 
7.002 99d 6 Late amplification - - 
7.042 85 d 6 Late amplification - - 
7.085 85 d 6 Late amplification - - 
7.113 99d 6 Late amplification - - 
TOTAL - 31/55 (56.4%) - 20/31 (64.5%) 
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Supplementary Table 9.3. Comparison of neonatal outcomes of infants exposed to Ureaplasma parvum and Ureaplasma urealyticum 
 U. parvum (n = 36) U. urealyticum (n = 6) Significance 
Gestational age 35.9 ± 0.4 (32 – 41) 34.7 ± 0.6 (32 – 36) NS1 
Apgar2 - 1 minute 7.9 ± 0.3 (1 – 9) 7.8 ± 0.6 (5 – 9) NS 
Apgar - 5 minutes 8.8 ± 0.1 (8 – 9) 8.7 ± 0.2 (8 – 9) NS 
Birth weight 2550.0 ± 102.5 (1380 – 3873) 2674.2 ± 148.2 (2290 – 3330) NS 
Placental weight 456.0 ± 22.9 (260 – 710) 400.4 ± 14.3 (374 – 461) NS 
Continuous positive airway pressure (CPAP) 8/36 (22.2%) 2/6 (33.3%) NS 
Demonstrated features of RDS 8/36 (22.2%) 3/6 (50.0%) NS 
Required oxygen or positive pressure support > 6 hrs 5/36 (13.9%) 3/6 (50.0%) NS 
Diagnosed RDS3 5/36 (13.9%) 2/6 (33.3%) NS 
Length of stay 6.0 ± 1.2 (1 – 28) 5.5 ± 1.7 (2 – 13) NS 
1 NS - not statistically significant 
2 Apgar – a measure of neonatal health scored at 1 min and 5 minutes post-delivery; measures appearance, pulse, reflex, activity and respiration of the 
newborn. 
3 RDS - respiratory distress syndrome.
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Supplementary Table 9.4. Comparison of pregnancy outcomes of women who were infected with U. parvum serovars 1, 3 or 6 
 Serovar 1 
(n = 10) 
Serovar 3 
(n = 9) 
Serovar 6 
(n = 12) 
Significance 
Signs/symptoms of infection1 2/10 (20.0%) 1/9 (11.1%) 0/12 (0.0%) NS2 
Chorioamnionitis3 documented previously 1/10 (10.0%) 0/9 (0.0%) 0/12 (0.0%) NS 
Chorioamnionitis in current pregnancy 7/10 (70.0%) 5/9 (55.5%) 7/12 (58.3%) NS 
- Maternal Stage 1.6 ± 0.2 (1 – 2) 1.2 ± 0.1 (1 – 2) 1.6 ± 0.3 (1 – 3) NS 
- Fetal Stage 2.5 ± 0.2 (2 – 3) 2.0 ± 0.3 (1 – 3) 1.7 ± 0.3 (1 – 3) NS 
Antibiotics administered < 3hrs prior to delivery 5/10 (50.0%) 3/9 (33.3%) 5/12 (41.7%) NS 
Cervical incompetence 4/10 (40.0%) 4/9 (44.4%) 5/12 (41.7%) NS 
Preterm premature rupture of membranes (pPROM) 3/10 (30.0%) 3/9 (33.3%) 3/12 (25.0%) NS 
1 Signs and symptoms of infection included: maternal temperature > 38 °C, uterine or abdominal tenderness, foul-smelling vaginal discharge, maternal 
tachycardia (> 120 bpm) or fetal tachycardia (> 160 bpm) 
2 NS - not statistically significant 
3 Chorioamnionitis was determined by US pathologists (blinded to outcome) according to (Redline et al. 2003)
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Supplementary Table 9.5. Comparison of fetal outcomes of those infants exposed to U. parvum serovars 1, 3 or 6 in utero.  
 Serovar 1 
(n = 10) 
Serovar 3 
(n = 9) 
Serovar 6 
(n = 12) 
Significance 
Gestational age 36.3 ± 0.9 (33 - 41) 35.9 ± 0.7 (33 - 39) 35.2 ± 0.7 (32-40) NS1 
Apgar2 - 1 minute 8.1 0.7 (2 - 9) 7.5 ± 0.7 ( 3 - 9) 7.7 ± 0.7 (1 - 9) NS 
Apgar - 5 minutes 8.9 ± 0.1 (8 - 8) 8.7 ± 0.2 (8 - 9) 8.9 ± 0.1 (8 - 9) NS 
Birth weight 2643.9 ± 182.6 (1975 - 3873) 2650.7 ± 219.5 (1525 - 3855) 2370.8 ± 186.6 (1380 - 3825) NS 
Placental weight 541.9 ± 39.5 (270 - 635) 482.4 ± 48.5 (279 - 710) 395.8 ± 31.7 (260 - 655) NS 
Demonstrated features of RDS3 3/10 (30.0%) 2/9 (22.2%) 3/12 (25%) NS 
Required oxygen or positive pressure support > 6 hrs 1/10 (10.0%) 2/9 (22.2%) 2/12 (16.7%) NS 
Respiratory distress syndrome (RDS) 1/10 (10.0%) 2/9 (22.2%) 2/12 (16.7%) NS 
Length of stay 7.6 ± 2.7 (1 - 28) 5.0 ± 2.1 (1 - 16) 6.9 ± 1.8 (2 - 17) NS 
1 NS - not statistically significant 
2 Apgar – a measure of neonatal health scored at 1 min and 5 minutes post-delivery; measures appearance, pulse, reflex, activity and respiration of the 
newborn. 
3 RDS - respiratory distress syndrome
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Supplementary Table 9.6. Comparison of maternal demographic data from pregnancies exposed to Ureaplasma spp. which demonstrated no mba/MBA 
size variation, and those pregnancies which were exposed to ureaplasmas that varied the size of their mba/MBA 
 No mba/MBA variants 
(n = 11) 
Single mba/MBA variant 
(n = 16) 
Multiple mba/MBA variants 
(n =4 ) 
Significance 
Maternal age 25.5 ± 1.2 (20 - 32) 23.9 ± 1.3 (17 - 32) 24.0 ± 2.3 (19 - 28) NS1 
Gravida2 1.9 ± 0.4 (1 - 4) 1.6 ± 0.2 (1 - 4) 3.2 ± 0.8 (1 - 5) NS 
Parity3 2.1 ± 0.3 (1 - 4) 1.4 ± 0.2 (1 - 2) 2.2 ± 0.7 (1 - 4) NS 
Marital status     
- Married 6/11 (54.5%) 5/16 (31.2%) 1/4 (25.0%) NS 
- Single 5/11 (45.5%) 11/16 (68.8%) 3/4 (75.0%) NS 
Medical Insurance     
- Private 7/11 (63.6%) 4/16 (25.0%) 2/4 (50.0%) NS 
- Medicaid 3/11 (27.3%) 8/16 (50.0%) 2/4(50.0%) NS 
- Self pay/uninsured 0/11 (0.0%) 4/16 (25.0%) 0/4 (0.0%) NS 
- Unknown 1/11 (9.1%) 0/16 (0.0%) 0/16 (0.0%) NS 
Evidence of prenatal care 10/11 (90.9%) 16/16 (100.0%) 4/4 (100.0%) NS 
1 NS - not statistically significant 
2 Gravida - number of clinical pregnancies 
3 Parity - number of viable offspring resulting from all pregnancies 
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Supplementary Table 9.7. Raw data and standard error of the mean (SEM) relating to figure 6.1 – Ureaplasma spp. growth in M199 media. As replicate data 
were remarkably similar for this graph, error bars were not generated using statistical software. 
 
Time M199 Media + 10% Fetal 
Calf Serum 
SEM M199 media + 10% Horse 
Serum 
SEM 10B broth SEM 
4 1 x 101 1.2 x 101 ± 1.0 1.1 x 101 1.3 x 101 ± 1 1 x 101 1 x 101 ± 0 
8 2.5 x 101 2 x 101 ± 2.5 2.1 x 101 2.3 x 101 ± 1 4.8 x 102 4.1 x 102 ± 2.5 
20 5 x 103 5 x 103 ± 0.0 3.1 x 101 3.2 x 101 ± 0.5 7.9 x106 8 x 106 ± 1 
30 6 x 103 5.7 x 103 ± 150 3.2 x 101 3.3 x 101 ± 0.5 5.9 x 103 6 x 103 ± 1 
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Supplementary Table 9.8. Raw data and standard error of the mean (SEM) relating to figure 6.3 – Ureaplasma spp. growth under different oxygen 
tensions. As replicate data were remarkably similar for this graph, error bars were not generated using statistical software. 
Time 5% O2 SEM 8% O2 SEM 20% O2 SEM 
0 1 x 101  1.1 x 101  ± 0.5 1 x 101  1.5 x 101  ± 2.5 1 x 101  1.1 x 101  ± 0.5 
4 1.1 x 101  1.2 x 101  ± 0.5  1 x 102  1.5 x 102  ± 42.5 1.2 x 102  1.5 x 102  ± 10 
8 1.2 x 101  1.4 x 101  ± 1 1.5 x 103  2 x 103  ± 250.0 1.3 x 103 1.3 x 103  ± 0 
12 1.3 x 102  1.5 x 102  ± 10 DNA1 DNA1 N/A2 1.5 x 103  1.7 x 103  ± 100 
24 1.5 x 102  1.8 x 102  ± 15 2 x 104  2 x 104  ± 0 1.9 x 103  2 x 103  ± 850 
 
1 Data was not available for this sample at this time point 
2 Not applicable – no data was available, so therefore no standard error of the mean was able to be calculated 
